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Glossary
A
Area Under the ROC Curve: The area under the ROC Curve (AUC or AUROC) see: Re-
ceiving Operating Characteristic summarises a medical classification tool by assessing all the
pairs of individuals, one who is diseased and one who is disease free, to determine the probabil-
ity of correctly assigning a higher risk or weighting to the individual with disease.
B
C
Calibration: The calibration is an assessment of how successfully the model predicts risks
in individuals by comparing the predicted and observed incidence rates. This is commonly
measured through the Hosmer-Lemeshow test.
Cancer: Cancer is a growth in a part of the body caused by uncontrolled cell division due to
cell mutation.
Computer Tomography Scan: A computerized tomography (CT) scan is a series of X-ray
images taken from different angles. These images are then combined to create detailed images
of an organ in the body.
95% Confidence Interval: There is 95% confidence the true value for the measure is contained
between the upper and lower bound of the interval.
Confounding: When measuring the association between a health outcome and a variable,
confounding is an additional variable that is correlated to both the health outcome and the
variable that may exaggerate the level of association.
D
Discrimination: The discrimination is a measure for all participants in the dataset how suc-
cessfully the model assigns a higher risk to cases in comparison to controls. This is commonly
measured by the area under the receiver operating characteristic curve (AUROC or AUC).
E
Endobronchial ultrasound: An endobronchial ultrasound is a medical procedure to diagnose
lung cancer. It creates an image of the lungs through ultrasound during a bronchoscopy to
identify any abnormalities.
F
First Degree Relatives: First degrees relative to an individual are their parents, siblings, and
children.
Five(5)-year survival rate: The 5-year survival is the percentage of participants that are
alive 5 years after diagnosis for a disease.
x
G
H
I
J
K
L
Lobectomy: Lobectomy is surgical removal of an organ such as a lung.
Low Dose Computer Tomography: This is a CT scan (see Computer Tomography Scan)
that uses less ionizing radiation. This is commonly used in lung cancer screening as Low Dose
Computer Tomography (LDCT) reduces the risk of other forms of cancer from increased radia-
tion exposure.
M
N
Non-Small Cell Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) is one of the two main
lung cancer subgroups; it is the most common type of cancer of lung occurring in approximately
87% of patients. There are three subgroups of NSCLC which are adenocarcinoma, squamous
cell carcinoma, and large cell carcinoma.
O
P
Pneumonectomy: Pneumonectomy is the surgical removal part of an organ such as a lung.
– Prediction Rules: The prediction rules are an assessment of the screening programmes screen-
ing criteria to identify high risk participants for screening. This can be simple criteria such as
age, or using a prediction model and identifying high risk participants whose risk exceeds a spec-
ified value. There are many measures to evaluate the prediction rules which commonly evaluate
the proportion of cases successfully classified as high risk and the proportion of controls that
were classified as low risk.
Q
Quality-adjusted life year: The quality-adjusted life year (QALY) is a measure of the im-
provement or lowering of the standard of living in a patient with a disease. The measure
considered the quality and the duration of life lived with the condition to calculate a QALY.
An alleviation of symptoms and prolonged life would improve a QALY score with one QALY
equating to one year with no symptoms.
R
Receiver Operating Characteristic: The receiver operating characteristic (ROC or ROC
Curve) is a plot of the sensitivity and (1 - specificity) at each risk threshold. It measures the
performance between these two measures and evaluates the ability of a model to distinguish
between diseased and disease free groups. This is commonly presented alongside the AUC.
Risk Prediction Model: A risk prediction model estimates the probability of a condition
presenting in an individual over a specified duration using predictors that are specific to the
individual.
xi
S
Screening Programme: A screening programme is testing participants once or periodically
to identify a disease or health outcome, such as lung cancer, in individuals who appear healthy.
A selective screening programme uses a defined criteria, such as an age range, to identify a
population subgroup that would most benefit from screening.
Sensitivity: The sensitivity is a measure of the performance for a selective screening criteria
to identify high risk participants. The sensitivity is the proportion of cases for a disease that
would be correctly classified as high risk if developing the disease and sent for screening, defined
as the true positive rate.
Small Cell Lung Cancer: Small Cell Lung Cancer is one of the two main lung cancer sub-
groups occurring in approximately 12% of individuals. This is a more aggressive strain of cancer
that spreads rapidly.
Smoking Pack Years: Pack years is a simple calculation to determine one’ smoking history
and can be calculated by CigarettesPerDay20 × SmokingDuration
Specificity: The specificity is a measure of the performance for a selective screening criteria to
identify high risk participants. The specificity is the proportion of non-cases for a disease that
would be correctly classified as low risk of developing the disease and declined for screening,
defined as the true negative rate.
T
U
V
Validation: Validation is an assessment of a model, its ability to generate accurate risks (see
calibration) and distinguish between cases and controls (see discrimination and prediction rules).
A validation can be internal, in the same population as the model was created; temporal, in
the same population the model was devised but participants excluded from the model building
stage; or external, a new environment.
W
X
Y
Z
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Chapter Summary
In Chapter One the lung cancer statistics are presented, which includes diagnosis and survival rates. The
main risk factors associated with elevating or minimising lung cancer risk are presented. The process to
identify, diagnose and stage is presented and how different stages influences the treatment options available
to cure lung cancer. Finally, the chapter presents selective screening trials that have been implemented to
improve early lung cancer diagnosis rates and reviews their success and limitations of the different screening
trials.
Chapter Two explores why prediction models are developed to estimate the likelihood of a disease
presenting in an individual within a time period. The chapter then focuses on how prediction models can
be used to identify high risk individuals who may benefit from periodic screening. Prior to prediction
models being considered to identify high risk individuals, there needs to be confidence that the model is
reliable. Therefore, the models need to be rigorously evaluated to create confidence in their performance;
the different methods available to evaluate a prediction model are presented.
Chapter Three conducts a systematic review of lung cancer prediction models. This identifies all
published lung cancer prediction models and reviews how they performed in validation studies. This
assesses the model’s potential as a selective screening tool and identifies the models with most promise for
further evaluation in this study.
Chapter Four presents datasets that were obtained from the International Lung Cancer Consortium.
The raw datasets were collected and the chapter details how the data was prepared so lung cancer prediction
models could be applied in the dataset. A review of methods to deal with or impute missing information
was conducted and an appropriate method identified.
Chapter Five reviews the prepared datasets that were collected. This identified any specific design
feature within the datasets during the participant recruitment, and how this could influence the prediction
models that are applied and validated in the dataset.
In this first section of the validation of the lung cancer prediction model, Chapter Six validates and
compares the models. The chapter analyses their potential to accurately estimate an individual’s risks and
assign a higher risk to individuals with lung cancer rather than disease free individuals. Additionally, the
chapter reviews the model’s prediction rules to assess how they would perform as a selective screening tool.
The second stage of the external validation is reported in Chapter Seven where the models are validated
in a more restrictive population that is more representative for lung cancer screening. All the models are
reviewed in this same target population to allow a direct comparison between the models. The prediction
rules are evaluated to review how each of the models would perform as a selective screening tool.
Prediction models can be updated or multiple models aggregated to create a new model which may
have an improved performance. Therefore, Chapter Eight identifies and reviews methods to update a
prediction model and assesses how the methods performed when they have previously been implemented.
The practicality of the methods for lung cancer prediction models is reviewed and appropriate methods
are identified to be applied in a later chapter.
Chapter Nine introduces the lung cancer prediction models which will be updated. The original models
that would be subsequently updated were validated in the dataset and the results presented. This will
provide a baseline performance that we shall compare the updated models to, to assess whether the model
updating methods create a model with an increased potential as a selective screening tool.
Chapter Ten applies methods to update a single prediction model. The updated models were presented
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and validated to assess if an improved prediction model was devised. The chapter also assesses the potential
and limitations of the different methods based on their performance when applied to the lung cancer
prediction model.
Chapter Eleven employs methods to aggregate multiple prediction models. The new lung cancer pre-
diction models are presented and validated to assess if an improved prediction model could be devised. The
chapter provides an opportunity to review how the different methods perform, using lung cancer prediction
models as an example, to identify robust methods that can subsequently be applied to new lung cancer
prediction or different types of prediction models.
The thesis concludes with a discussion, this presented the key findings within the thesis and how this
embedded in the current environment and previous research. Based on the results obtained recommenda-
tions were made on the future research that should be conducted that will hopefully propel lung cancer
prediction models being used as a selective screening tool and aim to improve lung cancer diagnosis and
survival rates. The limitations of the project were discussed but in context how the results obtained should
be interpreted and how this can be rectified in future studies.
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Thesis Abstract
Lung cancer is a global disease that affect millions of individuals worldwide [1]. Additionally, the disease
is beset with a poor 5-year survival rate, a direct consequence of a low early stage diagnosis rate [1]. In
an attempt to improve lung cancer prognosis, individuals at high risk of developing lung cancer should be
identified for periodic screening.
Prediction models are devised to predict an individual’s risk of developing a disease over a specified
time period. These can be used to identify high risk individuals and be made publically available to allow
individuals’ to be conscience of their own risk. While prediction models have multiple uses it is imperative
the models demonstrate a good standard of performance consistently when reviewed.
The project conducted a systematic review, analysing previously published lung cancer prediction mod-
els. The review identified that there had been inadequate reporting of the existing models and when these
models have been validated this had not been consistent across different publications. As a consequence
models have not been consistently considered as a selective screening tool.
The project then validated the prediction models using datasets from the International Lung Cancer
Consortium. The validation identified the leading models which will allow a more targeted focus on these
models in future research. This could culminate in the model being implemented as a clinical utility.
The final stage reviewed methods to update a single prediction model or aggregate multiple prediction
models into a meta-model. A literature review identified and evaluated the different methods, discussing
how different methods can be successful in different scenarios. The methods were also reviewed for their
suitability updating selected lung cancer prediction models, and appropriate methods were identified. These
were then applied to create updated lung cancer models which were validated to assess which methods were
successful at improving the performance and robustness of lung cancer prediction models. As lung cancer
research develops, particularly into researching genetic markers that may explain lung cancer risk, these
factors could be incorporated into already successful prediction models using appropriate model updating
methods that were identified in our research.
xvi
Part II
Thesis
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CHAPTER 1
Introduction to Lung Cancer and Screening Programmes
1.1 Introduction
Lung cancer can be a deadly disease that affects people worldwide, accounting for one out of four cancer
related mortalities [1]. This chapter provides an overview and context into lung cancer including statistics,
disease progression and staging, the importance of early diagnosis, and screening strategies. This chapter
will provide a background into lung cancer and evaluate the effectiveness of the current screening criteria
to identify lung cancer in patients.
1.2 Objectives
To provide a thorough introduction on lung cancer this chapter will;
1. Present essential information and terminology;
• Describe the key risk factors.
• Present the stages of disease progression.
• Discuss how lung cancer can be diagnosed.
• Introduce the available treatment options for each stage of the disease.
2. Present key statistics including disease prevalence and survival rates stratified by lung cancer stage.
3. Present screening programmes that have been implemented for lung cancer;
• Discuss why screening programmes have been implemented.
• Present the screening programmes methodologies.
• Summarise their effectiveness.
• Discuss how screening programmes could be improved.
4. Identify how further research could improve early diagnosis and survival rates for lung cancer.
1.3 Introduction to Lung Cancer
Tumours present in a body when cells begin to uncontrollably divide, the tumour can be malignant and
affect the surrounding tissue and organs and is then classified as cancer [2]. Cancer can occur throughout
the body and is defined by the organ where the tumour originated. Lung cancer is a malignant tumour
formed in the lungs or the cells that line the air passages.
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There are two main types of lung cancer which are classified by the types of cells from which the cancer
originates. The most common form of lung cancer is non-small cell, this occurs in 80% of cases, and can
be further subdivided into squamous cell carcinoma, adenocarcinoma, or large-cell carcinoma. The second
form, small-cell lung cancer, is less common but is more aggressive often spreading more rapidly across the
lungs [3].
1.4 Risk Factors of Lung Cancer
There are many risk factors which elevate lung cancer risk; these can be lifestyle choices or environmental
factors. The main risk factor is a positive smoking history and is present in around 85% of new lung cancer
cases [4, 5]. A systematic review estimated the magnitude of an increased risk due to a smoking history,
reporting an odds ratio of 8.96 (95% CI [6.73, 12.1]) for current smokers, and 3.85 (95% CI [2.77, 5.34]) in
former smokers [4]. The statistically significant odds ratio demonstrates how a positive smoking history
increases ones’ risk of developing lung cancer; despite this 1 in 5 UK adults currently smoke [6] and there
are 1 billion smokers worldwide [7].
Lung cancer risk is also increased from occupational exposures, and in the UK 20.5% of males with
lung cancer and 4-5% of females reported a positive exposure [8]. A positive exposure can be linked to one
of several types of harmful substances, including asbestos, wood, dust, and radon; all of which can elevate
lung cancer risk. Asbestos exposure has been shown to increase risk of lung cancer and longer durations
of exposure further elevates risk [4].
A family history of lung cancer in first degree relatives has also been linked to an increased risk of lung
cancer. A meta-analysis of 40 studies reported an odds ratio of 1.72 (95% CI [1.56, 1.88]) in people who had
at least one first degree relative diagnosed with lung cancer [4]. This suggests lung cancer can be influenced
by genetic factors that could prevent or increase susceptibility of developing lung cancer. Further research
is being conducted to identify the genetic markers associated with lung cancer including specific blood-
based biomarkers such as pro-surfactant protein B [9], micro RNAs [10] - [13], and cytokinesis-blocked
micronucleus assay [14].
Prior lung diseases have also been confirmed to report an elevated risk. These diseases can damage
the cells in the lungs and cell mutations and tumours can develop as the body replaces the damaged
cells. The main lung diseases; pneumonia, chronic bronchitis, Chronic Obstructive Pulmonary Disease
(COPD), emphysema, and tuberculosis were all associated with lung cancer risk when evaluated in a meta-
analysis [15]. This was supported by additional research which showed a significant elevated risk for chronic
bronchitis with an odds ratio of 1.47 (95% CI [1.29, 1.68]), tuberculosis (1.48 (95% CI [1.17, 1.87])), and
pneumonia (1.57 (95% CI [1.22, 2.01])) [16]. The study also demonstrated prior lung conditions elevated risk
independently of tobacco use, with never-smokers also reporting a significantly increased risk of developing
lung cancer [16]. However, reverse causality should be considered as lung cancer can weaken the immune
system and increase the chance of pneumonia and tuberculosis infections [15].
Finally, lung cancer risk is associated with an increased age [17] with lung cancer rarely presenting in
patients under 40. Although there could be confounding, as while lung cancer increases with age this could
also be linked to a developing smoking history present in 85% of new lung cancer cases.
1.5 Diagnosing and Staging Lung Cancer
Diagnosing and staging lung cancer is important; determining the lung cancer stage allows physicians to
make an informed decision about the available treatment options. Staging determines how far the disease
has spread and the size of the affected area. Cancers are categorised into four different stages (Stage 1 –
Stage 4) with a higher staging indicating that the disease has progressed further and affects a larger area.
A tumour, lymph nodes, metastasis (TNM) staging scale is used for lung cancer [18]. This categorises the
cancer by the size of the tumour, whether the cancer has spread to the surrounding lymph nodes, and
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whether the tumour has metastasized to other parts of the body [19]. A detailed summary how the TNM
scale can stage lung cancer is provided on-line [18].
There are a variety of methods available to diagnose and stage lung cancer. A CT scan is the most
common test [20], and is often conducted as the initial assessment to ascertain whether a tumour is visible
on the lungs. A bronchoscopy is another available method that examines the inside of the airways by
placing a narrow, flexible tube down the throat [20]. This is an invasive procedure that can affect the
patients and they will be required to not eat or drink after the procedure until the anaesthetic has worn
off. Endobronchial ultrasound (EBUS) can also be used to diagnose lung cancer; this is like a bronchoscopy
with an ultrasound. The probe creates ultrasound pictures of the lung tissue and lymph glands to determine
the cancer stage [20]. Finally, a percutaneous lung biopsy can be used which requires a thick needle injected
through the skin and muscle of the chest to extract a cell sample [20] or staged through keyhole surgery.
However, these tests are invasive and cause discomfort to the patient.
1.6 Lung Cancer Treatment
Treatment options for lung cancer depend on the type of lung cancer, the stage at diagnosis, and the health
of the patient. Early diagnosis means more treatment options are available such as surgery. However, as
the cancer spreads too much of the lung would need to be removed, making this a non-viable option. The
health of the patient is also important as risky procedures or major surgery may not be conducted if the
patient is deemed too unhealthy. Removing a proportion of the lung would be inadvisable in patients with
respiratory problems.
Diagnosing non-small cell lung cancer at stage 1 will normally result in surgery removing part of the
lung (a lobectomy) or the entire lung (a pneumonectomy) [21]. By stage 3, if scans show the cancer cells
have spread to the middle of the chest and close to the heart, then radiotherapy would be recommended
instead of surgery as the cancer is too close to vital organs to operate safely [21]. By a stage 4 treatment
options aim to control the cancer for as long as possible and attempt to shrink the cancer to alleviate
symptoms [21].
For the less common small-cell lung cancer chemotherapy and radiotherapy of the lung are the most
likely treatment options. This form of cancer can spread to the brain so radiotherapy of the brain is also
conducted. While surgery could be performed for small-cell lung cancer the aggressive nature of this strain
means the cancer has often spread to an advanced stage so this is not a viable option [21]. Therefore most
treatment options aim to improve quality of life and alleviate symptoms.
1.7 Lung Cancer Statistics
Lung cancer is a global concern. In the US in 2016 there will be an estimated 224,390 new cases of lung
cancer and 158,080 mortalities [1]. In the UK there are approximately 44,500 people diagnosed each year
[22]. Lung cancer is one of the leading cancers with the second highest incidence rates for both males and
females; behind prostate cancer in males and breast cancer in females [1]. However, it is the leading cause
of deaths from cancer and accounts for approximately 26% of all cancer related death in both genders [1].
As a leading cause in cancer incidence and mortality rates there is a greater focus in attempting to improve
the poor lung cancer prognosis.
Lung cancer risk increases with age with few incidences in individuals under 40. Cancer will develop
in 0.7% of individuals aged 50 – 59 years but this increases to 2% in 60 – 69 years and 6.4% in people over
70 of years [1]. The increased age at diagnosis may also contribute to the high mortality rates as some
treatment options, such as surgery, may not be practical due to poorer health and respiratory difficulties.
Lung cancer is commonly diagnosed at a later stage possibly because the major symptoms are masked
by a smoking history and no external symptoms to alert the patient. Therefore, patients do not report
symptoms to their physicians until more sinister symptoms develop at later stages. Only 16% of lung
cancers are diagnosed at stage 1, 27% at stage 2, and 57% are diagnosed at stage 3 or 4 [1]. The lack of
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early diagnosis rates are a major concern as late stage diagnosis for lung cancer has one of the poorest
survival rates for all cancers except liver and pancreatic cancer. The 5-year survival rate in patients
whose lung cancer is diagnosed at Stage 3 or 4 is only 4% [1], in contrast the 5-year survival for a stage
1 diagnosis is 56% [1]. The low survival rate for late diagnosis is due to the limited treatment options
available. Clearly, lung cancer would benefit from screening programmes to improve early diagnosis rates.
The evidence supports improving early stage diagnosis rates which will improve survival rates and lower
mortality rates as more patients have extensive treatment options available. Unfortunately, despite the
compelling evidence this has not been observed and 5-year survival has only improved from 12% to 18%
between 1975 and 2011 [1].
1.8 Lung Cancer Screening Programmes
To improve early diagnosis rates for lung cancer several screening trials have been assessed. These studies
identified high risk populations, using different criteria, and the participants were periodically screened.
There have been four main lung cancer screening trials, namely the United Kingdom Lung Screening
(UKLS), National Lung Screening Trial (NLST), Dutch-Belgian lung cancer screening trial (NELSON),
and Early Lung Cancer Action Project (ELCAP). The studies periodically screened high risk participants
using low-dose computed tomography (LDCT) because of its improved ability in comparison to x-rays to
detect small lung tumours at an earlier stage [23, 24]. However, it is imperative only participants who
would benefit from screening are selected, as with LDCT there can be anxiety and a fear of radiation
exposure, which lowered the willingness of patients to be screened [25].
The lung cancer screening trials are introduced.
1.8.1 NLST Screening Programme
The NLST programme evaluated whether LDCT, in comparison to x-rays, could diagnose cancer at an early
stage and reduce lung cancer mortality in high risk individuals [26]. If the NLST programme demonstrated
a cost-effective screening regimen that detected a high proportion of individuals with lung cancer while
limiting unnecessary screening then the trial would be considered for implementation on a national scale
funded by the government and managed care organizations [27].
In the NLST programme high risk participants were identified using an age and smoking history criteria;
participants were considered eligible for screening if they were current smokers aged 55-74 years with a
minimum 30 pack year smoking history; former smokers were also included if they met the same criteria and
had quit smoking within the previous 15 years [26]. The eligible high risk participants were randomised
with 26,722 selected for LDCT and another 26,732 selected for chest radiography and all participants
received annual screening for 3 years [26].
The trial reported a high positive screening rate with 39.1% of participants in the LDCT arm and 16%
in the radiography arm requiring further testing after screening reported abnormalities [26]. Unfortunately,
a high proportion of the additional testing was not necessary with 96.4% of participants in the LDCT group
and 94.5% in the radiography group having a false positive result [26]. This resulted in 7% in the LDCT
arm and 4% in the radiography arm having unnecessary invasive follow-up treatment [28]. The trial did
demonstrate the improvement using LDCT to screen participants in preference to the chest radiography;
indeed the LDCT group significantly lowered the lung cancer mortality rate by 20% (95% CI [6.8, 26.7])
in comparison to the radiography group [26]. There have been cost-effectiveness analysis studies of the
NLST programme and the results varied between studies. The cost-effectiveness of the study ranged from
a promising $2,500 per life-year saved to a less promising $269,000 per quality-adjusted life-year (QALY)
saved [27]. The results are quite variable because of variability in the volume of unnecessary disease free
individuals screened. The results vary across the US $100, 000 to US $160, 000 per QALY that is relatively
deemed acceptable [29, 30]. The NLST criteria reported a reduced lung cancer mortality, with a 10-year
survival between 18−25% [27] which is a large improvement upon the current 5-year survival rate. Studies
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indicate that the NLST programme would need to screen 320 patients using LDCT to identify one lung
cancer [27], while this is a high proportion of unsuccessful screening this improves upon an approximate
yearly prevalence rate of 0.1% for lung cancer [31]. Although, improving screening technology with quality
assurance [32] may reduce unnecessary follow-up screening of disease free individuals improving the lung
cancer capture rate and cost-effectiveness of the screening programme.
The trial showed annual LDCT screening of high risk groups could be beneficial [33]. Based on the
NLST results the “American Cancer Society (ACS), the American College of Chest Physicians (ACCP),
the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network
have now updated their clinical practice guidelines so that those who qualify for screening using the NLST
criteria may be eligible for annual screening” [27]. However, since the NLST results reported limitations
in some studies there are arguments “to maximize screening efficiency, results from more robust lung
cancer prediction models, which include variables beyond age and smoking history, may be helpful to guide
selection of patients for screening” [27].
1.8.2 UKLS Screening Programme
The UKLS programme evaluated LDCT to screen a population who were at high risk of developing lung
cancer [34]. The trial assessed whether lung cancer screening could be successfully implemented to improve
lung cancer diagnosis rates. Participants were screened using LDCT as evidence indicated this was the
leading procedure to identify early stage lung cancer [35].
The high risk participants were aged 50 to 75 years and had a risk exceeding 5% of developing lung
cancer in the next 5 years based on the Liverpool Lung Project Model [34]. This was the only trial that
considered additional factors other than age and smoking history to identify their high risk population
for screening. The study randomised half the participants to receive LDCT screening in comparison to a
control arm who did not receive screening [34]. The UKLS study initially considered 88,897 participants
which was reduced to 2,848 (12%) who were classified as high risk from the prediction model [34].
The trial screened 1,994 participants annually for 2 years, with 42 participants (2.1%) correctly di-
agnosed with lung cancer [36]. This is a higher diagnosis rate than the approximate UK lung cancer
prevalence rate [31] demonstrating that the trial successfully targeted screening to a high risk population.
Further, 28 (66.7%) participants were detected as being at Stage I and 8 (19%) at Stage II [36], a dramatic
improvement on the current early diagnosis rates for lung cancer. This allowed 91.6% of the early stage di-
agnosed participants to receive surgery [36]. The trial demonstrated some promising results costing £8466
per QALY gained [36] with net treatment costs per person of £60 [36] These results were promising in the
context of US $100, 000 to US $100, 000 per QALY [29, 30], and the cost of treatment is reasonable below
US $500 [37]. This highlights the fact lung cancer screening can be beneficial, cost-effective, and affordable
if targeted to the correct population. Although, the success of a trial needs to be reproducible because an
increase in unnecessary screening of disease free individuals will reduce the effectiveness of the screening
programme [38].
The screening programme demonstrated the potential of prediction models to identify a high risk
population for screening.
1.8.3 NELSON Screening Programme
The NELSON study selected participants for LDCT screening if they were male, aged 50-75 years, and
were former-smokers who had either quit smoking within the previous 10 years after smoking more than
15 cigarettes a day for at least 25 years, or were current smokers who smoked more than 10 cigarettes daily
for over 30 years [40]. These high risk participants were screened at baseline and after 1, 2, 4, and 6 years
[40].
The criteria identified 7,557 participants for screening. At the baseline screening, 196 (2.6%) of partic-
ipants had a positive result although 64.3% of these were determined to be a false positive [40]. The trial
is currently ongoing, with 3 years remaining in the study, with current results reporting the lung cancer
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detection rate was 0.9% [40], an improvement in comparison to a blanket screening approach where lung
cancer has a 0.1% prevalence rate.
1.8.4 ELCAP Screening Programme
The ELCAP programme was designed to evaluate the effectiveness of annual LDCT screening in comparison
to the current diagnosis procedures where a high proportion of lung cancers are diagnosed at an advanced
stage [41]. The study was targeted to individuals over 60 years with a minimum 10 pack year smoking
history [41] who received one round of LDCT screening.
A true positive lung cancer diagnosis was found in 2.7% (27 of 1,000) of eligible participants [41], an
improvement upon the capture rate in a blanket screening approach. The study found that annual screening
in the target population detected over 80% of lung cancers at Stage I [42, 43] in comparison to over 70%
commonly diagnosed at an advanced stage in current diagnosis treatment [41]. The study concluded that
LDCT could substantially improve early detection of lung cancer, decreasing mortality rates, provided the
correct target population was identified [41]. The screening programme increased survival by 0.1 years at a
cost of approximately $230 per increase based on costs for treatment and screening to identify lung cancer
[41]. The cost per life-year saved for one round of screening in the sample population was $2,500 [41].
These are reasonable results based on evidence suggesting screening programmes are effective if the cost is
limited to US $100, 000 to US $160, 000 per QALY [29, 30]. The study also determined the approximate
costs for treatment after diagnosis in USA would be $20,100, $23,000, $31,800-$32,700, and $25,900 for
each increasing stage at diagnosis [41] demonstrating how an earlier diagnosis will lower treatment cost.
Stage IV showed a slight decrease but this is because most treatment options are just to alleviate symptoms
at this advanced stage. Although, these results are not favourable as research indicates a cost exceeding
$500 can be problematic for patients [37]. However, these may not be a concern to patients in countries
with free or partially covered healthcare.
The study concluded that a single LDCT scan for high risk participants can be a cost-effective procedure
that is “likely to be within the range of practice and policy acceptability”.
1.9 Improving Screening Programmes
The independent screening programmes unanimously agree that LDCT is the preferred method to identify
early stage lung cancer. Identified participants were screened annually or biennial if multiple screenings
were conducted as this afforded the highest probability of capturing lung cancer in its infancy. The screening
programmes identified a high risk population to target resources because a blanket screening approach was
deemed impractical. All the screening trials restricted the population by age, with no-one under 55 being
screened. Smoking history was also a key marker for the majority of screening trials; screening heavy
smoking ever-smokers. The UKLS trial utilised the Liverpool Lung Project Model to identify high risk
participants.
The screening programmes displayed a higher prevalence rate in the high risk populations than observed
in the global population. This allows the screening resources to be targeted to a population that would
most benefit from periodic screening. However, there were conflicting results over the cost incurred in the
screening programmes with results ranging from $2,500 per life-year saved which was a promising result.
Other studies reported though the screening programmes required $269,000 per QALY. The results are
variable and across the estimated US $100, 000 to US $160, 000 per QALY that is acceptable for a screening
programme [29, 30]. The variability in the results can be attributed to the volume of disease free individuals
that would be screened, and considered for follow-up screening to identify one lung cancer incidence [38].
This can be evaluated by reviewing the screening guidelines in multiple sample populations. It can also
be improved by reducing unnecessary screening through better testing. Improved quality assurance of CT
scans may reduce the need for annual follow-ups [32] which will improve the ratio of disease free individuals
screened to identify one lung cancer. Reducing unnecessary screening is crucial as there can be uncertainty
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surrounding the cost of screening [39], hence improving the cost-effectiveness of screening programmes.
Based on the results screening programmes are being implemented with the NLST criteria identifying
participants for annual screening [27].
There is the potential to further improve screening programmes by reducing costs from unnecessary
screening and increasing true positive rates. This can be achieved by identifying a more appropriate
population for screening. Eligible participants could be identified by a prediction model, as seen in the
UKLS programme. These could identify participants at higher risk of developing lung cancer by considering
more in-depth patient information rather than merely an age and smoking history criteria.
1.10 Summary
Lung cancer is one of the leading cancers worldwide with 224,390 estimated new cases in 2016 in the
United States alone [1]. Lung cancer has a causal association with a smoking history, with 85% of new
incidences occurring in ever-smokers [4, 5]. Despite this smoking is still popular and there are over 1 billion
smokers worldwide [7]. Additionally, lung cancer diagnosis has a bleak survival rate; with a 17.7% 5-year
survival rate [1]. However, early identification increases the potential for curative treatment and improves
survival rates; with a 56% 5-year survival rate for diagnoses at Stage I [1]. Early diagnosis is problematic,
with no visual symptoms and common markers such as coughing, breathlessness, and chest pains common
in the ever-smokers and older population. Therefore, people do not normally report the symptoms until
more severe conditions, associated with later stages, develop. As a result different methods need to be
incorporated to capture early stage lung cancer.
Screening programmes can improve diagnosis rates by identifying high risk participants for annual
screening. The NLST and UKLS are two examples of lung cancer screening trials. While these trials have
successfully identified lung cancer in individuals, the cost-effectiveness, assessed by QALYs, of these trials
have been inconclusive [27] and vary either side of the acceptable screening and treatment costs per QALY.
Blanket screening for lung cancer is an unrealistic solution so a more robust criteria to identify a high risk
population for screening should be developed. A criteria that improves early diagnosis and true positive
rates while reducing unnecessary screening could be universally applied and improve available treatment
options and survival rates.
Prediction models could be used as a screening tool provided they demonstrate an ability to identify a
more appropriate population for screening. In the next chapter we introduce prediction models and how a
model’s ability as a selective screening tool should be evaluated.
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CHAPTER 2
Introduction to Prediction Modelling
2.1 Introduction
Prediction models estimate the risk of an outcome occurring within a specified time period. Prediction
models can be used to predict the likelihood of lung cancer presenting in an individual. These can be used
to identify the highest risk individuals who may benefit from screening, which may improve lung cancer
diagnosis and survival rates. Before a prediction model can be used by individuals and physicians the
model needs to be validated. This will assess the model performance and provide guidelines as to how the
model can be applied to identify a target population for screening.
The chapter will introduce prediction modelling and model validations. This will introduce the most
commonly used tests that assess the properties of a model, how the results of an assessment can be
interpreted, and identify which performance measures should be considered when validating a model.
These key tests will be encountered in previous validations of lung cancer prediction models and will be
used in future testing of prediction models in this project.
2.2 Objectives
To introduce prediction models and validation methodology the chapter will;
1. Introduce prediction modelling;
• Objectives of cancer prediction models.
• Applications of cancer prediction models.
• Requirements for a successful lung cancer prediction model.
2. Present the techniques to validate a prediction model;
• Introduce the different validation tests available, presenting the methodology and how to inter-
pret the results.
• Identify the key tests that should be conducted in a validation study.
2.3 Introducing Prediction Models and Their Applications
Risk prediction models predict the likelihood of an outcome occurring within a time period for an individual
with a particular predictor profile [44]. Prediction models are developed, in many cases, to guide healthcare
professionals and individuals to make informed decisions and determine the best course of actions, based
on the likelihood of the disease occurring [45, 46].
A major objective of prediction models is to identify a target population which can then be screened or
tested periodically. Prior to a selective screening criteria, based upon a prediction model being implemented
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as a public health tool, the selective criteria is required to demonstrate a good performance in validations
and trials. A model that has the potential to be a good selective screening tool would be expected to
robustly identify a target population for screening. This can be achieved by identifying a high proportion
of diseased individuals while limiting unnecessary screening of healthy individuals [47]. Then the screening
criteria will allow more benefits, from identifying true positives, than harms caused by false positives [44].
Indeed, in the UK, screening for a cancer will only be considered if a screening programme can demon-
strate a good performance by reliably detecting cancer, not causing too many false alarms, and being
cost-effective [47]. The demanding requirements has seen only three cancer screening programmes being
implemented in the UK; for bowel, breast, and cervix cancer. These screening criteria choose participants
based solely on age and gender; bowel cancer tests anyone aged 60-74 years, and breast and cervix cancer
target females aged 50-70 years and 25-49 years respectively [47]. The participants are then invited for
screening every 2-3 years [47]. A similar screening criteria has not been implemented for lung cancer;
indicating a blanket screening approach for everyone within a certain age bracket is not an appropriate
approach, despite most lung cancer cases occurring between 50-75 years [1]. Indeed, there is no current
lung cancer screening due to a “lack of a sensitive enough test”, a low proportion of cancers being identified,
and the high costs incurred [47]. However, costs and potential harms, such as radiation exposure, could be
reduced as new innovative tests are being designed. These include clinical trials to develop a non-invasive
breath test to detect lung cancer [48]. While these tests are being developed, current lung cancer screening
research is evaluating if it is possible to identify people at high risk of developing lung cancer by consid-
ering people who smoked or have contracted lung diseases such as COPD [47]. A prediction model could
combine these risk factors and additional measures to identify an even more appropriate target population
for screening which satisfies the UK screening guidelines.
Prediction models can also be used as an on-line risk calculator. This can then be used by the public
and physicians to evaluate an individual’s risk. Risk calculators have been created for many diseases and
was pioneered by the Gail Model for breast cancer [49]. Clinicians can incorporate the risk assessment
into routine screening [50]. An advantage of a risk calculator is the public become more aware of their
personal risk, which may prompt positive lifestyle changes to reduce their risk. The greater awareness can
also improve early stage disease detection rates as individuals report any relevant, concerning symptoms
to a physician earlier. Additionally, patients and physicians can open up a dialogue and make informed
decisions based on the risk estimate [51] which may include more frequent check-ups to monitor their risk
or to undergo screening.
While a promising prediction model can be beneficial a poor model that assigned inaccurate risks could
be problematic. It could cause disease free individuals to be unnecessarily screened and cause undue panic.
To determine the reliability of a model, which will identify both useful and unreliable models, they need to
be thoroughly evaluated. The model’s predictive ability should be evaluated in many different validation
studies to assess how it will perform as a risk calculator or selective screening tool in a variety of situations.
Alongside thorough testing, all potential models or screening criteria (whether age, smoking history or
previous lung diseases) should be compared in the same study [52]. This will allow an informed decision
about the leading selective screening criteria which identifies the most appropriate target population. The
different tests for model validation will now be presented, including how the results are interpreted, and
the key measures that should be considered for a thorough validation will be identified.
2.4 Introduction to Prediction Model Validations
The purpose of a validation study is to evaluate the performance of a prediction model [44]. The validation
evaluates a model’s ability to assign accurate risks to individuals and whether the model can successfully
assign a higher risk to diseased rather than disease free individuals. The results are commonly presented
through the calibration which evaluates the accuracy of risk predictions, discrimination which evaluates
the model’s ability to consistently assign higher risks to participants with the disease than without the
condition, and prediction rules which assess the model’s performance at a specific risk threshold while
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considering individuals with a predicted risk exceeding this threshold as high risk or as a target population
for screening.
There are different forms of validations that can be conducted; internal (using the original data in which
the model was devised), temporal (data from a new sample of the model building population), or external
(a new dataset with a different population). An internal validation is commonly conducted when a new
model is published. This will allow an indication of how the model will perform in practice. However, the
results of an internal validation may suggest the model performs to a higher standard than observed in
new populations as the model is being reviewed using the same population as the model was developed
[53]. This is defined as optimism [144]. There are techniques available to attempt to eliminate optimism,
in internal validations, with bootstrapping, jackknife, and cross-validation the most common methods [55].
A temporal validation considers participants who were excluded from the model building; however, these
participants often have a very similar patient profile as the model building participants. This is due to the
collected participants being grouped on certain conditions, whether age, exposure outcomes, or smoking
history. Therefore, there is still a chance of optimism in the temporal validation and excluding these
participants from model building could hinder the model as their evidence is not considered when building
the model. External validations offer the most reliable and robust indication into a model performance.
Here, the model is tested in a distinct population and if a model can consistently demonstrate a promising
performance in multiple external validations then it could be considered to aid medical professionals.
2.5 Model Calibration
Model calibration is a commonly reported measure to assess how well a model predicts the observed
incidence rate in the dataset [58]. This evaluates the extent to which a model predicts appropriate risks
for individuals. The calibration can be measured differently and can be shown in a calibration plot by
“plotting the observed proportions of events against the predicted probabilities for groups defined by ranges
of predicted risk” [142, 60]. The participants are grouped as the outcome is dichotomous, the outcome is
present or absent, so grouping participants based on their predicted risks for a set group size will allow
the observed rate to be continuous between [0, 1]. A perfect calibration would be observed on the plot as
a “y = x” line which indicates the observed incidence rates for each group was accurately predicted.
The most commonly reported method to assess model calibration is the Hosmer-Lemeshow Goodness-
of-Fit test [61]. This generates a p-value to evaluate the null hypothesis “the model does accurately fit
the observed results”. If the p-value is small it gives evidence to reject the null hypothesis. The Hosmer-
Lemeshow test is calculated for the number of groups, K, observed and expected incidence rates in each
group, O and E, number of participants in each group, N, and degrees of freedom, K − 2, as follows;
Hosmer =
K∑
i=1
(Oi − Ei)2
Ei × (1− EiNi )
(2.1)
There are some concerns using the Hosmer-Lemeshow test. The calibration results can vary depending
which size groups and how many groups are used to combine participants. The group size can be arbitrarily
chosen however this can lead to a large change in the Hosmer-Lemeshow p-value [56]. It is important the
correct group size is determined as a large volume of participants per group may not detect poor predictions
generated by the model, whereas too few participants per group makes it difficult to determine whether the
differences between the observed and expected risks are by chance or if the model is poorly calibrated [56].
Studies have recommended when applying the Hosmer-Lemeshow test the participants should be grouped
such that there are 10 participants in each group, therefore there will be N/10 total groups [56]. If the
null hypothesis is borderline rejected or accepted at p-value 0.05 then groups of similar sizes should be
considered. This will assess the trend as the p-values changes as the group sizes changes to determine if
the model has a good calibration. This approach will be taken when applying the Hosmer-Lemeshow test
in any validations.
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The model calibration is the key measure when assessing the ability of the model. If the model consis-
tently reports a good calibration then there can be confidence the model would not generate misleading
risks and could be considered as a public tool.
2.6 Brier Score
The Brier score is an additional measure to assess the model calibration [57]. This measures the squared
differences between the estimated risk and the binary outcome whether the disease is present or absent in
the participant. The score is calculated by;
1
N
N∑
i=1
(oi–ei)
2 (2.2)
where N is the number of participants in the dataset with an observed outcome ‘o’ which is either 0 for a
participant without the disease or 1 when the condition is present; and the estimated risk of developing the
disease ‘e’. A smaller Brier score indicates a better calibrated model with a perfect model reporting a Brier
score of 0. A score of 0.25 would indicate a non-informative model in a population with 50% incidence
[57].
There are some limitations to the Brier score. Unlike the Hosmer-Lemeshow test the Brier score requires
personal judgement on whether the model has a good calibration. Therefore it is not the preferred test
to validate model calibration and infrequently reported. However, it has an advantage over the Hosmer-
Lemeshow test as there are no requirements for the participants to be grouped so there are no concerns
about variable results. Additionally, it is a good comparison between multiple models evaluated in the
same population.
In validations conducted in this project the Brier score will be reported as it can offer a good comparison
between multiple models. This measure will be particularly useful if there are variable Hosmer-Lemeshow
results for different size groups and it is unclear which model has the best calibration.
2.7 Model Discrimination
Discrimination is a measure of the model’s “ability to distinguish between patients with and without the
outcome” [58]. A successful model will assign a higher risk to the majority of participants with the disease
rather than disease free participants.
Discrimination can be presented on a plot of the sensitivity, the proportion of individuals diagnosed
with lung cancer with a higher risk than a specific risk threshold, plotted against (1–specificity), where
specificity is the proportion of disease free individuals with an estimated risk lower than the considered risk.
This is conducted at every risk threshold. The plot is defined as the Receiver Operating Characteristic
Curve. Discrimination is measured by the Area Under the Receiver Operating Characteristic Curve (AUC
or AURoC). The AUC result will be a value between 0.5 – 1.0; with a higher result indicating a stronger
discrimination. A perfect result of 1 would mean all individuals with the outcome were assigned a higher
risk than all the disease free individuals. Whereas a result of 0.5 would indicate the model offered no better
than chance at assigning a higher risk to participants with the disease than without the disease; this would
be an ineffective model to discriminate between individuals.
For dichotomous outcomes, such as with or without lung cancer, the AUC is equivalent to the con-
cordance index. The concordance index, also referred to as the c-index, is a measure of the proportion of
all the possible pairs (one participant with or without the disease) where the estimated risk of disease is
higher for the individual with the condition [62].
Discrimination will indicate whether the model could be a successful screening tool and is a good
comparison between models. A result exceeding 0.8 indicates a model that could be a promising selective
screening tool [51] although slightly lower results 0.70−0.80 may also indicate a successful model. However,
12
the AUC alone is not beneficial to medical professionals as while it demonstrates the potential of a model
it does not indicate how the model should be applied as a selective screening tool. A selective screening
criteria using a prediction model needs a fixed risk threshold where everyone exceeding this risk would be
high risk participants considered for screening. To assess this, prediction rules have to be considered.
The AUC is an important measure that should be reported, as it is a good comparison between models
and an overview on how they distinguish between diseased and disease free individuals.
2.8 Prediction Rules
Prediction rules are a series of tests to assess a model’s ability at a defined risk threshold. This reviews
whether the model robustly identifies a high risk population that would be benefit from screening. At the
specified risk threshold any participants with a risk exceeding this threshold would be considered a target
population for screening.
The prediction rules can also be evaluated for additional selective screening criteria. Participants
satisfying the criteria would be a person of interest for screening. Therefore, this allows the prediction
rules to be compared between prediction models and alternative selective screening criteria so an informed
decision can be made into which would be a better approach to identify high risk participants.
There are many different measures to report the prediction rules which are now presented.
2.8.1 Sensitivity and Specificity
A key measure of performance are the sensitivity and specificity rates. At the pre-specified threshold the
sensitivity is the proportion of participants with the disease that have a risk exceeding this threshold [62],
and the specificity is the proportion of participants without the disease that have a risk lower than the
threshold [62]. Intuitively, as the selected risk threshold is increased, a large volume of diseased and disease
free individuals would have a risk below the threshold; this would lower the sensitivity but increase the
specificity. The converse also holds if a lower risk threshold is considered.
Clearly a higher performing model would have both a high sensitivity and specificity. Unfortunately,
the performances of these two measures trade-off each other so a risk threshold needs to be determined
that is a useful compromise between both measures. Alternatively, a sensitivity or specificity rate can be
predetermined and the risk threshold selected that allows this predetermined rate. Then the leading model
or criteria would have the highest performance for the other measure.
The sensitivity and specificity should be reported in a validation study to offer a review of the prediction
rules.
2.8.2 Youden ‘J’ Index
The Youden Index or J Index is a simple but effective measure to evaluate the relationship between the
sensitivity and specificity [62]. The test combines these two values into a single measure as follows;
J = senstivity + specificity − 1 (2.3)
This generates a result between 0 “if the test reports the same proportion of positive tests for both
control and diseased groups” [63] and 1. A higher result means a higher combined sensitivity and specificity;
this indicates a better performance. The Youden Index assumes an equal weight between capturing a
participant with the disease as excluding a participant without the disease. In some instances it may be
more beneficial to capture participants with the disease or exclude disease free participants. There is no
measure that considers an unequal weighting for the sensitivity and specificity rates as this would be down
to the medical professionals own judgement.
For a model to be used as a selective screening tool an optimal or very good risk threshold should be
identified as here the model would have the greatest benefit. The Youden Index can be a good indication
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of where the model has this optimal performance. This simple measure will be considered in the validation
of the models to identify optimal risk thresholds and compare between models.
2.8.3 Positive and Negative Predictive Values
The Positive and Negative Predictive Values (PPV/NPV) can also be presented when evaluating the
prediction rules. The PPV measures the percentage of true positives (participants with the disease)
amongst everyone assigned a risk above the specified threshold. The NPV measures the percentage of true
negatives (disease free participants) for all participants below the threshold. These values are calculated
as;
PPV =
NumberofTruePositives
NumberofTruePositives+NumberofFalsePositives
(2.4)
NPV =
NumberofTrueNegatives
NumberofTrueNegatives+NumberofFalseNegatives
(2.5)
These values, like sensitivity and specificity, are commonly reported together and a successful prediction
rule would offer a good balance between the two measures.
The difficulty with these measures is finding an optimal performance between the PPV and NPV as
they trade-off each other. A viable solution for comparison between screening criteria would be to fix
one measure at a predetermined rate and assess which screening criteria would offer the highest result for
the other measure. However, it is unlikely when considering a model as a selective screening tool, that
medical professionals would require a predetermined PPV or NPV rate. Additionally, the PPV and NPV
rates can be misleading as they are dependent on the prevalence rate in the dataset [64] and unless tested
in a population cohort dataset the results may be unrealistic. This is not an appropriate measure in a
case-control dataset as there is a higher prevalence rate observed. Additionally, the changing prevalence
rates across the datasets makes comparisons between datasets difficult. Finally, the measures cannot be
combined so they are unable to be utilised to identify an optimal risk threshold for a model or compare
between models.
Overall, the PPV and NPV can be useful measures but should not be selected over sensitivity and
specificity as these rates offer a clearer indication into the model performance for health decision makers
considering a model for a selective screening tool. The measures would be most effective if either the PPV
or NPV were restricted to a specific level; then a comparison of the other measure can be conducted between
models. Unfortunately, determining an appropriate level is difficult and the results can be misleading by
high prevalence rates in datasets which would not be replicated in real populations. For these reasons, the
PPV and NPV rates will not be considered as key measures in any validations conducted in this project.
2.8.4 Positive and Negative Likelihood Ratios
The positive and negative likelihood ratios (PLR/NLR) combine the sensitivity and specificity rates and
can be calculated by;
PLR =
Sensitivity
1− Specificity (2.6)
NLR =
1− Sensitivity
Specificity
(2.7)
(2.8)
The PLR is the ratio of the probability being considered high risk (above the threshold) when with the
disease versus the probability of being considered high risk when without disease. This informs as to how
14
much more likely a participant considered high risk has the disease [65]. The NLR is a measure of how
much more likely a participant considered low risk is disease free [65].
The ratios can be calculated in case-control datasets where there is a higher incidence than cohort
studies as the sensitivity and specificity measures remain unaffected. This means the likelihood ratios can
be compared between case-control and cohort studies as they are unaffected by prevalence rates.
The PLR and NLR can be important measures for clinicians as a model that has a higher probability
of identifying diseased individuals for screening would be preferred. Indeed a higher PLR would indicate a
better model. However, this result should not be evaluated alone and is required alongside the sensitivity
and specificity results. The PLR may be misleading, if not reported with the sensitivity and specificity,
as a prediction rule may have a higher value by excluding the majority of disease free participants from
screening but only identifying a few diseased individuals. The NLR is not an essential measure for clinicians
as this does not measure the benefit against the potential harms of the trial.
In validations conducted in this study the PLR will be reported as this informs how much more likely a
participant considered to be high risk has the disease. This is a good measure of the benefits of capturing
cases against the harms of screening controls if implementing a model as a screening tool.
2.8.5 Model Accuracy
The model accuracy evaluates what proportion of participants were correctly categorised; individuals with
the disease are correctly assigned a risk exceeding the threshold and disease free individuals categorised
below this risk threshold. The model accuracy is measured by;
ModelAccuracy =
TruePositiveCount+ TrueNegativeCount
NumberofParticipants
(2.9)
The result will range from [0, 1]; with a higher performing model achieving a result closer to 1. This can
provide a good comparison between models or criteria as physicians would desire a higher model accuracy
which would indicate the screening criteria is targeting a more appropriate population.
However, the model accuracy can be a misleading statistic as it is influenced by the disease prevalence
rate which can lead to distorted results [66]. The more prevalent the disease the higher weighting is applied
to the sensitivity, conversely a lower prevalence rate will see the model excelling at a higher specificity.
In a case-control dataset the high prevalence rate will be reflected in the model performing well at a
lower risk threshold where the model accuracy is skewed by the high sensitivity which counter balances
a poor specificity. This may not be observed if the model is applied in real populations due to the lower
prevalence rate. Additionally, the recommendation to apply the model where a high sensitivity is observed
will translate into high screening rates of disease free individuals and the screening criteria may not be
economically viable.
The model accuracy will not be considered when conducting validations. This is because it will add
to an already large volume of statistics to analyse the same prediction rule, the results can be misleading,
and it is not an essential measure for physicians selecting a screening tool.
2.8.6 Net Benefit Ratio
The Net-Benefit Ratio evaluates the relationship between the true positive and false positive rates at the
risk threshold. This test considers, somewhat simplistically, the importance of a correct diagnosis over the
potential harm of false positives. The net benefit ratio, at a risk threshold w, is calculated by;
Ratio =
TruePositive− (w × FalsePositive)
NumberOfParticipants
(2.10)
Here a risk threshold of 20%, resulting in a w score of 0.2, means identifying a true positive is five times
more important than a false positive. A result exceeding zero is a good net benefit ratio, with a higher
result indicating a more successful model.
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The net benefit ratio is rarely presented as the other tests provide clearer information about the propor-
tion of diseased participants screened and disease free participants rejected. Additionally, the importance
of a true positive in comparison to a false positive seems arbitrarily chosen by the risk threshold whereas
physicians may have a defined acceptable volume of false positives screened to identify a true positive.
Once a specific w can be determined then this would be a very useful measure; however since this has not
been determined for lung cancer then the model accuracy will not be considered in validations.
The difficulty with this measure lies in determining a good trade-off between the sensitivity and speci-
ficity. There is often not a clear rule of acceptable sensitivities for different specificity results, which would
allow an appropriate w to be determined. It is often much clearer to determine an acceptable rate for
the sensitivity (high enough for the model to have an impact in identifying the disease) or specificity
(high enough such that the screening is economically viable). Once one of these are determined and fixed,
then the other measure can be reported, which can infer whether the model would be successful and a
comparison between models.
2.8.7 Net Reclassification Index
The Net-Reclassification Index (NRI) is a measure between the performances of two different selective
screening criteria. One criteria offers the baseline performance and the NRI evaluates if the second criteria
offers an improvement. The NRI evaluates how many participants would be correctly or incorrectly reas-
signed as high or low risk. The reclassification of every participant for 2 different criteria can be observed in
Table 2.1 with green values representing a good reclassification and red a poor reclassification for Criteria
2 in comparison to Criteria 1.
Criteria 1 Criteria 2
< Risk Threshold ≥ Risk Threshold
Disease Free
< Risk Threshold x111 x112
≥ Risk Threshold x121 x122
With Disease
< Risk Threshold x211 x212
≥ Risk Threshold x221 x222
Table 2.1: Reclassification Table between Two Models at Specified Risk Thresholds
The NRI can then be calculated from the reclassification table;
NRI =
(
x121 − x112
NumberDiseaseFree
)
+
(
x212 − x221
NumberWithDisease
)
(2.11)
The NRI results are presented in terms of the improvement criteria 2 demonstrates over criteria 1, and
the result will range from [−1, 1]. A result greater than 0 indicates criteria 2 had an improved model
accuracy and would correctly reclassify more participants than incorrectly reclassify them. A result below
0 indicates the inverse. As the result tends closer to 1 or -1 the reclassification change occurs in more
participants.
While this is a good measure to compare between two screening criteria there are better measures
to assess a models ability as a selective screening tool. Additionally, it is more insightful for physicians
to understand the model’s performance in terms of true positives, false positives, and overall benefit
rather than a comparison between two different criteria. Therefore, the NRI will not be considered in any
subsequent validation studies.
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2.9 Summary
The chapter introduced prediction models and how they can be used to predict an individual’s risk or as
a selective screening tool. These can be beneficial; creating awareness of ones’ risk can promote lifestyle
changes to reduce risk and a selective screening tool can help identify high risk participants that would
benefit from lung cancer screening.
Before models can be considered for implementation they need to be validated. This will give a strong
indication into the model’s potential for medical decision makers who can then make an informed choice
on whether to utilise the model. There are many different measures to validate a prediction model and the
key measures have been identified. Calibration, measured through the Hosmer-Lemeshow test and Brier
Score, is the key measure to determine if a model is to be a good individual risk calculator. This quantifies
how successfully the model predicts the observed outcome rates. The AUC is an effective measure for the
model discrimination. This gives an indication into how well the model assigns a higher weight to diseased
individuals than disease free individuals for every pair in the dataset. This is commonly reported and is a
good measure for model comparison. The prediction rules should be tested to assess how the model would
perform as a selective screening tool. These measure the model’s performance at a specific risk threshold;
participants with a higher risk than the threshold would be considered for screening. The key measures
identified were the sensitivity (percentage of cases identified), specificity (percentage of controls rejected),
Youden Index, and PLR; these are commonly reported and essential measures to evaluate the prediction
rules. They allow the medical professionals to determine how a model would perform as a screening tool.
Evaluating prediction models with the identified validation tests would allow an informed decision into
which model would be the most effective screening tool. These measures were also selected as they are not
influenced by the prevalence rate; evaluating the models in case-control datasets may lead to misleading
results which would not be reflected in implemented selective screening trials.
The identified measures; calibration, discrimination, sensitivity, specificity, Youden Index, and PLR;
will be encountered in the systematic review of the lung cancer prediction models and used when validating
prediction models in this project.
Now the measures to evaluate a prediction model have been identified a systematic review of published
lung cancer prediction models and their performance in validations will be conducted. This will evaluate
the models’ calibration, discrimination, and prediction rules, indicating how successful they predict an
individual’s risk or identify a high risk population for selective screening.
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CHAPTER 3
Systematic Review of Lung Cancer Prediction Models
3.1 Introduction
The review will identify all published lung cancer prediction models and their validation results. This can
then assess the performance of models if they were implemented as a selective screening tool and if there
is a leading selective screening criteria that could be used by medical professionals. The review will offer
recommendations into how leading models should be implemented in selective screening trials based on
synthesising their evidence from multiple published validations. The review will also assess the current
standard of validations for lung cancer prediction models; highlighting any concerns with their reporting
and identifying how the validations should be improved to allow a clearer understanding of the models’
performance.
The systematic review outline was presented at the 2014 and 2015 International Lung Cancer Consor-
tium (ILCCO) conferences and published in an article [67].
3.2 Objectives
The systematic review chapter objectives are:
1. Present the systematic review search criteria.
2. Conduct a systematic review of published lung cancer prediction models.
3. Identify and present all published lung cancer prediction models and their performance in validations.
4. Present how the prediction models have been devised, the purpose of the models and any limitations
with the model design.
5. Synthesise all the evidence as presented in validation studies of prediction models to evaluate their
predictive ability.
6. Assess limitations with the current reporting of lung cancer prediction models and how these limita-
tions can be addressed.
7. Provide recommendations into how leading models could be optimally used in selective screening
trials.
3.3 Search Criteria
The key search terms and search strategy used to conduct a comprehensive systematic review are presented.
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3.3.1 Search Terminology
To identify all published lung cancer prediction models and validation studies in the systematic review key
search terminology was defined. The relevant articles were identified through a combination of:
1. Lung cancer terminology
2. Prediction model terminology
3. Known prediction model titles
The lung cancer terminology was identified using a medical thesaurus; the Medical Subject Headings
(MeSH) database [68].
Next prediction model terminology was identified. The key terms were identified through the most
commonly used words and phrases in a key lung cancer prediction model validation article. The article
was the “Comparison of discriminatory power and accuracy of three lung cancer risk models” by AM
D’Amelio Jr et. al [69]. The most common terms in the article were identified using the TerMine database
[70, 71]. More than 500 search terms were returned and those were then reduced to the highest and most
relevant terms for prediction models.
The final search term was the names of known models. Incorporating the model titles into the search
assisted in identifying any validation study that evaluated the named model.
The exhaustive list of search terms is presented;
Lung terminology Prediction model terms Model titles
Lc Model Bach
Cancer of the Lung Risk Model Liverpool Lung Project
Lung Cancer Risk LLP
Neoplasms, Lung Cancer risk Spitz
Neoplasms, Pulmonary Incidence rate Two-Stage Clonal Expansion
Pulmonary Cancer Risk prediction TSCE
Pulmonary Neoplasms Risk-prediction model
Lung tumours Absolute risk
Carcinoma, Non Small Cell Risk estimate
Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Carcinoma Oat Cell
Oat Cell Carcinoma
Small Cell Carcinoma
Table 3.1: Search Terms for Systematic Review
Using the above terms the following combinations were searched using a whole text search in the on-
line databases with an OR separating all terms under the same heading and an AND between different
headings.
1. Lung terminology and Prediction model terms.
2. Model titles and Lung terminology.
3. Model titles and Prediction model terms.
4. Lung terminology and Prediction model terms and Model titles.
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3.3.2 Electronic Databases
Upon identifying the key search terms, the appropriate databases to search for the articles were determined.
Lung cancer prediction models are likely to be published in medical (cancer and lung cancer) journals so
an exhaustive search of the follow medical databases was conducted;
1. Applied Social Sciences Index and Abstracts (ASSIA) via ProQuest
2. CINAHL via EBSCO
3. Cochrane library
4. Medline via WoS
5. Web of Science
3.3.3 Hand Searching of Key Journals
The next stage searched key medical and lung cancer journals. This aimed to identify recent publications
or publications in press that would not be identified in the electronic databases. PubMed PubRefiner
was used to identify the key journals with recent publications for a specific search term. “Lung Cancer
Prediction Models” was searched and the journals with the highest count of relevant publications since
2013 were included;
1. Annals of Thoracic Surgery
2. BMC Cancer Journal
3. British Journal of Cancer
4. Clinical Lung Cancer Journal
5. International Journal of Radiation Oncology
6. Lung Cancer Journal
7. PLoS One
The journal’s issues between 01/01/2013 and 01/07/2014 were manually searched which coincided with
the time frame of the review. Early view contents were also searched to identify any relevant articles in
press.
3.3.4 Grey Literature
A grey literature search was conducted in Google Scholar searching articles from 01/01/2013 till 01/07/2014
to identify new publications that may not be returned when searching the electronic databases.
3.3.5 Bibliography and Citation Search
After the inclusion criteria (Section 3.3.7) identified the relevant articles for the systematic review, a
citation and bibliography search was conducted on each article. This aimed to identify additional articles
that may have been missed in the original search. The bibliography search on validation studies would
identify the referenced original model if previously undiscovered. Additionally, citation searching on the
original model article would assist in identifying all validation studies that include the model.
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3.3.6 Author Contact
Author contact was not conducted to identify articles as completed models and validations would be
successfully published. Instead the objective of our systematic review were presented at international
conferences, including ILCCO, to allow authors who were in the process of publishing new models or
validation studies relevant to our research to contact us to be included in the systematic review. However,
any articles published close to the project completion on 01/10/2106 would only be presented as a footnote
of review.
3.3.7 Inclusion Criteria
Once the searches were conducted any article was included provided it satisfied all of the following criteria;
1. A model was proposed or validated that can be used to predict the risk of lung cancer incidence or
absolute risk (considering competing risk of death) at an individual level.
2. The full article was obtained in English.
3. The paper was published since 1985.
4. A human population was considered to create or validate a model.
5. The model created/validated does not only incorporate patients already targeted for primary care
using symptomatic predictors or a survival model for post-diagnosis.
For studies that only validate a prediction model and do not propose a unique model the following criteria
will also have to be satisfied;
6. The article provided statistical results that assess at least one published model’s predictive power.
7. A case-control or cohort study was used to validate the published lung cancer prediction model.
3.3.8 Outcomes Measured for Review Objectives
The objective of the systematic review was to present how the model was devised; review the model building
population, the purpose of the model and a summary of the variables included in the model.
Additionally, all validation results for the lung cancer prediction model were presented. The validations
evaluated the model calibration, discrimination and prediction rules and the most common measures were
presented in Section 2.4 and included in summary tables.
3.3.9 Data Collection
For each stage of the search the article collection and exclusion process was detailed.
3.3.9.1 Storage
References for the articles were stored using EndNote. This allowed articles to be excluded from the
systematic review in accordance with the inclusion criteria. A safety backup database was maintained
while the review is being conducted between 01/07/2014 to 01/10/2015.
3.3.9.2 Study Selection
Studies were collected if they satisfied the inclusion criteria.
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3.3.10 Data Analysis
The model design and all validation results will be reported through tables and discussion. The results
were analysed to review how successful the model has been when validated, the model performance in
comparison to other models and how successful the model would be as a selective screening decision tool.
This allowed an informed decision into the leading models and the potential of published lung cancer
prediction models to be used by physicians.
3.3.10.1 Study Quality
The study quality was not used to include or exclude papers from the systematic review. However, this
is an integral part of reviewing how lung cancer prediction models have been developed and validated.
Studies included in the systematic review were critically appraised with the population size and study
design examined. This critiqued the population upon which the model was devised and the credibility of
the dataset used to validate the prediction models. These were discussed for each model and the study
quality was presented in tables.
3.3.10.2 Data Extraction
Data extraction on the model design and performance results was reported and discussed for each model.
A series of tables throughout the review present the key information to allow comparisons of the model
designs and validation results.
3.3.10.3 Synthesis – Meta Analysis
A meta-analysis was not conducted in this review. All of the results were presented separately and reviewed
as there was no advantage to synthesising their evidence for the objectives of the systematic review.
3.4 Search Results
The electronic and hand searching stage of the systematic review was completed by 01/07/2014. The elec-
tronic search found 1,365 papers which were subsequently reduced to 66 articles after excluding duplicates
and irrelevant articles based on the title and abstract. The remaining 66 articles were assessed at full article
stage. 16 articles were not available in full because they were conference abstracts or letters to editors and
another 24 did not publish or validate a lung cancer prediction model. A further 5 articles were rejected
as they considered patients after diagnosis or symptomatic patients in primary care. Hand searching key
journals discovered 1 additional article and the bibliography and citation search on the current 22 articles
identified 4 new papers. The 66 articles reviewed at the full article stage were independently replicated by
supervisor Dawn Teare in December 2014, with total agreement, in preparation for the systematic review
article.
1. Epidemiological Models - basic information
2. Epidemiological and Clinical Factors Models - require some form of testing
3. TSCE Models - only consider one risk factor to measure association levels.
All models across the three categories were considered and reported in the review.
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Database Search: 1,360
Duplicates and irrelevant: 1,294
Full articles assessed: 66
No full article, presentation abstracts: 16
Author Contact: 3 Do not propose or validate model: 24
Symptomatic patients/Late stage model: 5Hand and citation searching: 5
Final Inclusion: 29
Epidemiological Model Articles: 12 Non-Epidemiological Model Articles: 17
Figure 3.1: The Systematic Review Results Process
This allowed new models that were not published to be included if they were published before 01/10/2015.
This identified the PLCOM2014 Model [82] paper published in December 2014 and the Pittsburgh Predictor
[85] published in March 2015. It also allowed one additional validation paper to be included in the study
[83]. After completing the search strategy, 29 articles were included in the systematic review.
The systematic review was completed by 01/10/2015 and any subsequent articles were not included.
If any additional papers were published after this date but before the expected submission of 01/10/2016
they were included as a footnote to the project.
The articles were subdivided into epidemiological and non-epidemiological (clinical and Two Stage
Clonal Expansion) models. Epidemiological models were defined as models that used only readily available
information such as age, gender and smoking history. Non-epidemiological required a clinical assessment
such as CT scan or blood test. The final set of non-epidemiological models are Two Stage Clonal Expansion
(TSCE) models, these commonly use one risk factor to determine incidence rates in a population but can
be applied at an individual level. The models and validations are presented in these three different groups.
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3.5 Epidemiological Lung Cancer Prediction Models
There were 12 epidemiological model articles identified, including 9 papers that published original models.
The identified epidemiology models are the Bach, Liverpool Lung Project, Spitz, African-American, PLCO,
PLCOM2012, PLCOM2014, Hoggart and Pittsburgh Predictor models.
These models are presented separately including their validation results. The model summaries and
validation results are also present in 4 tables; these present the model variables, building dataset description,
model results and a summary of model validation tests conducted.
3.5.1 Liverpool Lung Project Model
The Liverpool Lung Project (LLP) (Cassidy et al 2008) model was published in 2007 to estimate the risk
of lung cancer incidence occurring in an individual within the next five years. Risk of developing lung
cancer was modelled by a multivariate conditional logistic regression. The model was devised in a UK
case-control population matched by age and gender. The model uses UK population specific lung cancer
incidence rates stratified by age and gender in the prediction model. This could limit the model’s success
in different countries where the incidence rates may differ. However, considering the population specific
age and gender incidence rates aims to limit concerns with matching over these variables. The model also
considered diagnosis of a prior malignant tumour, smoking duration, pneumonia, asbestos exposure and
family history of lung cancer. The model is only applicable to people aged 40-80 years as the incidence
rates stratified by age and gender were only provided for this age range. The model is applicable to all
people in this age range; whether they are never- or ever-smokers [72].
The model was internally validated in the article using a 10-fold cross validation in an attempt to
eliminate optimism [72]. The internal validation reported an AUC of 0.71 which was a reasonable dis-
crimination. The internal validation also evaluated the prediction rules. These were reviewed at 2.5%
and 6% risk thresholds and the sensitivity and specificity were reported. At 2.5% threshold the sensitivity
and specificity results were 0.62 and 0.70 respectively. These results are promising, which was expected
as the model reported a good overall discriminative ability, highlighted by the AUC result. At the 6%
threshold the sensitivity was 34% while the specificity was 90%. This would allow the prediction model,
if implemented as a selective screening tool, to remove a high proportion of lung cancer free individuals
from unnecessary screening; a benefit if the screening programme objective was to reduce unnecessary
screening costs. The ability to still capture 34% of individuals with lung cancer while limiting screening
of disease free individuals is an advantage of the model. However, the results should be verified in an
external validation to allow a stronger understanding. Additionally, validating the model in a case-control
population often leads to enhanced validation results as the cases are commonly at an advanced stage and
have an enhanced risk.
The LLP model was validated in five distinct datasets and the results showed a similar level of per-
formance to the internal validation. One external validation [69] evaluated the model performance using
4,900 case-control study participants in a US sample population. This provided an opportunity to eval-
uate how the model performed in a distinct population while considering UK age and gender specific
lung cancer incidence rates. The AUC had a slightly poorer performance at 0.69 in comparison to the
internal validation; however, the model still performed well when considering the prediction rules. The
sensitivity and specificity rates were reported at the 2.5%, 5% and 7.5% thresholds for 5-year risk. The
model reported similar results at the 2.5% risk threshold as the internal validation, with a sensitivity and
specificity both of 0.67. This represents a good trade-off between the sensitivity and specificity highlighted
by a Youden’s (J index) score of 0.33 in comparison to 0.32 in the internal validation. At 5% risk, the
sensitivity dramatically reduced to 45.5% meaning over half of all individuals with lung cancer would not
be screened and the J index reduced to 0.304. This trend continued at 7.5%, where a very low sensitivity
of 31.2% was reported, although the specificity exceeded 90%, which resulted in a J Index of 0.235. The
external validation demonstrates that at the low 2.5% threshold the model would be able to capture a high
proportion of individuals who develop lung cancer, which may improve diagnosis and survival rates for lung
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cancer. In contrast, if a selective screening programme had a limited budget, then a high risk threshold of
6% (internal validation) or 7.5% would allow the model to avoid screening over 90% of controls.
The LLP model was validated in another article [73]; where the model was validated in three large
datasets. The studies collected were case-control and prospective population cohorts that were based
across Europe and North America. The results varied between studies but suggested that the LLP model
has strong potential as a selective screening criteria. The three AUC results were 0.67, 0.76 and an
impressive 0.82 in the large population-based prospective study cohort of 7,652 patients. However, this
was a Liverpool population similar to which the model was devised. In this cohort the sensitivity and
specificity rates at the 2.5% threshold were 74.3% and 67.4% respectively, which combine to give the
highest recorded J-Index for the LLP Model at 0.42; a very strong result. The model also reported a model
accuracy of 67.8% in the cohort. The results were very promising and the model’s ability to perform to a
high standard in a population cohort demonstrates its potential for a selective screening trial. The model
reported good results in the other studies although they were not as high, which are presented in Table
3.3. The difference between the three datasets indicate the model cannot perform to the same standard in
populations outside of Liverpool or the UK.
One final external validation was conducted [74]. This used a case-control study with 1,275 participants
and reported the sensitivity and specificity rates. The results were slightly poorer and were validated at
the 5.12% risk threshold. Here, the model reported a sensitivity of 49.9% but a specificity of 79.8%. The
calibration was not formally reported but the model recorded a “moderate overall calibration and improved
accuracy at higher values of predicted risks” [74].
Based on the success of the LLP Model in validation studies the model has been evaluated as a selective
screening tool in a screening trial. The trial is reported in Section 1.8.2. Participants were considered to
be at high risk and recommended for screening, if their risk exceeded 5%. At this risk threshold the model
would maintain a specificity of approximately 45-50% for a specificity around 75-80% based on reported
validated results. This level of performance would result in the LLP Model reporting a Youden’s Index
0.25, which is a good result.
Across studies, the AUC was reasonable with internal and external results ranging from 0.67 to 0.76
indicating a good discrimination. This was surpassed by an AUC of 0.82 in one validation, although
the validation and model building data were both samples from Liverpool populations where the UK age
and gender specific incidence rates are relevant. A slightly lower performance was observed in validations
conducted outside of the UK. Based upon these findings the model should be tested in non UK cohorts
to assess how successfully these can be used in different populations. Additionally, the calibration has
not been adequately tested and needs to be more comprehensively assessed. At this stage it is clear that
the model has potential but there is room for improvement and more thorough validations to assess the
calibration and differences between UK and non-UK populations.
3.5.2 Spitz Model
The Spitz Model (Spitz et al 2007) predicts one-year absolute risk of lung cancer. The logistic regression
model calculates an individual’s likelihood of developing lung cancer within one year and the competing risk
of mortality without a lung cancer diagnosis. The model is applicable to anyone; never- and ever-smokers.
While individuals are required to be at least 20 years of age, lung cancer rarely presents at younger ages
so this is not a limitation of the model. Therefore, versatility of the model to be applicable to everyone
older than 20 years of age is a key advantage.
The model was devised with 3,852 case-control participants matched by age, sex and smoking status
collected from the USA [75]. To avoid concerns with matching; age and gender lung cancer incidence and
death rates were incorporated into the model by using the SEER rates. The SEER rates are the observed
incidence rates across the USA. Smoking status is incorporated into the model using gender-smoking
incidence groups.
The dataset was split into a model building set (75%) and an external validation set (25%) and three
distinct models were devised for never, former and current smokers. These consider different variables in
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different logistic regression models. Ideally, the model building dataset would include all the participants
to allow as much evidence as possible to be included when devising the model. Then the Spitz Model could
be validated internally and subsequently assessed in external validations.
The calibration and discrimination were measured in the external validation in the original article [75].
The validation results were presented separately for the never-, former- and current-smoking models. For
the never-smokers model the model reported a good calibration with a Hosmer-Lemeshow p-value of 0.777.
However, the never-smoker model reported a poor AUC result of 0.57 (95% CI [0.47, 0.66]) which includes
0.5; suggesting the model has no better than chance in assigning a higher risk to an individual with lung
cancer than an individual who is disease free. The results slightly improved in the former-smokers model
with a good calibration (p-value 0.712) and an improved AUC of 0.63 (95% CI [0.58, 0.69]). However,
the AUC result does not suggest the model is a robust tool to distinguish between individuals with or
without lung cancer. Finally, the current-smokers model was also well calibrated (p-value 0.688) but
reported another poor AUC of 0.58 (95% CI [0.52, 0.64]). Across the three distinct models for different
smoking statuses there was a reoccurring pattern. The models were well calibrated indicating that the
model could be used to provide accurate risks for individuals. However, the model reported a very poor
discriminative ability suggesting the model would have a limited ability to identify high risk participants
for screening. However, this could be more extensively validated by evaluating the prediction rules, which
was not conducted in the article in which the Spitz Model was presented.
The Spitz Model was externally validated [69] but the model was extended to predict absolute risk over
5-years by “combining the risk of cancer from the relative risk model with age and gender incidence and
mortality models recursively five times” [69]. In the 4,900 case-control population the model reported a
much improved discrimination with an AUC of 0.69 (95% CI [0.66, 0.71]). This would suggest extending the
Spitz Model duration may improve the model’s discriminative ability as it can more robustly distinguish
between individuals with and without lung cancer. This could be due to the original 1-year time period
being too small as the majority of individuals, both diseased and disease free, have low risks of developing
cancer over such a small time period.
Despite the improved discriminative ability, the prediction rules results were surprising. The results at
the 2.5% risk threshold suggest this was too high with the majority of the participants being eliminated
as shown by a low sensitivity of 26.6% and a specificity rate of 94.4%. Decision makers would need to
decide whether the low sensitivity is beneficial as a trade-off of eliminating a high proportion of unnecessary
screening with the high specificity. To allow an informed decision the prediction rules should be evaluated
at a lower risk threshold. The PPV at the 2.5% risk threshold was 0.882 and the NPV was 0.45, this
is a very good PPV, although a case-control population favourably reflects these results due to the high
incidence rates in the validation set that would not be observed if implementing the model as a selective
screening tool.
The final external validation of the Spitz model used 1,340 patients in another case-control study
[76]. This study reverted back to applying the Spitz Model to predict the absolute one-year risk. The
discrimination was measured and the model reported AUC values of 0.67 and 0.68 for former- and current-
smokers respectively, which indicates a reasonable discriminative ability. Unfortunately, the prediction
rules were not assessed in the paper.
Current reporting for the Spitz Model has been subpar with only the AUC results being consistently
reported. Indeed, the optimal duration for the prediction model has not been determined at this stage
with validations alternating between applying the model to predict 1 or 5-year absolute risk. The AUC
results for the Spitz Model varied from very poor to reasonable but further testing needs to be conducted.
This includes reviewing the prediction rules, to offer a more comprehensive review of the model’s potential,
which currently have only been evaluated in one article. The wide applicability is a clear strength of the
model, which would suggest if a robust optimal risk threshold can be identified then the Spitz Model may
be considered to identify a target population for screening. Additionally, the model was well calibrated,
when validated and based upon these results the model could be made available to the public to calculate
their risk and increase awareness.
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Personal Information
Age X X X X X X X X
Gender X X X X
Ethnicity X
Body Mass Index X X
Education X X
Prior Malignant Tumour X X
X-Rays X
Smoking History
Smoking Status X X X X X X
Start Age X
Cessation Age X X
Smoking Duration X X X X X X
CPD X X X X
Pack Years X X X
Quit Duration X X X X
ETS X
Family History of Cancer
Cases of Smoking Related Cancer X
Cases of Lung Cancer X X X X
Age of Onset of Lung Cancer X
Exposures and Conditions
Asbestos Exposure X X X
Dust X X
Hay fever X X
Emphysema X
COPD X X X
Pneumonia X X
The following models have restrictions and designs;
Applicable to Never Smokers X X X X M2014
Applicable to Ever Smokers X X X X X X X X
Age 50 - 75 40 - 80 20+ 20+ 35+
Smoking History 30 PY
Predicts Incidence X X X X X X
Predicts Survival X X X X
Risk Length (Years) 1+ 5 1+ 5 9 6 1+ 6
Table 3.2: Epidemiological Model Variables and Restrictions
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3.5.3 Bach Model
The Bach Model (Bach et al 2003) was devised using a large 18,172 cohort collected in the USA [77].
The model estimates an individual’s absolute risk by combining two separate one-year logistic regression
models that calculate “risk of developing lung cancer” and the competing “risk of dying without a lung
cancer diagnosis”. The model duration can be extended by running the models recursively and the model
was designed to predict absolute risk for 10 years [77].
The Bach Model is quite restrictive and can only be applied to a target population aged 45–69 years
who are ever- smokers with a minimum 30 pack year smoking history and former-smokers are required to
have quit within the last 15 years [77]. The restrictive population lowers the model utility as the 15% of
lung cancer incidences that occur in never-smokers [4, 5] and further incidences that occur in lower smoking
ever-smokers will not be identified. This lowers the impact of the model as an early detection tool as a
sizeable proportion of lung cancers would not be identified in a selective screening trial.
The Bach Model was validated in a 300 participant cohort from the Mayo Clinic, USA in the original
article. The Mayo Clinic entries satisfied the original criteria as “subjects must be aged 55–74 years, have
smoked a minimum of 30 pack-years and be current smokers or former smokers who quit within the last
15 years” [77]. The validation compared the estimated one-year absolute risk and observed incidences
over the duration. The study found the participants with the lowest 25% of risk contained only 8% of
incidences whilst the top risk quartile contained 50%. While this demonstrates the model’s ability to assign
higher risk to individuals who develop lung cancer the risk thresholds at these quartiles were not reported
which may indicate how the model could be applied as a selective screening tool. The AUC result (0.72)
supported the suggestion the model had a reasonable discriminative ability. Unfortunately, no tests were
conducted to evaluate the prediction rules and the model’s clinical utility.
The Bach Model was externally validated in “Validation of a Model of Lung Cancer Risk Prediction
among Smokers” [78] with 6,239 smokers recruited by the Alpha-Tocopherol, Beta-Carotene Cancer Pre-
vention (ATBC) Study. The study recruited some participants outside the range specified in the original
article; men aged “50-69 who had smoked 5 or more cigarettes a day” [78]. This tested the model’s
adaptability in different environments, in this case for lower ever-smokers. The expected incidences in the
cohort over 10 years was 297.07 in comparison to the observed 333. This equates to expecting 89% of
the observed incidences. The under estimation could indicate the model struggled to estimate risk in the
lower risk participants with a reduced smoking history. The validation study only estimates total group
deaths rather than formally assessing the calibration, discrimination and prediction rules. The study could
be improved by splitting the validation to assess performance for patients inside and outside the original
entry criteria to determine if the model’s target population could be expanded.
Finally, the model was externally validated in an article that compared the Bach, LLP and Spitz models
[69]. The Bach Model predicted absolute risk over 5 years in the study. The study included a large range of
participants but non-smokers were excluded since their risk is not calculable by the model. The AUC was
0.66, indicating a reasonable discriminative ability and the study reported no significant difference in the
AUC when stratified between age groups. However, this was the lowest AUC of the models considered in
the same dataset (Spitz and LLP). This was reflected in the sensitivity and specificity rates with a highest
J-Index of only 0.19 at the 2.5% risk. The poor results could indicate that the model has difficulty in
predicting risk in less intense smoking populations and when applied for a shorter time frame than the 10
years original proposed.
In summary, the Bach Model is limited by only considering ever-smokers. The current validation testing
has been poor; the discrimination, calibration and prediction rules have been infrequently recorded so it
is difficult to judge the model’s performance. The preliminary testing indicates that the Bach Model may
not be as robust a selective screening tool as the LLP and Spitz models. Further testing is required to
thoroughly evaluate the model; this should assess if the model can demonstrate an improved discriminative
ability and the prediction rules should be more extensively evaluated to provide insight into the Bach
Model’s clinical utility.
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3.5.4 Hoggart Model
The Hoggart Model (Hoggart et al 2012) is a Weibull regression model, devised in a prospective cohort of
169,035 ever-smokers [79]. From this, 90% of the population was used to devise the model and the remaining
10% formed an external validation set. The model was applicable to ever-smokers aged 35+ years [79]. The
model only considers age and smoking history to calculate one-year absolute risk (incidence and competing
risk of death). The reduce volume of variables considered in comparison to other models could allow the
Hoggart Model to be successful in new environments by not over-fitting the model. Additionally, the model
has the potential to be improved at a later stage by extending the model to consider additional variables.
Conversely, the small number of variables could hinder the model performance and the model could be
limited when attempting to assign a higher risk to individuals with lung cancer when only considering
smoking history and age.
The formula and incidence rates presented in the article were incorrect. A correct version was obtained
through author contact and are presented in the Appendix.
The model can be run recursively and in the external validation in the original article, was evaluated
over 1 and 5 years. The model reported some very promising results and the AUCs were 0.843 and
0.787 for 1 and 5-years respectively. These are very promising results and suggest the model has a good
discriminative ability. The results suggest the model performs stronger over a smaller time frame and
there were no significant changes reported when stratified for former- and current-smokers. While the
initial results are encouraging it is important that the model is tested in distinct environments to see if a
similar or better performance can be obtained.
It is unfortunate that the model has only been validated in the original article and there has been no
evaluation of the prediction rules. Therefore, despite the primary success there are no guidelines on how
the model could be applied as a selective screening tool. Future testing should evaluate the prediction
rules to identify at which risk threshold the model performed optimally. Further testing will also provide
an opportunity to assess whether the Hoggart Model can replicate the initial results while only considering
a few variables.
3.5.5 PLCO Model
The Prostate, Lung, Clonal and Ovarian Cancer (PLCO) screening trial created two logistic regression
models to predict risk of developing lung cancer within 9 years, one was applicable to everyone and one for
ever-smokers. There were no further model restrictions. The models (Tammemagi et al 2011) use a cubic
spline for the predictors which include age, pack years, smoking duration, BMI, family history, COPD and
chest x-rays [80]. The two models were created in a cohort; the model applicable to everyone used 70,962
participants and the ever-smokers model used a sub cohort of 38,258 ever-smokers [80].
The model was internally validated in the original article and bootstrapping was conducted in an
attempt to eliminate optimism and give a fairer reflection of the model potential in distinct environments.
The calibration and discrimination were assessed. The model version that was applicable to everyone
reported a very high AUC of 0.859 and good calibration (p-value 0.274). The strong performance was
replicated in the ever-smokers model with an AUC of 0.809 and a Hosmer-Lemeshow p-value of 0.416.
Currently the models have not been externally validated. Future testing needs to be conducted on the
PLCO models which recorded the highest AUC results of any model currently, although this was reported
in an internal validation. The assessment should evaluate if the good model calibration and AUC results
can be replicated in new populations and the prediction rules need to be evaluated. The initial results
would indicate the model could be a useful tool for the public to calculate their risk or utilised to identify a
high risk target group for screening. However, failure to report the prediction rules means currently there
is no indication how the model could be optimally utilised as a selective screening tool.
Since publishing these models the author has developed two new versions of the model discussed in
Section 3.5.6 & 3.5.7.
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3.5.6 PLCOM2012 Model
Following the promising results of the PLCO models, these were revised to create the PLCOM2012 logistic
regression model to calculate risk over 6 years. This was applicable to ever-smokers with no further
restrictions [81]. However, the revised model did not consider pack years or x-rays but did include ethnicity.
The PLCOM2012 Model was devised in a cohort of 77,456 participants; these were heavy smokers as
participants used to devise the model were all eligible using the NLST criteria to offer a direct comparison.
Therefore, the model was devised in ever-smokers aged 55-74, with a minimum 30 pack year smoking
history and all former-smokers had quit within the last 15 years [81].
An external validation was conducted in the original article using a cohort of 53,454. This was also a
heavy smoking cohort with participants required to have a minimum 30 pack year smoking history. The
model was compared to the original PLCO Model and the study found “the AUCs in the validation data
suggest that predictive discrimination with the PLCOM2012 was slightly improved” with an impressive
result of 0.803 [81]. The strong discriminative ability was further supported by the prediction rules results
which were optimal at a risk threshold of 1.3455%. Here the model recorded a Youden’s Index of 0.459,
which is very high, as the model demonstrated a good trade-off between the sensitivity and specificity.
Indeed, the model reported a sensitivity of 83% while maintaining a high specificity of 63%; this very
impressive result indicates the model’s potential as a selective screening tool. However, it is important
that the model is validated in multiple distinct populations at the reported threshold to assess if a consistent
level of performance is recorded.
Tammemagi et al. (2014) externally validated the model [82]. The study found 0.0151 (1.51%) was
the optimal 6-year risk threshold, which is not too dissimilar to the 1.3455% reported in the original
article. The model was compared to the NLST screening population in a high risk 53,455 cohort that
satisfied the NLST screening criteria [83]. At the 1.51% risk threshold the model performed strongly and
demonstrated an improvement upon the NLST criteria. The PLCOM2012 Model reported a sensitivity of
80.9%, specificity of 65.9% and a PPV of 4.1%. This PPV result is an improvement on the NLST criteria
which scored 3.4%. The model and NLST criteria were validated in a cohort, with a reasonable lung cancer
incidence rate, so the PPV results are a fair reflection of what would be expected in a genuine screening
trial. However, it is important to note this is only in ever-smokers with a 30+ pack year history who were
aged 55-74 rather than all ever-smokers as the model is applicable to. This result and the sensitivity and
specificity rates may be weaker in a complete ever-smoker population. Future testing could evaluate the
model in a wider population to assess if the results can be replicated and if the model still improves upon
the NLST screening programme. The Hosmer-Lemeshow test and AUC were not recorded in the study but
the reported results demonstrated how prediction models may offer an improved criterion for selecting high
risk individuals. An 11-year risk version of the model was also examined. However, the article concluded
this is an excessive time frame and there was no improvement to the model [83].
Overall this is an extremely promising model offering an improvement over the original PLCO model
and NLST criteria. The articles also indicated the model was optimal around the 1.5% risk threshold for
6-year risk of incidence. The model needs further external validations, particularly in populations that are
not heavy smokers, to assess the model’s robustness in distinct populations. If the model continually reports
the high results such as sensitivities of 80% and specificities of 63% then the model may be considered in
screening trials. In contrast the reported calibration results have been poor when reported and the model
may not be preferred to be made available to the public to estimate their risks.
3.5.7 PLCOM2014 Model
Another PLCO logistic regression model was created (Tammemagi 2014) to include never-smokers when
predicting 6-year incidence [82]. The PLCOM2014 Model included a new variable for smoking status in the
logit model while the other variables included in the PLCOM2012 Model remained with a minor recalibration
to adjust for the never-smokers.
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The model was devised and internally validated in the PLCO cohort. The study included 154,910
participants who were aged 55-74 with no further restrictions [82].
Despite creating a model applicable for never-smokers, the article argued “it has not been demonstrated
that never-smokers can be at high enough risk to warrant screening” [82]. As a result, the study did not
comprehensively review the performance of the PLCOM2014 Model despite the model reported an impressive
AUC of 0.848 in an internal validation. This is a very promising result although the model needs to be
externally validated to give a more accurate review of the model’s discriminative ability. The article did
not formally record the calibration using the Hosmer-Lemeshow test but reported “the PLCOM2014 Model
calibration is good for risks below 0.10” but overestimates risk in individuals with a risk above 0.15 for
6-year risk of incidence [82]. However, only 0.2% of the participants had a risk above 0.15 in the validation.
The study assessed the model at the optimal risk threshold identified for the PLCOM2012 Model (1.51%).
The prediction rules were not reported since none of the 65,711 never-smokers in the cohort were estimated
a risk exceeding 1.47% and as a consequence would not be considered for screening [82]. This is despite
the fact never-smokers can be assigned a risk up to 3.5% using the prediction model. The study supported
their previous argument that never-smokers do not warrant a high enough risk for screening and they
recommended the PLCOM2012 Model in preference.
However, the model would benefit from an independent validation that identified an optimal risk
threshold specific for this model to evaluate the prediction rules. Additionally, the model recalibration may
have improved the model’s ability as a selective screening tool; even if never-smokers are not considered
for screening the model may improve how ever-smokers are classified as high or low risk. Clearly, the
model demonstrates a good discriminative ability in the internal validation. Future testing should evaluate
the model in an external population and identify a risk threshold specific for the PLCOM2014 Model to
evaluate the prediction rules. The calibration should also be evaluated using the Hosmer-Lemeshow test.
Currently there has been no independent validations of the model as a direct consequence of the model
being published very recently in December 2014 with the systematic review deadline 01/10/2015.
3.5.8 African-American Model
The African-American Model [84] is closely related to the Spitz Model and devised by the same lead authors.
The logistic regression model was devised to predict accurate risks in an African-American population
whereas previous models commonly considered a Caucasian population. The model was devised to predict
5-year absolute risk by considering lung cancer incidence rates and survival rates. However, the model was
devised using a very small 988 case-control population [84]. This could be a limitation of the model as
there is relatively little evidence to develop the prediction model. Although some concerns are alleviated by
considering the external SEER lung cancer incidence and survival rates for age and gender specifically for
African-Americans [84]. This may assist in developing a model that estimates reasonable risks of developing
lung cancer in African-Americans. By considering these age and gender specific incidence rates the model
cannot be applied to participants under 20, although lung cancer rarely occurs under 40 [1] so this is not
a concern. The model includes many of the same variables as the Spitz Model, although does not consider
asbestos exposure and emphysema in the prediction model [84].
The model was internally and externally validated in the original article [84]; unfortunately, these were
conducted in very small populations. The internal validation only included 156 participants where the
model reported a good AUC of 0.75 [84]. Unfortunately, this was not replicated in an external validation
of 388 participants with a poorer AUC of 0.63 [84]. It could be argued that the small external validation
dataset may have hindered the model performance as it is insufficient to determine if the model has a poor
overall discriminative ability or only performs poorly in the dataset. However, the result does raise the
concern that only using 988 participants to build the model could result in the model performing poorly
in new environments.
There has been no additional testing other than the original article and the calibration and prediction
rules have not been evaluated. While the original results are poor this model may report the leading perfor-
mance in African-American populations, as this is currently the only model developed for this target group.
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Certainly, there is the potential for specific models for different populations whether based on ethnicity or
location provided they offer a leading performance when assessing the model calibration, discrimination
and prediction rules. Future testing should validate the African-American Model in an African-American
population in a direct comparison to universal models to assess which report the leading performance.
Additionally, testing the model in a much larger validation should also allow a better understanding into
the model’s performance and answer concerns on whether the model is limited in new populations.
Overall Prediction Rules Same Dataset Testing
Model Calibration AUC Risk Threshold Sens and Spec PPV NPV Model Accuracy NRI Compared With?
Bach X X X X X X X LLP, Spitz, Pittsburgh
LLP X X X X X X Bach, Spitz
Spitz X X X X X X X Bach, LLP, African-American
African-American X Spitz
PLCO X X
PLCOM2012 X X X X X PLCOM2014, US Screening Trial
PLCOM2014 X X PLCOM2012, US Screening Trail
Hoggart X
Pittsburgh X X Recalibrated Bach, Recalibrated PLCOM2012
Table 3.5: Testing and Model Comparison Reported for each Epidemiological Model
3.5.9 The Pittsburgh Predictor
The Pittsburgh Predictor (Wilson 2015) [85] is a recent logistic regression model that was identified for
the systematic review through author contact. It is a simple model that considers only four variables; age,
smoking duration, CPD and smoking status in order to predict lung cancer risk of incidence within 6-years
[85]. The simplicity of the model may be an advantage when applied to new environments as the model
only considers age and smoking history, both linked to lung cancer risk worldwide. Indeed, the model was
designed to consider fewer predictors to make it “less complicated than currently available models, perhaps
more amenable to widespread application, yet devised to place individuals on a lung-cancer continuum.”
[85]. Conversely it could be argued, the limited number of predictors in the model may disadvantage
the model’s discriminative ability. The model is only applicable to ever-smokers, although there are no
additional restrictions [85].
Two versions of the model were created in slightly different cohorts. The first cohort recruited 53,454
high risk ever-smokers cohort aged 55-74 with a minimum 30 pack year smoking history. A second cohort
of ever-smokers recruited 3654 50–79 year-old ever-smokers who had smoked a minimum 10 CPD for at
least 25 years and former-smokers had quit within the previous 10 years [85]. Despite being applicable to
all ever-smokers the two cohorts collected only heavy smokers which may limit the model’s performance
in lower smoking populations.
The two model versions considered the same parameters but were slightly recalibrated based on the
evidence in the cohort. At this stage the models have only been internally validated in the original study
where they were compared to a recalibrated version of the Bach Model and the PLCOM2012 Model. The
models were recalibrated using an odds ratio scaling factor to reflect the observed incidence rates and are
presented in the article [85].
The calibration (Hosmer-Lemeshow) and discrimination (AUC) results were presented. The two ver-
sions of the Pittsburgh Predictor demonstrated a good calibration, exceeding 0.05 (p-values 0.19 and 0.08).
In comparison the recalibrated Bach Model also reported a good calibration but the PLCOM2012 (p-values
0.04 and 0.01) underperformed in both cohorts. In the internal validation the Pittsburgh Predictor showed
a reasonable discriminative ability with AUC results of 0.688 and 0.678. However, this was surpassed by
the other models. This adds weight to the argument that the small number of variables considered in the
Pittsburgh Predictor may limit the model’s ability to assign a higher risk to individuals with lung cancer.
Based on the AUC evidence in the internal validations the leading Pittsburgh Predictor published in
the article is as follows;
1
1 + exp−(−4.2195 + (0.1× S)) (3.1)
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Here S is the additive model using the 4 variables as presented in the article [85].
The AUC results indicate that the Pittsburgh Predictor may not be the favoured model for a selective
screening tool. At this stage the model should be validated in external populations which currently have
not been conducted due to the recent publication of the model. Future testing should also assess the
prediction rules which were not presented in the original publication. Any future validations should also
compare the performance to other models in the same datasets. This can then evaluate whether only
considering four variables has allowed the model to be successful in distinct environments in comparison
to more sophisticated models that might consider variables not relevant in new populations. Conversely,
the validation may highlight, by restricting the volume of variables this limited the model’s discriminative
ability.
3.6 Clinical Lung Cancer Models
The next group of models presented in the systematic are defined as clinical lung cancer models. Models
are categorised as such if they include variables that require a clinical assessment (CT/PET Scan, blood
test, sputum test) to estimate an individual’s risk. These models have the potential to incorporate crucial
markers that increase or decrease ones’ susceptibility to developing lung cancer. However, at this stage there
is ongoing work to identify the markers that best explain risk [86] indicating the possibility of more clinical
models being developed in parallel to further research into SNPs. Additionally, at the time the review was
conducted the key markers may not have been identified so a leading model may not be developed. There
is an expectancy that these markers will improve prediction model performance, however, these models all
require a costly procedure, such as a scan or blood test. Therefore, they will in all likelihood need to show
a significant improvement over leading epidemiological models to justify the costs involved to generate
risk predictions. Unfortunately, there is no exact measure to assess level of improvement for a clinical
model while considering increased costs incurred, this would most likely be reviewed in a cost-effectiveness
analysis during a screening trial which have not been conducted for the new clinical models.
The review identified and presented 7 non-epidemiological prediction models. These models are a
combination of new models and updated epidemiological models to include clinical variables. The results
are presented and discussed separately for each model with the results combined in one table.
3.6.1 Pulmonary Function and Sputum DNA Image Cytometry Model
In 2011 an article published two models that predicted lung cancer incidence risk over eight years in ever-
smokers [86]. The models were designed in a prospective cohort of 2,596 high risk participants aged at
least 40 years with a minimum 20 pack year smoking history [86]. The models were an extension of the
original PLCO models and presented by the same lead author. As a result, the epidemiological variables
considered in the model originate from the PLCO models [86]. The original model was then extended to
consider forced expiratory volume (FEV) and sputum DNA imaging.
To apply the models, participants would be required to be tested by a Spirometer and provide a sputum
sample which required “subjects were instructed to cough intermittently during the induction procedure
and for at least 2 hours afterward to produce sputum samples” [86].
The combined model including forced expiratory volume and sputum DNA imaging recorded the best
results in the internal validation with a high AUC (0.773) and good calibration (p-value 0.313) [86]. How-
ever, the AUC did not exceed the 0.859 or 0.809 observed from the original model when tested amongst
everyone and ever-smokers respectively in the internal validations. The initial results indicate that consid-
ering FEV and DNA have not improved the model’s discriminative ability, it would in all probability lead
to a poorer selective screening tool although this has not been thoroughly evaluated.
The model has only been tested in the internal validation. Therefore, the next stage should evaluate
the model in an external population ideally in comparison to the original PLCO models. Currently,
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the AUC result of the extended model were slightly inferior to the epidemiological PLCO model, which
would not require 2 hours from the participant to estimate their risk. This would suggest the clinical
model would not be a better screening tool in terms of convenience, costs incurred and discriminative
ability. However, FEV and DNA may be universal factors that allow the model to perform robustly in new
environments and outperform the original PLCO model. The current results would argue the new model
will have to demonstrate a significant improvement in AUC (and most likely prediction rules which have
not be assessed) for clinicians to favour this model as a selective screening tool over leading epidemiological
models, however, at the current stage of research this should be assessed.
3.6.2 Extended LLP Model
The LPP Model was recalibrated and extended to include the SEZ6L gene as an additional variable [74].
The model predicted 5-year absolute risk of developing lung cancer similar to the original LLP Model.
The model was devised using a subset of the case-control LLP study which collected information for this
genotype. As a result, the model was only based on 388 participants [74]. It is possible a larger population
may have indicated that the SEZ6L gene was not a key marker to explain lung cancer susceptibility.
Additionally, this may also lead to over-fitting as a result of the small case-control study upon which the
model extension was based; this variable may explain the difference between predicted and observed risks
in individuals in the original model rather than predicting an individual’s absolute risk of developing lung
cancer. However, there is only a small concern about over-fitting as the model is only extended to include
one additional variable [87].
The study participants were aged 20−80 but there were no further restrictions. Controls were matched
on age and gender and were also from the Liverpool, UK area [74]. However, the model used age and
gender specific lung cancer incidence and death rates, determined from the overall Liverpool area, rather
than the case-control study to reduce concerns with matching for these variables.
The SEZ6L gene was identified in participants by “extract(ing) the genomic DNA from blood peripheral
leukocytes” [74] using a blood kit which can be a costly procedure on a large scale.
The extended model was assessed in an internal validation and reported a good AUC (0.75), although
the original LLP Model had only a slightly reduced discrimination (0.72) in the same dataset. Unfor-
tunately, the prediction rules for both models were not presented as this would indicate by what extent
the extended model was an improved selective screening tool, which is expected from the improved AUC
results. Both the original and expanded model reported a good calibration.
There has been no subsequent testing and while there was an improvement in AUC, the inclusion of the
SEZ6L SNP does not appear to be more beneficial in comparison to the original LLP model. This marginal
improvement may not justify this model being preferred as a selective screening tool when considering the
extra cost incurred from conducting blood tests. Future testing of the model should compare the extended
and original models in the same external population with particular attention to comparing the prediction
rules.
3.6.3 Extended Spitz Model
The original Spitz Model was extended to consider two markers for DNA repair capacity [76]. The model
calculates 1-year absolute risk of developing lung cancer in ever-smokers [76], whereas the original model
was applicable to everyone, due to a lack of reporting for the new variables in never-smokers. To be
applicable participants were required to be at least 20 years of age, as this is the youngest age provided for
the age and gender lung cancer incidence rates using the SEER rates. However, this is not a limitation as
lung cancer rarely occurs in individuals younger than 40 [1]. Additionally, incorporating these SEER rates
into the model limits concerns about matching as the case-control study recruited 1,340 participants with
controls matched by age, gender, ethnicity and smoking status.
The extended model considers the same variables as the original model but included DNA repair
capacity and Bieomycin sensitivity as additional predictors [76]. These required blood samples to be
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measured. There is a concern in including these variables as the case-control participants were matched by
smoking status which may be confounded with DNA repair capacity and Bieomycin sensitivity. Therefore,
these new variables may not assist the model performance any more than considering smoking status.
The model was internally validated in the original article. The model demonstrated an improved AUC
in comparison to the original model with results of 0.70 and 0.73 for 746 former and 594 current-smokers
respectively. In comparison, the Spitz Model reported an AUC of 0.67 and 0.68 for former and current-
smokers in the same dataset. The clinical model demonstrated a good calibration with Hosmer-Lemeshow
p-values of 0.61 and 0.433. Unfortunately, the prediction rules were not evaluated in the article.
Further testing should be conducted in an external validation and compare between the original and
extended models. The prediction rules need to be evaluated as there is no current indication as to how the
model could be best utilised as a screening tool. Additionally, an external validation will demonstrate if a
more robust model has been created; considering the additional markers to improve the performance of the
original model may only explain the difference between the predicted risks of the original model and the
observed incidences in the dataset rather than predicting lung cancer risk. This would limit the model’s
ability in new environments, which can be evaluated by testing the calibration and discrimination.
3.6.4 Model for Korean Men
A new model was developed using a large cohort of 1,324,804 Korean men [88]. This is one of only two
models that were devised using a population outside of Western Europe and North America. The study
collected information on males aged between 30-80 with no further restrictions [88]. It is unfortunate
that the model was restricted to males, as lung cancer has the second highest incidence rate and highest
mortality rate of all cancers amongst females [1].
The model considered age, smoking history, BMI, physical activity and fasting glucose levels to predict
8-year risk of incidence. Fasting glucose levels requires blood and urine testing which classifies the model
as a non-epidemiological model. There were some concerns with the ambiguity of some of the variables
considered in the model and individuals may be unsure how to classify themselves. For example, physical
activity was defined as light, moderate, or heavy [88], which is subjective to the individual’s interpretation
as what qualifies as exercise, which could affect model accuracy.
The model was externally validated in the original article in a substantial 507,046 cohort of males aged
30 − 80 years [88]. The Korean Model recorded an extremely impressive AUC of 0.875; this was one of
the leading results of all models reviewed. In contrast, the calibration was poor (p-value < 0.0001) as the
model failed to accurately predict risks in individuals. The study did not report the prediction rules, which
is disappointing as the high AUC results could be reflected in impressive prediction rules results.
It would be of interest to assess how the model performed in other Asian and worldwide populations.
These should evaluate if the model can replicate its impressive performance in distinct environments. It
would be insightful to compare the model in the same populations (in Asia, Europe and North America)
to other leading models such as the PLCO and Hoggart models. This can evaluate if there is a leading
universal model or leading models for different populations. While the model showed potential based on
the AUC results the prediction rules require evaluation. This will allow medical decision makers to make
an informed decision as to whether the prediction model should be used as a screening tool and provide
guidance on how to apply the model to identify a high risk group who would benefit from screening. If the
model still maintains a leading performance, then the costs of taking blood samples for the fasting glucose
levels may be justified, after an assessment in a cost-effectiveness analysis, in preference to epidemiological
models.
3.6.5 COSMOS (Extended Bach) Model
The COSMOS Model is a recalibrated and extended version of the Bach Model [89]. The model was devised
using a cohort of 5,203 participants who were aged 50 years or over and heavy smokers with a minimum
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20 pack years smoking history [89]. This is similar to the Bach Model criteria, although it also included
ever-smokers with a lower smoking history compared to the Bach Model, which used ever-smokers with a
minimum 30 pack year smoking history. The COSMOS Model was developed as the Bach Model recorded
a poor calibration in this population. The COSMOS Model included nodule description and size from CT
scans as additional variables. It could be argued that if CT scans are required for each participant then
a blanket screening approach of everyone applicable to the model can be conducted as LDCT trials have
been successful in previous lung cancer screening programmes [27]. The model has a limited potential of
identifying general participants for screening as it considers nodules; these can develop into lung cancer,
therefore, it could be argued participants with nodules are already high risk participants.
The COSMOS Model was internally validated and the Hosmer-Lemeshow was measured (p-value 0.63)
[89]. The model successfully predicted lung cancer risk, although this is in asymptomatic participants.
An external validation was conducted by Veronesi et al. [90]. The model was tested in the same target
population as the model building population; aged at least 50 years and a minimum 20 pack year smoking
history. The study collected 1,035 patients who were receiving annual LDCT screening [90] and evaluated
the model’s estimated lung cancer incidence rate that would accrue during annual LDCT screening over
the next 10 years. The COSMOS Model accurately predicted lung cancer incidence rates for the first two
years of screening with expected incidence rates of 12.5 and 13.4 in comparison to the observed 12 and 11
incidences [90]. However, the COSMOS Model over predicted incidence rates for the next 8 rounds of annual
screening. Over the 8 screening rounds the COSMOS Model predicted an accumulated 156.2 incidences
in comparison to the much lower 60 incidences observed [90]. This heavily over-predicted, predicting a
260.3% increase on the observed rate. In comparison, the Bach model predicted 58.3 incidences over
the same 8-year period equating to 96.7% of the observed incidences [90]. The results suggest that the
COSMOS Model had been recalibrated too highly based on initial high capture rate at the baseline round
of screening. The expected versus observed calibration was the only measure reported. The poor result
suggests that the COSMOS Model failed to adapt to new environments.
Based on the calibration results provided, the extended COSMOS Model does not seem to offer an
improvement over the Bach Model despite requiring costly procedures to apply the prediction model.
Additionally, the model may not be appropriate as the objective of the prediction model is to identify par-
ticipants for screening. Requiring screening to make the predictions would negate the model’s practicality.
The COSMOS Model offers an indication into the observed incidence rate in this high risk population,
although the external validation results suggest the original Bach Model would be a better tool for this
purpose.
3.6.6 Gene Based Risk Score
A model was created to incorporate SNPs that could influence lung cancer susceptibility [91]. The model
was devised in a population based case-control dataset. Ever-smokers with a minimum 15 pack year smoking
history who were at least 40 years of age were considered [91]. The model considers for inclusion 20 SNPs
associated with lung cancer; research determined 12 of the SNPs increased susceptibility of developing lung
cancer and the remaining 8 SNPs reduced risk of lung cancer. Information for these SNPs were identified
through blood tests. These SNPs are considered alongside family history, gender, age and COPD in an
additive model.
In the original article a small internal validation was conducted using 439 participants. The model
reported a strong AUC of 0.79 [91], which demonstrates the potential to incorporate SNPs into predic-
tion models. However, additional testing in larger external populations would allow a more extensive
understanding into the potential of SNPs to create robust prediction models.
The research into key SNP markers is still ongoing and newly identified SNPs could be considered in
future lung cancer prediction models. Similar to all reported clinical model validations there has been no
focus on prediction rules which need to be evaluated before the model would be considered to identify
participants for selective screening trials. Additionally, research could assess whether the identified SNPs
can be incorporated into a robust prediction model that also considers never-smokers.
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3.6.7 Chinese Genetic Model
The Chinese Genetic Model (Li et al 2012) [92] was created using 75% of a 5,068 participant case-control
dataset with the remaining 25% utilised as a validation set. There were no restrictions in collecting the
2,283 individuals with lung cancer and disease free participants were matched by age, gender and residency
[92]. This was only the second prediction model that did not consider a European or North American
subpopulation.
The model considers 4 SNPs (rs2736100, rs402710, rs4488809 and rs4083914) alongside age, gender
and smoking status in a log additive model [92]. Several versions of the models that considered different
combinations of these risk factors were published in the article. The first version of the model only
considered SNPs and reported a poor performance despite “estimating these four SNPs accounted for
4.02% of genetic variance in lung cancer” [92]. The external validation in the original article reported a
weak AUC of 0.551 (95% CI [0.532, 0.564]) [92]. This suggests that solely considering non-epidemiological
factors cannot create a good prediction model and a combination of epidemiological and non-epidemiological
factors will generate better predictions. Indeed, a second version of the model considering gender and
smoking status alongside the SNPs improved the AUC to 0.639 (95% CI [0.621, 0.652]) [92], which is a
more reasonable discriminative ability.
In a final model version that considered the SNPs, age, gender and smoking status, the article evaluated
the prediction rules at the optimal risk threshold. This was identified by the highest Youden Index across
all risk thresholds. However, the article did not report the risk threshold that had the optimal performance
which means that this cannot be evaluated in future validations to assess if a similar performance can be
obtained. The model reported an optimal performance with a sensitivity of 53%, specificity of 68% and a
PPV of 57% [92]. This was not an outstanding performance with a Youden Index of 0.21 in comparison
to the performance of other models, which have reported a value exceeding 0.4. The model would still
screen a high proportion of individuals who are disease free while only identifying 57% of individuals who
developed lung cancer. The calibration was not evaluated in the article.
Overall the model had a poor performance with lower AUC and prediction rule results. The model’s
poor performance may suggest the most significant genetic markers for lung cancer susceptibility have
still not been identified. Unfortunately, genetic prediction models are continually being published without
identifying the key SNPs. This increases the volume of prediction models published, including some poor
performing models, leading to confusion as to which model(s) would be beneficial as a clinical utility.
3.7 Two-Stage Clonal Expansion Models
The final collection of models identified in the systematic review are the Two-Stage Clonal Expansion
(TSCE) models. These models differ from previously considered models as they consider one risk factor
and are commonly developed and applied to a subpopulation that has a high exposure to the risk factor.
The TSCE models offer a comparison of “the strength and goodness of fit of the association between
exposure and cancer risk” [93] and are normally devised to evaluate if a risk factor is associated with
the outcome. By only considering one factor they are most likely to be limited in accurately predicting
an individual’s risk of developing lung cancer as including additional variables can improve the models’
discriminative ability rather than an increased exposure equates to an increased risk. Despite their potential
limitations TSCE models can be applied to calculate an individual’s risk.
In the majority of studies, the model is validated by comparing observed and estimated lung cancer
incidences/mortalities to assess the model calibration. Since the models assess the level of association
of a variable with lung cancer risk they are often not applied in an external population as they are not
considered as a universal selective screening tool.
The review will offer an overview of the TSCE process followed by the different models and their results.
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3.7.1 TSCE Model Process
TSCE models are aptly named as they are split into two distinct stages. These stages evaluate the intensity
that normal cells become pre-malignant and the rate of expansion, which considers cell birth and death
rates plus the rate of transformation from pre-malignant to malignant.
3.7.1.1 Stage 1
The intensity of the transformation from normal cells to pre-malignant cells relates to the quantity of cells
that are susceptible at a time, t. This will be a fixed number of cells in the lung defined as X(t). Cells are
‘initiated’ into premalignant cells which is “a (nonhomogeneous) Poisson process” [94]. This rate is defined
as;
α1(t) = vt ×Xt (3.2)
Where α1(t) is the initiation rate for a fixed number of cells based on the intensity of initiation (vt) at
time t.
3.7.1.2 Stage 2
The second stage considers the rate of change of cells from pre-malignant to malignant. This mutation
rate is the asymmetrical division of a pre-malignant cell into one pre-malignant cell and one malignant cell
[94]. The rate at time t is denoted as α2(t).
3.7.1.3 Intermediate Section / Clonal Expansion Rate
The two final rates in the model are specific to the pre-malignant cells. These are the birth rate (cell
division) bt and death rate (differentiate) dt at time t [94].
The methodology of how to form the TCSE model, including notation at stages comes courtesy of
detailed description in Heidenreich et. Al [94] and Zeka et. Al [93]. The key terms of the TSCE models
are summarised as:
Xt Number of cells - fixed
vt Intensity of cell initiation, from normal to premalignant
α1(t) Initiation rate
α1(t) Mutation rate, from premalignant to malignant
bt Premalignant cell birth rate
dt Premalignant cell death rate
Figure 3.2: List of TSCE notation specific at time (t)
The overall process is best described by Zeka et. al. [93] and can be summarised as follows;
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Figure 3.3: Flow of TSCE Model Process
3.7.2 Review of TSCE Prediction Models
Eight models were identified and were each presented in a paper ([93], [95]-[101]). Across these models
asbestos or silica exposure was commonly considered as the sole variable. In all the TSCE models the
volume of lung cells remained fixed at 107, but the mutation rates varied based upon the variable considered
in the model and the study population. The working formulas with mutation rates are listed in the
published articles ([93], [95]-[101]).
The aim of all the identified models was to predict lung cancer mortality rates across a population
and were then evaluated by comparing the estimated and observed mortality rates and the results showed
potential [96]. None of the models have ever been validated or used in new environments outside the
original study. The lack of interest in conducting external validations for these models is partly due to
the model design; by only considering one, often uncommon variable, they would be limited as a selective
screening utility. Further, while they can be easily applied to high risk or high exposed populations their
simplicity can be a limitation; a single factor can struggle to distinguish between individuals who would
benefit or not benefit from screening. Finally, the models are applied in a highly exposed population and
are not very transferable to new environments.
The TSCE models are unlikely to ever be considered outside of the original study nor would these
models be employed to assist physicians. There is no further work or validations required for the TSCE
models as their primary purpose is to show the level of association of a risk factor with lung cancer in the
original article.
3.8 Discussion
The published literature on lung cancer prediction models indicates that the focus has been in publishing
new models rather than validating existing prediction model. As a result, there was a varied standard
of validations for models with some being extensively validated while others have only been considered
in the original article. The epidemiological models have been the most extensively reviewed, which is
expected since they were published earlier. Since then there has been a shift to consider incorporating
genetic markers in prediction models. These published clinical models are relatively new and therefore
have rarely been evaluated outside the original article. Finally, the TSCE models were seldom used and
have never been considered beyond the original study. These targeted high risk, niche populations so were
not practical in new environments.
When validating the epidemiological models the results are often presented for different models using
distinct datasets so direct comparisons between models has been difficult (Table 3.5). The calibration
was commonly reported and in most instances the model demonstrated a good calibration based on the
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Hosmer-Lemeshow p-values. This suggests a model could be used to accurately provide predictions for
an individual’s risk. The AUC was also commonly reported for the epidemiological models. The AUC
results ranged from a weak 0.57 (Spitz Model) to a very strong 0.86 (PLCO Model). The leading reported
AUC results were for the PLCO, PLCOM2012, PLCOM2014 and Hoggart models. The results would suggest
these models have the highest potential to be a successful selective screening tool. To assess the ability
of a model as a selective screening tool the prediction rules need to be validated, unfortunately, only for
the PLCOM2012 Model have these been extensively evaluated. This model at the optimal risk threshold
(1.34%) where it improved upon the previously implemented NLST criteria to identify a target group for
screening.
At this stage, the optimal risk threshold for the remaining epidemiological models needs to be identified
and the prediction rules externally validated. Janssen et al. (2008) recommends that all models should
be externally validated to quantify their predictive performance through calibration, discrimination and
classification predictors [45]. Additionally, comparing all the models in the same dataset is recommended.
This should address limitations with the current reporting, where direct comparisons between the models
is difficult. This may also identify a different leading model for distinct populations, based on ethnicity or
location, which may allow different optimal screening programmes to be conducted worldwide.
The review found that the models which consider clinical factors (such as blood testing and scans)
do not offer a universal improvement over epidemiological models. The discrimination was commonly
reported with an AUC between 0.639− 0.875 and the majority of results between 0.7− 0.79. The lack of
improvement for clinical models was highlighted by comparisons between the COSMOS (Bach), Extended
Spitz and Extended LLP Models and their original models where any improvement (AUC/calibration) was
minimal. The slightly disappointing results may be a result of not identifying the correct genetic factors
associated with lung cancer risk. Further work is being conducted to identify the key markers which could
lead to new prediction models that improve upon the existing literature. However, it is important that the
new clinical markers assist in developing a robust prediction model rather than publishing a poor prediction
model, as has been observed with some published clinical models. The performance of a clinical model is
critical; and before a clinical model would be considered as a selective screening tool the costs to apply the
model will need to be justified, which can be demonstrated by a high performing model to identify a high
risk target population.
Clinical models are still at a very early stage of development and have usually been published since 2010.
As a direct consequence they have not been properly tested at this stage and commonly only validated in
the original article in an internal validation. A conclusion of the systematic review was that it would be
beneficial if every clinical model was external validated to develop stronger conclusions about the models’
performances.
In conclusion the review found some flaws in the current validations of the models that will be addressed
in our study. Firstly, models have inconsistently been compared with each other in the same dataset making
it difficult to draw direct comparisons between models. This has been observed for models developed for
many different diseases, and the current reporting of validations across different studies has been poor [46].
Secondly, prediction rules have been poorly reported in validation studies and for some models these have
never been reported (Table 3.5). It could be argued that the lack of clear guidelines, through assessing
the prediction rules, on how to optimally apply models has prevented these being incorporated in selective
screening programmes. Therefore, this study will address the poor validation reporting for lung cancer
prediction models. The models will also be compared to the current screening programmes to evaluate if
there is conclusive evidence that a leading prediction model or criteria has been identified. This will be
conducted for the epidemiological lung cancer prediction models using a series of datasets received from the
International Lung Cancer Consortium (ILCCO). These models will be considered because the variables
will be commonly collected in the ILCCO datasets. Additionally, these models demonstrated the potential
to improve upon current screening guidelines whether the UKLS or NLST criteria. Therefore, a leading
model could be identified and implemented.
43
3.9 Summary
The systematic review identified 29 different models that predict lung cancer risk in individuals. These were
classified as epidemiological, clinical assessment and TSCE models. There were ten epidemiological lung
cancer prediction models identified; the Bach, LLP, Spitz, African-American, Hoggart, Pittsburgh, two
PLCO versions, PLCOM2012 and PLCOM2014 models. The epidemiological models showed potential to be
utilised as a clinical utility with some good performances for calibration, discrimination and prediction rules
in validations. However, the models had often been validated independently in distinct datasets so direct
comparisons between the models was difficult. The current reporting of validations was inconsistent with
some validation studies not considering prediction rules. Additionally, when a model had been evaluated
in multiple studies the prediction rules were often reviewed at different risk thresholds. This resulted in
no clear indication into a leading model or being able to provide recommendations into the risk threshold
that will allow the model to perform optimally. The standard of validations did not allow a confident
recommendation into a leading model and how this may be utilised as a selective screening tool.
Based on the systematic review the next stage of research should be to address the lack of consistent
reporting for models in the validations. An external validation, comparing all the models in the same
dataset, is required which should provide better understanding into the different model performances.
To perform an external validation individual patient level datasets (IPD) will be collected and prepared,
which is detailed in the next chapter. The collected datasets will then be analysed in the subsequent chapter
to identify any limitations with the datasets that could influence the model results in the validation. Then
the validation will be conducted and the results presented and analysed.
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CHAPTER 4
Dataset Collection, Preparation and Imputation
4.1 Introduction
To conduct external validations on the identified lung cancer prediction models datasets were made available
through the International Lung Cancer Consortium (ILCCO). Prior to performing the validation, there
needs to be confidence that the datasets would allow the models to be accurately evaluated. Therefore,
reported information on the variables in the datasets were reviewed and modified when required. This
included harmonising the reporting of the variables so they were applicable to the models’ specifications,
removing participants with unreliable information and imputing missing information. The modifications
made to any of the variables in the datasets were recorded and reported in this chapter.
4.2 Objectives
This chapter aims to detail how the datasets were obtained and prepared to perform an external validation
of lung cancer prediction models. The chapter will:
1. Detail the ILCCO application process to acquire datasets for the project.
2. Introduce the datasets that were made available by ILCCO.
3. Present which models were applicable to which dataset based upon having complete information for
each variable required by the model.
4. Present how the datasets required modifications to be compatible for the models.
• Report any modifications to the variable information to allow it to be in the correct form required
by the models.
• Detail any participants removed because of unreliable information that could negatively affect
the model validation.
5. Impute missing information in the datasets where possible.
• Introduce the imputation objectives.
• Present different imputation methods and identify an appropriate method.
• Conduct and report the imputation.
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4.3 Dataset Collection
To conduct an external validation on the identified epidemiological risk models, datasets with individual
patient level (IPD) data were required. Applications were sent, in December 2014, to the study holders
of datasets that were released to the ILCCO repository, asking for permission to use their datasets in our
study.
The studies shared to ILCCO’s repository were originally devised and collected for different lung cancer
research objectives. Therefore, the studies had differing participant recruitment strategies and collected
information for different variables which satisfied their research objectives. As a consequence, the studies
that were released to the ILCCO repository vastly differed and there was no minimum requirement of
essential participant information that should be provided in the datasets other than the case or control
status for each participant. For the objectives of our research datasets were requested provided they
collected enough variable information so that they could be applied to a minimum of two models. This
minimum standard was set as this would allow the external validation to compare between models in the
datasets and avoid evaluating models separately in distinct datasets.
When releasing studies to the ILCCO repository, the datasets principle investigators (PIs) were also
invited to provide information on the variables collected in the study and share the questionnaire used to
collect information. Approximately half of the studies provided this information. This allowed datasets
which would not be applicable for our research objectives, because they did not collect important infor-
mation required by the models such as a detailed smoking history, to be automatically excluded. The
remaining eligible studies and all studies that did not provide a questionnaire were invited to participate in
our study. An email was sent to all the study holder principle investigators informing them of our intention
to use the datasets to perform an external validation and potentially use them to update prediction mod-
els. Approximately 60 datasets requests were sent with 20 responses. Unfortunately, only 10 had enough
information for at least 2 of the prediction models and these were collected.
4.4 Dataset Introduction
The 10 studies obtained are listed by the names they will commonly be referred to throughout the project:
1. ReSoLuCENT
2. UCLA
3. CARET
4. New York (NY) Wynder
5. Singapore
6. New Zealand
7. CREST
8. Israel
9. ESTHER
10. MSH-PMH
These will be presented in more detail during the dataset descriptive analysis (Chapter 6) where the
participant recruitment policy and population demographic will be presented and discussed.
In the obtained datasets, only the variables required by a model were provided, except in the ReSoLu-
CENT dataset where the complete IPD was received.
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Unfortunately, none of the datasets were applicable to all the models and the Spitz and African-
American model could only be applied to the CREST dataset (Table 4.1). However, the remaining models
could be applied in multiple datasets, this should allow a comprehensive review of these models and allow
comparisons between the models and implemented screening trials’ criteria.
Bach LLP Spitz Af.-Am. PLCO (×2) Pitts. Hogg. NLST UKLS
ReS. X X X X X X X
UCLA X X X X
CARET X X X X X X X
NY Wyn. X X X X X
Singapore X X X
New Zea. X X X X
CREST X X X X X X
Israel X X X
ESTHER X X X
MSH-PMH X X X X X X X
Table 4.1: Models and Screening Trials which could be Evaluated in each Dataset
4.5 Summary of Dataset Modifications
Once the datasets were received, the reported participant’s responses for each variable was reviewed. Some
of the information provided needed to be harmonised to ensure it was classified correctly for a prediction
model. Additionally, all erroneous, unreliable, or incomplete information, that could negatively affect the
proposed validation, was reviewed and rectified. The dataset preparation allowed every participant in the
IPDs to have complete, reliable information.
Some information and participants had to removed or modified. A complete summary of dataset
modifications for every variable in each dataset with justifications is presented in Appendix 12.9. A
summary of the major modifications are discussed and presented in Tables 4.2 and 4.3. Imputation of
missing information was considered, if possible for the variable under consideration if there was over
10% of missing information across all the variables in the dataset. This aimed to avoid removing too
many participants. In datasets where there was under 10% missing information, participants with missing
information were removed and the complete case analysis was preferred. Imputation in the datasets is
presented in more detail later in the chapter.
Age and BMI were checked for unreasonable entries. There were no concerns with the ages provided in
the datasets. However, BMI entries not in the range [8, 60] were removed as these results were unrealistic
and most likely due to reporting error. Across the studies a few participants were removed for erroneous
information.
Education and ethnicity the entries had to be harmonised into the form required by the PLCO models.
This was problematic in the ReSoLuCENT dataset where participants could provide a free text answer for
their highest level of education. Details of the way in which participants were reclassified is provided in
the appendix (Section 12.10.1). For the remaining ILCCO studies participants were already grouped into
their highest education level; these were then successfully reclassified into PLCO group criteria, as detailed
in the Appendix.
Smoking history required some major modifications. If the smoking status was missing and could not
be inferred from other information, such as a cessation age to indicate a former-smoker, then these were
removed from the studies. Unrealistic information was also removed for start age and cigarettes per day
(CPD). It was unrealistic to have a CPD exceeding 100 and while there were some young start ages, any age
below 8 was deemed unrealistic and removed. Further checks confirmed if StartAge+SmokingDuration =
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CessationAge for all former smokers and StartAge + SmokingDuration = CurrentAge for all current
smokers. Finally, pack years and CPD could be inferred from each other using;
PackY ears =
CPD
20
× SmokingDuration (4.1)
Checks confirmed if these values agreed when both were provided. Any incorrect information during these
checks resulted in the participant being removed.
The ReSoLuCENT study collected information differently and reported CPD entries at 20, 30, 40, 50
years and currently. Participants reported their CPD for the entries that were applicable. From this the
average CPD and pack years were inferred assuming participants had a linear increase or decrease between
two adjacent groups. It was also assumed smoking before 20 years of age remained constant at the 20-
year rate, additionally, former-smokers who quit some years after their last CPD entry were assumed to
smoke consistently at the last provided rate until they quit. This assumption allowed us to determine
the average CPD using the most relevant information available however, there is a concern this could be
incorrect. Participants may fluctuate from the last known value; it could be expected individuals may
increase smoking once they have started (to the CPD rate observed at 20) and may gradually decline
before eventually stopping (since the last known CPD provided). However, with no information on which
to further ascertain a more in-depth smoking history, assuming smoking remained constant at the last
observable rate, provided the most reliable estimate for CPD. Additionally, some participants had missing
information for one of these entries despite occurring during their smoking range. Rather than removing
participants with missing information at this stage, attempts were made to impute the missing information
which is presented in more detail during the dataset imputation (Section 4.10).
Family history of cancer required data preparation. This needed to be classified for the models into
the following;
1. Any cancer
2. Any cancer (excluding skin melanoma)
3. Smoking related cancers
4. Lung cancer
Every cancer in the later groups are also included in the earlier groups. The cancers were classified using
the Cancer Research UK website using their information on the causes of each type of cancer [102]. Each
reclassified cancer is presented in the Appendix (Section 12.11). Checks were made to ensure that the
cancers were only recorded for first degree relatives; i.e. parent, sibling, or child. Additionally, the age of
onset was reported for each relative and, in the case of multiple relatives with a positive family history,
the youngest age was recorded for each cancer subgroup.
The final variables to review were the exposures and lung conditions. These were binary responses with
the majority of participants having complete information. To avoid removing participants, we explored
methods to impute missing information using additional information for the participants in the dataset
where possible.
At this stage the datasets were modified and the variables harmonised to be applicable to the models.
The final stage was to attempt to impute missing information and then the datasets will be prepared to
conduct the external validation.
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4.6 Dataset Imputation Objectives
The within-study imputation aimed to avoid removing a large volume of participants in the datasets
(exceeding 10%) by estimating the missing information. A larger dataset may allow a fairer validation of
the models as removing a large volume of participants may make the dataset less representative of the
original population.
It is imperative if conducting an imputation that there is confidence the imputed values are accurate
estimates. Incorrect imputations could negatively affect the validation results by generating biased predic-
tions for the participant’s risk of developing lung cancer using the prediction models. It would be better
to remove the participants and have smaller datasets than keep participants with incorrect, misleading
variable estimates.
Imputations will only be conducted if a suitable method can be identified and there is evidence in the
dataset the imputation can be conducted correctly. If an imputation is conducted the imputed values will
also be assessed to confirm that the new values are realistic, to allow confidence in the estimated values,
before using them in a validation.
4.7 Dataset Imputation: The “Missingness” of Data and Rubin’s Rules
Prior to imputing the missing information, it is important to demonstrate that the variables which require
imputing are “Missing at Random” (MAR), rather than “Missing Completely at Random” (MCAR) or
“Information Missing/Missing Not at Random” (IM/MNAR). This is defined as the missingness of the
data.
Data is MAR if the likelihood of the data being missing is independent of what the missing value is,
but can be explained by the observed data. If the data is MAR then the missing values can be imputed
[108, 109]. When the data is MCAR, where the missingness of data does not depend on the observed or
unobserved data [108, 109] and MNAR, where the missingness of data depends on the unobserved data
[108, 109], it should not be imputed.
It can be difficult to determine, based on only the observable data, if the data points are MAR or
MNAR. In some instances, to impute the data, it has to be assumed the information is MAR rather than
MNAR, although for low levels of missingness the imputed estimates should be robust. Additionally, very
extreme scenarios of MNAR would have to occur for the imputation to be unreliable.
A review of the data will be conducted to assess if the data is MAR. The first test will analyse the
observed values for the variable with the missing information. This will review whether the information
for the variable is likely to be withheld as it is sensitivity information. This may occur for information
such as CPD, where participants may be reluctant to reveal how much they smoke if the number is high.
A review of the observed data points aims to assess if it is likely the information has been concealed for
extreme values. This test will review, as best as possible using only observed data point, if the data is
MAR or MNAR.
A second test aims to assess if the data is MAR or MCAR. It evaluates whether the likelihood of the
data point missing can be explained by the observed entries for other variables. This will be evaluated
through t-tests across the variables, Xi, grouped on whether variable, Xj , is missing or observed. This can
be tested in Stata 12 by the following code;
t t e s t X i , by ( mis s X j )
This test evaluates whether the observed data in both groups are not significantly different. A |T | > 1.96
means the null hypothesis is rejected and there is a significant difference between the two groups. Then it
can be determined Xj is MAR dependant on Xi rather than MCAR.
Once the testing to evaluate whether the missingness is MAR in comparison MCAR and, as best
attempted to justify using only the observable data, that the missingness is MAR against MNAR, then
the imputation can be conducted.
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Upon identifying an appropriate method to impute the missing information (Section 4.8) the imputation
will be undertaken. The imputation will be conducted 11 times independently. This will produce 11
distinct datasets where the imputed values can differ between the datasets. 11 imputations were selected
to allow confidence there is an adequate level of reproducibility in the validation results. This is achieved
by considering approximately the same volume of imputations and the percentage of missing data [110].
At this stage, a review of the imputed values will be conducted to ensure the estimates are reasonable.
Once this has been conducted, the models will then be applied to the 11 distinct datasets and the model
performance in each of the datasets evaluated.
When presenting the model performance, the aggregated results across the 11 imputed datasets will be
presented where possible. This is calculated using Rubin’s Rules which combines the estimates and also
allows for variability in the model performance across the datasets by incorporating this uncertainty into
the 95% confidence intervals. The results for the Brier Score, sensitivity and specificity can be combined
using Rubin’s Rules as follows;
θˆMI =
1
J
J∑
n=1
θˆn (4.2)
Where θˆn is the Brier Score, sensitivity, or specificity result in the n
th dataset. The PLR results will be
calculated from the sensitivity and specificity results obtained from Equation 4.2.
The AUC will also be calculated using Equation 4.2 but the standard error is calculated to determine
the 95% confidence interval for the AUC. This is calculated to include the within-imputation variance, σˆ2w
and between-imputation variance, σˆ2b ;
σˆ2w =
1
J
J∑
n=1
σˆ2n (4.3)
σˆ2b =
1
J − 1
J∑
n=1
(
θˆn − θˆMI
)2
(4.4)
Where θˆMI is determined from Equation 4.2. Then the standard error for the combined estimate is as
follows;
σˆMI =
(
1 +
1
J
)
σˆ2b + σˆ
2
w (4.5)
Now the standard error has been calculated the 95% CI can be determined by;
95% Confidence Interval =
[
θˆMI − σˆMIt(v,0.975), θˆMI + σˆMIt(v,0.975)
]
(4.6)
≡
[
θˆMI − 1.96σˆMI , θˆMI + 1.96σˆMI
]
(4.7)
The Hosmer-Lemeshow result will not be aggregated using Rubin’s Rules. The result from the aggre-
gated dataset will be presented. However, if the result in any of the 11 imputed datasets changes for the
critical p-value of 0.05 all results will be disclosed.
The tests to evaluate the missingness of the data and to combine the validation results using Rubin’s
Rules will be employed to ensure there can be confidence using imputed values to evaluate the models’
performance. The next stage is to identify a practical method to impute the missing information.
4.8 Review of the Imputation Methods
A review of the available methods to impute missing information is presented to assess if there is a method
that is suitable for the purpose of our study.
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4.8.1 Complete Case Analysis
The first approach is to remove any participants with missing information. This is referred to as complete
case analysis. There are advantages to this method as it avoids concerns with inappropriate imputations.
Poor imputations for a participant will see the models estimate inaccurate risks for the likelihood of lung
cancer developing. This will influence the performance of the prediction models when validated. Complete
case analysis can be preferred as there are no concerns with subsequent results generated using imputed
information.
However, removing all participants with incomplete information could drastically reduce the IPD size.
A severely reduced dataset may compromise the validation results. There is also potential the complete
case analysis may cause bias [111]. By removing participants with incomplete information this can remove
evidence that should be considered if the missingness of data is MAR [111]. The final population may
become biased, when removing participants who have missing information for a variable, which can create
unreliable validation results, especially if a large proportion of participants would be removed. This is
a concern with complete case analysis and why imputation should be considered, particularly if a large
proportion of the study would be removed.
4.8.2 Mean Imputation
Mean imputation assigns the mean value, for all the missing values for a variable, using the complete
information for this variable [107]. This is not a preferential method as it fails to assign accurate estimates
for the missing variable. The method has the potential to create bias and understates the variability for
the missing information [112].
The purpose of the imputation is to create a complete dataset in which the prediction models can be
applied and reviewed. Therefore, assigning the same values for participants is unreasonable and unrealistic.
As a consequence, the performance of the models in the dataset will be reduced, the lack of variability
for the variable, will restrict the models’ ability to discriminate between individuals with or without lung
cancer, or generate accurate risks for an individual.
4.8.3 Last Value Carried Forward
The last value carried forward method imputes the information using previous information for a participant.
This method is used when data is collected ‘longitudinally’ over time and there are follow-ups for the
participants. The last plausible value for the participant is then carried forward [108]. This method is
most likely to be considered for clinical trials that conduct follow-ups, however the datasets we received
did not record the majority of the data ‘longitudinally’. There is the potential for this method to be used
for the smoking quantities in the ReSoLuCENT dataset which are recorded at 20, 30, 40 and 50 years. It
could be reasonable to assume there would not be a large variance between smoking quantities at different
ages for an individual.
There are limitations to this method. Basing the imputation on as much information as possible, rather
than the last plausible value, can generate more accurate estimates for the variable. Additionally, this can
underestimate the variability that can occur in a variable across time between follow-ups and create bias
[112]. Overall, this method is not the most appropriate for the participant information received across the
datasets.
4.8.4 Simple Random Imputation
This method imputes a random value for the missing information of a variable based on the observed results
for this variable [108]. The purpose of this method is to create random noise for the variable and account
for the variability that is observed [112]. To achieve this the imputed values are based on the observed
information for the variable recorded for different participants, rather than using additional information for
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the participant with the missing information. A random value is then assigned for the missing information
based on the evidence for this variable.
These are concerns in using simple random imputation to impute the missing information. The esti-
mated values are not based upon available evidence for the participants with missing information. There-
fore, the imputed values may be unreliable for the participant. This concern is magnified when imputing
missing information for multiple variables, all of which have the risk of being inappropriate for the observed
participant profile. Consequently, this will negatively affect the model’s ability to accurately predict the
likelihood of an individual developing lung cancer based upon these imputed values.
4.8.5 Regression Predictions to Perform Deterministic Imputation
This method uses observable information specific to the participant in a regression model to predict the
missing values [108]. By using the observed data for each participant, this method aims to accurately
estimate the missing variable. This can allow more confidence in the imputed variable as the method
utilises the most relevant explanatory variables in the estimate. This method can be successful when there
is a large range of additional information available for each participant to build a more accurate participant
profile.
This method is most appropriate for single imputation, when there is missing information for only one
variable [108]. This method has some limitations for imputation of multiple variables. If participants have
missing information for some of explanatory variables then these cannot be used to impute the missing
information. Additionally, if imputed values are then used in further imputations, there is no consideration
of the uncertainty of the accuracy of these imputed values. Any error in imputing the first variables will
distort the estimates in the subsequent rounds of imputation. It would be preferential if there was a penalty
to account for the uncertainty in these values. This concern could be avoided by only considering variables
with complete information to base the imputation. However, in a dataset with missing information, it is
unlikely the remaining variables will have complete information. It would also be unwise to exclude an
explanatory variable because it reported some missing information. Then the imputation would be based
on weaker information and lower the accuracy of the imputations.
4.8.6 Random Regression Imputation
Random regression imputation considers relevant participant explanatory variables in a regression equation
and incorporates randomness for the variable by including an error value in the estimate [108].
Similar to Regression Prediction to Perform Deterministic Imputation (Section 4.8.5) this method is
most appropriate for single imputation rather than missing information for a range of variables. If there
are imputed values used in subsequent imputations then there is a greater potential for poor predictions.
This could be counteracted by assigning a penalty to variables considered in the imputation that have
previously been imputed. Additionally, only variables with complete information could be considered in
the imputation but this reduces the volume of variables to accurately estimate the missing information.
Random regression imputation has some additional limitations; by incorporating randomness the esti-
mates differ from the most likely estimate for the participant. This aims to incorporate the variability that
observed in the variable [112]. However, this is an inappropriate method if the purpose of the imputation
is to create accurate participant profiles. The method could drastically deviate the estimated risk from the
most likely estimate.
4.8.7 Matching
This method matches a participant with missing information to another participant with a similar profile
that has complete information based on the observed information. The missing value is replaced by
the value the other participant has for that variable [108]. Matching considers the relationship between
participants using the observed data to pair participants with incomplete information with participants
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with complete information. This allows the method to generate realistic estimates for the missing values
as they are observed in the dataset.
It is imperative with this method that the participants are matched over key variables that most explain
the missing value. It is important that multiple variables to match participants are identified and weighted,
otherwise the participants could have similar profiles to multiple other participants but they could have
drastically different values for the variable that will be imputed. This method works best when matching
over continuous variables [108]; for dichotomous outcomes there will be many participants in the dataset
that have a matching profile.
This method can be limited in IPDs where there is missing information for multiple variables. This
makes it more difficult to successfully match participant profiles to generate accurate estimates for the
missing information.
4.8.8 Multiple Iterative Regression Imputation
Multiple imputation using chained equations (MICE) imputes missing values across multiple variables
simultaneously [113]. This is the only method that imputes information where the explanatory variables
can have missing information. As a result this allows a large volume of evidence to be considered in the
imputation regardless of whether there is complete or missing information for the variable. MICE can
consider categorical and dichotomous data through ordinal and logit functions allowing it to be used for
all forms of missing data.
To apply the method for the variables considered, any missing values for x1 are imputed using x2, ..., xn.
When imputing this value if any of the variables [x2, xn] have missing information they are not considered
in the imputation of x1. Next, x2 is imputed considering the imputed value or already compete value for
x1 and x3, ..., xn [113]. After a complete cycle this is re-run until the imputed results converge and are
stable between each cycle. This reduces the likelihood of inappropriate imputations in an earlier cycle
when there may be limited information.
While this method can deal with multiple missing values it is important that the participants have
some complete information. Otherwise, the imputation will may be based on insufficient evidence and may
generate poor estimates. Participants with too much missing information across all the variables considered
in the imputation should be considered for removal from the IPD before the imputation is conducted.
An advantage of this method is whether the variables originally have complete or missing informa-
tion they can still be considered during the imputation. Then by stabilising all variables with missing
information it can create confidence the estimated values are reasonable. This also allows the key explana-
tory variables to be used without concern even when these values contain missing information for some
participants.
4.8.9 Imputation Methods Summary
In the ILCCO datasets received there is missing information across multiple variables. Therefore, MICE
is the most appropriate method to generate accurate estimates for the missing information. The other
identified methods are more appropriate for missing information for a single variable. However, when
there are participants with missing information across multiple variables several independent imputations
would have to be considered. There is a concern that any erroneous imputed values could be considered
in subsequent imputations. Additionally, these methods need a set of core explanatory variables with
complete information to conduct the original imputation. This can reduce the evidence on which the
original imputation is based. In contrast MICE will consider all the variables in one single imputation
whether they have complete or missing information. This method also considers whether the variable
in the imputation has been imputed and then considered in the imputation for another variable. MICE
accounts for this by recursively imputing the imputation until all the imputed values have stabilised.
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4.9 Conducting the Imputation
MICE will be conducted in the ReSoLuCENT and MSH-PMH dataset as there was more than 10% of
participants with some level of missing information across the variables.
The first stage to conducting the imputation will review if the missingness of data is MAR or MNAR.
This will be achieved by evaluating the observed data and assessing if there are any indications the data
has been purposely withheld. However, since there are low levels of missing data the imputed values should
be robust whether the missingness of data is MAR or MNAR. Next the association between variables will
be reviewed through t-tests. This will evaluate if the data is MAR, as desired, or MCAR. This is explained
in more detail in Section 4.7.
One round of MICE will then be conducted separately in each of these two datasets which will impute
missing information across all the variables. This round of imputation will consist of 11 independent
iterations. This aims to eliminate the possibility of the imputation for specific participants being unrealistic.
11 imputations were selected as this seemed reasonable to allow the imputation results to not be significantly
skewed by an unusual result for one imputation. An odd number also allowed a clear result for imputed
variables with a dichotomous outcome.
When conducting the imputation multiple variables including both complete and missing information
will be considered in the imputation. However, case-control status will not be considered in the imputation
as this may bias the imputed values, such as assigning a heavier smoking history or prior lung conditions
to individuals with lung cancer. This will bias the models’ performance and improve their discriminative
ability [115].
The imputation will be reported to review whether the imputation has been successful and the imputed
values are reasonable. This will assess whether there are any erroneous values imputed. However, to avoid
incorrect imputations, such as a negative CPD, the imputed values will be matched to their nearest
neighbour based on the observed results when performing the imputation.
The imputed dataset will then be used in the model validations and the uncertainty in the imputed
values will be considered using Rubin’s Rules, across the 11 independent imputations, as presented in
Section 4.7.
The imputation in the ReSoLuCENT and MSH-PMH datasets will now be conducted, presented and
reviewed.
4.10 ReSoLuCENT Dataset Imputation
There were 18% of participants in the ReSoLuCENT dataset who had missing information for at least one
variable where imputation was attempted.
A summary of the missing information is presented in Figure 4.6. The figure shows there was a large
volume of missing information for the smoking variables (S31 1ya, S31 20, S31 30, S31 40 and S31 50).
The ReSoLuCENT dataset reported information on how much participants smoked last year and at 20,
30, 40, 50 years.
Table 4.6 also displayed a high level of missing information for the age of onset of cancers. However,
this value was only included if there was a positive family history. All missing values are accounted for,
as the participants did not have a positive family history of cancer. As a result this was not considered in
the multiple imputation.
There were 46 participants who did not report asbestos exposure and 17 who did not report their ETS
exposure. There was missing information for gender, ethnicity, education and other lung conditions which
will be imputed, although this was only missing for a small number of participants (1-7).
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Variable Missing Observed
Gender 1 1,077
Ethnicity 2 1,076
Education 7 1,071
Smoking Last Year 342 736
Smoking 20 32 1,046
Smoking 30 64 1,014
Smoking 40 146 932
Smoking 50 324 754
Age of Any Cancer 431 647
Age of Any Cancer (Excluding Melonoma) 433 645
Age of Smoking Cancer 534 544
Age of Lung Cancer 718 360
Asthma 1 1,077
Emphysema 1 1,077
COPD 1 1,077
Dust 4 1,074
Asbestos 46 1,032
Table 4.6: ReSoLuCENT Dataset: Identifying the Missing Information
Now that the variables that required imputation had been identified, the next stage was to evaluate if the
data was MAR. This missingness of information was unlikely to be MNAR as they agreed to participate
in a hospital study for lung cancer. Therefore, it is unlikely the information would then be purposely
withheld.
The next stage reviewed if the data was MAR in comparison to MCAR. A t-test was conducted using
the observed information for all the variables which had at least 10 participants with missing information
and additional variables. The results are displayed in Table 4.7.
Variable One Variable Two T-Test
Smoked at 50 Smoked Last Year -6.14
Smoked at 50 Smoked at 20 -2.70
Smoked at 20 Smoked at 30 -2.96
Smoked at 20 Smoked at 40 -3.83
Smoked at 20 Smoked at 50 -7.18
Asbestos Exposure ETS Exposure -2.85
Gender Asbestos Exposure 2.36
Table 4.7: T-Test Results by Missing Information in the ReSoLuCENT Dataset for Variables considered
in Imputation
The data was shown to be MAR in comparison to MCAR with |T | > 1.96 for all the variables considered
in the imputation. The smoking information was shown to be MAR in comparison to MCAR dependant
on entries for different smoking quantities.
ETS was MAR dependant on asbestos exposure; an increased asbestos exposure rate was shown in
individuals who did not report their ETS exposure. Finally, asbestos exposure was MAR dependant on
gender. Males were shown more likely not to report whether they had been exposed to asbestos. Now the
variables considered in the imputation have been shown to be MAR the imputation can be conducted.
The imputation was successfully conducted in Stata 12 using the following code;
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\ t e x t i t {∗ Set the imputation }
mi s e t wide
\ t e x t i t {∗Reg i s t e r the v a r i a b l e s f o r imputation }
mi r e g i s t e r imputed AgeRegistered BMI ETSNumeric PMT Pneumonia ///
SmokingStatusNumeric StartAge CessationAge Asbestos COPD Emphysema Asthma ///
LastYear Smoked20 Smoked30 Smoked40 Smoked50 PLCOEducationScale ///
E th n i c i t yS c a l e Gender
\ t e x t i t {∗ Impute the miss ing in fo rmat ion }
mi imp chained (pmm) AgeRegistered BMI StartAge CessationAge LastYear Smoked20 ///
Smoked30 Smoked40 Smoked50 ( l o g i t , augment ) ETSNumeric PMT Pneumonia Asbestos ///
COPD Emphysema Asthma ( o l o g i t , augment ) Gender SmokingStatusNumeric ///
E th n i c i t yS c a l e PLCOEducationScale , add (11) r s eed (19) dots
All missing values were all imputed.
The next stage was to evaluate the missing information to assess if the results were reliable. A review of
the imputed results indicated the missing information was successful imputed. There were no unexpected
values as the imputed values were matched to observed values after imputation.
In conclusion the imputation in the ReSoLuCENT dataset was successfully conducted to avoid removing
18% of participants. The missingness of data was shown to be MAR in comparison to MCAR. The missing
values were imputed and there can be confidence using these imputed values in an external validation of
models.
4.11 MSH-PMH Dataset Imputation
There were 26% of participants who had missing information for at least one variable in the dataset.
Attempts were made to impute this missing information rather than remove these participants.
The level of missing information for each variable is presented in Figure 4.8. There were high levels of
information missing for lung conditions; pneumonia, COPD and emphysema as well as asbestos exposure,
ethnicity, education and BMI. Finally, there was one missing entry for age and 37 participants who did
not provide ETS information.
Variable Missing Observed
Age Registered 1 2,743
Ethnicity 108 2,636
Education 116 2,628
BMI 123 2,619
ETS 37 2,707
Asbestos 214 2,530
Pneumonia 215 2,529
COPD 249 2,495
Emphysema 240 2,504
Eczema 95 2,649
Table 4.8: MSH-PMH Dataset: Identifying the Missing Information
As the MSH-PMH study recruited participants in a hospital setting, it is unlikely the information is
purposely withheld. Additionally, for the small level of missing information the imputation should be
robust whether MAR or MNAR. Then for all the variables that required imputation, except for age with
only 1 missing entry, t-tests were performed to evaluate if the missingness of data was dependant on the
observable information for another variable. The t-test results are presented in Table 4.9. All the variables
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were shown to be MAR in comparison to MCAR as the missingness of the data was dependant on the
results for different variables.
Variable One Variable Two T-Test
Age Ethnicity 3,41
Age Education -5.01
Age BMI -4.31
CPD ETS -3.38
Age Asbestos -5.99
COPD Pneumonia -9.36
Emphysema COPD -9.44
COPD Emphysema -17.01
Table 4.9: T-Test Results by Missing Information in the MSH-PMH Dataset for Variables considered in
Imputation
The next stage was to conduct the imputation and assess if all missing information was successfully
imputed. The following code was used in the imputation;
\ t e x t i t {∗ Set the imputation }
mi s e t wide
\ t e x t i t {∗Reg i s t e r the v a r i a b l e s f o r imputat ions }
mi r e g i s t e r imputed AgeRegistered Et h n i c i t y S ca l e PLCOEducationScale BMI ETS ///
Asbestos Pneumonia COPD Emphysema Eczema CPD Gender PMT LCC
\ t e x t i t {∗ Impute the miss ing in fo rmat ion }
mi imp chained (pmm) AgeRegistered BMI CPD( l o g i t , augment ) ETS Asbestos ///
Pneumonia COPD Emphysema Eczema Gender PMT LCC ( o l o g i t , augment ) ///
E th n i c i t yS c a l e PLCOEducationScale , add (11) r s eed (19) dots
The imputation was successfully conducted and all missing information imputed. The estimated values
were reasonable as a review of the new values did not identify any unexpected values. These values will be
used to apply the prediction models in the dataset.
4.12 Summary
Ten datasets were collected from ILCCO. These could be applied to multiple lung cancer prediction models
although not all models were applicable to each dataset. The datasets were prepared so that the variable
information was complete for each model that was applicable.
MI used to impute missing information in instances of large levels of missing information (exceeding
10%). This was conducted if the data was shown to be MAR in comparison to MCAR as the complete
case analysis may lead to biased results. Attempts were made to demonstrate the missingness of data was
MAR in comparison to MNAR, however, for small levels of missing information the imputations should be
robust. Two imputations were conducted, using MICE, in the ReSoLuCENT and MSH-PMH datasets.
The datasets were now fully prepared for the models to be applied and validated. The next stage is to
review the datasets, their population demographic and their participant recruitment strategy.
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CHAPTER 5
Dataset Descriptive Analysis
5.1 Introduction
This chapter will present the characteristics of the ten studies which will be used in the external validation.
The datasets were uniquely collected for different study objectives; this may result in some unusual study
populations. The chapter will provide a descriptive analysis which will highlight any similarities, differences,
strengths and limitations of the datasets available by reviewing how participants were recruited for the
study and population demographic. This will give an indication into any models that could have a sub-par
performance in a dataset due to distinct dataset characteristics. This follows the guidelines promoted by
TRIPOD in how to report any influences and limitations in the datasets used in a validation study to allow
confidence in the validation results [46].
5.2 Objectives
To perform a dataset descriptive analysis, the chapter will:
1. Present how participants were recruited for each study.
2. Present the population demographic for every variable required by the models for each dataset.
3. Discuss the dataset collection and population demographic to assess if this could influence any model
performance.
5.3 ReSoLuCENT Dataset
The Resource for the Study of Lung Cancer Epidemiology in North Trent (ReSoLuCENT) is a study in the
National Institute for Health Research Clinical Research Network (NIHR CRN) Portfolio. It is an ongoing
study (at the time the dataset was collected) and started data collection on 06.04.2006 with a proposed
finish on 31.08.2015. The dataset was made available in March 2015, as the study drew to a conclusion.
The participants were collected from various locations around the United Kingdom [123];
1. Airedale
2. Chesterfield
3. Doncaster
4. Edinburgh
5. Manchester
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6. Rotherham
7. Sheffield
8. Southampton
The study entry conditions were as follows [123];
“You can enter this trial if you have lung cancer or you need to have an operation for suspected lung
cancer. As well as this you can enter this trial if you
• Are 60 years old or less, OR
• Have a first degree relative aged 60 or less who has lung cancer, OR
• Have two or more first or second degree relatives of any age who have lung cancer
You may be able to be in the ‘control’ group if you
• Are the partner of someone taking part in the study, OR
• Are a first degree relative of someone taking part in the study and are at least 18 years old
A first degree relative is a parent, child, brother or sister. A second degree relative is an aunt, uncle,
grandchild or grandparent, for example.”
This study was designed to investigate lung cancer, considering both small cell and non-small cell type
cancers. The protocol stated “The aim of this study is to collect good quality epidemiological and biological
data from lung cancer patients with a family history of the disease or with early onset lung cancer.” [124]
The ReSoLuCENT study was designed to examine early onset lung cancer and recruited participants
accordingly. This results in a young collection of lung cancer patients in whom lung cancer is a rare
occurrence [1]. This is presented in the population demographic in Table 5.1 where the diseased and
disease free individuals are both concentrated around 50 years of age.
The ReSoLuCENT dataset is a case-control study and controls were recruited for the study if they
were a first degree relative of an identified case [124]. By initially collecting controls who are related to
a lung cancer case, a high proportion of controls in the study will have a positive family history of lung
cancer. In an attempt to counteract this concern, the ReSoLuCENT study proposed collecting 1,000 cases
and 1,500 controls with each case “to be matched with at least one control (ideally one related and one
non-related)” [124]. In a general population only a small proportion of participants would have a positive
family history and despite the additional controls collected the dataset still reported a positive lung cancer
family history in approximately 50% of controls (Table 5.1).
5.4 University of California, Los Angeles Study (UCLA)
The University of California, Los Angeles (UCLA) study is an American based case-control study. The
study was collected in LA using the following methodology [125];
“All subjects in this study were:
(a) residents of Los Angeles County at the time of diagnosis for cases or at the time of recruitment for
controls
(b) were 18 to 65 years of age during the study period, 1999 to 2004;
(c) spoke either English or Spanish, or had translators available at home.”
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The study did not focus solely on lung cancer incidents, but the data received from ILCCO repository
contained 611 lung cancer cases and 1,040 control participants. The original study also identified 601
individuals who had oral, pharynx, larynx and oesophageal cancers, but these were not provided in the
dataset recieved. Individuals with lung cancer were collected “by the rapid ascertainment system of the
Cancer Surveillance Program for Los Angeles County, which is administered by the Keck School of Medicine
and the Norris Comprehensive Cancer Center at the University of Southern California” [125]. Controls
“were individually matched to cases on age by decade, gender and residential neighbourhood” [125].
Another concern with the participant recruitment is limiting the maximum age of inclusion to 65 years
for cases and controls. The original study purpose was to evaluate lung cancer onset in unusual young
cases. This creates a final dataset where the participants are considered at low risk of developing lung
cancer. Therefore, the age range for this study is younger than the age range that any lung cancer screening
programme would likely consider. The young population is highlighted in Table 5.1 with the cases and
controls reporting an average age of 50 years old.
One final concern with the UCLA dataset was that participant’s education status was pre-categorised
into five levels. However, the PLCO models categorised participants’ education status into six levels. The
participants in the UCLA could not be reclassified into the six PLCO levels (Section 12.4) and so no
participants were classified as “More than high school” as the other UCLA categories coincided with a
PLCO Model category.
5.5 CARET Dataset
The CARET dataset obtained is a subset of the study used to create the Bach Model. Therefore it is likely
the results from the validation will be favourable for the Bach Model. The dataset will provide a high risk
population to evaluate the prediction models.
In contrast to the ReSoLuCENT and UCLA studies, this study recruited high risk participants who
were “heavy smokers and asbestos-exposed workers” [126]. To recruit high risk participants, never-smokers
were excluded from the study.
The participants were collected at various centres across the United States, with collections taking
place in “Seattle, Portland, San Francisco, Baltimore, Connecticut and Irvine” [126]. The study protocol
set out to recruit participants for their trial if they satisfied [126];
“CARET is a randomized, double-masked, placebo-controlled chemoprevention trial in two groups of
adults at high risk for lung cancer:
(a) men and women age 50-69 years with a history of at least 20 pack-years of cigarette smoking
(b) men age 45-69 years with evidence of extensive occupational exposure to asbestos and a history of
cigarette smoking.”
“Through April 30, 1993, CARET had randomized 4,000 asbestos-exposed workers, exceeding accrual
goals at all five CARET asbestos centres and 11,105 heavy smokers” [126].
The study design means that the participants were mainly males (Table 5.1) however; lung cancer
prevalence is evenly distributed among men and women so this is not a concern. Excluding never-smokers
might be a problem when coupled with the high volume of asbestos exposed workers. These two selection
criteria means that participants are at increased risk of developing lung cancer. These participants may all
be considered high enough risk, due to their smoking and asbestos history, to be considered for screening.
The age restriction during recruitment should not be a major concern as most target screening popu-
lations are included in this 45-70 years age group. Indeed, this is the main age bracket of individuals that
would benefit from screening.
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Finally, the CARET dataset is a cohort study, this means the cases and controls were not matched
and were recruited provided they satisfied the entry criteria. This should allow a fair validation of the
prediction models.
5.6 New York Wynder Dataset
The NY Wynder study is a large multicenter case-control study collected across the United States. Cases
were recruited as “men and women who were diagnosed with lung cancer were interviewed by trained
personnel in nine hospitals in New York, Michigan, Illinois and Pennsylvania” [127]. Controls were matched
by location and age where “controls were interviewed in the same hospital as the case and within 2 months
of the case interview. Controls matched on age to the cases (within 2-5 years)” [127]. There were no
further restrictions in recruiting the participants to the study.
Asbestos exposure and smoking status was categorised based on the questionnaire responses [127];
“Subjects were asked separate questions on whether they had been exposed to asbestos dust on the job
for at least 8 hr a week for 1 or more years.
Lifetime exposure to tobacco smoke was assessed according to current smoking status, number of cigarettes
smoked per day and number of years since quitting (for ex-smokers). Never smokers included subjects who
smoked fewer than 100 cigarettes; current smoking was defined as smoking one or more cigarettes per day.
Ex-smokers were defined as having quit smoking for at least 1 year.”
This is consistent with how smokers and exposures were defined by the prediction models.
Limited additional information was provided in the study protocol, although Table 5.1 shows that
education was collected using 5 levels rather than the 6 levels used in the PLCO models. This could not
be reclassified into the 6 levels required by the PLCO models; participants were not classified as “some
college”.
Overall, the NY Wynder study provides a good population to validate the models. This is supported
by the population demographic (Table 5.1); as the NY Wynder study collected a population that would
be considered for selective screening.
5.7 Singapore Dataset
The Singapore Chinese Health Study is a large prospective cohort study [128]. The cohort design prevented
the cases and controls being matched over key variables to provide a representative sample of participants
with which to evaluate the models. The study recruited participants between 1993 and 1998 accumulating
63,257 Asian participants. The trial restricted inclusion by age and location recruiting participants aged
between 45-74 years who were Singapore residents. The location will allow an opportunity to evaluate
the models outside of a European or North American population. Additionally, the age restrictions in the
recruitment will not be a concern, this incorporates the eligible population for previous screening trials
and it is most likely any selective screening programme would consider a similar age range.
Unfortunately, only a small proportion of the large cohort was received from the ILCCO repository.
The received datasets contained 314 lung cancer cases and 1,070 controls. Lung cancer was identified by
records “with the Singapore Cancer Registry and the Registry of Births and Death” [128]. All lung cancer
cases identified in the study were provided for our analysis. This included 16 cancers identified at baseline
testing and in the most recent dataset after final follow ups by 31st December 2005 a further “298 women
cohort participants who were free of cancer at baseline had developed lung cancer” [128]. However, the
received dataset restricted the volume of controls that were provided. By restricting the lung cancer free
individuals received, this subset of the cohort reports a higher lung cancer prevalence rate than would be
observed in a selective screening population.
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The Singapore dataset collected little information other than smoking history, therefore, only allowed
the Hoggart and Pittsburgh models to be applied.
Finally, the participants in the dataset were all female. While a mixed population would be preferred
this will not influence the validation results obtained as lung cancer has an equally high prevalence rate in
males and females [1] and there is no significant difference in lung cancer susceptibility between the two
genders [1]. Additionally, the Hoggart and Pittsburgh models do not incorporate gender into their risk
prediction model.
5.8 New Zealand Dataset
The New Zealand study is a small case-control dataset which prioritised collecting lung cancer cases
observed in younger participants. The study recruited participants between January 2001 to July 2005
from “hospital databases and the New Zealand Cancer Registry” [130] and by collecting subjects from
“eight district boards which represents just under half of the New Zealand population” and allowed a
different, nationwide sample of participants to be included.
The study targeted rarer occurrences because “cases were patients with confirmed lung cancer aged 55
years and under” [130] and controls were matched by “5-year age groups and district health boards” [130].
This created a young population demographic (Table 5.3). In additional to participants being young, they
reported a low pack year smoking history because of a reduced smoking period. As a result the majority
of participants could be considered at low risk of developing lung cancer. Therefore, this population would
most likely be extended to include older participants, who are at higher risk of developing lung cancer, in
any selective screening programme.
The study participants who smoked cigarettes occasionally, but not daily, were classified as never
smokers. There is no concern with this as their CPD and pack year values were nominal and in terms
of how the models originally defined ever-smokers they would also be classified as a never-smoker. Table
5.3 highlights that there is no significant difference in CPD rates between individuals with or without
lung cancer, as a result models may be limited in distinguishing between individuals with or without lung
cancer.
Finally, for a family history of cancer only information for siblings and parents was collected and
children excluded. However, since the cases and controls are of a young age their offspring are highly
unlikely to be of an age where lung cancer can realistically develop [130].
5.9 CREST Dataset
The CREST study provided a case-control population with participants collected in Genoa, Italy since
1996. The primary focus of the data collection was to create a biorepository at the National Cancer
Institute for all cancers.
The participants were collected for the study if they satisfied [131];
• “Patients with respiratory tract cancer. Patients who have been diagnosed with lung cancer or pleural
malignant mesothelioma and that are sampled before any treatment, including surgery. Samples are
collected within the framework of ad hoc molecular epidemiology studies or are obtained through a
collaborative regional network of pneumologic departments.
• Controls. Patients hospitalized for nonneoplastic and nonrespiratory conditions in orthopedic or
ophthalmology departments. Other reference subjects are recruited from blood donors, from social and
recreational clubs and homes for the elderly located in the same geographic area where cancer patients
are hospitalized. Community outreach programs, including information provided through local TV
and newspapers, are occasionally carried out to increase compliance in this group.”
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All lung cancer cases were eligible for the study with no age or smoking history restrictions enforced
during the recruitment. The controls were identified using a hospital population. However, participants
hospitalised with lung conditions were excluded, this is unfortunate because lung conditions are considered
by models to assign higher risk to individuals. The controls were also matched on age.
When the data collection had concluded by January 31st 2008, 446 lung cancer cases were identified
and 935 controls from the ILCCO repository. All cases were provided, although only 542 controls were
received. This is due to the ILCCO repository only receiving information for a proportion of the controls.
This may create bias as we have a restricted subgroup of the sample population.
5.10 Israel Dataset
The Israel study is a case-control dataset that collected participants who were located in northern Israel.
The study was conducted in 2006 and the cases were identified after diagnosis in local hospitals. The
controls were also collected from residents in northern Israel and were matched 1:1 between cases and
controls based on location, gender, age and ethnicity [132]. These three variables are required by models
which could limit the models’ discriminative ability. However, the PLCO models, the only models that
require ethnicity were not applicable to this dataset as other variable information was missing.
The final dataset provided is quite small with 301 cases and 316 controls. An analysis of this small
dataset, presented in Table 5.3, indicates an elderly population has been recruited. It could be argued
the participants in the Israel dataset are elderly with the mean age for cases approximately 67 years
and controls of 70 years. This is certainly higher than the average population in previously implemented
screening trials for lung cancer. As an elevated lung cancer risk is associated with an increased age then it
could be argued a marginally high risk population has been collected in the Israel dataset.
Despite the elderly population, the study does not appear to have targeted a specific sample population,
whether high risk ever-smokers or a population exposed to a material such as asbestos. Unfortunately, this
could not be categorically verified because the study protocol was not provided to enable a review of the
exclusion/inclusion criteria.
5.11 ESTHER Dataset
The ESTHER study collected participants from “Saarland in Southwest Germany” [133] and is a combi-
nation of two sub-studies; ESTHER 1 and ESTHER 2. Both studies were matched case-control datasets
collected at hospitals and general practices between June 2000 and December 2002. The final dataset
obtained included 185 cases and 184 controls.
ESTHER 1 collected participants who had a general check-up with the primary study focus on chronic
diseases. ESTHER 2 focused on common forms of cancers (colon/rectum, lung, prostate, breast) and was
composed of participants diagnosed between January 2001 to December 2003. Age was restricted to 50-74
years in both studies. However, this is a reasonable age range that is appropriate for lung cancer selective
screening programmes.
ESTHER 2 identified 197 lung cancer cases during the study, “confirmed using a serum sample” [133]
and these were included in the dataset received from the ILCCO repository. They were matched 1-1 with
participants from ESTHER 1 who served as controls in the datasets. Unfortunately, the specifics for the
matching between cases and controls could not be obtained. There were concerns that the controls were
identified from check-ups for chronic conditions and that this would lead to an unexpectedly high volume
of controls with lung conditions, particularly COPD. However, these conditions were not reported in the
ESTHER dataset received. Indeed, the lack of reporting for variables other than smoking history restricted
the dataset to only the Hoggart and Pittsburgh model. While all the participants are classified as white
this is not a concern as this variable is not considered by any models applicable to the dataset.
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5.12 MSH-PMH Dataset
The MSH-PMH study was a case-control dataset using a clinic based sample population [135]. The primary
information for the study was obtained through contact with the Principle Investigator (R.Hung [134]),
providing information on the key points of the study and design.
The key information obtained from the P.I. was as follows;
• The cases are recruited from Princess Margaret Hospital, a designated cancer hospital in Greater
Toronto Area.
• The controls are recruited from the family medicine registration database in Mount Sinai Hospital,
which is next to Princess Margaret Hospital and hosted one of the largest family medicine practices
in Greater Toronto Area.
• The cases and controls completed standardized study questionnaires and clarifications were followed
up by study personnel.”
The MSH-PMH study was collected in Ontario, Canada between 2006 and 2013. Controls were matched to
cases on a 1-1 ratio based on age, gender and location [136]. There were no other demographic restrictions
in the model recruitment as both males and females aged 18 years and up were eligible for the study [136].
The study only recruited NSCLC cases [136]. However, this does not affect the prediction models as the
cancer type is not important when predicting risk.
When obtaining the dataset participants were already classified into 5 education levels whereas the
PLCO models require 6 levels. As a result, no participant was classified in the lowest education level
(Table 5.3). Table 5.3 also shows that a high proportion of cases and controls with pneumonia and COPD
exposure was recruited.
Overall, the large dataset should allow a thorough evaluation of the models’ ability as the study did not
restrict eligibility for inclusion. This created a sample population to be collected that would be considered
in a lung cancer selective screening programme. One concern is the slightly high positive lung conditions
observed for both cases and controls; in particular for pneumonia and COPD.
5.13 Dataset Summary
Upon reviewing the study recruitment process, the key strengths and limitations of the datasets, in the
context of using the sample populations to validate prediction models, are summarised.
The majority of the datasets obtained were case-control studies. These were the ReSoLuCENT, UCLA,
Ny Wynder, New Zealand, CREST, Israel, ESTHER and MSH-PMH datasets. Cohort studies are prefer-
ential as the study will have collected a disease free population and observed whether lung cancer developed
in individuals. This is the precise purpose of the lung cancer prediction models, to be applied to a disease
free population and predict the likelihood of lung cancer developing. Therefore, a cohort would give a
comprehensive review of how the models perform. In contrast case-control studies may bias the results.
The cases are commonly at an advanced stage of the disease when recruited for the study. This could assist
the prediction models, as the cases may report a high risk of developing the disease, which will boost the
discriminative ability of the models. As a result, an optimistic model performance may be reported which
would not be observed in a selective screening programme. This is a limitation of using case-control studies
to validate prediction models and provide accurate summaries of how to apply the model as a selective
screening tool. While results for the discrimination, sensitivity and specificity, may be slightly higher than
would be observed in a selective screening tool, the case-control datasets will still allow a comprehensive
comparison between models and screening criteria to identify a leading model.
Secondly, the obtained datasets have a high proportion of individuals with lung cancer, commonly
around 50% of the dataset participants (Tables 5.1 and 5.3). This is a considerably higher prevalence rate
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than observed worldwide ([1]). This will affect the calibration results. The models were designed in cohort
studies with a prevalence rate similar to that observed globally. Therefore, the models are not designed to
predict such a high incidence rate observed in the datasets obtained. This may lead to models reporting
a poor calibration result through the Hosmer-Lemeshow test and Brier score. This could make it difficult
to identify which models may have any calibration deficiencies as we expect all the models may under
perform. Unfortunately, this is unavoidable but will be considered when reviewing the calibration results.
It is likely further validations will have to be conducted in cohorts with a realistic prevalence rate, to gain
a more accurate review of the models’ ability to accurately predict lung cancer incidence.
In recruiting the participants for the study, controls were often matched to cases. Commonly, lung can-
cer free individuals were matched on age (within 5 years), gender and location or hospital to an individual
with lung cancer. Age and gender are two key variables considered by prediction models. The UCLA,
NY Wynder, New Zealand, Israel and MSH-PMH datasets were matched on either age, gender, or both.
The Israel study also matched on ethnicity, however the PLCO models which utilise this variable was not
applicable to the dataset. Matching over these variables can impede the models’ performance as these are
key variables to discriminate between individuals with or without lung cancer [121]. This will be considered
when reviewing the models in these datasets as this may slightly lower the model performance. However,
further matching on location and hospital should not influence the models’ performance as these are not
variables considered by the models. In addition the hospital matched datasets did not specifically collect
over diseases that are key factors in models. If hospital controls had been recruited using key lung cancer
predictive markers then this would have hindered the discriminative ability of the models as the controls
would have an elevated risk predicted. Additionally, none of the recruited studies matched over smoking
history, this is an advantage as this is the crucial variable, considered by all the models, to discriminate
between individuals with or without or lung cancer.
The studies recruited individuals for different research purposes. This included some studies reviewing
lung cancer occurring at young ages (ReSoLuCENT, UCLA and New Zealand), or recruited heavy smoking
participants (CARET). These are unorthodox sample populations in comparison to what would be con-
sidered in a selective screening trial. The youthful sample populations recruited include a large proportion
of participants that are younger than have previously been considered for selective screening. This can be
addressed by performing two validations, one assessing the models in the complete dataset and a secondary
validation that reviews the models in the subpopulation that would be considered in screening trials. It
is important to consider when validating the models that they may be limited in assigning a higher risk
to individuals with lung cancer than without lung cancer, as the recruited sample population would be
considered low risk of developing lung cancer. Similarly, the CARET population which recruited heavy
smoking, asbestos exposed workers may prove challenging for the prediction models. These participants
would all be considered at high risk of developing lung cancer, so the models may be unsuccessful in as-
signing a lower risk to the disease free individuals. The different recruitment strategies will be considered
when reviewing the models in these datasets as this may lower their discriminative ability.
The Israel and ESTHER datasets only provided a small sample population to evaluate the models.
There may be uncertainty in the results reported in these datasets. However, this uncertainty will be
reflected in the 95% confidence intervals when reported for the AUC. While larger studies will allow for a
more comprehensive review of the prediction models, the small datasets will still provide a good comparison
between the models and an indication into their expected performance as a selective screening tool.
Another identified limitation of the datasets was how the variables were collected. This was highlighted
with how education was reported in the UCLA, NY Wynder and MSH-PMH datasets. The datasets
received had stratified education into five levels rather than the six levels the PLCO models required. In
some instances, this was due to collecting studies in distinct education systems to the USA education
system in which the PLCO models were developed. Unfortunately, the predefined education levels in the
studies could not be split into the six levels. Therefore one level had zero participants when applying
the model in the datasets. This has the potential to limit the ability of the PLCO models as this is an
important factor to distinguish between individuals with or without lung cancer. The missing education
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level cannot be rectified, but will be considered when reviewing the PLCO models in these datasets.
Next the recruitment strategy for some of the controls may limit the prediction models’ performance.
The ReSoLuCENT datasets collected disease free individuals who were a first degree relative of a case.
Consequently, the dataset has a high positive history of lung cancer amongst controls. This heightens the
risk generated by the LLP, Spitz and PLCO models for the disease free individuals and the models may
report a poor discriminative ability. Conversely, the CREST dataset excluded some disease free participants
with lung conditions. This may also bias the discriminative ability of the prediction models, as the disease
free participants with a heightened risk because they have a prior lung condition were excluded. This will
allow the models to easier discriminate between individuals with or without lung cancer.
The Bach Model was developed in a high risk study. The received CARET dataset was a subset of the
study used to develop the Bach Model. This could see the Bach Model have a heightened performance in
this dataset than may be observed in different populations. However, the CARET dataset will still provide
a good opportunity to validate the remaining models, especially in a sample population of participants
who would be considered of higher risk of developing lung cancer.
While there are concerns with the ILCCO datasets, which may lead to more variable results than
observed in selective screening populations, this will still provide a good opportunity to compare between
different models and selective screening criteria. Validations across the datasets may identify a leading
model which could then be reviewed in selective screening trials to comprehensively assess the models’
performance. Additionally, the ILCCO datasets provide an opportunity to evaluate the model in different
sample populations. This includes some sample populations that recruited participants who would be
considered at low or high risk of developing lung cancer. Also, the studies recruited participants from a
large range of countries, which includes Singapore and New Zealand. This provides a good opportunity
to assess the models in sample populations outside of Europe and North America, where the systematic
review identified models are commonly developed and validated. This can determine whether there is a
universally leading model or selective screening criteria, or whether there are leading models for different
locations due to the differing populations observed around the world.
5.14 Summary
The chapter discussed the datasets provided for this project and reviewed their distinct participant re-
cruitment strategies. Some studies recruited disease free individuals in an unorthodox manner; whether
with a positive history of lung cancer or rejecting individuals with prior lung conditions. Another limi-
tation of the studies was matching. Some studies matched individuals with or without lung cancer over
variables required by the models, such as age or gender. This may negate the variable in the models and
the models may report a sub-par performance. Finally, the high volume of individuals with lung cancer in
the datasets is unrealistic in comparison to the worldwide prevalence rates. These may all influence the
models’ performance in these datasets and should be considered when reporting the results.
However, the datasets provided do offer a range of distinct sample populations to review the models.
This includes some sample populations of participants that would be considered of low or high risk of
developing lung cancer. Additionally, the sample populations were recruited in different locations and
will allow an opportunity to review the models outside of European and North American subpopulations,
where most models have been developed and validated. The differing sample populations will allow a good
comparison between the models and selective screening criteria to identify a leading performer and can
also review if there is a global leading model or different models with a leading performance in differing
locations.
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CHAPTER 6
External Validation of Lung Cancer Models: Part One
6.1 Introduction
The systematic review identified that previous validations of lung cancer prediction models have been
inconsistent. Based upon the results in the systematic review a leading model with clear guidelines on
how it could be utilised as a selective screening programme could not be recommended. Therefore an
external validation of the lung cancer prediction models will be presented and reviewed. This will provide
an opportunity to review multiple models in the same datasets in a direct comparison. The datasets will
also allow the models to be reviewed in distinct sample populations to determine if there is a universal
screening strategy or different optimal screening strategies in different populations.
The discrimination, calibration and prediction rules will be evaluated and compared. The prediction
rules will be considered at six chosen risk thresholds. Here any participant with a higher risk generated by
the model than the specified risk in the threshold would be considered of high enough risk of developing
lung cancer to be considered for screening. This will assess if the models can consistently perform strongly
at one risk threshold that could then be considered in a selective screening programme. Finally, the models
will be compared to previously implemented screening criteria to assess if the models can select a more
appropriate high risk population with a high volume of individuals with lung cancer selected and disease
free individuals rejected for screening.
6.2 Objectives
To conduct an external validation, which could identify a leading model and how to apply the model to
perform optimally, the following objectives were devised:
1. Record the calibration and discrimination for each applicable model in each dataset.
2. Assess the prediction rules at several risk thresholds.
• Identify the risk threshold at which each model reports the strongest performance.
• Identify a model that would be optimal as a selective screening tool through comparing the
prediction rules.
• Compare the model to previously implemented screening criteria.
6.3 Methodology
The models were applied to predict risk for the duration specified in the original model; this meant that
the Bach, Spitz and Hoggart models that could be run recursively predicted risk for 10, 5 and 1 years
respectively. Models were applied to predict absolute risk when they could be applied to predict either risk
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of incidence or absolute risk; this was the case for the Bach and Hoggart models. An external validation
was then conducted which is divided into sections across the next two chapters. This chapter reviews the
models considering the objective of a selective screening programme is to identify a high proportion of
individuals with lung cancer for screening. The next chapter reduces the dataset population to that which
has previously been considered in selective screening trials. This then reviews how the models perform
while aiming to reduce a high proportion of unnecessary costs from screening disease free individuals.
The model calibration, using the Hosmer-Lemeshow test and Brier Score, was evaluated. The AUC was
calculated to measure the model discrimination potential and the prediction rules were evaluated through
the sensitivity, specificity, Youden index and PLR measures. The prediction rules were measured at the
0.1%, 0.25%, 0.5%, 1%, 1.5% and 2.5% risk thresholds. These thresholds were selected as they would
provide a range of different thresholds to evaluate the models. Fixed thresholds were selected rather than
evaluating the model at their optimal risk threshold, as this could vary between the datasets and therefore
not allow a recommendation as to where a model may perform robustly. The prediction rules will also
be compared to the NLST screening criteria to offer a baseline performance of previously implemented
screening trials. The objective of the external validation was to identify where the models consistently
reported a good performance. If a model is consistently optimal at a risk threshold then this information
could be used to inform future validation analysis using cohort studies to ascertain if the model maintains
the impressive performance.
The results are presented per dataset and reviewed. The chapter then concludes with a summary
analysis of each model’s performance.
6.4 ReSoLuCENT Dataset
The ReSoLuCENT dataset was collected to evaluate lung cancer risk factors in low risk populations. The
study recruited individuals with lung cancer who were under 60 years old. Additionally 50% of disease free
individuals reported a positive family history of lung cancer due to the participant recruitment strategy.
Finally, the dataset has a significantly higher prevalence rate than observed for lung cancer worldwide.
The Bach, PLCOM2012, PLCOM2014, Hoggart, LLP and Pittsburgh models were applied to the dataset
alongside the NLST criteria.
6.4.1 Model Calibration
The calibration was very poor in the ReSoLuCENT dataset for all models except the Bach Model. The
Bach Model had a good calibration with a Hosmer-Lemeshow p-value exceeding 0.05 (0.38). It is surprising
that the Bach Model, designed for heavy smoking ever-smokers, performed well in a dataset that recruited
participants considered as low risk of developing lung cancer. However, this could be a result of the high
volume of individuals with lung cancer in the ReSoLuCENT dataset. The other models were calibrated to
predict low incidence rates in this sample population. In contrast the Bach Model, which predicted risk
over 10 years and was only applicable to the older, heavy smoking participants in the dataset, predicted a
high incidence rate which resulted in a good model calibration.
6.4.2 Model Discrimination
Overall the AUC results were poor, particularly for the models designed to target ever-smokers. The
Bach Model reported 0.52 (95% CI [0.45, 0.59]) and there were only a slight improvements in the Hoggart
Model 0.57 (95% CI [0.52, 0.62]), Pittsburgh Predictor 0.59 (95% CI [0.54, 0.64]) and LLP Model 0.63
(95% CI [0.59, 0.67]). It is surprising the LLP Model had a limited discriminative ability as this model
was applicable to never-smokers and was expected to be more generalisible to the lower risk participants
recruited in the ReSoLuCENT study. In contrast the PLCOM2014 Model with an AUC of 0.74 (95% CI
[0.71, 0.77]) had a good discrimination and reported the leading performance in the dataset by a significant
margin.
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Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 1078 47.41 78.91 0.2632 2.2479
Bach
0.1
10 400
100.00 0.00 0.0000 1.0000
0.25 100.00 0.00 0.0000 1.0000
0.5 100.00 0.00 0.0000 1.0000
1 99.88 0.72 0.0061 1.0061
1.5 97.30 4.98 0.0228 1.0240
2.5 85.01 20.65 0.0567 1.0714
0.1 89.72 40.30 0.3002 1.5028
0.25 83.17 55.20 0.3837 1.8563
PLCO 2014 0.5 6 1075 72.43 66.84 0.3927 2.1843
1 53.86 77.08 0.3094 2.3501
1.5 37.98 84.86 0.2285 2.5094
2.5 19.83 92.73 0.1256 2.7287
0.1 96.07 15.85 0.1192 1.1417
0.25 90.89 33.02 0.2392 1.3571
PLCO 2012 0.5 6 854 79.40 48.32 0.2772 1.5364
1 58.55 63.62 0.2217 1.6095
1.5 45.63 76.46 0.2209 1.9387
2.5 20.96 88.72 0.0967 1.8571
0.1 93.34 13.96 0.0730 1.0848
0.25 82.48 33.44 0.1592 1.2392
LLP 0.5 5 952 67.69 52.60 0.2029 1.4279
1 49.66 68.68 0.1834 1.5858
1.5 38.90 76.95 0.1585 1.6877
2.5 25.76 84.74 0.1050 1.6883
Hoggart
0.1
1 798
86.08 17.50 0.0359 1.0435
0.25 81.47 37.92 0.1939 1.3123
0.5 54.00 51.99 0.0600 1.1249
1 33.51 67.54 0.0105 1.0324
1.5 28.84 71.89 0.0073 1.0258
2.5 22.11 78.95 0.0105 1.0500
0.1 100.00 0.00 0.0000 1.0000
0.25 100.00 0.00 0.0000 1.0000
Pittsburgh 0.5 6 823 85.15 34.65 0.1979 1.3029
1 59.83 54.27 0.1410 1.3084
1.5 42.06 70.27 0.1233 1.4149
2.5 15.32 84.00 -0.0068 0.9574
Table 6.1: ReSoLuCENT Dataset Prediction Rules
6.4.3 Prediction Rules
The NLST criteria reported a reasonable performance. This is despite the NLST criteria, which identifies
heavy ever-smokers for screening, being applied in a lower risk sample population. Therefore the NLST
criteria rejected a high proportion of disease free individuals from potential screening. However, the criteria
would still identify 47% of individuals with lung cancer for screening, which is very impressive. The results
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suggest that in younger populations, as observed in the ReSoLuCENT dataset, identifying heavy smokers
for selective screening is a good criterion. The good sensitivity and specificity results equate to an impressive
Youden index of 0.26 and the high specificity means the model reports a PLR of 2.25.
The Bach Model was limited in the dataset. The model is suboptimal in this sample population
where participants would be considered of lower risk of developing lung cancer. This could be a result
of considering predictors such as asbestos which was relevant in the model building dataset, whereas in
other populations these variables may not be important in explaining lung cancer. The model was poorer
in comparison to other models and the NLST criteria. The model was optimal at the 2.5% risk threshold
and it could be argued that the model would improve at a higher risk threshold. However, the Youden
index observed was very poor (Table 6.1) as the model failed to create a strong relationship between the
sensitivity and specificity as observed in the other models.
In contrast, the PLCOM2014 Model reported a good performance. It was expected that the model could
be a leading performer in the dataset as the model was designed to be applicable to anyone aged over 20
years. At the 0.5% risk threshold the model reported a sensitivity of 72% and a specificity of 67% generated
a Youden index of 0.39 and a PLR of 2.18; comfortably surpassing the other models and NLST criteria.
The PLCOM2012 Model was the next leading model with a good performance at the 0.5% threshold,
marginally below the NLST criteria. This was followed by the LLP Model which also reported a reasonable
performance (Table 6.1) however; the NLST criteria offered a more robust performance. The simpler
Hoggart and Pittsburgh models, considering fewer variables, had a poorer performance, as they failed to
successfully classify high or low risk participants.
6.4.4 Concluding Statement
The models were poorly calibrated except for the Bach Model. The PLCOM2014 Model had the strongest
overall performance with a significantly improved discrimination in comparison to the other models and
this was reflected in the best prediction rule results. The PLCOM2014 Model offered a clear improvement
upon the NLST criteria and reported its most robust performance at the 0.5% risk threshold.
6.5 CARET Dataset
The CARET dataset recruited high risk participants who were ever-smokers with a minimum 20 pack
year smoking history and a high proportion of participants were asbestos exposed workers. The CARET
dataset is a subset of the sample population from which the Bach Model was devised; this may result in
the model having an elevated performance than would be observed in an external validation.
The PLCO, Bach, Hoggart, Pittsburgh and LLP models were evaluated using the dataset.
6.5.1 Model Calibration
There were varied calibration results using the CARET dataset. The LLP, PLCOM2014 and Pittsburgh
models all reported a p-value below 0.05 indicating the models were poorly calibrated. However, the
Hoggart and Bach models both reported a good calibration. These models were both designed to predict
risk in ever-smokers so were more likely to be calibrated to predict the high volume of incidences in this
case-control dataset. Finally, the PLCOM2012 Model, another model devised to target higher risk ever-
smokers, did not accurately predict the observed data, although was close to the critical threshold with a
p-value of 0.045. However, the calibration result was quite variable and reducing the volume of participants
per group from 10 to 9 increased the p-value to 0.3314.
A comparison of the Brier results places all the models in a very narrow band between 0.3002 and
0.3197. The Bach Model reported the strongest performance. The success of the Bach Model was expected
as the dataset is a subset of the population used to devise the model. Conversely, the results may indicate
that models that can be applied to never-smokers are not well calibrated to predict incidence solely in
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ever-smokers; highlighted by the LLP and PLCOM2014 models, although testing should be conducted in
cohort studies.
6.5.2 Model Discrimination
The models reported a poor discriminative ability. The AUC results obtained were very low; the Bach
Model scored 0.55 (95% CI [0.52, 0.58]), PLCOM2014 Model 0.61 (95% CI [0.58, 0.63]), PLCOM2012 Model
0.60 (95% CI [0.58, 0.63]), LPP Model 0.58 (95% CI [0.56, 0.61]), Hoggart Model 0.56 (95% CI [0.53, 0.58])
and Pittsburgh Predictor 0.58 (95% CI [0.56, 0.61]).
Figure 6.1: AUC of Models in the CARET Dataset
The poor results could be explained by the CARET dataset design. The study participants would be
considered at high risk of developing lung cancer. Therefore, the models failed to successfully distinguish
between the diseased and disease free individuals, as both were assigned high risk by the models.
6.5.3 Prediction Rules
The NLST screening criteria reported a limited performance in the CARET dataset. This was because of
the high risk population collected for the CARET study. All participants were ever-smokers with a heavy
smoking history therefore most participants, whether diseased or disease free, satisfied the NLST screening
criteria. As a consequence, the NLST criteria reported a low specificity of 29% and a sensitivity exceeding
80%. The criteria did not report a strong relationship between the sensitivity and specificity with a Youden
index of 0.1021 and PLR of 1.144. The CARET dataset highlights the high volume of ever-smokers who
are lung cancer free and who would be unnecessarily screened using this selective screening criteria.
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Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 2075 80.86 29.35 0.1021 1.1445
Bach
0.1
10 2000
99.12 0.98 0.001 1.0010
0.25 95.15 7.05 0.022 1.0237
0.5 88.38 13.64 0.0202 1.0234
1 81.32 18.79 0.0011 1.0014
1.5 79.41 20.38 -0.0021 0.9974
2.5 76.03 25.98 0.0201 1.0272
PLCO2014
0.1
6 2075
99.86 0.43 0.0029 1.0029
0.25 99.86 1.23 0.0109 1.0110
0.5 99.28 4.2 0.0348 1.0363
1 83.88 26.52 0.104 1.1415
1.5 68.92 46.09 0.1501 1.2784
2.5 43.17 70.87 0.1404 1.4820
PLCO2012
0.1
6 2075
100 0.51 0.0051 1.0051
0.25 99.86 0.94 0.008 1.0081
0.5 99.71 2.39 0.021 1.0215
1 91.22 16.45 0.0767 1.0918
1.5 77.27 36.01 0.1328 1.2075
2.5 55.97 58.99 0.1496 1.3648
LLP
0.1
5 2074
100 0.07 0.0007 1.0007
0.25 99.71 1.45 0.0116 1.0118
0.5 93.23 13.77 0.07 1.0812
1 78.1 34.49 0.1259 1.1922
1.5 68.88 43.7 0.1258 1.2234
2.5 57.06 53.99 0.1105 1.2402
Hoggart
0.1
1 2074
96.12 8.33 0.0445 1.0485
0.25 90.22 15.14 0.0536 1.0632
0.5 83.17 24.57 0.0774 1.1026
1 66.76 39.06 0.0582 1.0955
1.5 58.42 48.48 0.069 1.1339
2.5 47.63 59.86 0.0749 1.1866
Pittsburgh
0.1
6 2075
100 0 0 1.0000
0.25 100 0 0 1.0000
0.5 97.7 3.48 0.0118 1.0122
1 92.23 12.03 0.0426 1.0484
1.5 80.72 30.65 0.1137 1.1640
2.5 62.45 50.65 0.131 1.2655
Table 6.2: CARET Dataset Prediction Rules
The Bach model reported a suboptimal performance. It could be argued the Bach Model suffered from
our validation design; with 2.5% the highest risk threshold considered, which may not be sufficiently high.
However, the evidence indicates the model does not improve upon the NLST criteria with a sensitivity
below the 80% set by the NLST criteria and a lower specificity. The model fails to distinguish between
diseased and disease free individuals in the CARET dataset.
The PLCOM2014 Model reported the leading prediction rules. This is slightly surprising considering that
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the model is applicable to everyone; it could be expected that a model that targets a higher risk population
such as ever-smokers (Hoggart, PLCOM2012, Pittsburgh) or heavy smoking ever-smokers (Bach) would be
better suited to the CARET dataset. This indicates that the PLCOM2014 Model is more versatile and can
be applied across a range of different sample populations more successfully than other models. The model
was optimal at the 2.5% risk threshold. This may be higher than where the model would be optimal in a
sample population that did not recruit such high risk participants. The model reported the highest Youden
index alongside the 2012 version of the PLCO model; but reported a higher PLR. While the improvement
observed by the PLCOM2014 Model in the CARET dataset is marginal, consistently reporting the leading
criteria in the datasets will indicate the model could be considered as a selective screening tool in preference
to any other model or criteria.
As reported, the PLCOM2012 reported a similar Youden index to the 2014 version, although it had a
poorer PLR. While, the model cannot be reported to be inferior to the 2014 version, it can be argued
that the model should have notably offered an improved performance since the model was devised for
ever-smokers. This could also be argued for the Hoggart and Pittsburgh models, both of which had an
underwhelming performance in this ever-smoking dataset (Table 6.2). The LLP Model was limited and had
a lower performance than the leading PLCO models. Although this model was designed to be applicable
to everyone rather than this heavy smoking study.
In conclusion, no model or criteria demonstrated a robust performance in the dataset, as they failed
to successfully distinguish between diseased and disease free individuals. There was no major difference
between any of the models but the PLCO models had the leading performance.
6.5.4 Concluding Statement
The Hoggart and Bach models demonstrated a good model calibration with the Bach Model reporting the
leading performance based upon the Brier Score. The model’s discriminative ability was poor and this was
reflected in the prediction rules. The PLCOM2014 reported marginally the best performance. This, coupled
with the leading performance in the ReSoLuCENT dataset, indicates the models ability to be applied in
different environments, whether specific populations considered of higher or lower risk of developing lung
cancer, if they were chosen for selective screening programmes.
6.6 UCLA Dataset
The UCLA dataset recruited a sample population that would be considered at low risk of developing lung
cancer. The mean age is approximately 50, which would be considered quite young as a population for lung
cancer selective screening. As a consequence the sensitivity may be lower and the specificity rate higher
than observed in a more appropriate population for lung cancer selective screening. Finally, there is a high
lung cancer incidence rate observed in this dataset. This is significantly higher than the prevalence rate
observed worldwide for which the models were calibrated so they may be poorly calibrated.
The PLCO, Hoggart and Pittsburgh models were applied to the UCLA dataset.
6.6.1 Model Calibration
The models were poorly calibrated in the UCLA dataset. All four models reported a Hosmer-Lemeshow
test p-value below 0.05, with the Hoggart model (0.0018) the only model not to report a p-value < 0.0001.
This was to be expected in the UCLA dataset with the high lung cancer incidence rate. Additionally, the
participants were estimated relatively low risks due to their young age (approximately 50) and reduced
smoking history (low pack years).
The Brier score for the Hoggart, Pittsburgh and PLCOM2012 models all reported a Brier Score between
0.46 and 0.48. In contrast, the PLCOM2014 Model reported a Brier Score of 0.3718; this is a notable
improvement than the other models, suggesting the model was better calibrated in the dataset over the
remaining models but ultimately a poor calibration was still observed for this model.
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6.6.2 Model Discrimination
The models exhibited a very strong discriminative ability. The PLCOM2012 Model reported the best
performance with an AUC 0.78 (95% CI [0.75, 0.81]); this was closely followed by the PLCOM2014 Model
with 0.77 (95% CI [0.75, 0.80]). The Hoggart (0.73 (95% CI [0.70, 0.77])) and Pittsburgh Predictor (0.75
(95% CI [0.72, 0.78])) also recorded exceptional results in the UCLA dataset (Figure 6.2). The exceptional
discrimination results are slightly unexpected as this was a youthful population recruited for the dataset
where the models may have failed to consistently assign a higher risk to individuals with lung cancer.
Figure 6.2: AUC of Models in the UCLA Dataset
6.6.3 Prediction Rules
In the UCLA dataset the NLST trial performed to a high standard. The criterion reported a specificity
of 91% while still maintaining a sensitivity of 33%. This equates to a Youden index of 0.243 and a high
PLR of 3.81 due to only screening approximately 9% of controls. Despite the good performance observed
by the NLST criteria this is improved upon by all four models applied to the UCLA dataset.
The PLCOM2014 Model demonstrated a clear improvement upon the NLST criteria and reported a
strong performance (Table 6.3). The model was optimal at the 0.5% risk threshold where a 21% increase
in the sensitivity was observed alongside a 5% improvement in specificity. This equates to an excellent
Youden index exceeding 0.4 and an improved PLR of approximately 2.1. This highlights the benefits of
the model. Despite the impressive performance this was not the leading model in the UCLA dataset.
The PLCOM2012 offered a slight improvement on the 2014 version and reported a remarkable per-
formance in the dataset at the 0.5% risk threshold. The model reported a sensitivity and specificity of
both approximately 71.5%. This equated to a very high Youden index of 0.433 and a PLR of 2.536 in
ever-smokers.
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The Hoggart and Pittsburgh models also reported a high performance in the UCLA dataset and demon-
strated a clear improvement upon the NLST criteria. However, these models reported a slightly poorer
performance than the PLCO models, suggesting more complex models are better at distinguishing between
diseased and disease free individuals especially in an unorthodox, low risk of developing lung cancer, pop-
ulation. The Hoggart and Pittsburgh models reported their optimal performance at the 0.25% and 0.5%
risk thresholds, respectively. The models demonstrated a strong relationship between the sensitivity and
specificity shown by Youden index scores of approximately 0.39 (Table 6.3). This is marginally poorer
than the PLCO models but a significant improvement upon the NLST criteria.
Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 1577 33.00 91.33 0.2433 3.8062
PLCO2014
0.1
6 1577
75.54 70.2 0.4574 2.5349
0.25 66.33 79.08 0.4541 3.1707
0.5 53.94 86.84 0.4078 4.0988
1 34.84 93.57 0.2841 5.4184
1.5 20.44 97.24 0.1768 7.4058
2.5 6.7 99.29 0.0599 9.4366
PLCO2012
0.1
6 1016
92.87 43.24 0.3611 1.6362
0.25 84.11 58.1 0.4221 2.0074
0.5 71.49 71.81 0.433 2.5360
1 50.51 84.76 0.3527 3.3143
1.5 36.25 91.43 0.2768 4.2299
2.5 17.11 97.14 0.1425 5.9825
Hoggart
0.1
1 988
92.65 24.21 0.1686 1.2225
0.25 79.39 59.06 0.3845 1.9392
0.5 66.94 69.49 0.3643 2.1940
1 58.37 76.57 0.3494 2.4913
1.5 51.22 80.31 0.3153 2.6013
2.5 34.08 87.2 0.2128 2.6625
Pittsburgh
0.1
6 1016
100 0 0 1.0000
0.25 100 0 0 1.0000
0.5 75.76 63.43 0.3919 2.0716
1 48.07 85.33 0.334 3.2768
1.5 33.06 90.86 0.2392 3.6171
2.5 13.24 97.9 0.1114 6.3048
Table 6.3: UCLA Dataset Prediction Rules
Overall in the UCLA sample population, all the models reported an exceptional performance with
Youden index scores around 0.4. The results supported findings in other datasets that the PLCO models
have the leading performance as a selective screening tool. In this case the 2012 version applied to ever-
smokers reported the leading performance. All the models demonstrated a significant improvement upon
the NLST criteria. The results indicate a model applied in an unorthodox population, which did not recruit
participants who are specifically high or low risk of developing lung cancer, such as the UCLA dataset, can
successfully distinguish between diseased and disease free individuals.
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6.6.4 Concluding Statement
The models were poorly calibrated in the dataset. However, the discrimination and prediction rules were
promising. Once again the PLCOM2014 was the leading model, although the improvement in comparison
to the other models was only marginal. The model was optimal at the 0.5% risk threshold.
6.7 New York Wynder Dataset
The New York Wynder dataset provided a large sample population that would be considered reflective of a
target population for lung cancer screening, to validate the models. This should provide a strong indication
into which models would be the leading performers in a selective screening programme. However, the case-
control dataset design may heighten the discriminative ability of the models and will be considered when
reviewing the results.
The Bach, Hoggart, Pittsburgh and PLCO models were applied to the dataset.
6.7.1 Model Calibration
In the NY Wynder dataset the models were poorly calibrated. The two PLCO models, the Hoggart and
the Pittsburgh models all reported a Hosmer-Lemeshow p-value of < 0.0001. The Bach Model was also
below the 0.05 critical level with a p-value of 0.045. While this was close to the critical value, changing
the number of groups across the dataset to calculate the Hosmer-Lemeshow test never observed a p-value
greater than 0.05.
The Brier Score results varied between 0.489 and 0.618 for the models. This indicates that the models
were some way from predicting the observed incidences in this dataset. This can be attributed to applying
the models in a dataset with a high lung cancer incidence rate whereas the models were designed in cohort
studies with more realistic, lung cancer incidence rate.
6.7.2 Model Discrimination
There were mixed results in the NY Wynder dataset when evaluating the AUC. The Bach (0.63 95%
[0.62, 0.65]), Hoggart (0.67 95% [0.65, 0.68]) and Pittsburgh (0.68 95% [0.67, 0.69]) models only reported
reasonable discriminative ability and recorded the poorest performance of the models. This could be a
result of the models only considering a small number of variables to distinguish between diseased and
disease free individuals.
This was slightly improved on in the PLCOM2012 Model (0.69 95% [0.68, 0.70]), although this too was
only a reasonable discrimination. Once again the PLCOM2014 Model reported the leading performance and
there was a notable increase in AUC (0.77 95% [0.76, 0.78]). The results clearly indicate the PLCOM2014
Model is the most successful at consistently assigning higher risks to diseased rather than disease free
individuals.
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Figure 6.3: AUC of Models in the NY Wynder Dataset
6.7.3 Prediction Rules
The NLST criteria demonstrated a robust performance in the NY Wynder dataset with a sensitivity of 55%
and specificity of 77%. This resulted in a Youden’s index exceeding 0.3, which demonstrates the criteria
could identify a high proportion of cases while still rejecting a sizeable proportion of controls. The high
specificity and fairly high sensitivity enabled the criteria to report an impressive PLR of 2.418.
The Bach Model, despite the poor AUC result, demonstrated a reasonable performance. The model
was optimal at the 0.5% or 1% risk thresholds as shown by the Youden Index (Table 6.4). The model
performs slightly better at the 0.5% risk threshold; here the model reported a sensitivity of 80%. However,
it would reject less than 40% of disease free participants, which would contribute to a large number of
unnecessary screenings. This may lead to a poor benefit to harm ratio supported by a poor PLR of 1.32.
It can be argued the 0.5% threshold is too low for a model that predicts absolute risk over 10 years, as
shown by too many participants, both diseased and disease free, considered for screening. However, the
model does not improve at higher risk thresholds such as 1.5% or 2.5% (Table 6.4. Additionally, despite a
reasonable performance, the Bach Model did not improve upon the NLST criteria.
The PLCO2014 Model performed best at the 0.5% risk threshold. Here the model demonstrated a strong
performance with a sensitivity of 81% and specificity of 62%. This resulted in a Youden Index of 0.43,
which is higher than the NLST criteria. This suggests the model offers a better criterion for classifying
diseased and disease free individuals. This was supported by a remarkable PLR of 2.14.
The PLCO2012 had a lower level of performance than the 2014 version. The model had a similar
standard of performance at the 0.5% or 1% risk thresholds. The model failed to reject a high volume of
controls unlike the Bach and PLCO2014 models, which was reflected in a poorer specificity and a lower
Youden Index. Overall, the model did not improve over the implemented NLST screening trial.
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The Hoggart and Pittsburgh models, despite having a reasonable performance, performed poorer than
the other models and the NLST criteria. The models were optimal at the 0.5% and 1% risk thresholds,
respectively. The Youden index results were lower (Table 6.4) as the specificity was lower coupled with the
sensitivity that did not improve upon the other models.
Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 9281 55.44 77.07 0.3251 2.4178
0.1 98.97 2.14 0.0111 1.0113
0.25 91.13 19.24 0.1037 1.1284
Bach 0.5 10 4982 80.32 38.94 0.1926 1.3154
1 68.72 51.57 0.2029 1.4190
1.5 64.33 54.58 0.1891 1.4163
2.5 61.09 57.58 0.1867 1.4401
PLCO2014
0.1
6 9271
95.11 28.28 0.2339 1.3261
0.25 89.23 49.42 0.3865 1.7641
0.5 81 62.14 0.4314 2.1395
1 66.07 73.28 0.3935 2.4727
1.5 54.28 80.66 0.3494 2.8066
2.5 37.45 88.52 0.2597 3.2622
0.1 97.88 12.42 0.103 1.1176
0.25 94.26 22.47 0.1673 1.2158
0.5 87.89 35.88 0.2377 1.3707
PLCO2012 1 6 7232 74.26 52.18 0.2664 1.5571
1.5 63.32 64.82 0.2814 1.7999
2.5 45.69 77.46 0.2315 2.0271
Hoggart
0.1
1 7198
94.66 13.84 0.085 1.0987
0.25 87.19 30.82 0.1801 1.2603
0.5 76.99 48.68 0.2567 1.5002
1 59.17 65.24 0.2441 1.7022
1.5 46.2 75.59 0.2179 1.8927
2.5 36.27 81.95 0.1822 2.0094
0.1 100 0 0 1.0000
0.25 100 0 0 1.0000
Pittsburgh 0.5 6 7242 87.58 31.33 0.1891 1.2754
1 71.91 56.57 0.2848 1.6558
1.5 60.81 66.05 0.2686 1.7912
2.5 44.33 78.23 0.2256 2.0363
Table 6.4: NY Wynder Prediction Rules
In summary the PLCO2014 Model and the NLST criteria had the strongest performance. The NLST
criteria would reject a high proportion of individuals without lung cancer from unnecessary screening,
whereas the PLCO2014 Model would capture a high proportion of diseased individuals for screening. While
other models performed reasonably well they did not eclipse the PLCO2014 Model or the NLST criteria.
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6.7.4 Concluding Statement
The models reported a poor calibration in the dataset. The NLST trial performed well and no model
exhibited a marked improvement. The PLCOM2014 Model reported a similar standard to the NLST criteria
and was the leading model in the dataset. The PLCOM2014 Model was once again optimal at the 0.5% risk
threshold.
6.8 Singapore Dataset
The Singapore dataset primarily collected information on smoking history. This restricted the dataset to
the Hoggart and Pittsburgh models only. The dataset provided an opportunity to evaluate models in an
Asian population. This can assess whether the models can replicate their results in distinct environments
or whether a geographic specific model for an Asian population should be created to offer a more robust
selective screening tool.
The high lung cancer incidence rate observed in the Singapore dataset may affect the model calibration
as seen in other datasets. The small dataset size also creates uncertainty in the results, which will be
reflected in a large confidence interval for the AUC.
6.8.1 Model Calibration
In the Singapore dataset both models were well calibrated with the Hoggart Model (0.2072) and Pittsburgh
Model (0.1189) both exceeding the 0.05 p-value threshold. Despite this both models still reported Brier
Score results exceeding 0.5. This indicates that for the majority of participants their estimated risk was
low which was not representative of the high incidence rate observed in the dataset.
The slight reduction of lung cancer incidences observed in the dataset (30%), in comparison to approx-
imately 50% in the other datasets, may be the factor that allowed the models to report a good calibration
based on the Hosmer-Lemeshow test. However ultimately, the baseline risk predicted by the models is too
low for the high incidence rate. This is a consequence of the case-control dataset design, and the high
incidence rate is unlikely to be observed in the real world.
6.8.2 Model Discrimination
The two models recorded a reasonable discriminative ability. The Pittsburgh Predictor (0.65 95% CI [0.57,
0.72]) and Hoggart Model (0.63 95% CI [0.56, 0.71]) demonstrated a similar level of performance presented
in Figure 6.4. However, if the models are to be considered as a selective screening tool they would be
expected to perform to a higher standard than observed. The results could indicate that geographic specific
devised models may be better suited as a selective screening tool because the Hoggart and Pittsburgh
models reported lower results than that observed in other datasets.
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Figure 6.4: AUC of Models in the Singapore Dataset
6.8.3 Prediction Rules
The NLST criteria had a limited performance in the Singapore dataset. This is a consequence of the
criteria rejecting a high proportion of participants, both diseased and disease free, from screening. The
NLST criteria reported a sensitivity of 8.3% and a specificity of 98.5%. While removing the majority
of disease free individuals from unnecessary screening is beneficial, it would be ineffective in identifying
lung cancer incidences. The poor trade-off between the sensitivity and specificity is supported by the
low Youden’s index of about 0.07. The results highlights how incidence occur in never-smokers and more
moderate ever-smokers, which would be automatically excluded by the NLST criteria, a clear limitation of
this approach to identify a target population for selective screening.
In comparison the Hoggart and Pittsburgh models reported a reasonable performance, demonstrating
a clear improvement upon the NLST criteria. Both models demonstrated a better relationship between
the sensitivity and specificity shown in Youden index results around 0.25 at their optimal risk thresholds.
The Hoggart Model at the 1.5% threshold reported a sensitivity of 49% for an impressive specificity of
75%. The Pittsburgh Model, with a slightly lower performance than the Hoggart Model but improvement
over the NLST criteria, was also optimal at the 1.5% risk threshold. Here the model reported a sensitivity
of 70% and a specificity of 50%. The Hoggart Model also reported the highest PLR exceeding 2 which was
an improvement upon the Pittsburgh Model at 1.397.
Overall, both models improved upon the NLST criteria. The Hoggart model at the 1.5% risk threshold
is the strongest performing model, slightly superior than the Pittsburgh Model. The results highlight how a
prediction model can identify a larger proportion of participants with lung cancer for screening. The NLST
criteria can be limited because it only targets heavy ever-smokers, and even more inclusive ever-smokers
models, such as the Hoggart and Pittsburgh models, would improve lung cancer diagnosis rates.
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Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 1070 8.28 98.54 0.0682 5.6712
Hoggart
0.1
1 208
83.9 20 0.039 1.0488
0.25 79.66 35.56 0.1522 1.2362
0.5 71.19 48.89 0.2008 1.3929
1 61.02 60.0 0.2102 1.5255
1.5 49.15 75.56 0.2471 2.0110
2.5 35.59 83.33 0.1892 2.1350
Pittsburgh
0.1
6 412
100 0 0 1.0000
0.25 100 0 0 1.0000
0.5 84.87 34.74 0.1961 1.3005
1 75.63 43.16 0.1879 1.3306
1.5 70.59 49.47 0.2006 1.3970
2.5 49.58 67.37 0.1695 1.5195
Table 6.5: Singapore Prediction Rules
6.8.4 Concluding Statement
The two models were well calibrated in the Singapore dataset. Despite not reporting a convincing discrim-
inative ability the two models improved upon the NLST criteria, with the Hoggart model having a slightly
superior performance of the two models. The results highlight how only capturing high risk ever-smokers
using the NLST criteria might not be successful because of the high number of diseased individuals rejected
from screening. As a consequence the criteria would not improve lung cancer diagnosis rates.
6.9 New Zealand Dataset
The New Zealand dataset recruited participants who had developed lung cancer before they were 55 years
old and would be considered low risk of developing lung cancer. This population is unlikely to be the
target population considered for lung cancer screening, based on the target age of previously implemented
selective screening trials. The low risk sample population may see the models being limited in correctly
classifying high and low risk participants. Additionally, the sensitivity may be lower and the specificity
higher than that which would be observed at the risk threshold in a more conventional, higher risk of
developing lung cancer, target population for screening.
The Bach, Pittsburgh and Hoggart models were applicable to the dataset. However, only 42 participants
were eligible from the dataset using the specified Bach Model criteria (50-75 years, 30+ PY smoking history)
so this model was not considered in the dataset because of a lack of eligible participants.
6.9.1 Model Calibration
The models were well calibrated in the New Zealand dataset. The Hoggart and Pittsburgh models recorded
a Hosmer-Lemeshow p-value exceeding 0.1. These models reported very similar Brier Scores of 0.283
and 0.284 for the Hoggart and Pittsburgh models, respectively. This supports both models being well
calibrated in the New Zealand dataset. Despite being applied to a lower risk of developing lung cancer
sample population; the models were well calibrated. This is likely a consequence of the lower observed
incidence rate in this dataset, that is more appropriate to lung cancer incidence rates observed worldwide.
The evidence suggests lung cancer prediction models, in particular the Hoggart and Pittsburgh models,
may be well calibrated in real populations. Indeed, even the case to control ratio of approximately 1:5 is
very high but the movement to a more realistic ratio has seen a notable improvement in the Brier Score (in
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comparison to scores commonly exceeding 0.4) and the models reporting a good calibration when tested
by the Hosmer-Lemeshow test.
6.9.2 Model Discrimination
The small proportion of participants in the dataset applicable to the Hoggart and Pittsburgh models
is reflected in wide confidence intervals. The Hoggart Model with 180 participants had a reasonable
discrimination of 0.662 (95% CI [0.574, 0.751]). This was similar to the Pittsburgh Model which used 183
participants and reported an AUC of 0.650 (95% CI [0.562, 0.739]). The results suggest that models have
a limited discriminative ability in different populations. This is supported by the Singapore dataset where
the same models also reported poor AUC results.
Figure 6.5: AUC of Models in the New Zealand Dataset
6.9.3 Prediction Rules
In the low risk of developing lung cancer sample population, the NLST criteria had a limited performance.
This was expected because with an average age of 50 years for participants in the study (Table 5.3)
the majority of participants would be rejected from screening. This resulted in a disproportionally low
sensitivity (6.5%) and high specificity (99%). The inability for the criteria to identify high risk participants
for screening is reflected in a weak Youden index of 0.054. While the criteria reported a high PLR exceeding
6 (Table 6.6) this is misleading because of the exceptionally high specificity. More significantly the NLST
criteria only identifying 6% of individuals with lung cancer for screening would not be very beneficial and
would not improve lung cancer diagnosis rates.
The Pittsburgh and Hoggart models demonstrated a reasonable performance in the dataset and a clear
improvement upon the NLST criteria. The models were optimal at a low risk threshold in this lower risk
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sample population, with the Hoggart Model optimal at the 0.25% risk threshold and the Pittsburgh Model
optimal at the 0.5% risk threshold. The Hoggart Model reported a sensitivity of 61.5% and a specificity
of 62.5% which is a good relationship between both measures, highlighted by a Youden index of 0.240.
The Pittsburgh Model improved upon this with a slightly increased sensitivity to 62.3% and an increased
specificity to 67% which resulted in a Youden index of 0.292. The Pittsburgh Model demonstrated the
potential to identify participants who would benefit from screening in lower risk ever-smokers.
In this lower risk of developing lung cancer sample population, the models were able to surpass the NLST
criteria. The results indicate how prediction models can identify diseased individuals in younger populations
which are automatically disregarded by the NLST criteria. The prediction models showed a reasonable
performance (Table 6.6). However, it is important to realise that the Hoggart and Pittsburgh models can
only be applied to ever-smokers and in the ReSoLuCENT dataset, another lower risk of developing lung
cancer sample population, the PLCOM2014 Model was more successful and included never-smokers.
Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 348 6.45 98.95 0.054 6.1429
Hoggart
0.1
1 180
84.62 25.78 0.104 1.1401
0.25 61.54 62.50 0.2404 1.6411
0.5 48.08 71.88 0.1996 1.7098
1 42.31 76.56 0.1887 1.8050
1.5 30.77 82.03 0.128 1.7123
2.5 19.23 92.97 0.122 2.7354
0.1 100 0 0 1.0000
0.25 100 0 0 1.0000
0.5 62.26 66.92 0.2918 1.8821
Pittsburgh 1 6 183 28.3 89.23 0.1753 2.6277
1.5 16.98 96.15 0.1313 4.4104
2.5 0 100 0 NA
Table 6.6: New Zealand Prediction Rules
6.9.4 Concluding Statement
The models were well calibrated in the New Zealand dataset. This is likely to be a reflection of the lower
lung cancer incidence rate in the dataset which would be more likely observed in a real world population for
which the models were calibrated. In contrast, the models had a relatively poor discriminative ability with
AUC results of approximately 0.65. However, the models eclipsed the performance of the NLST criteria,
when evaluating the prediction rules, as the heavy smoking NLST criteria was excessive for the majority
of the participants in the New Zealand dataset. This indicates how the NLST criteria would not be a
practical selective screening tool for lower risk populations as a high proportion of individuals with lung
cancer would be rejected from screening.
6.10 CREST Dataset
The CREST dataset provides a large sample population, recruiting participants who would be the target
for a lung cancer selective screening programme, with which to evaluate the models. However, the high
lung cancer incidence rate observed is likely to affect the model calibration.
The CREST dataset allowed all the models excluding the two PLCO models to be tested. This
included the first and only tests of the Spitz and African-American models. The African-American Model
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is disadvantaged as this is an Italian dataset with only white participants. The model is being tested in a
different environment to that of the model’s design and intention, which may see the model under-perform.
6.10.1 Model Calibration
In the CREST dataset there was evidence the models were poorly calibrated. The Hosmer-Lemeshow test
for the Spitz and African-American models reported a p-value < 0.0001. While the other models slightly
increased the p-value, the Pittsburgh Model (0.0002), Bach Model (0.017) and the Hoggart Model (0.0211)
were still below the critical 0.05 value. This was reflected in poor Brier Scores between 0.39 to 0.61.
This was expected because of the high lung cancer incidence rate observed in the dataset. The baseline
risks generated from the models are much lower than the observed incidence rate because the models were
calibrated to reflect real world lung cancer incidence rates.
6.10.2 Model Discrimination
There was a large variability between the models’ AUC results in the CREST dataset. The Bach Model
had a very poor overall discrimination 0.56 (95% CI [0.48, 0.65]). This confidence interval included 0.5,
which indicates the model may, at times, offer no better than chance at assigning a higher risk to diseased
individuals.
Figure 6.6: AUC of Models in the CREST Dataset
The Bach Model could only be validated in 215 participants who satisfied their criteria, which created
uncertainty reflected in the wide confidence interval. Nonetheless, the poor AUC of 0.56 indicates a very
poor overall discrimination. Give the small numbers considered the model is not presented in Figure 6.6
because the graph became distorted. The African-American Model had an improved performance (0.67
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95% CI [0.64, 0.71]) and performed well considering that this was a different sample population than the
target population for the model. However, other models did improve upon this performance indicating
there are more appropriate models that can be applied in a predominately Caucasian population and
potentially suggesting models are not robust if applied to different ethnic groups or populations other than
originally proposed.
The Hoggart Model had a similar, reasonable discriminative ability to the African-American Model,
(0.70 95% CI [0.66, 0.74]). However, the Spitz Model (0.76 95% CI [0.73, 0.79]) and the Pittsburgh
Predictor (0.77 95% CI [0.74, 0.81]) were the leading models by a considerable margin in the dataset and
demonstrated a very good overall discrimination.
6.10.3 Prediction Rules
The NLST criteria was successful in the CREST dataset, with a high sensitivity of 65% and a specificity of
69%. This equates to a Youden index exceeding 0.3, which indicates that there is a good trade-off between
the sensitivity and specificity. The impressive sensitivity and specificity if also reflected in a good PLR
result of 2.08. Overall, this is a good result in a sample population that would be considered a target
population for lung cancer screening.
While the Bach Model performed reasonably at the 0.25% risk threshold the model was poorer in
comparison to the NLST criteria, highlighted by a lower Youden index. The model would screen a high
proportion of participants with a high sensitivity of 88% but this is mirrored with a low specificity of
32.5%. Considering the model at a higher risk threshold may be beneficial to reduce unnecessary screening
of disease free individuals. However, the sensitivity heavily suffers as a consequence and the Youden index
was lower at the higher risk thresholds 6.7.
The African-American Model did not improve on the NLST criteria and was one of the poorest models
in the dataset. The model was limited when applied in a different sample population from the primary
population of the model. The model reported its leading performance at the 0.5% threshold, with a
sensitivity of 86% and a specificity of 38%. This reported a Youden index of 0.237, which is notably lower
than the NLST criteria and other models. A fairer reflection of the model performance, would be obtained
in an African-American sample population to review whether the model exhibits the leading performance.
The Hoggart Model reported a reasonable performance in the dataset. At the 0.5% risk threshold
the Youden index was an impressive 0.3. This was a reflection of the high sensitivity (81%) and a still
reasonable specificity (50%). The good model performance was reflected in a PLR result of 1.64.
The Spitz Model was optimal at the 0.5% risk threshold. The Youden index at this threshold was very
impressive, exceeding 0.4. This was achieved through a sensitivity and specificity both around 70% (Table
6.7). A model that could consistently report this level of performance could be a valuable screening tool
as it would identify a high proportion of individuals with lung cancer, although this should be evaluated
in cohort studies for a more robust understanding into the model performance. The model offered an
improvement over the NLST criteria and future testing should also evaluate if the high standard set by
the model at the 0.5% risk threshold can consistently eclipse the NLST criteria.
The Pittsburgh Model reported the joint leading performance alongside the Spitz Model. The Pitts-
burgh Model was optimal at the 1.5% risk threshold, also reporting a Youden index over 0.4. This was
achieved by a sensitivity exceeding 74% supported by a specificity of 67%. The model offered a large
improvement over the NLST criteria and demonstrates how simpler models can perform robustly in new
environments.
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Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 908 64.92 68.82 0.3374 2.0821
Bach
0.1
10 215
98.52 8.75 0.0727 1.0797
0.25 88.15 32.50 0.2065 1.3059
0.5 57.78 47.50 0.0528 1.1006
1 26.67 80.00 0.0667 1.3335
1.5 6.67 92.50 -0.0083 0.8893
2.5 0.74 98.75 -0.0051 0.5920
0.1 88.71 43.18 0.3189 1.5612
0.25 82.15 57.27 0.3942 1.9225
Spitz 0.5 1 821 71.92 69.55 0.4147 2.3619
1 56.43 78.64 0.3507 2.6419
1.5 37.53 87.95 0.2548 3.1145
2.5 11.29 98.41 0.097 7.1006
African-American
0.1
5 907
99.21 20.00 0.1921 1.2401
0.25 94.24 28.76 0.23 1.3229
0.5 85.60 38.10 0.237 1.3829
1 71.47 48.76 0.2023 1.3948
1.5 65.97 58.29 0.2426 1.5816
2.5 58.90 67.43 0.2633 1.8084
0.1 95.94 11.68 0.0762 1.0863
0.25 90.72 33.58 0.243 1.3659
Hoggart 0.5 1 619 81.45 50.36 0.3181 1.6408
1 64.35 62.41 0.2676 1.7119
1.5 48.70 73.36 0.2206 1.8281
2.5 40.87 82.85 0.2372 2.3831
Pittsburgh
0.1
6 640
100.00 0.00 0 1.0000
0.25 100.00 0.00 0 1.0000
0.5 94.20 38.31 0.3251 1.5270
1 81.74 59.66 0.414 2.0263
1.5 74.20 66.78 0.4098 2.2336
2.5 62.03 77.29 0.3932 2.7314
Table 6.7: Prediction Rules in the CREST Dataset
6.10.4 Concluding Statement
The models were poorly calibrated in the CREST dataset. Evaluation of the discrimination and the pre-
diction rules saw a large variability between the models’ performance. The Bach and African-American
models were not successful. The results suggest the African-American Model cannot be applied to different
populations and the African-American lung cancer incidence and death rates cannot be applied in a Euro-
pean population. The Spitz and Pittsburgh models reported a strong and leading performance, improving
upon the NLST criteria. The Spitz Model, optimal at the 0.5% risk threshold, should be validated at this
threshold in additional datasets to confirm whether the very promising results can be replicated.
93
6.11 Israel Dataset
The study recruited participants that are representative of a population that would be considered in a
selective screening trial. Unfortunately, only the Hoggart and Pittsburgh model can be evaluated alongside
the NLST criteria as there is only a detailed smoking history and basic information provided in this dataset.
6.11.1 Model Calibration
The Hoggart and Pittsburgh models were both well calibrated in the Israel dataset with a Hosmer-
Lemeshow p-value exceeding the critical value. This was surprising as 48.8% of participants in the dataset
had lung cancer. However, the models had a poor Brier Score with the Hoggart Model reporting a score
of 0.5833 and the Pittsburgh Model reporting a score of 0.5658.
6.11.2 Model Discrimination
The two models recorded a reasonable discrimination; the Hoggart Model marginally reported the highest
AUC with a result of 0.66 (95% CI [0.60, 0.72]) in comparison the Pittsburgh Model reported an AUC
of 0.63 (95% CI [0.57, 0.69]). The small volume of participants in the dataset is reflected in wide 95%
confidence intervals.
Figure 6.7: AUC of Models in the Israel Dataset
6.11.3 Prediction Rules
The NLST criteria was quite successful in the Israel dataset. The criteria combined a lower sensitivity
(39%) with an impressive specificity (84%), this equates to a strong Youden index. The criteria would
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capture a reasonable proportion of individuals with lung cancer which would improve lung cancer diagnosis
rates, while the impressive specificity reduces the potential harms of unnecessary screening highlighted by
a strong PLR result of 2.458.
The Hoggart Model had a slightly poorer performance than the NLST criteria. At the 1% risk threshold
the Youden index was marginally lower; despite a sensitivity of 68% the specificity was reduced to 54%.
The lower specificity meant the potential harms from unnecessary screening increased, which resulted in a
lower PLR of 1.5.
The Pittsburgh Model had a similar overall performance as the Hoggart Model (Table 6.8). The model
was optimal at the 2.5% threshold. In comparison to the Hoggart Model the sensitivity was lower at 55%
and the specificity increased to 66%. This trade-off was reflected in a similar Youden index between the
two models.
In summary, the models and the NLST criteria all demonstrated a reasonable selective screening ability
in the Israel dataset. The NLST criteria reported a marginally leading performance and was successful at
reducing unnecessary screening of individuals without lung cancer.
Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 615 39.00 84.13 0.2313 2.4575
0.1 97.21 12.5 0.0971 1.1110
0.25 92.09 20.59 0.1268 1.1597
Hoggart 0.5 1 351 80 38.97 0.1897 1.3108
1 68.37 54.41 0.2278 1.4997
1.5 52.56 69.85 0.2241 1.7433
2.5 39.07 83.09 0.2216 2.3105
Pittsburgh
0.1
6 352
100 0 0.0000 1.0000
0.25 100 0 0.0000 1.0000
0.5 88.37 20.44 0.0881 1.1107
1 74.42 44.53 0.1895 1.3416
1.5 68.37 53.28 0.2175 1.4665
2.5 55.35 66.42 0.2177 1.6483
Table 6.8: Israel Dataset Prediction Rules
6.11.4 Concluding Statement
The two models were well calibrated in the Israel dataset. In contrast the AUC results were poor with the
models reporting results of approximately 0.6. This was reflected in the prediction rules assessment where
the models failed to improve upon the NLST criteria, which reported a marginally leading performance in
the dataset.
6.12 ESTHER Dataset
The small case-control ESTHER study is only applicable to the Hoggart and Pittsburgh models. However,
the study will allow a good indication of how the models would perform as the recruited sample population
is representative of a target population for selective screening for lung cancer.
6.12.1 Model Calibration
The Hosmer-Lemeshow test demonstrated the Hoggart (0.0426) and Pittsburgh (0.006) models were not
well calibrated in the ESTHER dataset. The Hoggart Model was close to being accepted at the 0.05
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threshold and increasing the number of groups across the dataset saw the p-value rising above the 0.05
critical value. Evaluating the Brier score, both models reported a poor result with values of 0.57 and 0.55
for the Hoggart and Pittsburgh models, respectively. Overall, the models had a poor calibration in the
ESTHER dataset. This is expected because the models are not calibrated to predict such high incidence
rates as observed in the ESTHER study.
6.12.2 Model Discrimination
There were varied results for the models in the ESTHER dataset. The Hoggart Model reported a poor
AUC of 0.63 (95% CI [0.56, 0.70]). However, there was a notable improvement observed for the Pittsburgh
Model which reported an AUC of 0.72 (95% CI [0.66, 0.78]). This improvement, highlighted in Figure 6.8,
suggests that the model was more successful at distinguishing between cases and diseased and disease free
individuals.
Figure 6.8: AUC of Models in the ESTHER Dataset
6.12.3 Prediction Rules
The NLST criteria reported a good performance in the ESTHER dataset. The criteria reported a sensitivity
of 54% and an impressive specificity of 79%. This equates to a strong Youden index exceeding 0.3. Overall
the model performs robustly in the dataset and would succeed in rejecting a high proportion of disease
free individuals from unnecessary screening.
The Hoggart Model was optimal at the 0.5% risk threshold in the ESTHER dataset where it reported a
similar performance to the NLST criteria. The model would capture a much higher proportion of diseased
individuals (70%) while maintaining a specificity of 60%. This is a similar standard of performance to the
NLST criteria as shown by the Youden index.
Similarly, the Pittsburgh Model does not improve upon the NLST criteria. The model was optimal
at the 1% risk threshold with a sensitivity of 67% for a specificity of 65%. This equated to a Youden
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index of 0.32, which is the same as the NLST criteria. The lower specificity results in a PLR of 1.93. The
Pittsburgh Model did not translate the higher AUC into improved prediction rules in comparison to the
Hoggart Model.
Ultimately, while the models have a good performance in the ESTHER dataset, they do not improve
upon the NLST criteria. The models, similar to the NLST criteria, consider age and smoking history as
the predominate predictors. The results indicate that by incorporating more predictors into the models,
this may allow the models to more consistently improvement upon the NLST criteria.
Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 369 54.05 78.80 0.3285 2.5495
0.1 95.18 13.68 0.0886 1.1026
0.25 88.55 29.91 0.1846 1.2634
0.5 69.88 59.83 0.2971 1.7396
Hoggart 1 1 283 35.54 74.36 0.0990 1.3861
1.5 19.28 82.05 0.0133 1.0741
2.5 16.27 88.03 0.0430 1.3592
0.1 100.00 0.00 0.0000 1.0000
0.25 100.00 0.00 0.0000 1.0000
0.5 92.17 38.46 0.3063 1.4977
Pittsburgh 1 6 283 67.47 64.96 0.3243 1.9255
1.5 56.63 71.79 0.2842 2.0074
2.5 37.35 84.62 0.2197 2.4285
Table 6.9: ESTHER Dataset Prediction Rules
6.12.4 Concluding Statement
The Hoggart and Pittsburgh models were poorly calibrated in the dataset. When measuring the AUC
the Pittsburgh Model was the stronger of the two models. This was also supported in the prediction
rules where the prediction model performed well at the 0.5% risk threshold. However, despite the good
performance the models do not improve upon the NLST criteria. This could suggest models considering
more predictors would be more successful as a selective screening tool.
6.13 MSH-PMH Dataset
The MSH-PMH dataset provided a large case-control sample population to assess the performance of the
models. The participants recruited for the study should allow the models to be thoroughly evaluated as it
offers a sample population that is representative of a target population for selective screening.
The dataset was used to validate the Bach, PLCO, Pittsburgh, Hoggart and LLP models.
6.13.1 Model Calibration
The models were poorly calibration and recorded Hosmer-Lemeshow p-values < 0.0001, except the Bach
Model, which although improved, still reported a p-value below 0.05. The Brier Scores were also poor
because of the high lung cancer incidence rate in the MSH-PMH dataset.
6.13.2 Model Discrimination
The models demonstrated a strong discrimination in the dataset when combining the AUC results using
Rubins Rules. The Bach (0.71 95% CI [0.65, 0.77]) and the LLP (0.74 95% CI [0.70, 0.78]) had the lowest
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AUC but the results are still very strong. The remaining four models reported a very strong AUC with
results for the Hoggart Model (0.79 95% CI [0.77, 0.81]), Pittsburgh Model (0.82 95% CI [0.80, 0.84]),
PLCOM2012 Model (0.80 95% CI [0.77, 0.82]) and PLCOM2014 Model (0.79 95% CI [0.77, 0.81]).
Model Risk Threshold (%) Duration Observations Sens. Spec. Youden PLR
NLST NA NA 2744 41.48 93.85 0.3533 6.7447
Bach
0.1
10 517
100.00 0.00 0.0000 1.0000
0.25 100.00 0.00 0.0000 1.0000
0.5 99.81 0.00 -0.0019 0.9981
1 99.03 4.65 0.0368 1.0386
1.5 98.44 10.47 0.0891 1.0995
2.5 93.58 20.93 0.1451 1.1835
0.1 94.22 33.88 0.2810 1.4250
0.25 89.10 48.78 0.3788 1.7396
0.5 81.15 63.18 0.4433 2.2040
PLCO 2014 1 6 2423 67.76 78.38 0.4614 3.1341
1.5 55.04 85.04 0.4008 3.6791
2.5 39.93 91.98 0.3191 4.9788
0.1 83.84 49.88 0.3372 1.6728
0.25 73.81 71.99 0.4580 2.6351
0.5 65.06 82.29 0.4735 3.6736
PLCO 2012 1 6 1299 54.10 90.39 0.4449 5.6296
1.5 43.98 93.35 0.3733 6.6135
2.5 31.94 96.48 0.2842 9.0739
LLP
0.1
5 2096
95.49 15.35 0.1084 1.1281
0.25 87.82 34.20 0.2202 1.3347
0.5 75.82 55.47 0.3129 1.7027
1 62.13 75.24 0.3737 2.5093
1.5 54.74 82.07 0.3681 3.0530
2.5 44.51 90.11 0.3462 4.5005
0.1 93.44 19.33 0.1277 1.1583
0.25 85.29 50.77 0.3606 1.7325
0.5 73.12 74.48 0.4760 2.8652
Hoggart 1 1 1639 64.83 82.34 0.4717 3.6710
1.5 48.35 89.75 0.3810 4.7171
2.5 33.95 94.70 0.2865 6.4057
0.1 100.00 0.00 0.0000 1.0000
0.25 100.00 0.00 0.0000 1.0000
0.5 90.63 50.69 0.4132 1.8380
Pittsburgh 1 6 1639 74.37 75.85 0.5022 3.0795
1.5 64.66 83.95 0.4861 4.0287
2.5 50.63 91.13 0.4176 5.7080
Table 6.10: MSH-PMH Dataset Prediction Rules
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6.13.3 Prediction Rules
The NLST criteria reported an exceptional performance in the MSH-PMH dataset. The criteria reported
a sensitivity of 41.5% supported by a very high specificity of 94%. This equates to a Youden index score
exceeding 0.35 and while slightly higher scores have been observed in other datasets, this index score is
exceptional in comparison to the other models validated in this dataset. Indeed, the ability of the model
to still identify such a high proportion of lung cancer incidences despite rejecting 94% of disease free
individuals, allows the criteria to report a PLR of 6.74, much higher than has previously been observed.
The Bach Model, optimal at the 2.5% risk threshold underachieved in comparison. The model appeared
to require a higher risk threshold to yield a better performance because at this threshold a high proportion
of both diseased and disease free individuals would still be screened. This resulted in a poor Youden index
of 0.145 in comparison to the NLST criteria and the other models.
Next the LLP Model reported a similar performance to the NLST criteria. The model, optimal at the
1% risk threshold, had a sensitivity of 54.7% supported by a high specificity of 82%. While these results
created an impressive Youden index exceeding 0.36 this was significantly lower than the remaining models.
The two versions of the PLCO models and the Hoggart and Pittsburgh models all reported an excep-
tional performance in the MSH-PMH dataset (Table 6.10) with Youden index scores between 0.46-0.50.
This built upon the very high overall discriminative ability of the models. The Pittsburgh Model reported
the leading performance at the 1% risk threshold. The results were exceptional with sensitivity and speci-
ficity scores of approximately 75%. While the level of performance shown by the models is unexpected the
results support previous findings that the PLCO models and the Pittsburgh Model are the leading lung
cancer prediction models and can improve upon the NLST criteria and the LLP and Bach models which
were limited in the dataset.
6.13.4 Concluding Statement
The models recorded a poor calibration in the MSH-PMH dataset. However, all the models had a good
overall discrimination which gave rise to strong prediction rules with some exceptional results for the
PLCO, Hoggart and Pittsburgh models. These improved upon the NLST criteria, although the Bach and
LLP models failed to offer an improvement.
6.14 Model Summaries
The results will now be summarised per model and criteria. This will consider the models’ ability to
predict the observed incidence rates across the datasets, the overall discrimination and provide an estimate
of the optimal risk threshold for the models and a review of expected performance at this threshold. The
model limitations will be discussed alongside recommendations on whether a model is a leading lung cancer
prediction model and could be considered as a clinical tool.
6.14.1 Model Calibration and Discrimination
The models failed to consistently report a good calibration in the datasets (Figure 6.9). This is a limitation
of the study because the poor results could be attributed to the datasets obtained, which had a high lung
cancer incidence rate. This is higher than would be observed based on worldwide lung cancer prevalence
rates for which the models are calibrated to predict lung cancer incidence.
Despite the overall poor results the Bach Model does perform reasonably well on evaluation of the
calibration. The model reported a good calibration in 4 out of the 6 datasets in which the model could be
evaluated. This could be explained by the high risk population to which the model was restricted to predict
risk and applying the models to predict 10-year absolute risk. This will lead to a heightened predicted
incidence rates in comparison to a model that could be applied to everyone to predict 1-year risk. This
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Figure 6.9: Calibration and AUC for the Prediction Models
allowed the Bach Model to predict the incidence rates nearer to the observed prevalence rate. Additionally,
the model always reported a good calibration when previously validated (Systematic Review).
The remaining models underperformed with the Hoggart and Pittsburgh models sometimes reporting a
good calibration, although this was sporadic across the 10 datasets. The other models consistently reported
a Hosmer-Lemeshow p-value below 0.05 as they failed to predict the high observed lung cancer incidence
rate. It is recommended the calibration is reviewed in more appropriate studies, that reflect real world
lung cancer prevalence rates, to allow a more comprehensive review of the model calibration.
The discrimination results, measured through the AUC, provided more conclusive evidence than the
calibration results. The PLCOM2014 Model reported the highest or very close to highest AUC result of
all the prediction models that were applicable in same datasets. The model demonstrated the strongest
discriminative ability including in differing sample populations that would be considered lower risk (ReS-
oLuCENT) or higher risk (CARET) of developing lung cancer.
In contrast, the Bach Model was unable to distinguish between diseased and disease free participants.
This may be a limitation of the high risk target population to which the model is applied, so the model fails
to consistently assign a higher risk to the individuals with lung cancer than disease free participants. The
PLCOM2012 and Pittsburgh models reported a reasonable discriminative ability. The Pittsburgh results
demonstrate how a simple model that only considers four basic factors can still be practical to distinguish
between individuals with or without lung cancer. Finally, the Spitz Model reported a good discriminative
ability in the only dataset to which the model was applicable, further testing of the Spitz Model should
evaluate if the strong AUC of 0.76 (95% CI [0.73, 0.79]) can be replicated.
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6.14.2 Prediction Rules
The models reported a mixed performance when evaluating the prediction rules. There were some clear
leading models, with the PLCOM2014 Model reporting the leading performance at the 0.5% risk threshold.
The results are explored in more detail in the summary for each model.
Model Threshold (%)1 Sensitivity (%) Specificity (%) PLR2
NLST NA 30-40 80 1.75
Bach 0.5 80 45 1.455
LLP 1 75 50 1.5
Spitz 0.5 72 70 2.4
African-American 0.25 94 29 1.324
PLCOM2012 0.5 80-85 55-60 1.941
PLCOM2014 0.5 70 75 2.8
Hoggart 0.5 70 55 1.556
Pittsburgh 1 65 65 1.857
1Risk Threshold where the model performed robustly. 2PLR is Positive Likelihood Ratio
Table 6.11: Summary of Prediction Rules for the Models
6.15 NLST Trial Criteria
The NLST criteria has been previously implemented to identify high risk participants for annual LDCT
screening. The criteria selected people for screening if they were aged between 55-74 and had a 30+ pack
year smoking history.
The high risk criteria was designed to reject a large proportion of disease free individuals from un-
necessary screening. This was observed across the datasets with an average specificity of 80%. The high
risk criteria resulted in a lower sensitivity of approximately 30-40%. However, the criteria still offers some
benefit while the potential harms from unnecessary screening are heavily restricted, which is observed in a
PLR of 1.75.
Overall the criteria performed consistently with a reasonable performance. The criteria would be
optimal it the objective of a screening programme was to limit unnecessary screening. The criteria reported
a performance in sample populations that would be considered lower or higher risk of developing lung cancer
as it failed to distinguish between diseased and disease free individuals. Here, prediction models may offer
a more robust performance.
6.16 Bach Model
The Bach Model can be applied to predict either incidence or absolute risk over any duration. The model
was validated for predicting absolute risk over 10 years because this was how the model was presented in
the original article. The model has limitations as it is restricted to a small subset of high risk ever-smokers
who are aged 50-75 years and with a minimum 30 pack year smoking history. This restricts the impact
of the model to improve lung cancer diagnosis rates as the target population is already restrictive. The
Bach Model would be expected to identify the majority of cancers in this subset to positively influence
lung cancer diagnosis and survival rates. Indeed, the NLST criteria would screen all participants who are
eligible for the Bach Model.
The model had a low discriminative ability in comparison to other models and this was reflected in
poorer results when evaluating the prediction rules. The prediction rules for the Bach Model had only
been presented in one previous article. In this article, presented in the Systematic Review (Section 3),
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the model’s prediction rules performance was evaluated at 2.5%, 5% and 7.5% risk thresholds. At these
thresholds the results were poor because the model reported a low sensitivity in an already highly restrictive
target population. This series of external validations reported more promising results. Except for the high
risk CARET dataset the model was strongest in the remaining 4 datasets at 1.5%, 0.5%, 0.25% and 0.5%.
Evaluating the prediction rules at the thresholds the model recorded the most consistent performance at
the 0.5% risk.
At the 0.5% risk threshold the Bach Model sensitivity was around 80% and the specificity was approx-
imately 45%. This model would only be considered as a selective screening tool if the programme wanted
to identify the highest risk cases. If considering selective screening to everyone in a geographical area the
Bach Model at the 0.5% risk threshold would limit screening costs in comparison to the NLST criteria of
any of the remaining models. However, other models, by considering a larger target population, would have
a stronger impact in identifying lung cancer incidences and improving lung cancer diagnosis and survival
rates in comparison.
6.17 LLP Model
The LLP Model was applied to predict 5-year risk of lung cancer incidence in four ILCCO datasets. The
model can be applied to never-smokers but is restricted to participants aged 40-80 years because the age
and gender specific incidence rates are only provided for this age range. This is a reasonable age range as
would be expected for a lung cancer screening programme.
The model performed robustly at the 1% risk threshold, which was supported by the optimal per-
formance of the model at the 0.91% threshold in a previous external validation [74]. At this threshold
the sensitivity was around 75%, although the specificity was lower at 50%. While the model reported a
reasonable performance when evaluating the prediction rules this was not one of the leading models. The
PLCOM2014 Model reported a much improved performance and was also applicable to a large population by
having more flexible age restrictions (20+). Additionally, the Pittsburgh and PLCOM2012 models reported
an improved performance, although these were restricted to ever-smokers. In summary, the results indicate
other models would offer a more robust selective screening tool in comparison to the LLP Model.
6.18 Spitz Model
The Spitz Model was applied to predict 1 year absolute risk of lung cancer. Unfortunately, the model
could only be applied to the CREST dataset so any promising results would have to be replicated in other
populations. Without replicating the results in new external validations there can be no confidence the
Spitz Model would be consistent and successful as a selective screening tool.
The impressive discriminative ability was reflected in the prediction rules; where the model was optimal
at the 0.5% risk threshold. In previous external validations the model had been reviewed at the 2.5% risk
threshold because the model was run recursively over 5 years rather than 1 year in this study. The model at
the 0.5% threshold reported a sensitivity of 72% and specificity of 70%. The high sensitivity would improve
lung cancer diagnosis rates and the equally high specificity would limit unnecessary screening. A model
which could consistently replicate these results at the same risk threshold could be a successful selective
screening tool. Therefore, future testing should evaluate the Spitz Model at the 0.5% risk threshold.
6.19 African-American Model
The African-American Model, applied to predict 5-year absolute risk, was reviewed in the CREST dataset.
While the model can be applied to anyone aged 20+ years, the model was designed to predict risk in African-
Americans. Unfortunately, the model could not be applied to an African-American sample population,
instead a European population in this external validation.
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The model was optimal at the 0.25% risk threshold, with a sensitivity of 94%, although the specificity is
low at 29%. This was poorer than other models in the same dataset and the NLST criteria. This suggests
that the model cannot be robustly applied in different populations from the original model purpose.
No conclusive results can be determined from the external validation. The African-American Model
appears to fail in different populations. Future work should evaluate this model and the other lung cancer
prediction models in an African-American population. This will evaluate if this is then the leading model
or if there is an universal model that can be applied in differing populations.
6.20 PLCOM2014 Model
The PLCOM2014 Model was applied to five ILCCO datasets to predict 6-year risk of lung cancer incidence.
The model could be applied to never-smokers as well as ever-smokers provided they were aged at least 20
years. Since people under 20 years would not be considered for lung cancer screening, there are no concerns
with the model restrictions.
The impressive discriminative ability was reflected in the prediction rules. The model was optimal at
the 0.5% risk threshold where the model reported a sensitivity of approximately 70% and a specificity of
75%. This is an exceptional performance with a Youden index of 0.45 and a PLR of 2.8. There are many
advantages to this prediction model because the high sensitivity would improve lung cancer diagnosis rates
if applied as a selective screening tool. Additionally, the strong specificity would limit potential harm by
reducing unnecessary screening.
The results demonstrate that if a selective screening programme aims to identify a high proportion of
individuals with lung cancer, then the PLCOM2014 Model should be considered at the 0.5% risk threshold.
This offered a significant improvement over the NLST criteria and would double the proportion of diseased
individuals identified, however an extra 5% of disease free individuals would be screened. If a selective
screening programme preferred to identify cases amongst ever-smokers then the PLCOM2012 or Pittsburgh
models may be preferred, although the impressive discriminative ability of the model, including in ever-
smokers studies, suggests that the model would still be successful in these specific target population.
6.21 PLCOM2012 Model
The PLCOM2012 Model predicted 6-year risk of lung cancer in ever-smokers aged 20+ years. The model
was applied to 5 ILCCO datasets.
The PLCOM2012 Model had only been evaluated at one risk threshold in previous validation studies.
That study found 1.51% was the optimal risk threshold for the model and it would improve on the NLST
criteria. The optimal 1.51% risk threshold was not supported in this study. The 1.51% threshold was
identified in a heavy 30+ pack year ever-smoker cohort where participants would be considered at high
risk of developing lung cancer. This external validation found the model performed robustly at the 0.5%
risk threshold across the datasets.
At this low optimal risk threshold the model would screen a high proportion of ever-smokers. The
sensitivity was between 80-85% with results of 83%, 87%, 71% and 81%, which are consistently high. The
specificity was more variable across the datasets and was approximately 55-60%. This may be deemed too
high a proportion of disease free participants unnecessarily screened in a clinical setting, although if this
is acceptable, then the high sensitivity would improve lung cancer diagnosis rates.
This model should be preferred in comparison to the NLST criteria if the selective screening programme
aimed to capture a high proportion of lung cancer incidences in ever-smokers. This model marginally had
the better performance over the Pittsburgh Model; the other leading ever-smokers model. The results
across the datasets demonstrated that the model was robust and successful in many different populations.
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6.22 Hoggart Model
The Hoggart Model was applied to all 10 ILCCO datasets to predict 1-year absolute risk in ever-smokers
aged 35+ years. Across the 10 datasets the Hoggart Model reported mixed results.
The prediction rules had not been previously validated. The results across 9 datasets, after excluding
the higher risk CARET dataset, provided clear evidence that 0.5% was the optimal risk threshold. The
Hoggart Model generated reasonable results at this risk threshold. Across the datasets the sensitivity was
around 70% with a slightly low specificity around 55%. This resulted in a reasonable Youden index of
approximately 1.25 and a PLR of 1.56.
Across the datasets the Hoggart Model reported a similar performance to the NLST criteria. However,
this was not the leading model as the Pittsburgh and PLCOM2012 models demonstrated a stronger per-
formance. Additionally, the validation results indicate the PLCOM2014 Model would be a more successful
selective screening tool and could also be applied to never-smokers.
6.23 Pittsburgh Model
The Pittsburgh Model was applied in all the ILCCO datasets to predict 6-year risk of incidence in ever-
smokers.
The Pittsburgh Model reported the strongest prediction rules performance at the 1% risk threshold.
Here the model reported a sensitivity and specificity of approximately 65% which allowed for a Youden
index of 0.30 and a PLR of approximately 1.85. This was a very good performance amongst ever-smokers
and one of the leading models alongside the PLCOM2012 Model. This may be preferred to the NLST
criteria because the model would capture a higher proportion of lung cancer incidences, improving lung
diagnosis rates. However, the model would have to screen additional disease free individuals.
In summary, if a selective screening programme was implemented to identify lung cancer cases in
ever-smokers then the Pittsburgh Model could be considered as this was the leading model alongside the
PLCOM2012 Model. Applying the model at the 1% risk threshold would identify approximately 65% of lung
cancer individuals although this would require screening approximately 35% of all disease free ever-smokers.
6.24 Summary
The external validations show that the previously implemented NLST criteria can be improved by con-
sidering different prediction models to select a target population for screening. The PLCO models and
the Pittsburgh Model had the best performance. These models reported the highest AUC results and the
strongest prediction rules results. The models were poorly calibrated in these datasets due to the high lung
cancer incidence rates, and they should be evaluated in cohort studies with more appropriate incidence
rates to gain a better understanding of the model calibration.
The PLCOM2014 Model was the strongest performing model with an AUC result between 0.68-0.79 in
most datasets. The model had an optimal performance at the 0.5% risk threshold with a sensitivity of 70%
and a specificity of 75%. In comparison to the implemented NLST criteria, the PLCOM2014 Model would
capture 30-40% more individuals with lung cancer, although it would require screening 5% more disease
free individuals. This is a considerable amount of additional screening when considering the lung cancer
prevalence rate. Health decision makers may prefer to utilise this model with the improved lung cancer
capture rate at the determinate of extra unnecessary screening of disease free individuals.
The PLCOM2012 and Pittsburgh models, which both target ever-smokers, reported a similar perfor-
mance to the NLST criteria. These models performed robustly at the 0.5% and 1% risk thresholds respec-
tively for 6-year risk. While they reported a high lung cancer capture rate they would require screening
a greater volume of disease free individuals (10-15%). Therefore, the costs of applying this criteria in
a selective screening trial would be increased in comparison to the NLST trial criteria or the PLCO2014
Model.
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The Spitz Model displayed a promising performance at the 0.5% risk threshold. However, this was only
evaluated in one dataset so further testing of the model is required to assess if the promising results can
be replicated. The remaining models had a poorer performance so should not be considered as a selective
screening tool.
There can be some difficulty interpreting the results as to what constitutes a good compromise between
the sensitivity and specificity. The next validation, presented in the subsequent chapter, tries to address
this by fixing the specificity to a rate that seems appropriate based on prior lung cancer screening. Then
the sensitivity is measured and to review which models are more successful.
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CHAPTER 7
External Validation of Models in comparison to UKLS Guidelines:
Part 2
7.1 Introduction
The previous validation identified the PLCOM2014 as a leading model. This model at the 0.5% risk threshold
reported a sensitivity of 70% and a specificity of 75%. This would capture a high proportion of individuals
with lung cancer however, screening 25% of disease free individuals could be unrealistic and may not be
economically viable. Therefore, a second validation was conducted to evaluate the models while restricting
the specificity in the target population. The models were compared to each other and the UKLS screening
guidelines, which aims to restrict unnecessary screening by only identifying extremely high risk participants.
This proposed validation will identify the models’ risk thresholds to maintain a high specificity yet still be
a successful selective screening tool but identifying individuals with lung cancer for screening.
7.2 Objectives
To conduct the external validation and identify economical screening criteria the chapter has the following
objectives;
1. Identify an appropriate specificity level based on the UKLS guidelines.
2. Assess the performance of the prediction rules of the models and the UKLS criteria.
• Identify the risk threshold that allows the model to maintain the desired specificity level.
• Assess the sensitivity, Youden Index and PLR, at this risk threshold.
3. Identify the leading model and subsequent risk threshold that would be the optimal selective screening
criteria.
7.3 Methodology
A second validation was conducted to evaluate the models in a target population and attempt to consider
the economic costs and feasibility of screening a large volume of disease free individuals. This can be
observed in previous lung cancer programmes, such as the NLST and UKLS criteria, which target high
risk individuals. The objective of this validation is to identify if a prediction model can be utilised to
improve these selective screening programmes while heavily restricting unnecessary screening.
The first stage of the validation was to determine an acceptable specificity. There is no minimum
acceptable standard for a screening programme in terms of budgeting, sensitivity and specificity. Therefore,
the minimum standard was inferred from what has been acceptable in previous screening programmes; this
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was obtained from the UKLS trial criteria. The UKLS trial applied the LLP Model in a target population
of 50-74 year olds and participants were sent for annual screening if their 5-year risk of lung cancer exceeded
5% [34]. The high LLP Model threshold was chosen because this constrained the proportion of disease
free individuals that would be screened. The crude average specificity of the LLP Model in the validation
datasets will be determined. This will become the minimum acceptable specificity for the remaining lung
cancer prediction models. If a models screen the same proportion of disease free individuals as seen in
UKLS trial, then the costs incurred from false positives could be deemed acceptable. This requires the
assumption that any true positive identified through screening, while requiring a screening cost, is a benefit
and a willing cost. Since the specificity is fixed across the models, a model with a higher sensitivity will
demonstrate an improved benefit to harm ratio.
The first objective is to identify a target population that would most benefit from a lung cancer screening
programme. The UKLS trial restricted the target population to participants aged 50-75 years, with no
additional restrictions. This population was selected because lung cancer risk below 50 years is negligible
[1] and participants over 75 years may not be healthy for screening or for any subsequent treatment. The
age range is also used by the NLST screening trial which restricted the target population to participants
between 55-74 years, although the trial was further restricted to ever-smokers with a minimum 30 pack
year smoking history. The additional ever-smoker restriction will not be enforced. Therefore, the target
population has been defined to 50-75 years old, all participants outside this age range in the datasets will
not be considered in the external validation.
Some models have further restrictions, such as not being applicable to never-smokers. To allow all the
models to be compared, any participant who is in the target population (50-75 years old) but cannot have
their risk calculated using a specific model, will still be considered when validating the performance of that
model. They would automatically be rejected from screening, as their risk has not been calculated by the
model. Therefore, when reporting the sensitivity and specificity they will be considered as not high risk or
identified for screening.
The next stage is to define the minimum specificity. This is determined by the performance of the LLP
Model at the 5% risk threshold for 5-year risk in the datasets, as prescribed by the UKLS specifications.
The LLP Model reported an average specificity of 90% in the three applicable datasets and the results are
presented in Section 7.4. This is an expected result as previously published validations found the LLP to
have a specificity of 85% at the 5% risk threshold [69]. The remaining models will be evaluated in the
target sample populations at the risk threshold that allows the model to achieve this specificity of 90%.
This can restrict a high proportion of unnecessary screening while acknowledging some people who will
not develop cancer will have to be screened while identifying lung cancer incidences.
In summary, for each model the risk threshold that allows the model to achieve a specificity of 90%, in
the target population of 50-75 year olds, will be reported. At this risk threshold the sensitivity and PLR
will also be reported. Any leading models will be identified by a higher sensitivity at the fixed specificity.
7.4 Liverpool Lung Project Model
The LLP Model was applied in three datasets at the 5% risk threshold. The model was applied in the lower
risk of developing lung cancer ReSoLuCENT dataset, the higher risk of developing lung cancer CARET
dataset and the MSH-PMH dataset. As highlighted in Table 7.1 the LLP Model reported a crude average
specificity of 90%. As expected, applying the model at the high risk threshold allowed the model to report
a high specificity. This is replicated in previous studies, where applying the model at the 5% threshold
reported a specificity of 85%.
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Dataset Sensitivity Specificity PLR
ReSoLuCENT 11.79 90.48 1.238
CARET 27.01 80.78 1.405
MSH-PMH 23.56 96.37 6.490
Table 7.1: Liverpool Lung Project Model Validation Results
This high risk threshold, that allows the high specificity, is counter balanced by a poor sensitivity. The
results were variable in the different datasets. There is a lower sensitivity in the ReSoLuCENT dataset
and the converse is observed in the higher risk of developing lung cancer sample population in the CARET
dataset. Across the three datasets the average sensitivity is approximately 20-22%.
In summary, the high risk threshold for the LLP Model would reject a high proportion of participants
from screening. The model would avoid screening 90% of disease free individuals. However, this limits the
proportion of lung cancer incidences that would be identified. The sensitivity was approximately 20-22%
across the three datasets.
7.5 Pittsburgh Model
The Pittsburgh Model was applicable to all the ILCCO datasets. The Pittsburgh Model is a logistic
additive model [85] where the generated risks are not continuous. As a result the participants are grouped
at different risks and the sensitivity and specificity rates also increased in groups. The model is only
applicable to ever-smokers; all never-smokers who were aged between 50-75 years old were still considered
in the sensitivity and specificity rates although they would not be selected for selective screening.
To maintain a specificity of approximately 90% a risk threshold around 2.9-3% would be required. A
conservative risk threshold option of 3% would limit screening of disease free individuals aged 50-75 years,
in most real populations, to a maximum of 1 in 10 disease free individuals.
Dataset Risk Threshold (%) Sensitivity Specificity PLR
ReSoLuCENT 3.17 5.85 93.53 0.904
CARET 5.63 10.2 94.92 2.008
UCLA 1.45 35.48 91.85 4.353
NY Wynder 3.84 31.63 90.78 3.431
Singapore 0.4 35.44 90.87 3.882
New Zealand 0.98 32.35 93.43 4.924
CREST 3.84 41.9 91.47 4.912
Israel 4.66 23.11 90.26 2.373
ESTHER 2.61 33.51 90.22 3.426
Canadian 1.08 58.65 91.42 6.836
Table 7.2: Pittsburgh Model Validation Results
The sensitivity was an improvement upon the UKLS criteria and was consistently around 30-33%. This
is a notable improvement over the UKLS criterion which reported a sensitivity of approximately 20-22%.
However, in a direct comparison of the Pittsburgh Model and the UKLS criteria in the ReSoLuCENT,
CARET and MSH-PMH datasets, the Pittsburgh Model failed to report an improved sensitivity in two of
these datasets. This may suggest that the Pittsburgh Model would not improve upon the NLST criteria
when applied to the same target populations.
To summarise, the Pittsburgh Model at the 3% risk threshold should allow a specificity of 90%. Here
a sensitivity of 30-33% would be observed. The model should be evaluated at this 3% risk threshold in
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some cohorts in direct comparison to the UKLS criteria as the current findings suggest the model would
not offer an improved selective screening criteria, despite the overall improved sensitivity.
7.6 Hoggart Model
The Hoggart Model was applied to all the ILCCO datasets to predict 1-year absolute risk. The model was
only applicable to ever-smokers but never-smokers were considered in the sensitivity and specificity rates
where they would be rejected from selective screening.
The results indicate a risk threshold around 3% would allow the model to achieve a specificity of
90% in most screening programmes. However, the results were quite varied across the different datasets
(Table 7.3). As expected the higher risk sample population in the CARET dataset reported a very high
threshold (4.68%) in comparison to the New Zealand and Singapore datasets alongside a surprisingly low
risk threshold in the MSH-PMH dataset (0.60%). The remaining results were contained between 2.15-
3.67%; based on these results it was concluded a risk threshold of 3% should allow the Hoggart Model to
maintain a specificity of 90% in most real world screening programmes in this target population.
Dataset Risk Threshold (%) Sensitivity Specificity PLR
ReSoLuCENT 3.67 10.72 90.95 1.185
CARET 4.68 11.81 90.28 1.215
UCLA 2.6 35.25 91.01 3.921
NY Wynder 3.18 32.09 90.59 3.410
Singapore 0.87 34.47 90.11 3.485
New Zealand 1.31 38.24 90.51 4.030
CREST 3.24 32.7 90.1 3.303
Israel 3.1 30.66 90.26 3.148
ESTHER 2.15 16.76 90.22 1.714
Canadian 0.6 56.69 90.21 5.791
Table 7.3: Hoggart Model Validation Results
Across the datasets the Hoggart Model reported a specificity around or slightly exceeding 30%. Table
7.3 shows consistent results between 30-35% in the majority of datasets. The Hoggart Model reports
similar results to the UKLS criterion in a direct dataset comparison. Assessing the datasets applicable to
the UKLS and Hoggart criteria there is little improvement in the sensitivity except for a large improvement
in the MSH-PMH study. However, applying this model at the 3% risk threshold, as recommended, in the
MSH-PMH study would dramatically lower the sensitivity. Overall, an approximate specificity of 30%
would offer an improvement over the UKLS criteria. However, when comparing the Hoggart Model to
other models applicable to the dataset there were more successful models identified.
The Hoggart Model should be applied at the 3% risk threshold for 1-year risk to allow the model to
obtain a specificity around 90% in most populations. This allowed the model to obtain an approximate
sensitivity of 30%, which is an improvement over the UKLS sensitivity. However, the results were not
as conclusive when comparing the UKLS and Hoggart guidelines in the same dataset where there was no
apparent improvement. Further testing in the same dataset of the Hoggart Model at the 3% and the UKLS
criteria could assess which is a more successful selective screening tool.
7.7 PLCOM2014 Model
The PLCOM2014 Model was applicable to 5 of the ILCCO datasets. The model was applicable to the same
datasets as the UKLS criteria so a direct comparison between their performances can be conducted. The
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model was applicable to all the participants aged 50-75 years.
The risk threshold was quite variable across the 5 datasets and as observed in the UKLS, Pittsburgh and
Hoggart validations the MSH-PMH dataset reported an unexpectedly low risk threshold. Evaluating the
model in the remaining 4 datasets the results (Table 7.4) indicate a risk threshold of 3% would ensure 90%
of diseases free individuals would be rejected from screening. This is based on the ReSoLuCENT dataset
and the NY Wynder datasets which reported a threshold close to 3%. This is slightly higher, as expected,
in the heavy ever-smoker CARET dataset, but we would expect that in a more real world population a
lower risk threshold would be required to maintain a specificity of 90%. The UCLA slightly deviates from
the other results with a lower risk of 1.02% however in the Pittsburgh and Hoggart validations the UCLA
dataset also reported a lower risk threshold than observed in the other datasets. Taking into account these
factors a risk threshold of 3% should allow a specificity of approximately 90%.
Dataset Risk Threshold (%) Sensitivity Specificity PLR
ReSoLuCENT 3.04 15.98 90.09 1.613
CARET 4.17 17.49 90.06 1.760
UCLA 1.02 45.16 90.02 4.525
NY Wynder 2.95 34.99 89.98 3.492
Canadian 0.86 59.75 90.1 6.035
Table 7.4: PLCOM2014 Model Validation Results
The sensitivity results were quite variable but also very promising across the datasets (Table 7.4). The
average sensitivity was approximately 35%, which is exemplary and a notable improvement in comparison
to the UKLS trial and the Pittsburgh and Hoggart models. In a direct comparison to the UKLS guidelines
the model showed a clear improvement, in the ReSoLuCENT and MSH-PMH datasets. Although this was
not observed in the CARET dataset it is important to recall the UKLS criteria only reported a specificity
of 80% in the dataset rather than the fixed 90% for the PLCOM2014 Model. Indeed, this is supported
by the higher PLR the PLCOM2014 Model reported in comparison to the UKLS criteria in the CARET
dataset. Additionally, the model improves upon the previous Hoggart and Pittsburgh validation results.
In direct comparison of the sensitivity in the five datasets applicable to all the models the PLCOM2014
Model reported a higher sensitivity.
In summary, the PLCOM2014 Model is the most successful model currently evaluated. The model
should be considered at the 3% risk threshold. This should allow the model in most screening populations
to report a sensitivity of 35% for a specificity of 90%. This should be reviewed in cohort studies to assess
if the impressive results can be replicated. In a direct comparison between models and the UKLS criteria
in the datasets this model alongside the 2012 version consistently reported the leading performance and as
such should be considered as a selective screening tool.
7.8 PLCOM2012 Model
The PLCOM2012 Model is applicable to five datasets similar to the PLCOM2014 Model. Unlike the 2014
version the PLCOM2012 Model is not applicable to never-smokers. All never-smokers excluded by the model
will be considered by automatically excluding them from selective screening when reporting the sensitivity
and specificity results.
Across the five datasets the mean risk threshold is 2.98% for 6-year risk and would generate a specificity
of 90% in the datasets. However, in real world populations the risk threshold should be increased as the
mean is distorted by the very low MSH-PMH dataset risk threshold. Indeed, across the remaining 4 datasets
3.5% is a reasonable estimate to allow the model to consistently achieve a specificity of approximately
90%. However, the risk thresholds were quite variable across the models so it is recommended that the
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Dataset Risk Threshold (%) Sensitivity Specificity PLR
ReSoLuCENT 3.91 12.67 90.09 1.279
CARET 5.29 17.2 90.06 1.730
UCLA 1.25 45.62 90.02 4.571
NY Wynder 3.48 35.56 90.01 3.560
Canadian 0.96 60.49 90.1 6.110
Table 7.5: PLCOM2012 Model Validation Results
PLCOM2012 Model is evaluated at the 3.5% in additional validations to assess the creditability of this
recommendation.
The PLCOM2012 Model reported a very promising sensitivity. The crude average for the sensitivity
across the datasets is just below 35%. A direct comparison between the PLCO models per dataset shows
that they report similar sensitivity and PLR results. This should be expected because the two models
consider the same predictors with just some recalibration and the inclusion of one additional variable to
incorporate never-smokers in the 2014 version [82].
In summary, the two versions of the PLCO Models currently share the leading performance of all the
models. In a direct dataset comparison they offer a clear improvement over other models and the UKLS
guidelines. The PLCOM2012 Model should be considered at the 3.5% risk threshold for 6-year risk to
maintain a sensitivity of 35% and specificity of 90%, although it would be beneficial to evaluate the model
in cohorts to assess if the impressive performance can be replicated.
Decision makers would need to decide between the two PLCO models. The PLCOM2014 Model may
probably be preferable in screening programmes because it incorporates never-smokers. Although incor-
porating never-smokers in the risk prediction the PLCOM2014 Model was unable to identify any additional
lung cancer incidences, so there should be no preference towards the PLCOM2014 Model. However, if the
selective screening programme wanted to identify lung cancer only in ever-smokers then the PLCOM2012
Model should be implemented at the 3.5% risk threshold because more individuals with lung cancer would
be identified in comparison the 2014 version.
7.9 Bach Model
The Bach Model was applicable to five datasets. This included the MSH-PMH datasets which generated
unusual results in comparison to the other datasets. The Bach Model was applied to predict 10-year
absolute risk as presented in the original article [77]. The model is very restrictive and could only be
applied to ever-smokers with a minimum 30 pack year smoking history. This resulted in a large volume
of participants being automatically excluded by the model criteria. These will still be considered when
reporting the prediction rules.
The risk thresholds for the Bach Model were extremely variable across the datasets (Table 7.6). There
were 2 datasets with a very low risk threshold for 10 year risk around 0.25%; this may be a result of the
high automatic exclusion using the Bach Model criteria which boosts the specificity. Another 2 datasets
generated a risk threshold of approximately 6.5% and finally in the CARET dataset a very high risk
threshold of 12.25% was required to maintain a specificity of 90%. The results were so variable an accurate
prediction for a risk threshold to maintain a specificity of approximately 90% could not be estimated.
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Dataset Risk Threshold (%) Sensitivity Specificity PLR
ReSoLuCENT 6.81 11.31 90.09 1.141
CARET 12.25 13.56 89.99 1.355
NY Wynder 6.05 36.1 90.01 3.614
CREST 0.25 30.79 89.76 3.007
Canadian 0.26 58.77 90.1 5.936
Table 7.6: Bach Model Validation Results
Further evaluation of the Bach Model is required if considering this model as a selective screening tool
in order to assess if a consistent risk threshold can be identified. However, based on the results observed
in the validation the Bach Model would be too variable in different populations to recommend the model
as a universal screening tool.
7.10 Spitz Model
The Spitz Model was only applicable to the CREST dataset. The model can be run recursively but is
applied for 1-year risk because the model was applied over this duration in the original article [75]. The
Spitz Model can be applied to all participants in the 50-75 years age range which may improve the model
performance because no participants are automatically excluded.
The Spitz Model exhibited promising results in the CREST dataset. The model was applied at the
1.31% risk threshold to achieve a specificity of 90%. The model should be validated at this threshold in
new environments to assess if this will maintain the specificity of 90%. The sensitivity was very promising
at 40%; if this high standard can be replicated in other studies then the model would be very successful.
This sensitivity is higher than the two PLCO models, which currently exhibited the leading performance.
Unfortunately, the models cannot be directly compared because the PLCO Models were not applicable to
the CREST dataset. It would be advisable to compare these models in the same datasets at the identified
risk thresholds to assess which would be more successful as a selective screening tool.
Dataset Risk Threshold (%) Sensitivity Specificity PLR
CREST 1.31 40 90.1 4.040
Table 7.7: Spitz Model Validation Results
In summary, the initial results were very promising and showed the best performance of all the models
currently validated. Further analysis is required in external datasets to review if the sensitivity and
specificity results can be replicated at the 1.31% risk threshold for 1-year risk. The Spitz Model should
also be compared to the PLCO Models in the same dataset because these were the other leading models.
A direct comparison of the models’ performance would indicate conclusively which model would be more
successful as a screening tool. Currently an inference cannot be made between the models.
7.11 African-American Model
Like the Spitz Model the African-American Model was only applicable to the CREST dataset. The model
could be applied to all participants in the age range which could help improve the model performance.
However, the model was applied in a different dataset to the model’s target population which could nega-
tively influence the performance of the model. The African-American model predicted lung cancer risk for
5 years.
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The African-American Model required a high risk threshold at 5.19% to report a specificity of 90%.
At this threshold the model reported a sensitivity of 27%. This was similar to the UKLS guidelines and
any future validations should assess the African-American Model at the 5% or 5.19% risk threshold. The
African-American model did not report a high sensitivity in comparison to other models in the CREST
dataset. However, testing the model in a more appropriate sample population of African-Americans may
improve the model performance.
Dataset Risk Threshold (%) Sensitivity Specificity PLR
CREST 5.19 26.67 88.4 2.299
Table 7.8: African-American Model Validation Results
The African-American Model underperformed in the CREST dataset in comparison to other models.
However, the model was applied in a different sample population rather than the target population. Val-
idating the model in a correct sample population may allow the model to excel and this may still be the
most appropriate model for an African-American population considered for selective screening.
7.12 Summary
The models were validated in comparison to the UKLS screening guidelines. The UKLS programme was
designed to identify high risk participants. There was an average specificity of 90% which allowed the
criteria to reduce unnecessary screening. As a result of the high risk individuals identified for screening
the sensitivity suffered at 20-22%. The validations discovered that some models could improve upon the
UKLS screening guidelines by increasing sensitivity without reducing the specificity below 90%.
The PLCO models offered the largest improvement, with a sensitivity of around 35% for a specificity
of 90%. The PLCOM2012 Model should be applied at the 3.5% risk threshold and the PLCOM2014 Model
requires a 3% risk threshold. While other models also improved upon the UKLS guidelines they did not
report the same level of performance as the PLCO models across all the datasets and in a direct comparison
between models in the datasets. The results indicate the PLCO models would be more successful as a
selective screening tool. It is recommended the PLCO models should be evaluated in cohort studies as
these case-control datasets may lead to optimistic results. The PLCO models should be evaluated at the
risk thresholds identified in this validation to review if the models can consistently perform to the same
standard. If they can report a similar performance level then it would be beneficial to consider these
models as a selective screening tool.
The next stage of the project is to update prediction models to assess if an improved lung cancer model
can be devised.
113
CHAPTER 8
Literature Review of Updating and Aggregating Prediction Models
8.1 Introduction
Single prediction models can be updated or multiple models aggregated into a meta-model in an attempt
to create an improved prediction model. Single model updating can involve recalibrating the model, re-
estimating the model parameters or extending the model with new parameters. This aims to improve the
model’s predictive and discriminative ability. An improved model is desirable as it combines the evidence
in the model building dataset and the model updating dataset which can create a model that is robust in
differing populations and a more successful selective screening tool.
Methods to update a single model and aggregate multiple prediction models are presented and discussed
in a literature review. The methodology is presented with examples of where they have been used while
considering the advantages and limitations of the methods.
The practicality of the methods for lung cancer prediction models will then be discussed. The appro-
priate methods will then be applied to lung cancer models to evaluate their ability to create a more robust
model.
8.2 Objectives
The chapter will conduct a literature review on methods to update a single prediction model or aggregate
multiple prediction models. To achieve this the chapter will;
1. Identify model updating methods and present their methodology.
2. Demonstrate where the methods have been applied previously to update prediction models and report
on their success in creating a more robust model.
3. Discuss the potential benefits, limitations, and concerns of each method.
4. Assess the practicality of the methods for lung cancer prediction models.
• Identify which methods will be applied to the lung cancer prediction models.
8.3 Introduction to Review of Single Updating Methods
There are several approaches to update a single prediction model using a model updating IPD. These
include updating the intercept, recalibrating the parameters, and extending the model. The different
methods can be utilised in different scenarios depending on how the original model performed in the dataset.
A model that had a successful discrimination and prediction rules but a poor calibration may benefit from
minor updating whereas a model that was less successful with a poor calibration and discrimination may
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require more extensive model updating [45, 138]. The available methods to update a single model in a new
dataset are listed as follows;
1. No updating
2. Model Recalibration
(a) Update Intercept
(b) Recalibration of the intercept and slope
3. Model Re-estimation
(a) Recalibration and selective re-estimation
(b) Re-estimation
4. Model Extension
(a) Re-estimation and extension
(b) Selective re-estimation and selective extension with recalibration
(c) Re-estimation and selective extension without recalibration
8.4 No Model Updating
When a model exhibits a strong overall performance when externally validated then model updating may
not be required. Unnecessary updates could result in over-fitting if additional parameters are only included
to explain the minor difference between predicted and observed risk in the dataset. Additionally, the new
model may have a poorer performance in external sample populations in comparison to the original model.
This will unnecessarily create a new model to the existing prediction model literature generating confusion
about which model should be used to predict an individual’s risk or identify high risk participants in a
selective screening programme.
8.5 Model Recalibration
The first updating methods are recalibration techniques [58]. These aim to improve the accuracy of
the model estimate based on the observed incidence rates in a sample population. These methods can
improve the model calibration, while the discrimination and prediction rules remain unaltered because
all participants’ risks are adjusted equally [45]. Therefore, these methods are beneficial for a model with
a strong discriminative ability but needs recalibration. These methods are most likely to be applied to
successful models which are now being applied in a different target populations and require recalibration
based on a sample population of the new target population.
8.5.1 Updating the Intercept
This method updates the intercept of the logistic regression equation. This centers the mean risk estimated
by the model for all participants to reflect the mean incidence rate observed in the sample population.
All participants are centered around the mean by having their risk scaled up or down equally. While
the discrimination and prediction rules remain unaltered, the risk threshold at which the model reports a
certain sensitivity and specificity will change.
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To update the intercept the correlation factor is calculated, which is based on the observed incidence
rate and the predicted risk in across the dataset;
Correlation Factor = ln
(
Observed Rate
1−Observed Rate ×
1−Mean Predicted Risk
Mean Predicted Risk
)
(8.1)
where Observed Rate =
Number of Participants With The Condition
Total Participants
(8.2)
This is added to the original intercept to create the final model.
While this method can improve the calibration it could be seen as a quick fix solution. The model could
require repeated updating in different target populations before being used to estimate an individual’s risk.
Before a model would be considered for implementation as a clinical utility in multiple differing populations,
a final baseline incidence rate would need to be determined [45].
This method has been commonly applied to update clinical prediction models. Studies found the
calibration was improved when the original model exhibited a poor calibration in the new populations
[139, 140, 141]. The studies also concluded that this method was beneficial when the model updating
sample population was small [139]. However, it is important that the sample population used to update
the model reflects the target population where the model will be applied. Otherwise, model updating may
be detrimental and the new model may underperform when implemented [140].
In summary, the method improves the model calibration while the discriminative ability and prediction
rules are unaltered. Therefore, this method is most appropriate for a robust model that needs minor
adjustment of the estimated baseline risk to reflect the incidence rate observed in a sample population that
reflects the new target population.
8.5.2 Recalibration of Intercept and Slope
This approach updates the intercept and the variable coefficients [142]. The recalibration factor can be
determined by the line of best fit in a plot of the observed and predicted risk as follows;
ObservedRisk = αCalibration +
(
βCalibration × (LinearPredictor)Original
)
(8.3)
For an original log odds model the line of best fit is plotted between the linear predictor and the natural
logarithm of the observed risk. A perfect original model has an intercept (Alpha) of zero and gradient
(Beta) of one. The logistic regression is updated using this information. The intercept is the sum of the
original intercept and the alpha (calibration) and the coefficients are scaled by beta (calibration) [45, 138].
LinearPredictorNew = αNew +
(
βcalibration × (LinearPredictor)Original
)
(8.4)
The method can improve the model calibration as the estimated risks are modified to reflect the observed
incidence rate in the sample population. Therefore, this method is most effective for a model with a good
discriminative ability which is applied in a new population to provide accurate risks. If the model has
other deficiencies, such as a poor discriminative ability, then this method may not be preferred; scaling all
the variables by a constant will not address any weaker variables which should be removed or constrained
in the model.
Model recalibration has been applied to update clinical prediction models with mixed success. The
method is most successful when there are only small differences between the original model building and
model updating datasets [141] and the mode updating dataset is relatively small. If the model exhibits
a poor calibration, potentially due to over-fitting, then this can be corrected by adjusting the calibration
slope [143]. However, some studies have suggested that updating the intercept led to a more robust model
when applied in external populations [140, 141] rather than recalibrating the intercept and the slope.
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8.6 Model Re-estimation
The next series of model updating methods re-estimate variables in the prediction model. These methods
identify which variables are significant to the model’s predictive ability in the validation dataset. The
variables that are not significant have their regression coefficients reduced or shrunk in the model. This
means these variables are not weighted as heavily in the updated prediction model and therefore do
not have as large an impact in predicting ones’ risk of developing the disease. The model re-estimation
techniques combine the original evidence, in the model building dataset, and evidence in the external sample
population. Combining the evidence from the original dataset and an external sample population may allow
a more robust model to be devised that could be applied across several different target populations.
These methods can improve the model calibration and also influence the model discrimination and
prediction rules. Therefore, these methods can be advantageous when an external validation identifies that
the model’s discriminative ability is poor.
There are two methods to re-estimate the model. To apply these methods a technique called shrinkage
is required which is introduced below.
8.6.1 Shrinkage
Shrinkage is applied to a prediction model such that the “regression coefficients can be shrunk either
towards the mean incidence rate or towards the recalibrated values” [138]. This is applied to avoid over-
fitting the model to the external data. This is particularly beneficial for large models with many variables
that are updated on small datasets where over-fitting could be prevalent [144].
The shrinkage factor is a value between [0, 1], and is dependent on the calibration of the original
model in the external data. A well calibrated model will require a smaller revision towards the mean or
null model. Whereas a model with a poor calibration, will have the regression coefficients heavily shrunk
towards the mean or more predictive null model. This means the weaker variables have less of an impact in
the updated model. This means an individual’s risk cannot deviate as far as originally from the observed
dataset incidence rate or the more predictive null model based on an inadequate variable the model.
8.6.2 Recalibrated Null Model and Selective Re-estimation
This method identifies the variables in the original model that are most predictive of the disease in the
model updating dataset, the model only including the parameters that significant to the model predictive
ability is defined as the null model. This identified using either a forward or backward selection process.
Prior to identifying the null model, the original model should be recalibrated using the techniques identified
in Section 8.5.2. It is important to recalibrate the original model otherwise for a poorly calibrated model
the majority of variables will show a significant improvement in the model goodness of fit and be included
in the null model. Once the recalibrated null model has been identified then shrinkage is required between
the recalibrated null model and recalibrated original model. The shrinkage reduces the weighting of the
parameters that were identified as not being significant in the original model. Therefore, these parameters
do not have as large an impact in deviating ones’ risk from what was predicted in the null model.
The shrinkage coefficient is calculated using an F-test which evaluates the difference in performance
between the null model and recalibrated original model. The factor, denoted as cˆ, is calculated as follows;
cˆ =
∣∣F1|0 − 1∣∣
F1|0
(8.5)
Then the null model and the recalibrated original model can be combined using the shrinkage factor
to create the selectively re-estimated model as follows;
LPRecalibrated&SelectiveRe−estimated = ((1− cˆ)× LPNullRecalibratedModel) + cˆLPRecalibratedModel (8.6)
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The final model is a weighted average of the null recalibrated model and the recalibrated original
model [138]. If the shrinkage factor is zero, indicating the variables not selected in the null model offered
no improvement in the model’s predictive ability, this is reflected in the final model being simply the
null model. The variables identified for the recalibrated null model remain unaltered while the remaining
variables are selectively re-estimated. Therefore, if the null model includes all the variables then this
method is redundant and identical to simple recalibration (Section 8.5.2).
This method can improve the model calibration, discrimination, and prediction rules. By evaluating
the variables in the second dataset where model updating occurs, this could create a more robust model as
the key variables associated with the disease are identified. It is important to identify any distinct charac-
teristics in the model updating dataset that may influence whether variables are considered predictive.
Model re-estimation has been applied to update clinical prediction models. Some studies found the
updated model failed to offer a large improvement in discrimination or improve the calibration in compar-
ison to more simplistic methods [141]. Additionally, if the original model has a good discriminative ability
then simple recalibration may be more appropriate. Conversely, other studies found this was the best
method when a large dataset is available to update the model [139]. Additionally, when variable effects
are heterogeneous between the development and validation samples and calibration plots show inconsistent
predictions across the whole range of predicted probabilities, then re-estimation of individual predictors
or even inclusion of additional predictors is the most beneficial method [143]. Re-estimation towards the
null model is most successful in a large dataset where the model building and model updating datasets are
heterogeneous.
8.6.3 Shrinkage and Re-estimation
The second re-estimation method does not recalibrate the original model. All the parameters are re-
estimated and then shrunk towards the mean incidence rate observed in the external sample population.
The evidence from the external sample population is incorporated through the mean rates which may
create a more robust model in new target populations.
Firstly, the shrinkage factor is calculated using the F-statistic of the original model as follows;
cˆ =
|FLPModel − 1|
FLPModel
(8.7)
This factor allows the variable coefficients to be re-estimated towards the mean observed incidence.
The method modifies the intercept, Y¯ as the mean incidence in the sample population. Participants are
then distributed around the mean using their value for the variable in comparison to the mean variable
value, X¯i. These factors are then scaled using the shrinkage coefficient.
LPRe−estimated = Y¯ + cˆβ1
(
X1 − X¯1
)
+ . . .+ cˆβp
(
(Xp − X¯p
)
(8.8)
The method improves the model calibration because the predicted risks are distributed around the ob-
served incidence in the sample population. The method can also improve the discrimination and prediction
rules. However, a biased dataset (collection based on unusual occurrences for one or more of the variables)
could hinder the model in new populations because the observed mean for the variable coefficient could be
unrealistic. Re-estimation towards the mean does not evaluate each variable independently therefore will
not identify any underlying problems to accurately estimate risk caused by irrelevant variables included in
the prediction model.
Re-estimation towards the mean has been applied to update prediction models. This method has been
successful when the original model was poorly calibrated and also reported a poor discriminative ability
[139]. Additionally, for a model with a poor discriminative ability and a large model updating dataset
available, then extending the model further improved the model performance rather than re-estimation
[145].
In summary, this method is most successful for a model with a strong discriminative ability but requires
recalibration for accurate predictions in a new target population where the model updating dataset is a
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sample population of the new target population. If the model has a poor discriminative ability, then model
extension or the other model re-estimation method (Section 8.6.2 may be more appropriate methods.
8.7 Model Extension
The final set of single model updating methods are defined as model extension. These methods incorporate
additional variables in the prediction model. A more robust model could be created because additional
key variables that explain risk can be incorporated.
Although, there are potential risks with model extension including over-fitting by attempting to explain
the difference between the predicted and observed risks rather than the underlying condition [144]. The
model may then underperform if applied in different target populations. These concerns can be avoided by
only considering variables with a significant association with the disease. Additionally, the original model
should be recalibrated to avoid all additional variables being included because they improve the model
goodness of fit due to an original model calibration deficiency.
To identify additional predictors to be included in a model the hazards or odds ratios can be evaluated.
If a statistically significant ratio is observed then the variable should be considered. However, a variable
associated with the disease does not guarantee an improvement in model performance as “Ware and Pepe
showed simple examples in which enormous odds ratios were required to meaningfully increase the AUC”
[139, 146, 147]. It is important to consider not including too many additional predictors which may not
significantly improve the model performance and could result in over-fitting and the model may then be
unsuccessful in new populations.
8.7.1 Re-estimation and Extension
To apply this method, the first stage is to recalibrate the original model. The model variables are re-
estimated towards the recalibrated null model using the techniques previously presented in Section 8.6.2.
The model is then extended to include all additional variables available in the model updating dataset or
identified as being associated with the disease through previous testing.
As previously discussed, including all additional parameters may not improve the model performance,
and could limit the model in new populations. This approach can cause over-fitting by considering too
many parameters especially if the model updating dataset is small [144]. This could create a final model
that while being successful when internally validated may perform poorly in new populations. A more
selective model extension technique that identifies the appropriate variables, rather than including all
available different information, could create a more robust model.
Previous studies have been critical of this method when applied to clinical prediction models. While
this method has been shown to be beneficial if the original model had a poor overall performance [143, 145]
the updated models have been criticised. This method should be applied with caution in small datasets,
because the method places a comparatively large significance on the updating data, and hence would be
prone to peculiarities of the updating dataset [141]. In a study updating a prostate cancer prediction
model, while additional markers have the potential to improve discrimination these should be selected
using forward selection rather than all being included as this created an inferior prediction model when
externally validated [145].
8.7.2 Selective Re-estimation and Selective Extension with Recalibration
The first stage is to recalibrate and re-estimate the original model which has been presented in Section
8.6.2 before the model is extended. New variables can be included if they are shown to have an association
with the condition in the model updating dataset. A second approach is to include the new variables using
forward selection from the selectively re-estimated model if they offer a significant improvement to the
model goodness of fit, measured by chi-squared. Incorporating the new parameters using forward selection
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is preferred as previous studies have shown incorporating new variables based on their association with the
condition may not lead to an improved calibration or discriminative ability [139, 146, 147].
This method can create a robust model with an improved calibration, discrimination, and prediction
rules. Including only parameters that improve the model goodness of fit limits the risk of over-fitting caused
by including all additional variables. The main concern with this method is that if the model updating
dataset has an unusual participant recruitment and variables may be included in the final model that do
not assist in estimating the likelihood of a disease developing. One such example would be if all diseased
individuals are collected dependant on having a different prior existing condition; this is likely to show
a significant association with the condition which may not be observed in real populations. Precautions
can be taken by conducting a review of the dataset recruitment process and analysing the population
demographic. The model should also be externally validated in comparison to the original model to assess
if a more robust model has indeed been developed.
Models have commonly been extended and is likely to be an increasingly popular method as genetic
markers are incorporated into existing models, as has been observed in lung cancer (Section 3). One study
found when predictor effects are heterogeneous between the development and validation samples then
extensive updating was required [143]. Re-estimating the existing variables and then selectively including
additional variables was a successful method [143]. A separate study compared different strategies for
model extension for a new variable. The study found that when the dataset used to extend the prediction
model was small, simple re-estimation methods led to the largest increase in discriminative ability of the
prediction model, but as the available sample population increased more extensive extension methods
outperformed re-estimation techniques [145].
8.7.3 Re-estimation and Selective Extension without Recalibration
This method is similar to the model extension method described in Section 8.7.2, however the preliminary
work differs. The original model is not recalibrated because the model is shrunk around the mean incidence
rate observed in the model updating dataset, as presented in Section 8.6.3, then extended using forward
selection to identify new variables that improve the model goodness of fit, as presented in Section 8.7.2.
Selective extension limits the risk of over-fitting [144] because only variables associated with the disease
are included rather than including all available variables. However, the method could still be affected by an
unusual recruitment of diseased and disease free individuals in the model updating dataset. Additionally,
a poor original model calibration may see a large quantity of new variables included to rectify the original
model calibration deficiency. This could result in an extended model that underperforms in new populations
because the included variables explained the variance between the predicted and observed risk in the model
updating dataset rather than the underlying condition. Therefore, it is important to assess how the model
performs in new populations, and whether the new variables included in the extended model created a
more robust model in comparison to the original model.
In summary, this method has been successful when the original model is poorly calibrated and reported
a poor discriminative ability [143]. Indeed, with a large dataset available to perform the model updating, for
a model with a poor original performance, model extension outperformed more simplistic model updating
methods [145]. Additionally, using stepwise forward selection created a more robust model than including
all available additional variables [145]. However, any peculiarities in the model updating dataset will be
reflected in the new model, which then could under-perform in new populations [141].
8.8 Summary of Methods to Update a Single Prediction Model
There are a number of available methods to update a single prediction model which can be advantageous
in different scenarios. Model recalibration only alters the model calibration. These methods would be
preferable for a model with a strong discrimination and prediction rules performance but a poor calibration
in a sample population, which is reflective of a new target population in which the model will be applied.
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However, for a model with a poor overall performance, more extensive updating methods may be beneficial.
This can include re-estimating or extending the model to incorporate new variables. The updated models
will improve the original model calibration in an internal dataset but the calibration, discrimination, and
prediction rules should be evaluated in external datasets to evaluate if a more robust model has been
produced in comparison to the original model.
8.9 Aggregating Multiple Prediction Models
Multiple prediction models can be aggregated into a meta-model. The different methods are presented
and evaluated. These methods aggregate models built in different sample populations and combine their
evidence in an attempt to create a more robust model. This avoids disregarding models in preference
to creating a new model based exclusively on the available dataset. These methods can improve model
prediction as “Madigan and Raftery note that averaging over all the models in this fashion provides better
average predictive ability than using any single model” [151].
Currently, there has not been a large volume of meta-modelling methods reported. This is because of
an emphasis on creating new models rather than aggregating existing models. However, there has been
an advance in methods to aggregate models in recent years. These methods are designed to either use the
models and their standard errors in the model building dataset or use an external dataset to aggregate the
models.
The next section of the review will present the methods to aggregate multiple prediction models.
8.9.1 Model Averaging
Model averaging, presented by Debray et al (2014) [148], combines multiple models based on their cali-
bration in an external dataset. The models are weighted with better calibrated models assigned a large
weight in the final model.
To apply this method, the original models are initially recalibrated in the external dataset, using the
method presented in Section 8.5.2. This ensures that poorly calibrated models, potentially due to being
applied in a different sample population, are not nullified by being assigned a low weight in the meta-model.
Next the models are applied to the external dataset and a risk for each patient, p, can be generated
from every model (1, . . . , M). The final risk for each individual is the weighted sum of the individual model
predictions as follows;
p¯i =
M∑
1
wipi, (8.9)
where
M∑
1
wi = 1 (8.10)
The weights for each model (w1, . . . ., wM ) now needs to be determined. The simplest solution assigns
each model an equal weight ( 1M ). However, this does not reward stronger performing models. Debray
proposed to assign a weight to each as follows;
wn =
e−0.5BICm∑M
l=1 e
−0.5BICl
, (8.11)
where BICm = −2lm + umln(N) (8.12)
Here, N is the number of patients in the model aggregation IPD and u the number of estimated
parameters used to recalibrate the model. Since all the methods will be recalibrated using an intercept
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and scaling parameter u will be fixed at 2. However, if models require more extensive updating then this
is reflected with a higher u as a penalty [148]. Then, for each model the log-likelihood, l, is determined as
follows;
lm =
N∑
i=1
yiln(pim) + (1− yi)ln(1− pim), (8.13)
where yi =
{
0 if disease not present
1 if disease present
(8.14)
In a hypothetical scenario, a model with perfect calibration would assign a probability of 0 to disease
free individuals and 1 to all diseased individuals. This would result in a log-likelihood of zero. As the
model accuracy lowers from this perfect scenario, the log-likelihood increases and as a result the model has
a lower BIC in the final weighting.
This method is advantageous because it rewards better calibrated models by assigning them a higher
weight in the meta-model which could create a more robust meta-model. The method is straightforward
to apply and applicable to a range of diverse model forms. Additionally, this method has reported some
favourable results. One study found the meta-model had an improved calibration and discriminative ability
[141]. This was supported by an additional study finding the aggregated meta-model outperformed the
existing models [150]. Another study found model averaging created an improved model, although only
reporting a minor improvement it did consistently improve upon the original models when validated [149].
However, there are some disadvantages to model averaging. Updating before aggregating the models
could create a meta-model that is then successful in the sample population but has a poor performance
if the target population differs from the sample population. Secondly, to use the final meta-model the
original models are run separately to generate a participant’s risk and then combined. As a result of this
the meta-model can be large, complex and cumbersome which health professionals and the public may be
reluctant to use [148]. This was highlighted in a study in which the final meta-model was too complicated
to present [151], although this can be averted by creating an easy to use model interface. The method
also assigns extreme weights to some models so the final model is heavily determined by a combination of
a few models rather than all the models considered. This is a consequence of the method being similar
to Bayesian model selection and assumes “only one of the models is correct” [148]. Therefore, it will not
utilise the full wealth of evidence available by rejecting some of the models. Finally, the weightings are
based upon the model calibration. As a result, the final model may have an improved discriminative ability,
as models with a poorer discriminative ability may be minimised in the final model if they also have a poor
calibration. Additionally, other studies found meta-model approaches are a relatively new area of research
and needed to be applied to more clinical prediction models before they can be recommended [141].
8.9.2 Stacked Regression
The next method, developed by Debray et al. [148], called stacked regression, is “a method for forming
linear combinations of different predictors to give improved prediction accuracy” [152]. The method ag-
gregates the models’ linear predictors based on their calibration performance in an external dataset using
a minimising likelihood function.
This method does not recalibrate the models using the external dataset before aggregating the models.
The model variables are identified by calculating the maximum likelihood of α0. . . αM by minimising the
following function in the dataset with N participants for M + 1 unknown constraints;
=
N∑
i=1
(yiln(1 + e
−a0−
∑M
m=1 amLPim)) + ((1− yi)ln(1 + ea0+
∑M
m=1 amLPim)) (8.15)
With constraint am ≥ 0 (8.16)
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Here yi is a binary variable which takes the value 0 if the disease is not present in the individual and
1 if it is present. For each model (1, . . . ,M) for an individual, i, their risk is defined as LPiM . α0 is the
intercept parameter for the “optimal baseline risk for the validation study” [148]. The constraint for the
alpha values to be greater than zero eliminates co-linearity in the meta-model. This inhibits the inclusion
of two similar models, such as a model and a recalibrated version of the model, in the meta-model because
they would negate each other.
The weighting of the variables in the final model is determined by minimising the likelihood function
for all the variables as follows;
Intercept: βˆ0 = αˆ0 +
M∑
m=1
αˆmLP0m (8.17)
Parameters: βˆi =
M∑
m=1
αˆmLPim (8.18)
These variables are the different variables in the original models and if a variable is not present in a
specific model then the alpha is zero so as to not influence the final aggregated model. Then the final logit
model can be calculated as follows;
logit−1 = βˆ0 +
K∑
i=1
βˆixjk (8.19)
There are advantages to the stacked regressions approach to aggregate multiple prediction models.
Firstly, this method creates a final formula that is neat and simpler to apply rather than applying multiple
distinct models and weighting these. Additionally, the method does not assign an extreme weight to
individual models in the final meta-model so the method is a fairer combination of their respective evidence.
This method has been implemented and devised a more robust model in comparison to the original models
in one study [141]. This was supported by other independent studies which discovered stacked regressions
decreased calibration error rates and yielded an improved predictive performance [152, 153].
However, there could be issues with a large quantity of variables in the model designed to measure the
same exposure. This can be seen in lung cancer prediction models such as smoking history (i.e. pack years,
CPD, smoking duration, quit duration) or family history of cancer (i.e. any cancer, lung cancer, present in
more than 2 family members) and these different variables will all need to be incorporated separately in the
meta-model. Additionally, the method can be difficult to apply and is more restrictive as to which original
models can be incorporated into the meta-model. Different model designs will not have a similar linear
predictor or a single coefficient for each variable; some may have cubic, splines, or conditional coefficients.
For example, for one variable age, i, considered in two distinct models, X and Y , could be incorporated
into each model as follows;
ix = α×Age (8.20)
iy = (β0 ×Age) + (β1 ×Age) (8.21)
where β0 =
{
x, if age < 65
0, if age ≥ 65 (8.22)
where β1 =
{
0, if age < 65
y, if age ≥ 65 (8.23)
These two variables could not be combined because of the different model forms. The systematic review
(Section 3) supports these concerns as distinct model forms were identified. Additionally, some models
consider scaling factors in the linear predictor which is observed for lung cancer in the form of age, gender,
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and smoking status specific incidence rates. Therefore, combining the models using stacked regressions
is problematic. In the original article Debray et al. [148] assumes that there is a set of core variables
across all the models and the models have the same form. However, this is not commonly the case and
many distinct models have been designed to predict the same outcome. A study highlighted this concern
that the quantity of models averaged is generally low because of difficulties combining the distinct clinical
models [152]. A solution is to reduce the pool of models to models with a similar form. However, this
could exclude successful models and their evidence from the final meta-model. Finally, not recalibrating
the original models may result in some successful models being unfairly assigned a lower scaling factor if
applied in a different sample population. It has been argued that not recalibrating the original models
means the meta-model borrows less information from the model aggregation dataset in comparison to model
averaging [150]. This is a relatively new field and more research is required before stacked regressions can
be recommended [141].
8.9.3 Bayesian Model Averaging
The next approach to aggregate models is Bayesian Model Averaging (BMA), a similar method to the
weighted averaging method (Section 8.9.1) [148].
Bayesian model selection methods can be used to identify the strongest model, often from a series of
nested models, in an external dataset. However, BMA combines multiple models into a meta-model [154].
The methodology for BMA has been available for a considerable time [155].
The models are weighted based on their calibration in an external dataset but the methods are applied
without model recalibration. This may result in successful models being unnecessarily assigned a low final
weighting if the dataset is different from the model building dataset. Each model is assigned a weight based
on their calibration in comparison to the other models, the final meta-model is the sum of the weighted
averages from the different models. For example, the aggregated probability for a patient, j, using models
1, . . . ,M is expressed as;
Yj =
M∑
i=1
wiYˆj (8.24)
Where Yˆj is the risk from one model for person J (8.25)
The weights for BMA are determined by calculating the posterior model which is expressed as Pr (Mj |Data).
This approach then compares different models together using the Bayes factor. The following equation is
used to assess the ‘evidence’ of preferring Model 2 in comparison to Model 1;
Bayes Factor: Bn =
Pr(M2|Data)
Pr(M1|Data) ÷
Pr(M1)
Pr(M2)
(8.26)
Setting all prior odds as equal, Pr(M1) = Pr(M2) = Pr(MM ), means that there is no initial bias
towards assigning a higher weight to any model. This is the case in most instances, where there is no
information to determine whether a model should be assigned a higher weight. As a result, the Bayes
Factor becomes a measure of posterior odds between the models.
However, a second version of BMA could be applied which offers a bias towards models based on their
discriminative ability. This aims to allow models that are successful at identifying individuals with a
disease to be higher rewarded. Models with a stronger AUC performance can be assigned a higher weight
by assigning each model prior odds as follows;
Pr(Mj) =
Pr(Mj)∑K
i=1 Pr(Mi)
(8.27)
where
K∑
i=1
Pr(Mi) = 1 (8.28)
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The posterior odds can be calculated based on the model calibration and the final model weights can
be determined;
wj = Pr(Mj |Yn = yn) = mj × Pr(Mj)∑K
i=1mi × Pr(Mj)
(8.29)
where
K∑
j=1
wj = 1 (8.30)
Here Pr(Mj) is either equal for all models when considering a non-informative prior or calculated using
equation 8.9.3 to incorporate the discriminative ability into the weights as an additional weighting. To
calculate the weightings mj needs to be calculated as follows;
mj =
∫
Lj(θj)pj(θj)dθr (8.31)
This integral can be converted, and was presented as follows [155];
log(mj) = log(Lj(θj))− dj
2
log(n) (8.32)
where lj =
N∑
i=1
yiln(pil) + (1− yi)ln(1− pil), (8.33)
where yi =
{
0 if disease not present
1 if disease present
(8.34)
This is the log likelihood minus the dimension of the model, dj , where n is the number of participants
in the datasets. Then the individual model weights can be determined.
This method is easy to apply and all models of different forms to be included in the meta-model. Addi-
tionally, the discriminative ability of the models can be incorporated into the meta-model, by considering
an additional weighting, which may allow a more robust selective screening tool to be devised. It may
prevent models with a good discriminative ability but poor calibration being harshly penalised in the meta-
model. When previously implemented BMA has outperformed the original model in terms of calibration
but also discriminative ability. While the benefit is typically minor it has been shown to be consistent
[149]. An independent study concluded BMA improved the model predictive performance and when there
is prior information this should be included to further improve the model predictive performance [151].
Finally, BMA was argued to provide a coherent approach for incorporating uncertainty due to variable
selection and model form [157].
There are some concerns with BMA. The final meta-model formula can be complex as each model
is run independently discouraging pubic application [151]. Bayesian model selection operates under the
assumption that one model is the correct model; with this assumption BMA will assign a high weight
to one or two leading models and minimise the remaining models. This may not effectively combine the
evidence across the models. Additionally, with this approach the calculation is more challenging and “the
number of terms can be enormous rendering exhaustive summation infeasible and the integrals implicit
can in general be hard to compute” [151]. Finally, BMA does not initially recalibrate the models this could
negatively influence more successful models which have a poor calibration in a differing external dataset.
Some studies argued that while BMA marginally improved upon the original models there was no leading
method to aggregate the models [149].
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8.9.4 Univariate Meta-Analysis
The next method is univariate meta-analysis and was published by Debray et al [158]. To apply this
method for each model the regression variable coefficients and standard errors are required, although an
external dataset is not required. Univariate meta-analysis considers the variable coefficients as sample
statistics with sample standard deviations.
The least squares approach is to combine the variable coefficients [158] as follows;
wij =
1
σ2ij + τ
2
j
(8.35)
“Where τ2j is the between-study variance of βj” [158] which is the variable coefficient in the model and
sigma the standard error in the ith model for the jth variable. These weights are then applied to the model
specific variable coefficients assuming a random effects model. Each variable is calculated separately to
devise the final meta-model.
The method expects the models to have a large overlap of variables and “that identical model formu-
lations are available for the published prediction models” [158]. This allows the variable coefficients to be
combined in the meta-model [158]. As identified in the systematic review (Section 3) distinct prediction
models often incorporate a large range of variables, including different measures for the same exposure
(smoking history and family history of cancer) and the model form differs. This could limit the practical-
ity of univariate meta-analysis as models may be removed to satisfy these conditions. This may reduce
the pool of applicable models that can be combined and unnecessarily exclude successful models. A study
found implementation can be difficult when the literature models greatly differ in terms of included vari-
ables [150]. Additionally, the method does not utilise evidence in the external datasets. The weighting is
based on the strength of the coefficients in the model building datasets. However, these can have unusual
dataset designs, such as high or low risk of developing a disease sample population. With this approach,
models are not penalised if they are unsuccessful in new populations. When this approach has been used
the meta-model did not report an improved performance in comparison to the original models [150].
In summary, while univariate meta-analysis may create a presentable final model there are concerns with
this method. The models require the same form and a core set of variables. Models with different forms
will be unnecessarily excluded reducing the pool of evidence included in the meta-model. The evidence is
further reduced by not using an external dataset to base the meta-model, which may also identify poorer
or stronger performing models which should be penalised or enhanced in the final model respectively.
8.9.5 Multivariate Meta-Analysis
The next method presented by Debray et al. [158] is multivariate meta-analysis. This combines multiple
models by estimating the with-in prediction model variance to capture correlation between variables within
the prediction model, and the between study covariance, to capture the heterogeneity between the studies
[158]. To apply this method the models require the same model form with a core set of variables to combine
the different model variable coefficients into a single estimate. Unfortunately, it is unlikely a large quantity
of prediction models will have the same form with a core set of predictors. Thus, many models may be
excluded from the meta-model because they have differing model forms.
The method evaluates the variables to assess if they are highly correlated [158]. Variables which are
not highly correlated across the models are minimised in the meta-model [158]. However, if there are a
large range of distinct variables then these potentially successful variables are negatively affected in the
meta-model.
This method is based on the performance of the models in the original dataset, which omits the evidence
available in an external dataset. Although, by considering the between study covariance, the parameters
that successfully predict risk in multiple models are rewarded in the meta-model.
Multivariate meta-analysis has previously been implemented. One study found the multivariate meta-
model is not without limitations. In particular, there can be difficulty estimating between-study correlations
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[159]. As a result, models can be excluded from the meta-model and their evidence is lost in the final meta-
model. The study also concluded the meta-model only reported a marginal improvement upon the original
models [159].
8.9.6 Bayesian Inference
The final model aggregation method is Bayesian Inference [158]. This method combines multiple models by
creating a prior and posterior for each model using an external IPD. When there is sufficient prior evidence,
which comes from the prediction models, then there is less necessity to include the external evidence, which
forms the posterior [158]. These prior and posterior are then used to assign a weight to each model in the
final meta-model.
When using Bayesian Inference, it is important to consider there may be a problem with bias when
“literature models are derived using data-driven selection with stepwise methods” [158]. For Bayesian
Inference to be successfully applied the models require a set of common variables across the models,
which can be pooled into a meta-model [158]. This is not observed in many scenarios, including lung
cancer prediction models. Other methods which do not exclude models or variables are preferable as
these synthesise all the evidence of the original models in an attempt to make a model with a better
predictive ability [151]. This makes the method impractical for most prediction models considered for
model aggregation as models are likely to be unnecessarily disregarded if they do not have a universal
model form or core set of predictors.
8.10 Summary of Methods to Aggregate Multiple Models
There were six identified methods to aggregate prediction models. The methods vary, some evaluate the
model performance in an external IPD while other methods update the variable coefficients using their
values and standard errors. There are also differences between updating the coefficients or combining the
models by running them simultaneously and weighting the separate results.
BMA and Weighted Averaging assess the performance of the original models in an external validation,
which are then weighted based on their calibration. This combines the evidence of the original models,
their robustness in a different sample population, and the evidence in the sample population in devising the
meta-model. This method is advantageous because different model forms can be combined so no models are
unnecessarily excluded and their evidence lost. Additionally, the model discrimination can be considered
when weighting the models by assigning a prior to each model during BMA, based on the AUC results.
However, the methods commonly assign a higher weight to one or two models and the remaining models
are minimised. Also, the final meta-model can be lengthy and complicated to apply by running multiple
models simultaneously, this could see a successful prediction model not being considered as a clinical tool.
However, creating a useable calculator would address this concern.
Univariate and multivariate meta-analysis aggregate models using the variable coefficients and standard
errors in the model building dataset. This does not require an external validation dataset, an advantage if
one is not available, but loses the evidence available in this dataset if one is available. By not reviewing the
models, this does not reward models that perform robustly in new populations. Additionally, these methods
do not consider if a model was devised using an unusual dataset, this can include a high risk dataset with
a high exposure to a particular condition. These methods also require a set of core variables and the same
model form to be aggregated into a meta-model. Models with distinct forms may be disregarded despite
being a successful prediction model.
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8.11 Updating and Aggregating Lung Cancer Prediction Models: Ap-
plicability and Concerns
The reviewed methods will be applied to selected lung cancer prediction models to evaluate their practicality
and success in creating a model with an improved calibration and discriminative ability. Before the methods
can be applied the lung cancer prediction models need to be selected and which methods are appropriate
for the identified lung cancer models.
The single updating methods will be applied to the PLCOM2014 Model. This model was selected as it
was identified as the leading prediction model in the external validation (Section 6).
The PLCOM2014, PLCOM2012, Bach, Hoggart, Pittsburgh, and LLP models are all considered for the
model aggregation at this stage. The Spitz and African-American models were excluded from the model
aggregation as they do not share an ILCCO dataset with the PLCO models that can be used to perform
the model aggregation. The PLCO models were preferred as they performed robustly across a range of
datasets whereas the Spitz and African-American models were only evaluated in one dataset.
The concerns that need to be considered before aggregating prediction models are presented to deter-
mine which models should be included in the model aggregation.
8.11.1 Model Prediction
The first concern to consider is what the model predicts. Prediction models can predict either incidence
or absolute risk. Combining multiple models that predict different outcomes would be problematic. This
would combine conflicting risks for an individual and there would be uncertainty into what outcome the
meta-model predicts.
The PLCO, LLP, and Pittsburgh models predict lung cancer incidence, whereas the Hoggart and Bach
models can be applied to predict either lung cancer incidence or absolute risk because they combine two
different equations. By only considering the lung cancer incidence equation of the Bach and Hoggart
models then no models need to be removed from the lung cancer model aggregation.
8.11.2 Model Duration
Prediction models predict an outcome developing over a specific duration which can vary between models.
Models that predict risk over different durations cannot be combined as the estimated risk for an individual
is influenced by the duration the outcome can occur within. Combining estimates over different durations
would give a conflicting final risk estimate. Additionally, the final meta-model should predict risk over a
defined period, which cannot be determined if this varies across the aggregated model.
The PLCO and Pittsburgh models predict risk over a fixed 6-year duration. The Hoggart and Bach
models predict risk for 1 year, but can be run recursively to estimate 6-year risk. However, the LLP Model
is fixed to predict lung cancer risk over 5 years. Therefore, this cannot be combined with the other models
and thus excludes the LLP Model from the lung cancer model aggregation.
8.11.3 Target Population
The next consideration is the target population for the prediction models. Models that predict risk for
distinct target populations cannot be combined. The aggregated models require a specific target population
that is applicable to all the original models.
For lung cancer prediction models the target populations are restricted by smoking status, age, and a
minimum smoking history. The six prediction models have a different target population, as presented in
table 8.1.
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No Age 20+ 35+ 40-80 50-75
Everyone PLCOM2014 LLP No Smoking Restrictions
Ever-Smokers Pittsburgh PLCOM2012 Hoggart No Smoking Restrictions
Ever-Smokers Bach 30+ PY
Table 8.1: Lung Cancer Prediction Models Target Populations
Combining the models will necessitate that they are restricted to a population that is applicable to
all the models considered in the aggregation. The Bach Model is the most restrictive model and if this is
considered in the aggregation then the models would be confined to predicting risk in 50−75 year olds with
a minimum 30+ pack year smoking history. Excluding this model, and the LLP Model already excluded,
would allow the aggregated model to be applied to ever-smokers aged at least 35 years. While this would
still not screen never-smokers, this allows all ever-smokers likely to be considered in a selective screening
programme to be evaluated in the meta-model.
It may be beneficial to run two versions of the model aggregation for lung cancer prediction models,
one with the Bach Model included and a second version excluding the Bach Model allowing a larger range
of participants to be evaluated.
8.11.4 Model Form
The same model design is important for some of the model aggregation techniques. Unfortunately, the
same model form is not always present for distinct models created by different authors. Distinct model
forms will limit the available methods to aggregate prediction models as variables across the models cannot
be combined into a single variable as desired. This may be a result of considering specific incidence scaling
rates, considering splines for a variable, or different degree polynomials for the models.
The lung cancer prediction models have distinct model forms. The PLCO models consider a logistic
regression equation centered on the mean for each variable, the Pittsburgh Model considers an additive
logistic regression, the LLP Model considers age-gender lung cancer specific incidence rates from the
Liverpool, UK area, the Bach Model is a cubic spline model, and the Hoggart Model considers Weibull
incidence and death rates specific to smoking status and smoking duration in a stratified survival model.
These models cannot be combined into a meta-model with a single coefficient for each variable as desired
by some model aggregation methods.
The lung cancer prediction models cannot be combined using the stack regressions, univariate and
multivariate meta-analysis, or Bayesian inference approaches. However, the literature review identified
additionally methods which do not require a similar model form across the models. These methods, model
averaging and BMA, allow each method to be run separately and then the estimates combined by assigning
a weight to each model. These methods can still be considered for model aggregation.
8.11.5 Model Variables
To aggregate the models, some methods require a set of core variables that are present in all original
models.
For the lung cancer prediction models there is not a core set of variables. There are many different
variables considered between the models as there are different measures to quantify a similar condition
in participants. For example, smoking history is measured by CPD, pack years, smoking duration, or
quit duration and family history of cancer is measure by early or late onset, specifically lung cancer or
smoking related cancer, or any type of cancer. This excludes stack regressions, univariate and multivariate
meta-analysis, and Bayesian inference but these were rejected previously. Model averaging and BMA are
still acceptable methods as these do not require a core set of variables to be present in the models.
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8.11.6 Model Co-Linearity
Co-linearity can be problematic in model aggregation. The final meta-model would bias towards one of
the models and minimise the other model [148]. This can be avoided by only considering one of any of the
similar models.
There was a concern with model aggregation for lung cancer prediction models where the PLCOM2012
and PLCOM2014 models are similar. The 2014 model was a recalibrated and extended version of the 2012
model. The PLCOM2012 Model will not be considered in the model aggregation in preference of the 2014
version. Although the meta-model can only be applied to an ever-smokers population and the 2012 version
is applicable to ever-smokers, the 2014 version was preferred as this had the universal leading performance
including in the UKLS target population.
8.12 Summary
This chapter identified methods for model updating and model aggregation in a literature review. A range
of different methods were identified for single updating. These include model recalibrated, re-estimation
of the model parameters, and extending the model to include additional parameters. These methods all
use an external dataset to perform the model updating, provided by the ILCCO datasets. The methods
will be applied to the PLCOM2014 Model, which was selected for single model updating because it was the
leading model in the external validations.
The literature review also identified six different methods for model aggregation. The methods varied
including methods which combine models by assigning them all a weight based on their performance in an
external dataset, combining the evidence of the original models and the external dataset in an attempt to
devise a more robust model. Other methods combine the variable coefficients that commonly occur across
the models, requiring the same model form and common variables across the models considered in the
aggregation.
The model aggregation methods could be applied to the Bach, PLCOM2014, Pittsburgh, and Hoggart
models. The identified methods that were appropriate for the lung cancer prediction models are Model
Averaging and BMA (with and without an additional weighting based on the AUC).
The literature review evaluated methods to update and aggregate prediction models. Appropriate
methods to update lung cancer prediction models were identified which will now be applied and the new
models validated to assess if they create an improved prediction model.
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CHAPTER 9
Updating and Aggregating Lung Cancer Models: Methodology and
Dataset Analysis
9.1 Introduction
The literature review identified methods to update and aggregate prediction models. These will be applied
to lung cancer prediction models to review their practicality and their ability to devise a model with an
improved calibration, discriminative ability, and potential as a selective screening tool. This chapter will
present the IPD that will be used to update the models and the external validation dataset to validate
the newly devised models. The methodology of how the models will be validated will be presented, and a
validation of the original models will be conducted which will provide a baseline performance for the new
models to improve upon.
9.2 Objectives
This chapter will perform a dataset analysis and present the guidelines to review the original models and
the new updated models. Next it will conduct an external validation of the original models that will be
subsequently updated. To achieve this the chapter will;
1. Present a methodology to review the model calibration, discrimination, and prediction rules for the
original models and the new updated models to identify a leading model.
2. Perform a dataset analysis on the IPD and the external validation dataset to identify any concerns
that could influence the model updating or validation results.
3. Conduct a validation of the original prediction models, as per the methodology, to provide a baseline
performance to compare with the new models in the subsequent chapters.
9.3 Methodology
The literature review identified methods to update a single prediction model and aggregate multiple pre-
diction models, using an external dataset. Single model updating will be conducted on the PLCOM2014
Model as it had the leading performance in the external validation, a good basis on which to attempt to
devise a leading prediction model for lung cancer.
For the identified model aggregation methods two versions of each method will be conducted. The first
version will aggregate the PLCOM2014, Bach, Hoggart, and Pittsburgh models and the second version will
exclude the Bach Model. Exclusing the Bach Model will allow the meta-model to be applicable to a larger
population.
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To apply the model updating methods an external IPD was created from the ILCCO datasets. The
PLCOM2014 Model was applicable to five datasets; these are the ReSoLuCENT, UCLA, CARET, MSH-
PMH, and the NY Wynder datasets. The ReSoLuCENT, UCLA, CARET and MSH-PMH datasets were
combined into one dataset to conduct the model updating methods. These four datasets were chosen
because it pools two sample populations that would be reflective of a target population for lung cancer
screening and both a sample population that would be considered lower and higher risk of developing
lung cancer. The NY Wynder dataset will provide an external validation dataset to evaluate the updated
models. This approach was preferred rather than combining 80% of each dataset into a model updating
dataset and the remaining 20% forming the validation dataset, as this allowed the external validation
dataset to be distinct from the model updating datasets. This avoids the potential for optimistic results
[46]. In the single updating datasets anyone aged over 20 years can be included because this is the only
restriction when using the PLCOM2014 Model.
The same datasets are considered for the model aggregation methods. The datasets will be reduced
in size because the models have a more restrictive target population. By excluding the Bach Model from
the model aggregation the dataset can include all ever-smokers aged at least 35 years. When including
the Bach Model this is further restricted to ever-smokers aged 50-75 years with a minimum 30 pack
year smoking history. Additionally, the Bach Model requires asbestos exposure, which is not reported in
the UCLA dataset therefore this dataset is excluded and the remaining three datasets (ReSoLuCENT,
CARET, MSH-PMH) will form the model aggregation dataset, with the NY Wynder dataset remaining
as the external validation dataset.
When validating the updated models, it is important to remember these will be recalibrated to reflect
a high lung cancer incidence rate in the dataset. Therefore, evaluating the models at the 0.1, 0.25, 0.5, 1,
1.5, and 2.5% risk thresholds may not be appropriate. Instead, the optimal risk threshold for each model
will be identified in an internal validation using the model updating and aggregation dataset. The model
will then be evaluated at the identified risk threshold in the external validation to assess if a consistent
performance is identified. The second validation will assess the models while maintaining a specificity of
90%. Here the models will be reviewed in a reduced sample population of anyone aged between 50-75 years
in the dataset, as per the UKLS screening trial guidelines.
9.4 Dataset Analysis
The three differing model updating datasets and differing NY Wynder datasets (caused by model restric-
tions) which are applicable for the separate model updating techniques are presented.
The ReSoLuCENT and MSH-PMH datasets are included in the model updating datasets. Missing
information in these datasets was previously imputed, as presented in Sections 4.10 & 4.11. The missing
information was imputed in 11 separate iterations. The average for the imputed value will be considered
in the final dataset.
Single model updating will be conducted using a combination of case-control datasets which resulted
in a high proportion of individuals with lung cancer in the final dataset (41.7%). Since model updating
recalibrates the model to reflect the observed incidence rate in the dataset the models may be recalibrated
to predict a lung cancer incidence rate that would be considered excessive for a real world population.
The calibration results may also be misleading in the external validation because the NY Wynder dataset
reports a high lung cancer incidence rate. Therefore, it is expected the recalibrated updated models will
be more suited to the NY Wynder dataset in comparison to the original PLCOM2014 Model.
A review of the population demographic for the model updating and NY Wynder datasets (Table 9.1)
demonstrated a sample population similar to what which would be expected if a lung cancer screening
target population has been obtained. The ages of the participants are centered around 60 years, although
the disease free individuals in the model updating dataset are slightly lower at 55 years. There is a mixture
of ethnicities and education levels; however, the NY Wynder dataset only reported 5 education levels. A
high proportion of the individuals with lung cancer are ever-smokers and have a heavy smoking history.
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Asbestos exposure will be considered as an additional variable for model extension. In the model updating
dataset, asbestos exposure is significantly associated with an elevated lung cancer risk. However, in the
NY Wynder dataset asbestos exposure is not significantly associated with an increased lung cancer risk.
Therefore, while it may be included as an additional parameter in the prediction model this may not
improve the model discrimination in the external validation.
The model aggregation, excluding the Bach Model, included ever-smokers aged at least 35 years. This
removed a higher proportion of disease free individuals. In the final dataset around 50% of individuals had
lung cancer (Table 9.2) so the models are likely to be poorly calibrated. Since the model aggregation is
based upon the model calibration this is a limitation of the datasets obtained. There were no additional
concerns with the model aggregation or NY Wynder datasets.
Finally, including the Bach Model in the model aggregation, resulted in smaller aggregation and external
validation datasets, as these were restricted to ever-smokers aged between 50-75 years with a minimum 30
pack year smoking history. There are similar concerns in this model aggregation datasets as previously,
with a high ratio of individuals with lung cancer to disease free individuals (Table 9.3), which is likely to
result in poor model calibration on which to base the model aggregation. This is exacerbated in the NY
Wynder dataset where 72% of participants reported lung cancer incidence.
In summary, the main concern with the datasets is the high proportion of diseased to disease free
individuals. The original models are likely to be poorly calibrated. This may result in extensive model
updating being required, and a tendency to extend the model to include all available variables as these can
significantly improve the model goodness of fit. Finally, the recalibrated models may generate unrealistic
risk estimates based on the high incidence rate in the model updating dataset, and may therefore not be
appropriate in real world populations with substantially lower incidence rates. While, the discriminative
ability and prediction rules will remain unaffected and an improved model can be created, the selected risk
thresholds are likely to be higher as the models are recalibrated to estimate higher risks.
9.5 Validation of the Original Models
The original models are validated to provide a baseline performance for the updated and meta-models
to be compared. The model updating datasets and the NY Wynder dataset are both external datasets
for the original models. In contrast the newly updated models will be internally validated in the model
updating dataset. Therefore, it is expected that the updated models will have an improved performance
when internally validated. Therefore, the NY Wynder dataset will offer a more rigorous assessment of the
updated models to assess if a more robust model has been devised.
9.5.1 Single Model Updating
There were concerns the high lung cancer incidence rates would hinder the PLCOM2014 Model calibration.
Indeed, the Hosmer-Lemeshow test in the IPD returned a p-value below 0.001 and a χ2 exceeding 1,250.
The PLCOM2014 Model also reported a poor calibration in the NY Wynder dataset. The poor calibration
demonstrated through the Hosmer-Lemeshow test is supported by the Brier Score which exceeded 0.4.
The original model reported a reasonable discrimination in the model updating dataset, with an AUC
of 0.68, although this decreased to 0.66 when restricted to a sample population of participants aged 50-75
years. The model was optimal at the 0.316% risk threshold; here, the model reported a sensitivity of
78.33% and a specificity of 50%. The high sensitivity and specificity resulted in a Youden index just below
0.3 and a PLR of 1.58. When applying the model to the UKLS target population the prediction rule
performance, similar to the AUC, was lowered. The PLCOM2014 Model should be applied at the 3.16% risk
threshold to maintain a specificity of 90%. In the IPD the sensitivity dropped below 20%, a poor capture
rate highlighted by a Youden index below 0.1 and a PLR of only 1.96 despite the high specificity.
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Validation Internal/External Hos-Leme. Brier Score AUC [95% CI] Threshold (%) Sens. Spec. Youden PLR
1
Internal 0 (1266.26) 0.4007 0.6813 [0.669, 0.694] 0.32 78.33 50.32 0.2865 1.5768
External 0 (3428.03) 0.4887 0.7667 [0.757, 0.776] 0.32 86.85 54.68 0.4153 1.9163
2
Internal 0 (726.84) 0.4173 0.6567 [0.642, 0.671] 3.19 19.59 90.00 0.0960 1.9601
External 0 (9793.05) 0.4906 0.7834 [0.773, 0.794] 2.95 35.02 89.99 0.2502 3.5002
Validation 1 at the optimal risk threshold Validation 2 using the UKLS guidelines
Table 9.4: External Validation of PLCOM2014 Model in the Single Updating Datasets
The PLCOM2014 Model performed better in the NY Wynder dataset. The AUC was 0.767 and reported
an encouraging prediction rules performance. At the optimal risk threshold, identified in the model up-
dating dataset as 0.316%, the model reported an increased sensitivity of 86.85% and specificity of 54.68%.
Therefore the Youden index was above 0.4. In the target UKLS population the performance improved fur-
ther. The AUC increased to 0.783 and at a risk threshold of 2.95% the sensitivity was 35% for a specificity
of 90%.
Overall, the model was poorly calibrated as was expected. It is likely that the recalibrated models
will report a higher performance because they will predict the higher incidence rate. Additionally, the
PLCOM2014 Model had a limited discriminative ability in the model updating dataset. However, the AUC
and prediction rules performance improved in the NY Wynder dataset such that the new models will be
required to produce an exceptional performance to demonstrate an improved model.
9.5.2 Model Aggregation without the Bach Model
The original models reported a poor performance in the model aggregation dataset. The high incidence
rates resulted in all the models reporting a poor calibration measured by the Hosmer-Lemeshow tests and
supported by a Brier score which was higher than 0.4 for all the models.
The models also reported a low discriminative ability in the aggregation dataset with all the models
reporting an AUC of approximately 0.6. This was reflected in poor prediction rules results where none of
the models achieved a Youden index exceeding 0.2 and the PLR was low with most results below 1.5. This
poor performance was also observed in the UKLS target population.
Model Validation Internal/External Hosmer-Lemeshow Brier Score AUC [95% CI] Threshold (%) Sens. Spec. Youden PLR
PLCO2014
1
Internal 0 (687.51) 0.4666 0.6222 [0.607, 0.637] 0.82 72.00 45.34 0.1734 1.3172
External 0 (1059.44) 0.5917 0.6806 [0.668, 0.693] 0.82 75.58 49.57 0.2515 1.4988
2
Internal 0 (563.05) 0.4623 0.6148 [0.598, 0.631] 3.62 17.85 89.99 0.0784 1.7829
External 0 (1292.11) 0.5891 0.7016 [0.688, 0.716] 3.94 24.99 89.98 0.1498 2.4948
Hoggart
1
Internal 0 (948.39) 0.3874 0.6040 [0.589, 0.619] 2.24 81.20 37.19 0.1839 1.2929
External 0 (748.86) 0.4801 0.6778 [0.665, 0.691] 2.24 81.42 42.86 0.2428 1.4250
2
Internal 0 (795.28) 0.3792 0.5907 [0.574, 0.607] 29.05 12.58 90.03 0.0261 1.2615
External 0 (589.00) 0.4678 0.6819 [0.668, 0.696] 24.84 25.80 89.94 0.1574 2.5642
Pittsburgh
1
Internal 0 (744.99) 0.4638 0.5911 [0.576, 0.607] 0.72 83.14 33.69 0.1682 1.2537
External 0 (370.90) 0.5887 0.6793 [0.667, 0.692] 0.72 81.51 43.91 0.2542 1.4531
2
Internal 0 (672.30) 0.4579 0.5751 [0.558, 0.592] 5.12 14.93 89.33 0.0426 1.3988
External 0 (292.67) 0.5842 0.6951 [0.681, 0.709] 4.66 24.13 89.98 0.1411 2.4085
Validation 1 at the optimal risk threshold Validation 2 using the UKLS guidelines
Table 9.5: External Validation of Models in the Datasets without the Bach Model
The performance improved in the NY Wynder dataset although the models were still poorly calibrated.
The AUC increased to between 0.67-0.70 for the models and this improvement was observed in the predic-
tion rules performance. At their optimal risk threshold, the models reported a Youden index of 0.25. The
models reported a sensitivity of approximately 25% when the specificity was fixed at 90% in the UKLS
target population.
In summary, the models were poorly calibrated and reported a similar discriminative ability. This is
likely to reduce the difference in weightings between the BMA methods because the additional weighting
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will not allow a drastic change from the non-informative prior. Additionally, basing the aggregation on the
calibration may be unreliable since the models were poorly calibrated, particularly for methods that do
not originally recalibrate the model. In the NY Wynder datasets the models will aim to eclipse an AUC
of 0.70, a Youden index of 0.25 at the optimal risk threshold, and a sensitivity of 25% using the UKLS
criteria.
9.5.3 Model Aggregation with the Bach Model
In the final validation the models were poorly calibrated in both datasets as a result of the high lung cancer
incidence rate. The poor calibration is supported by the Brier score, which is above 0.4 for all the models.
The models also had a poor discriminative ability in the aggregation dataset. The PLCOM2014 Model
marginally reported the highest AUC with a result of 0.59, highlighting the low discriminative ability
standard of the models in the dataset. Further the Bach Model reported an AUC below 0.5.
Model Validation Internal/External Hosmer-Lemeshow Brier Score AUC [95% CI] Threshold (%) Sens. Spec. Youden PLR
PLCO2014
1
Internal 0.1283 (296.53) 0.4682 0.589 [0.568, 0.611] 2.26 51.85 62.24 0.1409 1.3731
External 0.0890 (455.37) 0.6757 0.597 [0.578, 0.616] 2.26 57.69 55.59 0.1329 1.2993
2
Internal 0.1283 (296.53) 0.4682 0.589 [0.568, 0.611] 4.42 18.96 89.99 0.0896 1.8949
External 0.0890 (455.37) 0.6757 0.597 [0.578, 0.616] 5.40 18.43 90.03 0.0845 1.8476
Hoggart
1
Internal 0 (460.43) 0.3725 0.529 [0.508, 0.551] 24.96 29.70 76.33 0.0604 1.2551
External 0.0001 (251.50) 0.5146 0.609 [0.590, 0.628] 25.01 31.14 81.01 0.1215 1.6396
2
Internal 0 (460.43) 0.3725 0.529 [0.508, 0.551] 32.29 12.37 90.07 0.0244 1.2452
External 0.0001 (251.50) 0.5146 0.609 [0.590, 0.628] 31.25 18.76 90.03 0.0878 1.8807
Pittsburgh
1
Internal 0 (550.24) 0.4631 0.526 [0.504, 0.547] 4.66 26.37 82.18 0.0855 1.4796
External 0.0001 (251.50) 0.6696 0.611 [0.592, 0.630] 4.66 20.94 88.81 0.0975 1.8714
2
Internal 0 (550.24) 0.4631 0.526 [0.504, 0.547] 5.63 10.81 94.30 0.0512 1.8981
External 0.0001 (251.50) 0.6696 0.611 [0.592, 0.630] 5.63 15.62 91.85 0.0747 1.9161
Bach
1
Internal 0.1529 (293.8) 0.4577 0.554 [0.533, 0.576] 2.12 76.30 32.36 0.0866 1.1280
External 0.0001 (251.50) 0.6614 0.601 [0.582, 0.620] 2.12 76.39 36.51 0.1290 1.2032
2
Internal 0.1529 (293.8) 0.4577 0.554 [0.533, 0.576] 6.87 13.56 89.99 0.0355 1.3546
External 0.0001 (251.50) 0.6614 0.601 [0.582, 0.620] 7.01 18.53 90.03 0.0855 1.8575
Validation 1 at the optimal risk threshold Validation 2 using the UKLS guidelines
Table 9.6: External Validation of Models in the Datasets with the Bach Model
The models improved in the NY Wynder dataset with no leading model being identified because they
all reported an AUC of approximately 0.66. The prediction rules were similar for the models also with
a Youden index of 0.12 at the optimal risk threshold. Evaluating the models using the UKLS guidelines
a sensitivity around 18% was reported for all models. This is the baseline performance upon which the
meta-model will attempt to improve upon.
There are concerns the poor calibration may hinder the aggregation methods based on this evidence,
and the poor AUC across all the models may not provide sufficient information for the additional AUC
weighting for BMA.
9.6 Summary
The chapter presented the methodology to review both the original models and the new models. A dataset
analysis of the model updating and the NY Wynder datasets was conducted. The original models were then
validated. The calibration was poor in the datasets due to the high lung cancer incidence rates observed.
This was identified as a concern for single models updating, as the new models will be recalibrated to
reflect the high lung cancer incidence rate. The proposed models then may be unrealistic when applied
in a population with a more realistic lung cancer incidence rate. Additionally, the calibration information
may be unreliable on which to base the model aggregation.
The PLCOM2014 Model will be updated using single model updating techniques. In the external vali-
dation this model reported an AUC of 0.767, a Youden index of 0.4 at the optimal risk threshold, and a
138
sensitivity of 35% using the UKLS guidelines, for which the updated models will attempt to surpass. For
model aggregation excluding the Bach Model the baseline performance in the external validation which
the meta-models should aim to surpass was an AUC of 0.70, a Youden index of 0.25 at the optimal risk
threshold, and a sensitivity of 25% for the UKLS guidelines. Finally, when considering the Bach Model,
the proposed meta-models will attempt to eclipse an AUC of 0.66, a Youden index of 0.12 at the optimal
risk threshold, and a sensitivity of 18% in the UKLS target population in the NY Wynder dataset.
The meta-model including the Bach Model may allow a better evaluation of BMA with an additional
weighting based on the AUC as there was more disparity in the AUC results across the models.
The next stage of the project will apply the methods for the single model updating and the model
aggregation to devise new models. These will then be validated and compared with these original model
results, to assess if an improved lung cancer prediction model has been devised.
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CHAPTER 10
Updating a Single Lung Cancer Prediction Model
10.1 Introduction
The literature review identified practical methods to update a single prediction model. These methods
will be applied to the PLCOM2014 Model, which was selected because the model demonstrated the leading
performance in the external validations. The new updated models will be presented and externally validated
to assess if the methods have created an improved model that could be considered as a clinical utility. This
will also identify successful methods which could be used for prediction models of different diseases or
prediction models that consider clinical markers once these models demonstrate an improvement over
epidemiological prediction models.
10.2 Objectives
The chapter will apply updating methods to the PLCOM2014 Model in an attempt to create an improved
lung cancer prediction model. The chapter objectives are;
1. Apply the identified methods from the literature review to update a single prediction model to the
PLCOM2014 Model.
2. Present the updated model coefficients.
3. Externally validate the model in comparison to the original model to assess if an improved lung
cancer prediction model was devised.
4. Present the Stata code and screening guidelines for any model shown to have an improved perfor-
mance.
5. Review when methods are appropriate to update a prediction model.
10.3 PLCOM2014 Model Formula
The PLCOM2014 Model is a log-odds model [82]. The methods update the logistic regression equation in
the model. To update the model the risk generated by the models needs to be converted so the logistic
regression equation in the log-odds model is explicitly defined;
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Risk =
eLR
1 + eLR
(10.1)
eLR =
Risk
1−Risk (10.2)
LR = log
(
Risk
1−Risk
)
(10.3)
Where LR = Linear Regression Equation of the log odds model
Presented below is the original linear regression equation that will be recalibrated, re-estimated, and
extended;
LogisticRegressionEquation = −7.02198 + [0.079597× (Age− 62)]− [0.0879289× (Education− 4)]
− [0.028948× (BMI − 27)] + (0.3457265× COPD) + (0.3211605×Black)
− (0.8203332×Hispanic)− (0.5241286×Asian)− (1.364379× Islander)
+ (0.952699×Native) + (0.4845208× PMT ) + (0.5856777× FH)
+ (2.542472× Former) + (2.799727× Current)
−
(
[0.1815486×
(
CPD
100
−1
− 4.021541613
)]
+ [0.0305566× (Duration− 27)]
− [0.0321362× (QuitDuration− 8.593417626)]
(10.4)
To apply this equation the following applies;
Condition/Race/SmokingStatus =
{
0 if not present
1 if present
CPD/Duration/QuitDuration =
{
0 if not applicable
Participant Value if present
(10.5)
10.4 Applying Single Updating Methods
The methods to update the single models are now applied to the PLCOM2014 Model. The updated models
are presented and their performance reviewed to assess if an improved model has been devised.
10.4.1 Updating the Intercept
Updating the intercept to reflect the observed incidence rate in the dataset was a straightforward method
to apply. However, due to the high proportion of participants with lung cancer the intercept was drastically
modified (Table 10.3). The new risks generated by the model would be inappropriate in a population with
a more realistic lung cancer incidence rate.
The calibration improved in the internal and external validations, as both had high lung cancer incidence
rates, shown by the Hosmer-Lemeshow chi-squared and the Brier score (Table 10.4). However, the model
did not report a good calibration which would indicate the PLCOM2014 Model may benefit from more
extensive model updating.
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This method could be very successful if the model was updated using a cohort that represented any
future screening population. This is demonstrated by the improvement in calibration, and if the model
is updated in a sample population that is reflective of the target population, which essentially the model
updating and NY Wynder dataset were, then this method may produce a well calibrated model.
Overall, updating the intercept is a simple method to improve the calibration. This method is ideal
for a successful model with a calibration deficiency in a new population. The results demonstrate how
the method alone will not guarantee a good calibration for the updated model if the original model has
a large calibration deficiency. In these instances, more extensive model updating techniques may yield
better results. Since the discriminative ability remains unaltered, and the model has been recalibrated to
estimate unreasonable risks, an improved prediction model has not been devised.
10.4.2 Recalibration of Intercept and Slope
The intercept and regression equation were recalibrated using the line of best fit between the predicted and
log odds of the observed risk. Since the presence of lung cancer is a binary outcome, the participants in
the dataset were grouped. Participants were grouped to their closest neighbours based on their predicted
risks, in groups of 10. The observed incidence rate for the group was determined and plotted against the
mean risk generated by the model for the participants per group. At this stage the intercept and slope
modifiers could be simply calculated. The plot and line of best fit for the recalibration is presented.
Coefficient Scaling Parameter
Intercept 0.5667
Slope 0.0259
Table 10.2: Recalibrating the Intercept and Slope
The intercept from the line of best fit was added to the original model intercept term and the remaining
parameters were scaled using the line of best fit gradient. This created the final recalibrated model as
presented in Table 10.3.
The updated model reported a poor performance and updating only the intercept led to a greater
improvement in the model calibration when externally validated (Table 10.4).
Overall, the method is easy to apply but was limited when applied to the PLCOM2014 Model. The
model underperformed probably due to the poor discriminative ability in the model updating dataset. As a
result, when grouping the participants, individuals with lung cancer were not commonly grouped in higher
predicted risk groups. An improved lung cancer prediction model was not created.
10.4.3 Recalibrated Null Model and Selective Re-estimation
The next method selectively re-estimates the variables of the model. Firstly the model was recalibrated
using the previous method although this model was still not well calibrated. The variables included in
the null model were identified through forward selection. Family history of lung cancer, CPD, and quit
duration were removed from the null model as they did not improve the model goodness of fit. The final
stage compared the goodness of fit between the recalibrated and null recalibrated model and the shrinkage
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was applied. As shown in Table 10.3 these three variables were modified from the recalibrated model in
method two.
The model calibration improved considerably in comparison to the recalibrated model in method two.
This highlights how the three identified variables which did not explain lung cancer risk, and were minimised
in the final model, successfully improved the model calibration. Although due to the calibration deficiencies
of the original and recalibrated model, the new model was still not well calibrated. Additionally, the
discrimination, and prediction rules were slightly inferior to the original model. The AUC was lower in
both the internal and external dataset and the prediction rules were consistently lower (Table 10.4).
Overall the method underperformed although demonstrated how minimising weaker variables improved
the model calibration. However, if the original and recalibrated models have calibration deficiencies then
more extensive model updating may be required. Additionally, this method reported a lower discrimination
and lower prediction rules indicating minimising variables may improve the model calibration but this does
not guarantee a more robust selective screening tool has been devised.
10.4.4 Shrinkage and Re-estimation
The second re-estimation method centers the variables on the mean incidence rate observed in the dataset.
These are then subtracted from the variable coefficients so that the risks are normalised around the mean.
The intercept was modified to reflect the mean observed incidence rate.
The variables are not minimised if they do not improve the model goodness of fit, as with the previous
re-estimation method, instead all are shrunk by the same shrinkage coefficient, which was easily determined.
The final model is presented in Table 10.3, although the mean values are not presented in the table.
The updated model was still poorly calibrated. This could be a result of the calibration deficiency
of the original model and the predictors in the model being limited in explaining lung cancer risk. This
method can affect the model discrimination and prediction rules. Indeed, the model reported the highest
AUC in both the internal and external validation, an improvement over the original model, although the
improvement was not significant. The prediction rules had a slight improvement with an increased Youden
index and PLR (Table 10.4). The risk thresholds for the optimal performance and to maintain a specificity
of 90% was distorted when recalibrated to reflect the high incidence rate in the model updating dataset,
and were 90.5% and 99.17% respectively. This would be inappropriate in a real screening programme and
is a result of updating the models in a dataset with a high lung cancer incidence rate. Overall, this method
had some encouraging results, offering a slight improvement in discrimination and prediction rules, the
method may be successful when applied in cohort studies where the model would not be recalibrated such
that inappropriate risks are generated.
10.4.5 Re-estimation and Extension
The next method updated the PLCOM2014 Model by re-estimating the original parameters and extending
the model to include any additional parameters. In the dataset, gender was the sole variable available for
model extension. Unfortunately, only including one parameter will not allow a good comparison between
the different model extension methods; to evaluate whether over-fitting is caused by forced extension as
with this method.
It was expected that this method may under-perform as the new variables are added without considering
whether they sufficiently explain lung cancer risk. The method was straightforward to implement and used
the previous techniques to first re-estimate the model. Then the new parameters were included through
standard model building techniques. The coefficients are presented in Table 10.3. It is noticeable that the
new coefficient for gender is inappropriate and heavily distorts risks between males and females. This is
due to the calibration deficiencies of the re-estimated model.
The inappropriate estimates for risk caused by the new gender variable can be seen in the external
validation. The calibration improved upon the re-estimated model in the internal validation. However,
in the external validation the calibration suffered and the model was poorly calibrated (Table 10.4). The
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AUC was heavily reduced from the original models and the prediction rules performance were much poorer
(Table 10.4).
This method underperformed and reported the weakest results of all the methods. This large reduction
in calibration performance (in the external validation), AUC and prediction rules demonstrates model
extension is inappropriate if the original model significantly under or over estimates the disease prevalence
rate. The new variables are not added appropriately and while an improvement may be seen in an internal
validation the model is not robust in external population.
10.4.6 Selective Re-estimation and Selective Extension with Recalibration
The next approach was a variation on the previous method by only including additional variables if they
demonstrated a significant improvement in the model goodness of fit. Gender, the only variable available,
was included at the 0.05 significance level (Figure 10.5) and the final model is identical to the previous
method.
Variable Coefficient T-Value P-Value
Gender 6.81 91.47 < 0.001
Table 10.5: Extending the Recalibrated Model
In summary, the final model corresponds to the previous method. The final model performance is
suboptimal, resulting from the new variable for gender being inappropriate in new sample populations.
This is due to the calibration deficiencies of the original model.
10.4.7 Re-estimation and Selective Extension without Recalibration
The final method extended the recalibrated mean model. Gender was considered as the additional variable
for inclusion using forward selection with a critical p-value of 0.05. Gender was rejected as it did not
significantly improve the goodness of fit. Therefore, the final model was the same as the recalibrated mean
model in method 4 (Table 10.3).
Variable Coefficient T-Value P-Value
Gender -1.11 -1.93 0.053
Table 10.6: Extending the Recalibrated Mean Model
This method reported the leading performance with an improved AUC and prediction rules over the
original model, although the improvement was marginal. Additionally, the high lung cancer incidence rate
in the dataset recalibrated the model to produce unrealistically high lung cancer risk estimates, including
by estimating 6-year risk exceeding 90% in individuals. Therefore, this model would not be appropriate in
a population with more realistic lung cancer prevalence rates.
10.5 Summary
The chapter updated the PLCOM2014 Model in an attempt to create an improved model. The validation
of the new models revealed that the updated models generated unrealistic risks for an individual’s 6-year
risk of developing lung cancer, as a result of the model being updated in a dataset with an unrealistic lung
cancer incidence rate. None of the models reported a good calibration but this can be attributed to the
calibration deficiency of the original model in this dataset.
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Additionally, none of the updated models showed a significantly improved discrimination or prediction
rules in comparison to the PLCOM2014 Model. The mean model had the strongest performance of the
updated models and while offering some improvement, in comparison to the original model, there was not
a large difference. Since the risk estimates generated by this model are unrealistic with participants having
a 6-year risk of developing lung cancer exceeding 99%. This would create unnecessary panic and it would
be unwise to promote this model to the public.
None of the methods were successful in devising an improved model, but this may be a limitation of the
datasets collected for this project. The methods failed to improve the models discriminative ability and
prediction rules performance. This included extending the model to include gender, which was inadequately
utilised in the extended model to address the poor model goodness of fit. When extending a model to
include additional variables the model needs to be reasonably well calibrated in the dataset to prevent
inappropriate coefficients being generated.
The next chapter will evaluate methods to aggregate multiple prediction models to create a meta-model.
147
CHAPTER 11
Aggregating Multiple Prediction Models
11.1 Introduction
Model Averaging and BMA, with or without an additional weighting based on the models’ discriminative
ability, were identified as appropriate methods to aggregate the Bach, Hoggart, Pittsburgh, and PLCOM2014
models. Two versions of model aggregation will be conducted, with or without the Bach Model, because
excluding the Bach Model allowed for a larger IPD to base the model aggregation, and the final meta-
model is applicable to a wider range of people. The new models will be presented and externally validated
to assess if model aggregation created an improved lung cancer prediction model. This chapter will also
review the ability of the methods to create a more robust model. The successful methods will be identified
so they can then be implemented in future research to aggregate multiple prediction models; whether for
newly developed lung cancer models or a completely different disease. Although, we will have to consider
whether the high lung cancer incidence rate influences the methods’ ability to aggregate the models.
11.2 Objectives
This chapter will apply the model aggregation methods and validate the meta-models to assess if an
improved prediction model can be devised, and review the different methods. To achieve this the chapter
will;
1. Apply Model Averaging and BMA methods to the Bach, Pittsburgh, Hoggart, and PLCOM2014
Models.
2. Present the new meta-models.
3. Externally validate the new models in comparison to the original models to assess if an improved
model is devised.
4. Present any improved model with a Stata code alongside recommendations on how to apply the
model.
5. Review the practicality and performance of the model aggregation methods.
11.3 Method One - Model Averaging
Model averaging assigned a weight to each model based on their calibration results in the dataset. This
method is advantageous as it can combine models with unique forms.
Firstly, the original models were recalibrated in the dataset. The four lung cancer models were re-
calibrated by updating the intercept and modifying the slope using a single scaling factor. This method
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was previously applied updating the PLCOM2014 Model, and was a simple method although there are
limitations to this method in a dataset with such a high lung cancer incidence rate.
The recalibrated models were then applied in the dataset to calculate each individual’s risk. Then
separately, for each model, the following equation was applied to assess the model calibration;
Li =
N∑
j=1
(yj × ln (mj)) + ((1− yj)× ln (1−mj)) (11.1)
where yj =
{
0, if participant is a control
1, if participant is a case
(11.2)
Here, yi is the observed outcome for the participants. This is a binary outcome which is either 0 if they
are lung cancer free or 1 if they have lung cancer. After applying Formula 11.1 the BIC was determined
as follows;
BICM = (−2× LM ) + (2× ln(N)) (11.3)
Here, N is the number of participants in the dataset. The 2 was determined by the number of parameters
estimated in the model recalibration. This is fixed for each model as they were all updated using the
same method calculating the intercept modifier and the scaling factor for the slope. If more extensive
recalibration was required then this would penalise the model. Next, the final weighting for each model
was easily calculated as follows;
wM =
exp (−0.5×BICM )∑4
m=1 exp (−0.5×BICm)
(11.4)
Model Averaging was simple to apply with the final weights easily determined. The final model weightings
are presented in Table 11.1.
Model Weightings
With Bach Without Bach
Bach 0.25271 NA
PLCO 0.25201 0.33766
Hoggart 0.24460 0.32651
Pittsburgh 0.25068 0.33582
Table 11.1: Model Weightings from Model Averaging
For both versions the final weights given to the separate models was very similar. This may be a result
of all the models being poorly calibrated even after the recalibration. This is most likely a consequence
of the high lung cancer incidence rate in the model aggregating dataset. Therefore, the method could not
identify the better calibrated models to assign a higher weight.
The new models were validated to assess if model averaging created a more robust prediction model.
Bach Validation Internal/External Hos.-Leme. Brier Score AUC [95% CI] Threshold (%) Sens. Spec. Youden PLR
With
1
Internal 0.3617 (277.63) 0.4863 0.5337 [0.512, 0.556] 1.05 28.444 82.980 0.1142 1.6713
External 0.4776 (416.96) 0.2859 0.6239 [0.605, 0.643] 0.76 99.967 0.000 -0.0003 0.9997
2
Internal 0.3617 (277.63) 0.4863 0.5337 [0.512, 0.556] 1.06 19.556 89.993 0.0955 1.9541
External 0.4776 (416.96) 0.2859 0.6239 [0.605, 0.643] 0.67 19.056 90.026 0.0908 1.9105
Without
1
Internal 0.0001 (648.84) 0.4753 0.5920 [0.577, 0.608] 1.41 84.755 31.648 0.1640 1.2400
External 0.0003 (855.97) 0.3873 0.6808 [0.668, 0.694] 1.23 100.000 0.037 0.0004 1.0004
2
Internal 0 (669.64) 0.4705 0.5801 [0.563, 0.597] 1.33 12.294 89.987 0.0228 1.2278
External 0.0527 (779.39) 0.3885 0.6883 [0.674, 0.702] 1.08 25.399 89.982 0.1538 2.5353
Validation 1; Optimal Risk Threshold - Validation 2; UKLS Guidelines
Table 11.2: Model Averaging Validation Results
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The calibration results for the meta-model including the Bach Model was promising. The meta-model
was well calibrated in both the internal and external datasets (Table 11.2), most likely a consequence
of recalibrating the models before aggregating them. However, the promising calibration results are not
replicated in the meta-model excluding the Bach Model, while the calibration improves, highlighted by the
Hosmer-Lemeshow chi-squared and the Brier Score results, the model did not report a good calibration.
Unfortunately, the promising calibration improvement was not reflected in an improved discriminative
ability or prediction rules performance. Indeed, the proposed aggregated model performs poorer than the
original models.
In summary, Model Averaging is a simple method to apply and distinct models can be combined.
However, when the original models are poorly calibrated, even after recalibration, then the weights assigned
to each model in the final meta-model are very similar. While this method notably improved the model
calibration, to the extent the meta-model with the Bach Model was well calibrated in both the internal and
external validation, the discriminative ability of the new model was poorer than the original models. While
Model Averaging can create a well calibrated model, if the model updating datasets has a high disease
prevalence rate, as observed in this instance, then the proposed meta-model would be inappropriate in
populations with more realistic incidence rates. Overall, Model Averaging failed to improve the prediction
rules in comparison to the original models and a more robust lung cancer prediction model was not created.
11.4 Method Two - Bayesian Model Averaging
The next approach is Bayesian Model Averaging (BMA) with a non-informative prior. There are similarities
between this method and Model Averaging, the models are applied separately and then weighted in the
meta-model. The models are assigned a weight based on their calibration in the dataset. However,
the weights are calculated slightly differently and the models are not initially recalibrated unlike Model
Averaging. The original models were poorly calibrated in the dataset due to the high incidence rate. Not
recalibrating the model originally could see some of the models being penalised in the final meta-model
while actually being successful models.
For each model the likelihood function in the dataset was calculated in the same way as Model Averaging
(Equation 11.5), as follows;
Li =
N∑
j=1
(yj × ln (mj)) + ((1− yj)× ln (1−mj)) (11.5)
where yj =
{
0, if participant is a control
1, if participant is a case
(11.6)
Where, mj is the predicted risk for participant j in the model.
After calculating the likelihood function, Li, for each model the following calculation was performed,
as presented in Equation 11.7. To perform this calculation the model dimension, dj , is required, which is
the number of distinct variables in the model;
Mi = e
(
Li+
di
2
ln(N)
)
(11.7)
Here, N is the number of participants in the dataset which is fixed because they are applied in the same
sample population for which all the models are applicable. For the lung cancer prediction models their
model dimensions are as follows;
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Model Model Dimension
PLCOM2014 12
Hoggart 12
Pittsburgh 4
Bach 7
Table 11.3: Lung Cancer Model Dimensions
Now, Mi can be determined and the final model weightings calculated;
wi =
Mi∑n
j=1Mj
(11.8)
This was a straightforward method to combine multiple lung cancer prediction models. The weighting
applied to each model to produce a final lung cancer risk are as follows, for both options including or
excluding the Bach Model;
Model Weightings
Model with Bach Model Model without Bach Model
Bach 2.585E-09 NA
PLCO 1.852E-03 0.500002
Hoggart 0.99815 0.499998
Pittsburgh 7.292E-17 1.86E-18
Table 11.4: Model Weightings from BMA
The two different versions led to unusual model weights. When considering the Bach Model, the model
weightings does not best synthesis the evidence from the distinct models by minimising the impact of
some models in the meta-model. Indeed, the final model was effectively the Hoggart Model which was
assigned a weight exceeding 0.998. The remaining models were assigned weights very close to zero. This
demonstrates how BMA can assign excessive weights to some models because the approach assumes some
models are correct and the remaining models should be penalised. When excluding the Bach Model from
BMA the model weights were more evenly distributed. The meta-model is effectively a combination of the
PLCOM2014 and Hoggart models, both assigned a weight of effectively 0.5. The Pittsburgh Model was still
minimised in the final model.
Bach Validation Internal/External Hos.-Leme. Brier Score AUC [95% CI] Threshold (%) Sens. (%) Spec. (%) Youden PLR
With
1
Internal 0 (494.26) 0.3726 0.5295 [0.508, 0.551] 25.05 29.63 76.48 0.0611 1.2597
External 0.0021 (503.49) 0.5148 0.6103 [0.591, 0.629] 24.98 31.14 81.01 0.1215 1.6396
2
Internal 0 (494.26) 0.3726 0.5295 [0.508, 0.551] 32.24 12.59 89.99 0.0259 1.2583
External 0.0021 (503.49) 0.5148 0.6103 [0.591, 0.629] 32.50 18.66 90.03 0.0869 1.8708
Without
1
Internal 0 (726.68) 0.4220 0.6114 [0.596, 0.627] 1.50 82.86 36.21 0.1907 1.2990
External 0 (998.86) 0.5307 0.6922 [0.680, 0.705] 1.50 84.06 42.15 0.2622 1.4532
2
Internal 0 (735.91) 0.4152 0.5981 [0.581, 0.615] 15.97 12.67 89.99 0.0266 1.2654
External 0 (876.01) 0.5227 0.7000 [0.686, 0.714] 14.05 25.91 89.98 0.1589 2.5865
Validation 1; Optimal Risk Threshold - Validation 2; UKLS Guidelines
Table 11.5: BMA Validation Results
The meta-model including the Bach Model had a similar performance to the Hoggart Model, as ex-
pected, when validated across all tests 11.5. When excluding the Bach Model in the meta-model, there was
an improvement in performance. However, this did not exceed the performance of the original PLCOM2014
Model. Additionally, the Hoggart Model predicts unreasonable high estimates of developing lung cancer
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over 6-years. Therefore, the meta-model to maintain a specificity of 90% would need to be applied at
approximately the 15% risk threshold (Table 11.5). This may be inappropriate and suggests recalibration
before applying the method may allow more appropriate risks to be developed. However, this may not be
advisable in a dataset with an unrealistic lung cancer incidence rate because the recalibrated models may
estiamte even further distorted risks.
In summary, there was a contrasting performance between the two meta-models created by BMA.
When considering the Bach Model the method’s limitations are highlighted as all except one model are
negated in the final meta-model. When excluding the Bach Model the weighting is slightly less biased
but the Pittsburgh Model is still minimised in the final model. The method may benefit from initially
recalibrating the models to allow a fairer inclusion of the models. While the meta-model excluding the
Bach Model had a reasonable performance this did not sufficiently improve upon the original models in
the external validation so a more robust model was not created.
11.5 Method Three - Bayesian Model Averaging with an Additionally
Weighting
The next method is an adaptation of BMA to include an additionally weighting in an attempt to create an
improved selective screening tool. This is to allow more evidence to be included in determining the weights
for the models. The additionally weighting is based upon a comparison of the discriminative ability of the
models in the dataset. A model with an increased discrimination, measured by the AUC, is assigned a
stronger prior. Although, unless there is a large difference in the model AUC the change in final weights
will be minor. BMA with an additionally weighting is simple to apply, as with the original BMA method,
once the AUC for each of the models has been determined.
The posterior, Mj of the model is calculated in exactly the same way as previously presented using
Equations 11.5 & 11.7. The additionally weighting takes the form of the prior odds for each model and is
determined as follows;
Pr(Mi) =
AUCi∑n
j=1AUCj
(11.9)
Then, for each model, j, we can assign a new value for mj determined by the likelihood ratio. Then the
final model weights can be calculated;
wj =
Pr(Mj)×mj∑n
i=1 Pr(Mj)×mi
(11.10)
This provides the finals weights for each model, which for the lung cancer prediction models were determined
as follows;
Model Weightings
Bach 2.71E-09 NA
PLCO 0.00206 0.50742
Hoggart 0.99794 0.49258
Pittsburgh 7.24E-17 6.66E-16
Table 11.6: Model Weightings from BMA with an Informative Prior
As can be seen in Tables 11.4 & 11.6, the difference in weights between BMA and BMA with an
additionally weighting was negligible because the AUC results were similar and the external data did not
provide enough evidence to significantly alter the model weights. However, the PLCOM2014 was slightly
rewarded with a higher weight as it had the leading discriminative ability. Considering a prior based on
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the AUC results would be a more appropriate method if there was a clear leading model which should be
favourably weighted in the final model.
Bach Validation Internal/External Hos.-Leme. Brier Score AUC [95% CI] Threshold (%) Sens. (%) Spec. (%) Youden PLR
With
1 Internal 0 (491.05) 0.3726 0.5295 [0.508, 0.551] 25.04 29.63 76.48 0.0611 1.2597
External 0.0024 (501.84) 0.5149 0.6103 [0.591, 0.629] 24.98 31.14 81.01 0.1215 1.6396
2 Internal 0 (491.05) 0.3726 0.5295 [0.508, 0.551] 32.23 12.59 89.99 0.0259 1.2583
External 0.0024 (501.84) 0.5149 0.6103 [0.591, 0.629] 31.20 18.79 90.03 0.0882 1.8840
Without
1 Internal 0 (744.14) 0.4226 0.6115 [0.596, 0.627] 1.50 82.70 36.44 0.1914 1.3011
External 0 (1030.13) 0.5316 0.6924 [0.680, 0.705] 1.50 83.91 42.38 0.2628 1.4562
2 Internal 0 (716.55) 0.4158 0.5983 [0.582, 0.615] 15.81 12.62 89.99 0.0261 1.2607
External 0 (971.88) 0.5236 0.7003 [0.686, 0.714] 13.87 25.97 89.98 0.1595 2.5919
Validation 1; Optimal Risk Threshold - Validation 2; UKLS Guidelines
Table 11.7: BMA Validation Results with an Informative Prior
Since the meta-model had a very similar weighting as the original BMA meta-models there were no
major differences in the validation results. Neither version of the meta-model including or excluding the
Bach Model reported a good calibration, although the version with the Bach Model nearly reported a
good calibration in the external validation. This was an improvement upon the original models; further
supported by the improved Brier Score. This suggests BMA can improve the accuracy of predictions.
The discriminative ability of the new models was similar to the initial models. The meta-model that
excluded the Bach Model reported the strongest discriminative ability and prediction rules. This reported a
small improvement over the BMA version without the informative prior. This demonstrates how considering
the discriminative ability as prior knowledge can improve the potential of developing a robust selective
screening tool. This had a comparable performance to PLCOM2014 Model. Indeed, the model in the
external validation had a higher Youden index and PLR than the leading original models. This meta-model,
excluding the Bach Model, was optimal at the 1.5% risk threshold where the sensitivity was approximately
83% across the internal and external validation dataset. Here, the model reported a specificity between
36-42%. Using the UKLS guidelines the model should be applied at a risk threshold between 13.8-15.8%.
This maintained a specificity of 90%, although the sensitivity was variable reporting a sensitivity of 12.6%
in the internal validation which increased to 26% in the external validation. The results have only been
confirmed in one external dataset; the model should be validated in additional sample populations to assess
if it can consistently perform to a higher standard in comparison to the original models.
In summary, BMA with an additionally weighting led to a slightly improved model. The model version
excluding the Bach Model had a strong performance. In the external validation the calibration improved
upon the original models, although the meta-model still did not report a good calibration because of
the calibration deficiencies of the original models. The discrimination and prediction slightly improved
upon the leading original models. However, the results were variable between the internal and external
validation. The model should be applied in new populations to ascertain if an improved prediction model
has been created in comparison to the original models.
Overall, this method showed potential for creating a more robust model. Considering a prior for each
model could be a better alternative to the original BMA method. The additionally weighting, based on the
models discriminative ability, could allow a more robust selective screening tool to be devised. However, if
there is not a large difference in the original models AUCs then the prior information does not significantly
alter the model weights from the original BMA method.
11.6 Summary
The chapter applied Model Averaging and BMA methods to aggregate multiple lung cancer prediction
models. Model Averaging dramatically improved the model calibration both in the internal and external
validation. This was an advantage of recalibrating the original models before aggregating the models in the
dataset. The models were recalibrated in a dataset with a high lung cancer incidence rate, so that when
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they were applied in the external validation dataset, which also reported a high lung cancer incidence rate,
they remained well calibrated. Unfortunately, the discrimination and the prediction rules were inferior to
the original models. Additionally, the final weights were evenly split across all models considered in the
meta-model. This may be a result of the original models still being poorly calibrated in the dataset so the
method failed to identify more robust models.
BMA did not improve the calibration and minimised the impact of some of the original models by
effectively assigning them a weight of zero in the final model. This was observed when considering the
Bach Model in the model aggregating; the final model was effectively the Hoggart Model. When excluding
the Bach Model, the final model was formed using an equal weighting between the PLCOM2014 and Hoggart
Model, however, the Pittsburgh Model was still minimised in the final meta-model. When incorporating
in the models’ discriminative ability as an additionally weighting the final weights differed only slightly
because the AUC results were relatively similar. This method, however, created a meta-model with a
slightly improved discrimination and prediction rules to the original models.
A lung cancer prediction model was devised with a strong performance in comparison to the original
models. This model combined the evidence of the PLCOM2014, Hoggart and Pittsburgh models. It can be
applied to ever-smokers aged at least 35 years to predict six year risk of lung cancer incidence. The model
performed optimally at the 1.5% risk threshold with a sensitivity of 83% and specificity between 36-42%.
To maintain a specificity of 90% the model should be applied at a risk threshold between 13.8-15.8%,
which is excessive because of the Hoggart Model estimated high risks. At this threshold the sensitivity
varied between 12.6% and 26%. The model should be applied in new external validations to ascertain if
an improved prediction model has been created in comparison to the original models. The final model is
the weightings of the PLCOM2014, Hoggart, and Pittsburgh models as presented in Table 11.6, and a Stata
code of each of the original models are provided in 12.13.
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CHAPTER 12
Discussion
12.1 Developing Project Objectives and Brief Summary
The primary objective of this project was to review how lung cancer diagnosis rates could be improved.
We highlighted how the key to improving the diagnosis rate was to identify lung cancer early. This could
be achieved by implementing a screening trial, where people who are high risk of developing lung cancer
are periodically reviewed and screened to identify early lung cancer developments. Therefore, we aimed to
review how lung cancer screening could be implemented and improved.
Initially, an overview of lung cancer and current screening programmes was conducted. This highlighted
how research was still needed as to how to effectively select populations for lung cancer screening. Firstly,
there was an indication the current proposed populations for screening trials were somewhat arbitrarily
chosen without evidence to support why they had been selected. The two major current screening pro-
posals either selected the LLP Model despite this model not demonstrating a leading prediction model
performance, or selecting older ever-smokers without consideration into other key factors that could ex-
plain lung cancer risk. Despite these limitations, the trials, when evaluated, demonstrated some promising
results, including improving early stage lung cancer diagnosis. This highlighted the potential benefit of a
lung cancer screening programme. However, before a programme could be implemented there should be
more justification as to why a specific criterion had been chosen with evidence demonstrating why this
would be the most beneficial method available. Without this evidence available with the current screening
programmes, a systematic review was proposed to quantify all information into available prediction models,
which could become a selective screening programme, and any evidence into their expected performance
as a clinical utility.
We also discussed the key measures that would be expected of a criterion before it could be implemented,
with focus on the UK screening trial guidelines. Namely, a screening criterion would be required to
demonstrate a high level of benefit in identifying lung cancer while reducing the potential for negative
impacts caused by unnecessary screening. It also had to demonstrate the potential to be cost-effective,
which could be challenging due to the expensive CT scanning commonly required to identify lung cancer.
This was considered during all assessments of how prediction models could be implemented as a selective
screening trial.
The next stage of the project aimed to identify any leading selective screening criteria formulated
using either the existing lung cancer screening programmes or available prediction models. Therefore,
a systematic review was conducted to identifying any leading screening guidelines currently published.
However, our research found the current reporting into how lung cancer prediction models’ could be
utilised as a selective screening tool was limited. The results reported were inconsistent and, with a lack of
compelling evidence demonstrating their potential benefits, this contributed to lung cancer screening not
currently being considered on a large scale.
This formed the next objectives of this research to identify a leading selective screening criterion.
We requested datasets from ILCCO to provide a range of sample populations to review existing lung
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cancer models and currently considered selective screening criteria. The models and criteria were then
analysed in the datasets and recommendations on how to define a high risk population for screening were
presented. By the conclusion of the external validation we presented two alternatives, both using the
successful PLCO2014 Model. One criterion would identify a large proportion of lung cancer cases but have
a substantial proportion of additional screening of controls; this would be beneficial if and when lung
cancer screening becomes easier, cheaper, and less invasive. The second option, while still identifying a
substantial proportion of lung cancer cases aimed to reduce screening of people who were lung cancer free,
to allow the screening programme to be more economically viable and reduce harms. By the conclusion of
external validation the objectives had been met and a leading selective screening tool had been presented.
Next, the project presented how models could be updated to combine the evidence and information
available in the model building dataset with new information in an external dataset. This can be achieved by
updating a single model or combining multiple models based on their performance in the external dataset.
The literature review presented the different methods that were available which have differing merits
depending on the success of the original model in the external dataset. Model aggregating techniques were
also presented. These methods to combine models had not been utilised often, so we evaluated the methods
and how they have been previously successful or can be successfully applied. We also reviewed whether the
methods were appropriate and discussed any constraints when applying different methods, such as requiring
the same model form. Once the methods had been presented and reviewed the final objective of the
project assessed if an improved lung cancer screening tool could be created. Unfortunately, a significantly
improved model could not be developed. This was mainly a consequence of the datasets obtained which
reported a very high lung cancer incidence rate. Therefore, the models were poorly calibrated, which is
the main assessment in the model updating, and therefore the methods were hindered. Additionally, the
proposed models would be unrealistic to apply in the real world because they were recalibrated to predict
exceptionally high levels of lung cancer risk based on the dataset.
Overall, the majority of the objectives were achieved. The systematic review synthesised the evidence
of lung cancer prediction models and highlighted where they had been successful and where further re-
search was required; namely how the models could be successfully applied as a selective screening tool.
This became the project’s objective and we conducted more extensive research into lung cancer prediction
models. We provided clear evidence into the leading model and how this should be applied to maximise
potential benefit. The different methods that are available for model updating were presented and anal-
ysed. These could then be used in subsequent research to update prediction models for lung cancer or
other diseases. We also provided our own suggestion to model aggregation that considered the models’
discriminative ability rather than solely aggregating models based off their calibration. This aimed to
ensure models with a good discriminative ability were not too harshly penalised and nullified in the final
meta-model. In addition the systematic review research has been published and there are plans to publish
the external validation results.
Unfortunately, an improved model could not be created, and we decided not to publish a proposed
model that did not improve on the existing literature. In addition we could not provide any conclusive
evidence into the success of different model updating methods based off our own analysis. This was a
consequence of the datasets where the model updating was conducted.
In summary, the work can provide a contribution to the field of lung cancer screening. Previously,
multiple lung cancer models had been developed without further research into how the models should be
applied. This has hindered models being implemented as a selective screening tool. In this research we
demonstrated how all prediction models would benefit from thorough validations that allow constructive
results. In addition we have provided clear recommendation into how to apply the PLCO2014 Model as a
selective screening tool, with recommendations for the next stage of research before hopefully this model
being implemented as a screening tool at a regional, national or international level.
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12.2 Detailed Results Review
12.2.1 How Lung Cancer Survival can be Improved
The first stage of the project presented the impact of lung cancer. Lung cancer is a global disease affecting
millions of people worldwide with the second highest cancer incidence rate in both males and females [1].
In addition to this lung cancer is beset with a poor survival rate which results in a high mortality rate,
indeed lung cancer is accountable to around 26% of all cancer related mortalities [1]. The poor long term
survival for lung cancer can be attributed to late stage diagnosis. Like all cancers, early diagnosis is critical
in improving available treatment options. Specifically for lung cancer the 5-year survival rate for Stage 1
diagnosis is 56%, however by Stage 3 or 4 this has been drastically reduced to 4% [27]. Unfortunately, by
this stage the cancer has often metastasised and affected large areas of the lung, so the treatment options
are limited to palliative care. It was clear from our initial research into lung cancer; the crux of improving
lung cancer survival is to identify cancers at an early stage. However, this is not straightforward with 57%
of lung cancer reported at Stage 3 or 4. Indeed, despite research into early diagnosis identification this
has only improved from 12% to 18% of lung cancers between 1975 and 2011. This could be attributed to
the ‘hidden’ symptoms of lung cancer as unfortunately the visual lung cancer symptoms, such as coughing
blood, do not appear until later stages. Indeed, most early symptoms, including coughing, are masked by
a prior smoking history which is prevalent in most lung cancer incidences.
Lung cancer diagnosis could be improved by taking the responsibility away from patients to report
symptoms. Instead, people who would be considered likely to develop lung cancer could be placed on a
priority list with regular check-ups and potentially periodic screening. This has been observed for other
cancers, such as bowel and cervical cancer but has not been implemented for lung cancer. This would
be infeasible on a large scale due to the costs associated with CT scanning. Therefore, before large level
screening would be considered for lung cancer it needs to be shown that the programme can reliably identify
lung cancer in the target population, limit false alarms for incorrect diagnoses, and be cost-effective. This
has not been demonstrated at this stage, and in the presented lung cancer screening trials, namely NLST,
UKLS, ELCAP and NELSON, they have not been conclusively effective. The main reporting in these
trials has been on whether LDCT scanning can be effective over chest radiography. However, there were
promising results from the previous screening trials. The results did demonstrate how the identified target
population was more effective than blanket screening and therefore resources were correctly allocated.
Crucially, lung cancer was diagnosed at early stages, with 66.7% diagnosed at Stage I and a further 19%
diagnosed at Stage II in the UKLS trial [36]. Clearly, there is merit in screening a target group periodically.
However, at this stage we felt the target group may not be correctly defined. The trials were not successful
in restricting false alarms or being cost-effective. Too many people were unnecessarily screened and the
trials reported up to $269, 000 per QALY [27]. The results indicated further research is required into
identifying the correct target population for screening.
After the initial analysis, it became clear prediction models could play a key role in identifying this
correct target population. They consider a range of different variables to determine an individual’s risk
of developing lung cancer over a defined time period. Then a risk can be selected such that anyone who
reports a result higher than this threshold could be invited for screening periodically. Therefore, this
project decided to review how models and arbitrary criteria could or should be utilised such that a target
population is identified for screening that will balance having a positive impact of improving early stage
lung cancer diagnosis with the negative effect of unnecessary screening and the negative costs associated
with this.
12.2.2 Model Requirements
The next objective of the project was to review what can be expected for prediction models before they
would be considered as a clinical utility. The review presented the different techniques available to review a
model or screening guideline. These were separated into reviewing the model calibration, how accurately the
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model estimated an individual’s risk of developing lung cancer; the model discrimination, how successfully
the model assigned a higher risk to people who have developed lung cancer; and the model prediction
rules, which reviewed the effectiveness of the target population who would be selected for screening using
the defined criteria. We presented all the available methods and concluded to review the calibration
the Hosmer-Lemeshow and Brier Score should be reported as these have commonly been reported and
were effective measures to review the model calibration. To calculate the Hosmer-Lemeshow result the
participants need to be grouped, our research identified that these should be grouped into sets of 10
participants with neighbouring risks as generated from the model under consideration. Next, the AUC
should be reported as this is an effective measure of the model discrimination. Finally, out of the wide range
of methods available to review the model prediction rules the sensitivity, specificity, Youden Index and PLR
were selected. The sensitivity and specificity were selected as these are commonly reported and are an
easy measure to interpret the effectiveness of the screening criteria. The Youden Index is an extension of
the sensitivity and specificity to review how effectively these separate measures work together. Finally,
the PLR was selected as this measure will provide an indication into the probability of being considered
high risk when you have lung cancer versus the probability of being considered high risk when lung cancer
is not present. These methods were ultimately selected because of their analysis value and crucially they
were not influenced by the prevalence rate in the dataset. It was anticipated that the datasets recruited
for the planned validation would be case-control datasets with a high lung cancer incidence rate that
would not be observed in the real world. Other methods such as the PPV could report elevated results
suggesting the model had a better performance than would be realistic. Therefore, these methods were not
preferred for our planned analysis. Once, all methods had been presented, and reviewed how the results
could be interpreted, then the next stage was to review how lung cancer models had performed in previous
validations.
12.2.3 The Systematic Review
The systematic review was conducted with the objective of identifying all lung cancer prediction models
and their validation results. All models were identified so a critical analysis could be undertaken to identify
their potential to be used as a selective screening tool. This was achieved by a review of how the models
had performed when validated.
Once the review had concluded it was clear there was a large number of differing models had been
developed. In total 29 different models were presented and these were classified into epidemiological,
clinical, and TSCE models. Epidemiological models are free to run models so would be preferred if effective
in comparison to clinical models which could become expensive when applied to a large volume of people
in order to determine if an individual should go for regular screening. Therefore, for clinical models it was
imperative to demonstrate an enhanced performance to justify the associated cost applying the model. This
was not observed; indeed when a clinical model was produced that expanded on an existing epidemiological
model the improvement was negligible. This was observed for the extended Spitz, LLP and Bach models.
We concluded from the systematic review that at this stage more research is required into the genetic
factors which should be included in clinical models and be able to demonstrate they significantly improve
a model’s predictive ability. The TSCE models were presented but disregarded as a potential screening
tool as they commonly only consider one factor to review this factor’s association with lung cancer risk.
These would be impractical as a tool to identify populations for screening, particularly since the variable
in question was often rare in individuals, such as asbestos or silicone exposure.
The epidemiological models did demonstrate some promising results, these included high AUC results
up to 0.86 (PLCO Model). This highlighted these models could be successfully implemented into a screening
criteria provided robust guidelines were identified and presented. However, this was not observed in the
current reporting of epidemiological models. The validations varied in the results reported and the models
were commonly considered in isolation. This made it difficult to infer a leading model from the large
volume of models created. Additionally, the prediction rules have been inadequately reported, even when
these have been reported in subsequent validations the models had not been tested at the same thresholds
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to assess if the results were consistent. Therefore, there was no confidence into a leading model and how
best to apply any identified leading model to maximise the impact in a selective screening programme. The
results of the systematic review allowed the next stage of the project to develop. The poor reporting seemed
to be a key contributor that models are not being implemented as a selective screening tool. Therefore we
decided to address this limitation in our research. The models had been identified through the systematic
review. The epidemiological models were selected for our research as we would be able to attain the basic
patient information required to apply these models. In addition they had shown promise and if a leading
model with consistent strong performance as a selective screening tool could be identified then it could
be implemented. Since we would not be able to obtain datasets that would contain clinical factors and
these models failed to demonstrate an improved performance to justify the cost required to estimate an
individual’s risk, these were discounted in our research. We recommend as a conclusion of the systematic
review, that further research is required to assess whether the cost associated with applying clinical models
is beneficial. The results presented in the systematic review currently suggested clinical models may not
be more beneficial with the exception of the Korean Men Model which requires fasting glucose levels but
reported an exceptional performance. Indeed, further validations would be required, but if this model can
consistently demonstrate this level of performance it could be an exceptional tool to identify people for
periodic screening.
The TSCE models were also disregarded for the next stage of the research in this project, as these were
impractical to apply to identify a high risk population for screening.
By the conclusion of the systematic review we proposed to review all available epidemiological models
that had been identified and address the inconsistent reporting and the lack of inter model comparisons.
We decided to conduct our own series of external validations that would allow us to deduce which models
were successful and how they should be applied to maximise benefit as a selective screening tool, and what
would be the expected performance. This hoped to allow medical professionals and decision makers to
make informed decisions whether prediction models should be considered as a screening tool.
12.2.4 Dataset Collection and Preparation
To evaluate the models, datasets were collected from ILCCO. This provided the sample populations to
review the models and devise recommendations into how leading models should be applied as a screening
tool. In total 60 datasets were requested for inclusion in our research. The only prerequisite was that they
needed to contain the variables required by the prediction models. From the 60 requests sent there were 20
responses but only 10 datasets had enough information to review at least 2 models, which we felt was the
minimum requirement so we could compare between them. Unfortunately, none of the datasets allowed
all the models to be validated. An additional limitation was that the Spitz and African-American models
could only be applied to one dataset. However, overall the datasets provided a great opportunity to test
multiple models in a range of differing sample populations and evaluate their performance.
The datasets were reviewed and prepared. This assessed whether there were any peculiarities in the
datasets that needed to be highlighted and in some instances addressed. The main finding was the datasets
had a high lung cancer incidence rate that would not be observed in a real world population. In general the
datasets had one-to-one matching between participants with or without lung cancer. For the most part this
was not a major limitation as it would not influence the model discrimination or the selected prediction
rules tests. However, the prevalence rate would influence the model calibration results because at an overall
level the models predicted a much lower volume of lung cancer incidence than the 50% that was observed
in the datasets. It was decided to still present the calibration results but acknowledge that these may not
be a true reflection of the model calibration. In addition the majority of the datasets were case-control
designs, this can slightly boost the models’ discriminative ability as the cases are often at an advanced
stage of lung cancer so may also be higher risk. Therefore the model finds it easier to assign a higher risk
to individuals with lung cancer. However, this is negated somewhat by focusing on a comparison between
the models; our primary objective was to identify a leading model or criteria that should be considered in
preference to other models. This would not be influenced by the case-control dataset design. While we
159
provided recommendations where the model performed optimally based on our results, when these were
presented we recommended assessing if the model continued to perform as strongly in a cohort study using
our recommendations. While the model may have a boosted performance this should only be slight and
this model would still be the leading criteria in other populations. The other peculiarity of the datasets
was the population recruited for the study. The studies had different primary purposes when recruiting
participants. In some instances this was to review participants where they could be considered very
unlikely or highly likely to develop lung cancer. The ReSoLuCENT and New Zealand datasets recruited
young people who may not have been expected to develop lung cancer whereas everyone in the CARET
study were heavy smokers and a high proportion had a prior asbestos exposure. This may have made it
difficult for the models to distinguish between cases and controls; however this was not a concern as it was
still insightful to compare the models in these challenging populations. They still allowed an indication of
how the models performed as it is desirable to capture all lung cancer cases, including those belonging to
lower risk groups, while it is also beneficial to eliminate unnecessary screening in high risk groups like the
CARET study. Overall, while the datasets were different and had some peculiarities, there were no major
concerns with the sample populations recruited for our purpose of comparing between multiple models.
The datasets had randomly missing information for some participants across the variables. We reviewed
how best to deal with the missing information with our primary objective to retain as much data as
possible to thoroughly evaluate the models. However, we highlighted the importance when imputing the
missing information this needed to be accurately estimated to fairly evaluate the models. There was
caution that if the missing information was inadequately imputed then this would negatively influence
the model’s performance, particularly if there was missing information imputed for one variable that was
required by one model. This would cause an unfair comparison between the models. A review of the
available imputation methods was conducted and this allowed us to make informed decisions into the most
appropriate approach to deal with the missing information. It was decided that there would always be
some uncertainty with imputing missing information, therefore, for datasets with low levels of missing
information (under 10%) then the participants with missing information were removed. However, for
high levels of missing information this did not seem the most appropriate approach as we would lose too
much valuable information. For the participants which reported with missing information they reported
information for other variables which could form the imputation. After a review of the imputation methods,
MICE was selected as this allowed missing information across multiple variables to be imputed in one
imputation. Therefore, the imputation was able to consider whether any information was missing for the
other variables used in the imputation and take the uncertainty around the value for these variables into
consideration. It also iteratively applied the imputation, using all explanatory and imputed variables,
until the imputed values stabilised, therefore giving the most appropriate estimation. We also undertook
additional measures to allow us to have uppermost confidence in the imputed values. We conducted testing
to demonstrate the missing information was MAR. We also restricted the imputed values once determined,
to match to the closest observed value for that variable, such that inappropriate values like a negative CPD
value would be corrected. Finally, the imputation was conducted on eleven independent occasions. Eleven
was selected as this seemed a reasonably high number that in taking the average across these datasets, to
allow for any imputation where the result was peculiar, this should not have a large impact on the model
performance. Additionally, Rubin’s Rule was applied when calculating the validation results for the AUC,
Brier Score, sensitivity and specificity, which would then be used to calculate the PLR. This allowed the
most reliable results possible from the imputation taking into account the variance in performance between
the datasets. Therefore, we had confidence in the imputed values and the subsequent validation results
obtained. The imputation allowed us to maximise the evidence available in the datasets to thoroughly
evaluate the models.
12.2.5 External Validation
The next stage of the project used the prepared datasets to validate the models. To provide a thorough
evaluation of the models and contextualise how the models should be applied it was decided two validations
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should be conducted. The first validation aimed to give context into where the models’ consistently reported
a robust performance. This would be achieved by identifying a high proportion of lung cancer cases while
restricting a reasonable proportion of participants without lung cancer from screening. In this validation
the models were applied to their identified target population. This intended to demonstrate how the models
could be maximised in a balance between sensitivity and specificity to have a large impact on lung cancer
diagnosis. When lung cancer diagnosis options become more efficient with fewer false diagnoses, with less
strenuous diagnosis options, and cheaper testing than the current CT screening method, then the results
where the models performed optimally should be considered as this would be most beneficial. However,
it can be argued that this is not currently appropriate as it would not be cost effective, by periodically
screening up to approximately 30% of people who would not subsequently develop lung cancer. Therefore,
a second validation was proposed which aimed to limit unnecessary screening to only 10% of people aged
between 50-75 years old. This appeared to be a restrained and reasonable cost provided the model could
still demonstrate a substantial impact in identifying lung cancer cases. There was no available evidence to
assume a 90% specificity would be a feasible cost so this was chosen since in the process of identifying lung
cancers there will be some people who are subjected to screening who won’t develop lung cancer. Therefore,
10% did not seem an unreasonable number if the screening would capture a high number of lung cancer
cases. This was supported by the UKLS trial which also would screen around 10% of lung cancer controls
and the NLST criteria which reported a specificity of approximately 80% across the datasets. It was
decided to compare the models to the two main screening trials, the NLST and UKLS, as these should still
be considered as viable screening criteria in comparison to the models.
The first validation conclusively provided evidence that the PLCO2014 Model was the strongest perform-
ing model and offered the most beneficial screening guidelines. The AUC result was consistently promising
across the sample populations with results between 0.79-0.86. This was commonly the highest AUC result
reported in the dataset. Furthermore the model performance was consistent and impressive whether in
low risk datasets such as the ReSoLuCENT or New Zealand dataset and the higher risk CARET dataset.
Based on the results we were also able to ascertain that to maximise the model performance this should
be applied at the 0.5% risk threshold. Here the model should report in most populations a sensitivity
of 70% for a specificity of 75%. This is an impressive performance with a Youden Index score above 0.4
uncommon across our validation and the validation results obtained in the systematic review. Clearly if
periodically screening 25% of people without lung cancer is realistic then the PLCO2014 Model could have
a substantial impact in identifying people with lung cancer which would then lead to improved early stage
diagnosis and ultimately can directly impact improved survival rates.
The second validation also demonstrated the PLCO2014 was the leading performer. Applying this
model at the 3% risk threshold would restrict screening of people who do not develop lung cancer to 10%
amongst 50-75 year olds. The model would still manage to capture 30% of people who will develop cancer.
This is still a high proportion of lung cancer cases and would have a positive impact on the current poor
lung cancer prognosis. In addition the model eclipsed the UKLS trial which for no improvement in the
specificity, would only identify 20-22% of lung cancer incidences. It should be noted the PLCO2012 Model,
which only considers ever-smokers, reported the same high standard of performance. This model should
be applied at the 3.5% risk threshold.
The results clearly demonstrate the positive impact the PLCO2014 Model can have as a selective screen-
ing tool. We were able to provide two potential options with a different balance between maximising lung
cancer capture rates and restricting unnecessary screening, with clear instructions on how the model should
be applied to achieve either objective. In addition, this could maximise the benefits in comparison to the
other models and also the current screening criteria which have been considered for implementation. There
are additional steps that need to be taken using the results that were obtained in these validations which
will be discussed in more detail in the proposal for future work.
While the results obtained were conclusive, unfortunately the Spitz and African-American models could
not be thoroughly evaluated as they were only applicable to one dataset. These should be evaluated in other
sample populations, but in doing so, it would be our recommendation that these models were compared
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to the PLCO2014 Model for whichever of the two guidelines we recommended best match the validation
objectives. Currently the PLCO2014 Model could not be compared on the same dataset as these two models
so a direct comparison could not be conducted.
12.2.6 Literature Review
The next stage of the project reviewed whether we could create an improved model that combined the
ability of the leading PLCO2014 Model or multiple models, and the additional evidence available in the
external dataset. This required a literature review to be conducted to present the methods that are available
and review how they have been applied previously to give an indication into how different methods are
successful in different scenarios. The methods were also reviewed for their practicality in being applied
to the identified lung cancer models. All single updating methods were applied to the PLCO2014 Model
as this was the leading original model so any improvements would create a new leading screening tool.
Model aggregating was initially restricted to the PLCO2012, PLCO2014, Bach, LLP, Hoggart and Pittsburgh
models as these could be applied in the same dataset which would serve as the external data to form the
model updating.
The literature review identified multiple methods to update a single model and aggregate multiple
models. The single updating methods were presented as model recalibration, re-estimation, and model
extension methods. Model recalibration takes the existing model but recalibrates the parameters to reflect
the observed incidence rate in the external dataset. The re-estimation methods re-estimate the model
parameters, with focus on parameters that do not significantly improve the model goodness-of-fit. These
parameter coefficients are reduced in the model such that an individual’s risk cannot deviate as far as in
the original model using this parameter. Finally, model extension methods were presented, which added
new variables to the model. The review highlighted where the different methods could be successful. The
general conclusions were that model recalibration should be applied to a successful model, particularly if
the model discrimination is good, such that the model is slightly adjusted to predict accurate risks in the
model dataset. Re-estimation can be successful for model with a calibration and discrimination deficiency,
and is more successful when the dataset reviewing the model is small. Adding new parameters could result
in over-fitting therefore readdressing weaker variables in the model would not allow these variables such
as large an impact in the final model. Finally, model extension is more appropriate for a model with poor
calibration and discrimination and a large external dataset is available. This will allow confidence in the
variables that are added to the model are correct and do not cause over-fitting. For all methods, the model
is updated based on the model calibration therefore, a well calibrated model will not require extensive
updating.
The model aggregation methods were also presented in the review. After the literature review, Model
Averaging and BMA were identified as appropriate methods to use on the lung cancer models. The other
methods were discounted as they either did not use an external dataset to conduct the model aggregation or
required the parameters in the models to be combined into one parameter. This required the models to have
the majority of similar parameters and a same model type. This was not observed across the lung cancer
models. Model Averaging combined the models by assigning them a weight based on their calibration and
is an excellent method to allow distinct models to be combined. However, the method initially recalibrates
the models; therefore if the external dataset has any peculiarities such as a high prevalence rate then this
will be reflected in the final model. Additionally, this method heavily weights one model therefore, the
evidence available from the remaining models is somewhat negated by being assigned a small weighting.
The second method, BMA, is also a good method to combine distinct models. Like Model Averaging
this method combines the models based on their calibration, which may result in a model that is poorly
calibrated but a good screening tool being removed from the final model. Therefore, we proposed assigning
an additional weighting to each model which considers their AUC performance to ensure any models that
have a superior AUC result are not disregarded in the final model.
At the end of the literature review the model updating methods were presented and the methods
that were appropriate for lung cancer models identified. The PLCO2014 Model was selected to conduct
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single model updating. The PLCO2014, Pittsburgh, Hoggart and Bach models were available for model
aggregation. After deliberation, two version of model aggregation would be conducted, with and without
the Bach Model. This was chosen as including the Bach Model allowed us to use the evidence in the model
rather than automatically disregarding this model. Excluding this model though, allowed a larger dataset
to be used for model aggregation and the final model to be applicable to a larger range of people as per
the Bach Model was more restrictive to heavy ever-smokers.
12.2.7 Model Updating
The single model updating methods did not create an improved lung cancer model. The main limitation
was that the datasets used to conduct the model updating had a very high lung cancer incidence rate.
As a consequence when the model was recalibrated the proposed model predicted very high risks for an
individual’s developing lung cancer within the next 6-years. In some instances the model predicted risks
exceeding 99%. This could not be used by the public as inappropriate risks like this could be detrimental
by creating panic. In addition to this, the methods did not substantially improve the model discrimination
or prediction rules in comparison to the original model. Therefore, it would be unwise to promote any
of the updated models as they would add to the large volume of published lung cancer models without
improving upon the existing literature.
The model aggregation methods also underperformed due to the high lung cancer prevalence rates in
the dataset. The models were poorly calibrated so the methods found it difficult to assign appropriate
weights to each model. Despite this a model with a reasonable performance was presented, this was the
aggregation of the Hoggart, PLCO2014 and Pittsburgh models using BMA with an additional weighting
based on the models’ AUC results in the external dataset. This slightly improved upon the original
models although would have to be further evaluated to assess if the performance can be replicated. The
separate model weightings were presented in the thesis with recommendations to ascertain if the model
can replicate the impressive sensitivity of 83% and specificity of 36-42% at the 1.5% risk threshold. In
addition the model should be reviewed at a high risk threshold, between 13.8-15.8% to allow the specificity
to remain at approximately 90% and then review the sensitivity. However, there is the possibility that the
proposed model may be inappropriate in new environments with lower prevalence rates, in comparison to
the original models.
12.3 Project Strengths
Overall the systematic review went well and achieved the objectives of the project. All available lung
cancer prediction models were identified and critically reviewed. We highlighted how the current reporting
of validations was inadequate but could be improved by comparing multiple models together and using
consistent testing. The systematic review was not able to identify a leading model that could be considered
further as a selective screening tool therefore, this became the new project objective. The systematic review
could have an impact how models are reported and validated to facilitate models being considered as a
screening tool. The results were also published in an article.
The external validation presented comprehensive results which provided a better indication into each
model performance and demonstrated how the PLCO2014 Model was the leading performer. It also provided
clear recommendations how to apply this model to best achieve the objectives of a screening programme,
whether this be to identify a high number of lung cancer cases or to reduce screening of people who would
not develop lung cancer. Based off the success of the external validation there are plans to present these
results in an article to be used to plan future research and potentially implement the model in a selective
screening trial.
The literature review of model updating and model aggregation had some successes. This identified and
presented all available methods to update a single model or aggregate multiple models as per the literature
review objectives. The also presented where the different updating methods have been previously successful
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for different original model deficiencies. The critiqued methods can then be applied in future research to
improve the performance of prediction models. For instance model extension could be a key method as
new markers that are predictive of lung cancer incidence are identified and added to existing successful
models.
12.4 Limitations and Different Approaches
There were some aspects of this project that had limitations. This primarily stemmed from the datasets
collected for our research which had a high lung cancer prevalence rate. This affected some aspects of the
external validation and the model updating. The models were not able to predict the observed incidence
rate. Therefore, it was difficult to truly evaluate the model calibration in the external validation. However,
we acknowledged this during the validations and the other testing conducted was not influenced by the
dataset prevalence rate so we could provide constructive results.
This also had an impact on the single model updating review using lung cancer prediction models.
The model updating methods were based upon the model calibration. Therefore, the poor original model
calibration meant the model was dramatically recalibrated. This was particularly noted when extending
the model as the new parameters were extreme to try and predict a much higher lung cancer incidence in an
attempt to improve the model goodness of fit. Some updated models predicted extremely high lung cancer
incidence rates and would be inappropriate as a public tool as a consequence. In addition when conducting
model aggregation the poor original models’ calibration forced the final meta-model to assign extreme
weights to some models while negating the other models. This made it difficult to critically appraisal the
methods as they were heavily impacted by the datasets. However, while we could not demonstrate the
successes and limitations of the methods using lung cancer models we were still provided critical analysis
of the techniques in the literature review. This was based on their performance in published material when
they had been applied to update models in more appropriate datasets.
Unfortunately the limitations with the datasets could not be rectified. We had to collect datasets to
conduct the project within the time constraints rather than collating our own data. If more datasets had
been received then these could have been more selectively included but this was not appropriate with the
volume of data we received.
Overall, the datasets were the main limitation in this project however, it would have been impractical
to correct this by collecting our data with the project time constraints. To address this concern the project
focus adapted to compare models and review their potential as a selective screening tool which was not
impacted by the high lung cancer prevalence rate. Tests were also selected when reviewing the prediction
rules that were unaffected by the datasets.
12.5 Future Research
At the conclusion of our research we provided suggestions for future research that would be required before
the PLCO2014 Model would be considered as a selective screening tool.
The first focus should validate the PLCO2014 Model to assess if the level of performance can be replicated
at the risk thresholds presented. The validation could also review how the model performs in different
environments, this can assess whether the model would be universally successful or if more research is
required for specific populations. If the model demonstrates the same level of performance as observed in
the external validation then the next stage of research needs to evaluate the model in a screening trial. This
can review how many lung cancers would be identified and the volume of screening required to identify
a lung cancer case. This can also determine how frequently someone should be screened if their risk is
above the threshold. It should also review how periodically someone’s risk should be calculated to assess if
their risk varies across the risk threshold. Finally the screening trial should report at what stage the lung
cancers were diagnosed and whether this would impact the current poor lung cancer survival. This research
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will demonstrate whether the model would have a positive impact and be a viable screening programme.
Based off the conclusion of the screening trial then the PLCO2014 Model could be implemented.
Other research should review the level of performance of the Spitz and African-American models as
these could only be considered in one dataset. These should be compared where possible to the PLCO2014
Model to identify if they would offer any improvement.
12.6 Can Prediction Models be Successful Selective Screening Tools?
Before models would be considered they need to be thoroughly evaluated. There needs to be clear recom-
mendations how to apply the model, with an expectation how the model would be perform. Specifically
for lung cancer prediction models this had not been adequately reported and has hindered models being
implemented as a screening tool.
The research in this project demonstrated how prediction models can have a positive impact. The
models demonstrated the best option to identify a target population that would benefit from screening.
Therefore, provided model reporting is improved and the focus shifts towards implementing the existing
successful models rather than developing new models, then lung cancer prediction models can be a successful
screening tool.
165
Part III
References
i
References
Bibliography
[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. Ca-a Cancer Journal for Clinicians 2016;66(1):7-
30.
[2] National Cancer Institute. (2016). What Is Cancer? [online]Availableat:http://www.cancer.gov/
about-cancer/understanding/what-is-cancer [Accessed 28 Jun. 2016].
[3] Nhs.uk. (2016). Lung cancer - NHS Choices. [online] Available at: http://www.nhs.uk/conditions/
cancer-of-the-lung/Pages/Introduction.aspx [Accessed 28 Jun. 2016].
[4] Anon, (2016). Risk Factors for Lung Cancer: A Systematic Review. [online] Avail-
able at: https://canceraustralia.gov.au/sites/default/files/publications/
risk-factors-lung-cancer-systematic-review/rtf/risk_factors_for_lung_cancer_-_a_
systematic_review_-_wcag_version.docx [Accessed 27 Jun. 2016].
[5] Parkin DM. 2. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer 2011;105(S2):S6-S13.
[6] Cancer Research UK. (2015). Lung cancer risk factors. [online] Available at:
http://www.cancerresearchuk.org/health-professional/cancer-statistics/
statistics-by-cancer-type/lung-cancer/risk-factors [Accessed 27 Jun. 2016].
[7] World Health Organization. (2016). Tobacco. [online] Available at: http://www.who.int/
mediacentre/factsheets/fs339/en/ [Accessed 6 Jul. 2016].
[8] Parkin DM. 14. Cancers attributable to occupational exposures in the UK in 2010. Br J Cancer
2011;105(S2):S70-S72.
[9] Sin DD, Tammemagi CM, Lam S, et al. Pro-Surfactant Protein B As a Biomarker for Lung Cancer
Prediction. Journal of Clinical Oncology 2013;31(36):4536-+.
[10] Sozzi G, Boeri M, Rossi M, et al. Clinical Utility of a Plasma-Based miRNA Signature Classifier
Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study. Journal of
Clinical Oncology 2014;32(8):768-+.
[11] Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development
and prognosis of computed tomography detected lung cancer. Proceedings of the National Academy of
Sciences of the United States of America 2011;108(9):3713-3718.
[12] Wozniak MB, Scelo G, Muller DC, et al. Circulating MicroRNAs as Non-Invasive Biomarkers for Early
Detection of Non-Small-Cell Lung Cancer. Plos One 2015;10(5).
[13] Bediaga NG, Davies MPA, Acha-Sagredo A, et al. A microRNA-based prediction algorithm for
diagnosis of non-small lung cell carcinoma in minimal biopsy material. British Journal of Cancer
2013;109(9):2404-2411.
ii
[14] El-Zein RA, Lopez MS, D’Amelio AM, Jr., et al. The Cytokinesis-Blocked Micronucleus Assay as a
Strong Predictor of Lung Cancer: Extension of a Lung Cancer Risk Prediction Model. Cancer Epi-
demiology Biomarkers & Prevention 2014;23(11):2462-2470.
[15] Brenner DR, McLaughlin JR, Hung RJ. Previous Lung Diseases and Lung Cancer Risk: A Systematic
Review and Meta-Analysis. PLoS ONE 2011;6(3):e17479.
[16] Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis
from the International Lung Cancer Consortium. Am J Epidemiol 2012; 176(7):573-85.
[17] Merrill, R. (2000). Measuring the Projected Public Health Impact of Lung Cancer Through Lifetime
and Age-Conditional Risk Estimates. Annals of Epidemiology, 10(2), pp.88-96.
[18] American Joint Committee on Cancer. (2016). Lung Cancer Staging. [online] Available at:
http://cancerstaging.org/references-tools/quickreferences/documents/lungmedium.pdf
[Accessed 27 Jun. 2016].
[19] Cancer Research UK. (2016). More about staging for lung cancer — Cancer Research UK. [on-
line] Cancerresearchuk.org. Available at: http://www.cancerresearchuk.org/about-cancer/type/
lung-cancer/treatment/more-about-lung-cancer-staging [Accessed 27 Jun. 2016].
[20] Cancer Research UK. (2016). Diagnosing lung cancer — Cancer Research UK. [online] Available
at: http://www.cancerresearchuk.org/about-cancer/type/lung-cancer/diagnosis/ [Accessed
28 Jun. 2016].
[21] Cancer Research UK. (2016). Types of treatment for lung cancer — Cancer Research UK. [online]
Available at: http://www.cancerresearchuk.org/about-cancer/type/lung-cancer/treatment/
which-treatment-for-lung-cancer [Accessed 28 Jun. 2016].
[22] Nhs.uk. (2016). Lung cancer - NHS Choices. [online] Available at: http://www.nhs.uk/conditions/
cancer-of-the-lung/Pages/Introduction.aspx [Accessed 28 Jun. 2016].
[23] Black WC (2007) Computed tomography screening for lung cancer: review of screening principles and
update on current status. Cancer 110(11):2370–2384
[24] McWilliams A, Lam S (2005) Lung cancer screening. Current Opinion Pulmonary Medicine
11(4):272–277
[25] Jonnalagadda S, Bergamo C, Lin JJ, Lurslurchachai L, Diefenbach M, Smith C, Nelson JE, Wisnivesky
JP (2012) Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer 77:526–531
[26] Aberle DR, Adams AM, Berg CD, et al. Reduced Lung-Cancer Mortality with Low-Dose Computed
Tomographic Screening. New England Journal of Medicine 2011;365(5):395-409.
[27] Tota JE, Ramanakumar AV, Franco EL. Lung Cancer Screening: Review and Performance Compari-
son Under Different Risk Scenarios. Lung 2014;192(1):55-63.
[28] Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results
from the National Lung Screening Trial (NLST). J Med Screen 2011;18:109–11.
[29] Goulart, Bernardo. ”Lung Cancer CT Screening Is Cost-Effective But Implementation Matters”. Ev-
idence Based Medicine 20.2 (2015): 78-78. Web.
[30] Neumann, Peter J., Joshua T. Cohen, and Milton C. Weinstein. ”Updating Cost-Effectiveness — The
Curious Resilience Of The $50, 000-Per-QALY Threshold”. New England Journal of Medicine 371.9
(2014): 796-797. Web.
iii
[31] Cancer Research UK. (2015). Lung cancer incidence statistics. [online] Available
at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/
statistics-by-cancer-type/lung-cancer/incidence#heading-Nine [Accessed 5 Jul. 2016].
[32] ”Lung CT Screening Reporting And Data System”. American College of Radiology. N.p., 2017. Web.
15 Feb. 2017.
[33] Doria-Rose VP, Szabo E. Screening and prevention of lung cancer. In: Kernstine KH, Reckamp KL,
eds. Lung cancer: a multidisciplinary approach to diagnosis and management. New York: Demos
Medical Publishing, 2010:53-72.
[34] McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK Lung Screen (UKLS): Demographic Profile
of First 88,897 Approaches Provides Recommendations for Population Screening. Cancer Prevention
Research 2014;7(3):362-371.
[35] Field JK, Duffy SW. Lung cancer screening: the way forward. Br J Cancer 2008; 99: 557–62
[36] Field, J. Duffy, S. et al. (2015). UK Lung Cancer RCT Pilot Screening Trial: baseline findings from
the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax,
71(2), pp.161-170.
[37] Black, William. ”Cost-Effectiveness Of CT Screening In The National Lung Screening Trial”. New
England Journal of Medicine 372.4 (2015): 387-388. Web.
[38] Ebell, Mark. ”Poems: Lung Cancer Screening Is Cost-Effective, But Only If Done Correctly - American
Family Physician”. Aafp.org. N.p., 2017. Web. 15 Feb. 2017.
[39] Scotland, G S et al. ”Cost-Effectiveness Of Implementing Automated Grading Within The National
Screening Programme For Diabetic Retinopathy In Scotland”. British Journal of Ophthalmology 91.11
(2007): 1518-1523. Web.
[40] Ru Zhao Y, Xie X, de Koning HJ, Mali WP, Vliegenthart R, Oudkerk M. NELSON lung cancer
screening study. Cancer Imaging 2011;11 Spec No A:S79–84.
[41] Wisnivesky JP, Mushlin AI, Sicherman N, et al. The cost-effectiveness of low-dose CT screening for
lung cancer - Preliminary results of baseline screening. Chest 2003;124(2):614-621.
[42] Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design
and findings from baseline screening. Lancet 1999; 354:99-105
[43] Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project. Cancer 2001;
92:153-159
[44] Moons KGM, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal
validation, and assessing the incremental value of a new (bio)marker. Heart 2012;98(9):683-690
[45] Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how?
BMJ 2009;338:1317–20.
[46] Moons, Karel G.M. et al. ”Transparent Reporting Of A Multivariable Prediction Model For Individual
Prognosis Or Diagnosis (TRIPOD): Explanation And Elaboration”. Annals of Internal Medicine 162.1
(2015): W1. Web.
[47] Cancer Research UK. (2015). Screening for cancer. [online] Available at: http://www.
cancerresearchuk.org/about-cancer/screening [Accessed 23 Jun. 2016].
iv
[48] www2.le.ac.uk. (2016). Groundbreaking lung cancer breath test in clinical trial — University of Le-
icester. [online] Available at: http://www2.le.ac.uk/offices/press/press-releases/2015/february/ground-
breaking-lung-cancer-breath-test-in-clinical-trial [Accessed 23 Jun. 2016].
[49] Cancer.gov. (2016). Breast Cancer Risk Assessment Tool. [online] Available at: http://www.cancer.
gov/bcrisktool/ [Accessed 23 Jun. 2016].
[50] Vogel VG. Management of the high-risk patient. Surg Clin North Am. 2003;83:733–751.
[51] Steyerberg, E. (2009). Clinical prediction models. New York: Springer
[52] Bang, H. (2016). Building and Using Disease Prediction Models in the Real World. [online] Hpr.
weill.cornell.edu. Available at: http://hpr.weill.cornell.edu/divisions/biostatistics/
ppt/Roundtable_JSM_20071.ppt [Accessed 23 Jun. 2016].
[53] Steyerberg, E., Bleeker, S., Moll, H., Grobbee, D. and Moons, K. (2003). Internal and external
validation of predictive models: A simulation study of bias and precision in small samples. Journal of
Clinical Epidemiology, 56(5), pp.441-447.
[54] HARRELL, F., LEE, K. and MARK, D. (1996). MULTIVARIABLE PROGNOSTIC MODELS: IS-
SUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEA-
SURING AND REDUCING ERRORS. Statist. Med., 15(4), pp.361-387.
[55] Efron B, Gong G. A LEISURELY LOOK AT THE BOOTSTRAP, THE JACKKNIFE, AND CROSS-
VALIDATION. American Statistician. 1983;37(1):36-48.
[56] Paul, P., Pennell, M. and Lemeshow, S. (2012). Standardizing the power of the Hosmer-Lemeshow
goodness of fit test in large data sets. Statist. Med., 32(1), pp.67-80.
[57] Steyerberg, E., Vickers, A., Cook, N., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M. and Kattan,
M. (2010). Assessing the Performance of Prediction Models. Epidemiology, 21(1), pp.128-138.
[58] Toll, D., Janssen, K., Vergouwe, Y. and Moons, K.(2008).Validation, updating and impact of clinical
prediction rules: A review. Journal of Clinical Epidemiology, 61(11), pp.1085-1094.
[59] Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic research: validating a
prognostic model. British Medical Journal. 2009;338.
[60] Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic research: Developing a
prognostic model. British Medical Journal. 2009;338
[61] Moons, K., Kengne, A., Grobbee, D., Royston, P., Vergouwe, Y., Altman, D. and Woodward, M.
(2012). Risk prediction models: II. External validation, model updating, and impact assessment. Heart,
98(9), pp.691-698.
[62] Youden, W. (1950). Index for rating diagnostic tests. Cancer, 3(1), pp.32-35.
[63] Bohning, D., Bohning, W. and Holling, H. (2008). Revisiting youden’s index as a useful measure of the
misclassification error in meta-analysis of diagnostic studies. Statistical Methods in Medical Research,
17(6), pp.543-554
[64] Parikh, R., Mathai, A., Parikh, S., Chandra Sekhar, G. and Thomas, R. (2008). Understanding and
using sensitivity, specificity and predictive values. Indian J Ophthalmol, 56(1), p.45.
[65] McGee, S. (2002). Simplifying likelihood ratios. J Gen Intern Med, 17(8), pp.647-650.
v
[66] Alberg, A., Park, J., Hager, B., Brock, M. and Diener-West, M. (2004). The use of “overall accuracy”
to evaluate the validity of screening or diagnostic tests. J Gen Intern Med, 19(5), pp.460-465.
[67] Gray, Eoin P. et al. ”Risk Prediction Models For Lung Cancer: A Systematic Review”. Clinical Lung
Cancer 17.2 (2016): 95-106. Web.
[68] Medicine USNLo. Medical Subject Headings 1999. 1]. Available from:https://www.nlm.nih.gov/
mesh/.
[69] D’Amelio AM, Jr., Cassidy A, Asomaning K, Raji OY, Duffy SW, Field JK, et al. Comparison
of discriminatory power and accuracy of three lung cancer risk models. British Journal of Cancer.
2010;103(3):423-9.
[70] Frantzi K, Ananiadou S, Mima H. Automatic recognition of multi-word terms. International Journal
of Digitial Libraries. 2000;3(2):117 - 32.
[71] (NaCTeM) TNCfTM. TerMine 2013 [cited 2014 27/02/2014]. Available from: http://www.nactem.
ac.uk/ Available from: http://www.nactem.ac.uk/software/termine/.
[72] Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model:
an individual risk prediction model for lung cancer. British Journal of Cancer. 2008;98(2):270-6.
[73] Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, et al. Predictive Accu-
racy of the Liverpool Lung Project Risk Model for Stratifying Patients for Computed Tomography
Screening for Lung Cancer A Case-Control and Cohort Validation Study. Annals of Internal Medicine.
2012;157(4):242-+.
[74] Raji OY, Agbaje OF, Duffy SW, Cassidy A, Field JK. Incorporation of a Genetic Factor into an
Epidemiologic Model for Prediction of Individual Risk of Lung Cancer: The Liverpool Lung Project.
Cancer Prevention Research. 2010;3(5):664-9.
[75] Spitz MR, Hong WK, Amos CI, Wu XF, Schabath MB, Dong Q, et al. A risk model for prediction of
lung cancer. Journal of the National Cancer Institute. 2007;99(9):715-26.
[76] Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. An Expanded Risk Prediction Model for
Lung Cancer. Cancer Prevention Research. 2008;1(4):250-4.
[77] Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung
cancer risk among smokers. Journal of the National Cancer Institute. 2003;95(6):470-8.
[78] Cronin, K., Gail, M., Zou, Z., Bach, P., Virtamo, J. and Albanes, D. (2006). Validation of a Model of
Lung Cancer Risk Prediction Among Smokers. JNCI Journal of the National Cancer Institute, 98(9),
pp.637-640.
[79] Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Ostergaard JN, et al. A Risk Model for
Lung Cancer Incidence. Cancer Prevention Research. 2012;5(6):834-46.
[80] Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung Cancer
Risk Prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Models and Validation.
Jnci-Journal of the National Cancer Institute. 2011;103(13):1058-68.
[81] Selection Criteria for Lung-Cancer Screening. (2013). New England Journal of Medicine, 369(4),
pp.394-394.
[82] Tammemagi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of
the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the
PLCO and NLST Cohorts. PLoS medicine. 2014;11(12):e1001764-e.
vi
[83] Moyer VA, Force USPST. Screening for Lung Cancer: US Preventive Services Task Force Recommen-
dation Statement. Annals of Internal Medicine. 2014;160(5):330-+.
[84] Etzel CJ, Kachroo S, Liu M, D’Amelio A, Dong Q, Cote ML, et al. Development and Validation of a
Lung Cancer Risk Prediction Model for African-Americans. Cancer Prevention Research. 2008;1(4):255-
65.
[85] Wilson, D. and Weissfeld, J. (2015). A simple model for predicting lung cancer occurrence in a lung
cancer screening program: The Pittsburgh Predictor. Lung Cancer, 89(1), pp.31-37.
[86] Tammemagi MC, Lam SC, McWilliams AM, Sin DD. Incremental Value of Pulmonary Function
and Sputum DNA Image Cytometry in Lung Cancer Risk Prediction. Cancer Prevention Research.
2011;4(4):552-61
[87] Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models,
evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine.
1996;15(4):361-87.
[88] Nam B-H, Shin H-R, Lee JS, Yang H-R, Lee JA, Han JT, et al. Individualized Risk Prediction Model
for Lung Cancer in Korean Men. Figshare. 2013.
[89] Maisonneuve P, Bagnardi V, Bellomi M, Spaggiari L, Pelosi G, Rampinelli C, et al. Lung Cancer Risk
Prediction to Select Smokers for Screening CT-a Model Based on the Italian COSMOS Trial. Cancer
Prevention Research. 2011;4(11):1778-89.
[90] Veronesi, G., Maisonneuve, P., Rampinelli, C., Bertolotti, R., Petrella, F., Spaggiari, L. and Bellomi,
M. (2013). Computed tomography screening for lung cancer: Results of ten years of annual screening
and validation of cosmos prediction model. Lung Cancer, 82(3), pp.426-430.
[91] Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, et al. A gene-based risk score for lung
cancer susceptibility in smokers and ex-smokers. Postgraduate Medical Journal. 2009;85(1008):515-24.
[92] Li H, Yang L, Zhao X, Wang J, Qian J, Chen H, et al. Prediction of lung cancer risk in a Chinese
population using a multifactorial genetic model. Bmc Medical Genetics. 2012;13.
[93] Zeka A, Gore R, Kriebel D. The two-stage clonal expansion model in occupational cancer epidemiology:
results from three cohort studies. Occupational and Environmental Medicine. 2011;68(8):618-24
[94] Heidenreich WF, Wellmann J, Jacob P, Wichmann HE. Mechanistic modelling in large case-control
studies of lung cancer risk from smoking. Statistics in Medicine. 2002;21(20):3055-70.
[95] Meza R, Hazelton WD, Colditz GA, et al. Analysis of lung cancer incidence in the nurses’ health and
the health professionals’ follow-up studies using a multistage carcinogenesis model. Cancer Causes &
Control 2008;19(3):317-328.
[96] Foy M, Spitz MR, Kimmel M, et al. A smoking-based carcinogenesis model for lung cancer risk
prediction. International Journal of Cancer 2011;129(8):1907-1913.
[97] Foy M, Deng L, Spitz M, et al. Rice-MD Anderson Lung Cancer Model. Risk Analysis 2012;32:S142-
S150.
[98] Schultz FW, Boer R, de Koning HJ. Description of MISCAN-Lung, the Erasmus MC Lung Cancer
Microsimulation Model for Evaluating Cancer Control Interventions. Risk Analysis 2012;32:S85-S98.
[99] Deng L, Kimmel M, Foy M, et al. Estimation of the effects of smoking and DNA repair capacity on
coefficients of a carcinogenesis model for lung cancer. International Journal of Cancer 2009;124(9):2152-
2158.
vii
[100] Akushevich I, Veremeyeva G, Kravchenko J, et al. New stochastic carcinogenesis model with
covariates: An approach involving intracellular barrier mechanisms. Mathematical Biosciences
2012;236(1):16-30.
[101] Hazelton WD, Jeon J, Meza R, et al. The FHCRC Lung Cancer Model. Risk Analysis 2012;32:S99-
S116.
[102] Cancer Research UK (2015). Your cancer type — Cancer Research UK. [online] Cancerresearchuk.org.
Available at: http://www.cancerresearchuk.org/about-cancer/type/ [Accessed 6 Apr. 2015].
[103] Allison, P., 2001. Missing data — Quantitative applications in the social sciences. Thousand Oaks,
CA: Sage. Vol. 136.
[104] Little, R. J. A. (1993), “Pattern-Mixture Models for Multivariate Incomplete Data,” Journal of the
American Statistical Association, 88, 125–134.
[105] Molenberghs, G. and Kenward, M. G. (2007), Missing Data in Clinical Studies, New York: John
Wiley & Sons.
[106] Nakai M, Weiming Ke. Review of Methods for Handling Missing Data in Longitudinal Data Analysis.
Int. Journal of Math. Analysis. 2011;5(1):1-13.
[107] Farhangfar, A., Kurgan, L. and Dy, J. (2008). Impact of imputation of missing values on classification
error for discrete data. Pattern Recognition, 41(12), pp.3692-3705.
[108] Missing-data imputation, (2015). Missing-data imputation. [online] Available at: http://www.stat.
columbia.edu/~gelman/arm/missing.pdf [Accessed 7 Apr. 2015].
[109] Missing Data, (2015). Missing Data & How to Deal: An overview of missing data. [online] Available
at: https://www.utexas.edu/cola/prc/_files/cs/Missing-Data.pdf [Accessed 5 Jun. 2015].
[110] White, Ian R., Patrick Royston, and Angela M. Wood. ”Multiple Imputation Using Chained Equa-
tions: Issues And Guidance For Practice”. Statistics in Medicine 30.4 (2010): 377-399. Web.
[111] White, Ian R. and John B. Carlin. ”Bias And Efficiency Of Multiple Imputation Compared With
Complete-Case Analysis For Missing Covariate Values”. Statistics in Medicine 29.28 (2010): 2920-2931.
Web.
[112] Horton, Nicholas J and Ken P Kleinman. ”Much Ado About Nothing”. The American Statistician
61.1 (2007): 79-90. Web.
[113] White, I., Royston, P. and Wood, A. (2010). Multiple imputation using chained equations: Issues
and guidance for practice. Statist. Med., 30(4), pp.377-399.
[114] Lee, K. (2015). Regression Modelling with Missing Data: Principles, Methods, Software, and Exam-
ples. In: 36th Annual Conference of the International Society for Clinical Biostatistics. Utrecht: ISCB
2015.
[115] Allison, P., 2001. Missing data — Quantitative applications in the social sciences. Thousand Oaks,
CA: Sage. Vol. 136.
[116] Nakai M, Weiming Ke. Review of Methods for Handling Missing Data in Longitudinal Data Analysis.
Int. Journal of Math. Analysis. 2011;5(1):1-13.
[117] D’Amelio, A., Cassidy, A., Asomaning, K., Raji, O., Duffy, S., Field, J., Spitz, M., Christiani, D. and
Etzel, C. (2010). Comparison of discriminatory power and accuracy of three lung cancer risk models.
Br J Cancer, 103(3), pp.423-429.
viii
[118] Hanley, J. and McNeil, B. (1983). A method of comparing the areas under receiver operating char-
acteristic curves derived from the same cases. Radiology, 148(3), pp.839-843.
[119] Comparing Two Diagnostic Tests. (2016). Design and Analysis of Clinical Trials. [online] Available
at: https://onlinecourses.science.psu.edu/stat509/node/152 [Accessed 1 Aug. 2016].
[120] Song, J. and Chung, K. (2010). Observational Studies: Cohort and Case-Control Studies. Plastic and
Reconstructive Surgery, 126(6), pp.2234-2242.
[121] Evans, J. and Macdonald, T. (1997). Misclassification and selection bias in case-control studies using
an automated database. Pharmacoepidemiology and Drug Safety, 6(5), pp.313-318.
[122] Cms.gov, (2015). ICD-9 Code Lookup. [online] Available at: http://www.cms.gov/medicare-
coverage-database/staticpages/icd-9-code-lookup.aspx [Accessed 10 Apr. 2015].
[123] Cancer Research UK, (2015). A study to find out more about the causes of lung cancer (ReSoLu-
CENT). [online] Available at: http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-
study-to-find-out-more-about-the-causes-of-lung-cancer [Accessed 29 Sep. 2015].
[124] Resolucent.group.shef.ac.uk, (2015). ReSoLuCENT Resource for the Study of Lung Cancer Epidemi-
ology in North Trent. [online] Available at: http://resolucent.group.shef.ac.uk/ [Accessed 29 Sep. 2015].
[125] Hashibe, M., Morgenstern, H., Cui, Y., Tashkin, D., Zhang, Z., Cozen, W., Mack, T. and Greenland,
S. (2006). Marijuana Use and the Risk of Lung and Upper Aerodigestive Tract Cancers: Results
of a Population-Based Case-Control Study. Cancer Epidemiology Biomarkers & Prevention, 15(10),
pp.1829-1834.
[126] The β-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk
populations: Smokers and asbestos-exposed workers. (1994). Lung Cancer, 11(5-6), p.423.
[127] Muscat, J., Stellman, S. and Wynder, E. (1995). Insulation, asbestos, smoking habits, and lung
cancer cell types. Am. J. Ind. Med., 27(2), pp.257-269.
[128] Epi.grants.cancer.gov, (2015). Singapore Chinese Health Study. [online] Available at:
http://epi.grants.cancer.gov/Consortia/members/singapore.html [Accessed 29 Sep. 2015].
[129] Niehs.nih.gov, (2015). Singapore Chinese Health. [online] Available at:
http://www.niehs.nih.gov/research/atniehs/labs/epi/studies/singapore/ [Accessed 29 Sep. 2015].
[130] Aldington, S., Harwood, M., Cox, B., Weatherall, M., Beckert, L., Hansell, A., Pritchard, A., Robin-
son, G. and Beasley, R. (2008). Cannabis use and risk of lung cancer: a case-control study. European
Respiratory Journal, 31(2), pp.280-286.
[131] Donatella, U., Monica, N., Aldo, C., Cristina, C., Giuseppe, C., Paolo, I., Cecilia, L., Paola, M.,
Michela, P., Barbara, P., Paola, V., Riccardo, P. and Stefano, B. (2008). The CREST Biorepository: A
Tool for Molecular Epidemiology and Translational Studies on Malignant Mesothelioma, Lung Cancer,
and Other Respiratory Tract Diseases. Cancer Epidemiology Biomarkers & Prevention, 17(11), pp.3013-
3019.
[132] Rennert, G., Kremer, R., Rennert, H., Wollner, M., Agbarya, A., Pinchev, M., Lejbkowicz, F.,
Spitz, M. and Muscat, J. (2015). Lower lung cancer rates in Jewish smokers in Israel and the USA.
International Journal of Cancer, 137(9), pp.2155-2162.
[133] Wang, H., Rothenbacher, D., Lo¨w, M., Stegmaier, C., Brenner, H. and Diepgen, T. (2006). Atopic
diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum. International
Journal of Cancer, 119(3), pp.695-701.
ix
[134] Lunenfeld.ca, (2015). Dr. Rayjean Hung — The Lunenfeld-Tanenbaum Research Institute. [online]
Available at: http://www.lunenfeld.ca/researchers/hung [Accessed 29 Sep. 2015].
[135] Zhang, L., Morgenstern, H., Greenland, S., Chang, S., Lazarus, P., Teare, M., Woll, P., Orlow, I., Cox,
B., Brhane, Y., Liu, G. and Hung, R. (2014). Cannabis smoking and lung cancer risk: Pooled analysis
in the International Lung Cancer Consortium. International Journal of Cancer, 136(4), pp.894-903.
[136] Centerwatch.com. (2016). A clinical research study of Selumetinib, Pemetrexed and Cisplatin
for the treatment of Non-Small Cell Lung Cancer, Non-Squamous — Clinical Research Trial
Listing in Toronto, Canada (Non-Small Cell Lung Cancer) (NCT02337530). [online] Available
at: https://www.centerwatch.com/clinical-trials/listings/external-studydetails.aspx?
StudyID=NCT02337530&City=Toronto&Country=Canada [Accessed 3 Aug. 2016].
[137] Kettering Cancer Center, M. (2016). Lung Cancer: Lung Cancer Screening Decision Tool —
Memorial Sloan Kettering Cancer Center. [online] Mskcc.org. Available at: https://www.mskcc.org/
cancer-care/types/lung/screening/lung-screening-decision-tool [Accessed 5 Oct. 2016].
[138] Janssen, K., Moons, K., Kalkman, C., Grobbee, D. and Vergouwe, Y. (2008). Updating methods im-
proved the performance of a clinical prediction model in new patients. Journal of Clinical Epidemiology,
61(1), pp.76-86.
[139] Steyerberg, E., Borsboom, G., van Houwelingen, H., Eijkemans, M. and Habbema, J. (2004). Val-
idation and updating of predictive logistic regression models: a study on sample size and shrinkage.
Statist. Med., 23(16), pp.2567-2586.
[140] Rauh, S., Heymans, M., Mehr, D., Kruse, R., Lane, P., Kowall, N., Volicer, L. and van der Steen,
J. (2016). Predicting mortality in patients treated differently: updating and external validation of a
prediction model for nursing home residents with dementia and lower respiratory infections. BMJ Open,
6(8), p.e011380.
[141] Su, T., Jaki, T., Hickey, G., Buchan, I. and Sperrin, M. (2016). A review of statistical updating
methods for clinical prediction models. Statistical Methods in Medical Research.
[142] Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic research: validating a
prognostic model. British Medical Journal. 2009;338.
[143] Debray, T., Vergouwe, Y., Koffijberg, H., Nieboer, D., Steyerberg, E. and Moons, K. (2015). A new
framework to enhance the interpretation of external validation studies of clinical prediction models.
Journal of Clinical Epidemiology, 68(3), pp.279-289.
[144] Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models,
evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine.
1996;15(4):361-87.
[145] Nieboer, D., Vergouwe, Y., Ankerst, D., Roobol, M. and Steyerberg, E. (2016). Improving prediction
models with new markers: a comparison of updating strategies. BMC Medical Research Methodology,
16(1).
[146] Greenland S. METHODS FOR EPIDEMIOLOGIC ANALYSES OF MULTIPLE EXPOSURES
- A REVIEW AND COMPARATIVE-STUDY OF MAXIMUM-LIKELIHOOD, PRELIMINARY-
TESTING, AND EMPIRICAL-BAYES REGRESSION. Statistics in Medicine. 1993;12(8):717-36.
[147] Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging
the performance of a diagnostic, prognostic, or screening marker. American Journal of Epidemiology.
2004;159(9):882-90.
x
[148] Debray, T., Koffijberg, H., Nieboer, D., Vergouwe, Y., Steyerberg, E. and Moons, K. (2014). Meta-
analysis and aggregation of multiple published prediction models. Statist. Med., 33(14), pp.2341-2362.
[149] Schorning, K., Bornkamp, B., Bretz, F. and Dette, H. (2016). Model selection versus model averaging
in dose finding studies. Statist. Med., 35(22), pp.4021-4040.
[150] Debray, T. (2016). Meta-analysis of clinical prediction models.
[151] A Hoeting, J., Madigan, D. and E Raftery, A. (2016). Bayesian Model Averaging. [online] Techni-
cal Report 335. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.451.
4125&rep=rep1&type=pdf [Accessed 12 Jan. 2016].
[152] Breiman L. Stacked regressions. Machine Learning. 1996;24(1):49-64.
[153] Bello, G., Gennings, C. and Dumancas, G. (2015). Development and Validation of a Clinical Risk-
Assessment Tool Predictive of All-Cause Mortality. BBI, p.1
[154] Wasserman, L. (2000). Bayesian Model Selection and Model Averaging. Journal of Mathematical
Psychology, 44(1), pp.92-107.
[155] Raftery, A., Madigan, D. and Hoeting, J. (1997). Bayesian Model Averaging for Linear Regression
Models. Journal of the American Statistical Association, 92(437), p.179.
[156] Jackson, C., Thompson, S. and Sharples, L. (2009). Accounting for uncertainty in health economic
decision models by using model averaging. Journal of the Royal Statistical Society: Series A (Statistics
in Society), 172(2), pp.383-404.
[157] Clyde, M. (2016). Model Averging. [online] Available at: https://www2.stat.duke.edu/courses/
Spring05/sta244/Handouts/press.pdf [Accessed 4 Oct. 2016].
[158] Debray, T., Koffijberg, H., Vergouwe, Y., Moons, K. and Steyerberg, E. (2012). Aggregating published
prediction models with individual participant data: a comparison of different approaches. Statist. Med.,
31(23), pp.2697-2712.
[159] Riley, R., Price, M., Jackson, D., Wardle, M., Gueyffier, F., Wang, J., Staessen, J. and White, I.
(2014). Multivariate meta-analysis using individual participant data. Research Synthesis Methods, 6(2),
pp.157-174.
xi
Part IV
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Appendix
12.7 Ethical Permission for Datasets
Ethical permission was applied for to the University of Sheffield in the first year of the project to work
with anonymised data. This was requested in preparation for the datasets that would be collected from
the International Lung Cancer Consortium. This was granted for the duration of my project.
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12.8 Systematic Review Search Terms
The search criteria include a range of searches using the terms in the table.
Lung terminology Prediction model terms Model titles
Lc Model Bach
Cancer of the Lung Risk Model Liverpool Lung Project
Lung Cancer Risk LLP
Neoplasms, Lung Cancer risk Spitz
Neoplasms, Pulmonary Incidence rate Two-Stage Clonal Expansion
Pulmonary Cancer Risk prediction TSCE
Pulmonary Neoplasms Risk-prediction model
Lung tumours Absolute risk
Carcinoma, Non Small Cell Risk estimate
Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Carcinoma Oat Cell
Oat Cell Carcinoma
Small Cell Carcinoma
Table 12.1: Search Terms for Systematic Review
Using the above terms the following combinations will be utilised using a whole text search in the on-
line databases with an OR separating all terms under the same heading and an AND between different
headings.
1. Lung terminology and Prediction model terms
2. Model titles and Lung terminology
3. Model titles and Prediction model terms
4. Lung terminology and Prediction model terms and Model titles
12.9 Detailed Dataset Preparation
An overview of the changes made to each dataset was presented in Chapter 4. A more detailed analysis
for each variable is required. Modifications were required to ensure every participant had accurate and
reliable information before they were used to validate the lung cancer prediction models.
The dataset preparation focused on for each variable;
1. Removing participants with missing information unless there was the option to impute this informa-
tion.
2. Assessing the inputted values for erroneous information; these participants would be removed or the
information changed to missing in preparation for imputation.
3. Modifying how the variable is categorised/presented so that the information is applicable for the
prediction models.
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The first stage is to present which variables were assessed per dataset. Not all datasets provided
information for every variable. The only variables modified were variables required by a model that was
applicable to the dataset. These are presented in Table 12.2 where each variable and the models that
required this variable are presented per dataset;
XXXXXXXXXXXVariable
Dataset
ReS UCLA CARET NY Sing NZ CREST Israel ESTHER MSH-PMH
Case/Control Histology
Case/Control Status (All) X X X X X X X X X X
Eligibility (All) X X X X X X X X X X
Personal Factors
Age (All) X X X X X X X X X X
Gender (B,LLP,S,AA) X X X X X X X
Ethnicity (PLCO) X X X X X
BMI (PLCO) X X X X X
Education (PLCO) X X X X X
Prior Tumour (LLP,PLCO) X X X X X X
Smoking History
Basic Smoking Info (All) X X X X X X X X X X
CPD & Pack Years (All) X X X X X X X X X X
ETS (S) X
Family History of Cancer
Cases of Smoking Cancer (S) X
Cases of Lung Cancer (LLP,PLCO,S) X X X X X X
Age of Lung Cancer (LLP) X X X X
Exposures and Conditions
Asbestos Exposure (B,LLP,S) X X X X X X
Dust (S,AA) X
Hay fever (S,AA) X
Emphysema (S) X
COPD (PLCO,AA) X X X X X X
Pneumonia (LLP,AA) X X X X
Model Key: B = Bach; AA= African-American; S = Spitz
X = The variable is available in the dataset and will be prepared
Table 12.2: Table Showing Important Variables per Dataset
For each variable per dataset any modifications are reported. Discrepancies or data preparation required
will be listed under each variable and subdivided under each dataset.
12.9.1 Case Control Histology
The datasets require complete information on case control status which will be used in the model validation
and updating. This information is essential and any participants with missing information will be removed.
12.9.1.1 All Studies
There are no concerns; every participant is classified so no alterations were required.
12.9.2 Eligibility
Records identified if the patients were eligible when the study was collected. Ineligibility could be a product
of misdiagnosis or incorrectly selecting a participant for inclusion in the study. Ineligible participant should
be removed as these could negatively affect the models in the external validation.
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12.9.2.1 ReSoLuCENT Study
The ReSoLuCENT study had 29 participants that were ineligible with no further explanation provided.
These were removed from the study alongside one additional participant who had not been classified as
either eligible or ineligible.
12.9.2.2 Remaining Studies
This information was not reported in these studies so every participant was assumed eligible and remained
in the study.
12.9.3 Age
Age is an essential variable required by every model. Testing of this variable needs to ensure there are no
missing entries or any unreasonable responses that may be inputted through error.
12.9.3.1 Israel, MSH-PMH, and Singapore Studies
There are 1, 6, and 7 participants with missing information in the Israel, MSH-PMH, and Singapore studies
respectively. This information cannot confidently be imputed so these individuals were removed. All other
participants in these studies had reasonable age entries so no further modifications were required.
12.9.3.2 Remaining Studies
All the remaining studies had complete age information and the entries were reasonable so no formatting
was conducted.
12.9.4 Gender
Gender is reported in all the studies. This information would be difficult to impute if missing so participants
who did not provide this information with be removed from the study.
12.9.4.1 ReSoLuCENT
In the ReSoLuCENT dataset 3 participants had missing information and were removed. No further mod-
ifications were required.
12.9.4.2 Remaining Studies
The other ILCCO datasets provided complete information for this variable so no formatting was required.
12.9.5 Ethnicity
Ethnicity is required by the PLCO models and the reported ethnicities in the datasets need to be reclassified
into one of the six specified ethnicities that are required by the PLCO models;
1. White
2. Black
3. Hispanic
4. Asian
5. American India or Alaskan
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6. Hawaiian or Pacific Islander
Participants will be able to be reclassified into these categories and any participants who cannot through
missing information will be removed from the studies.
12.9.5.1 ReSoLuCENT Study
In the ReSoLuCENT study there were 182 patients with missing information which were removed from the
study. There were an additional three participants who were classified as “Other” who were also removed.
The remaining participants could be correctly classified so were eligible for inclusion.
12.9.5.2 Remaining Studies
When collecting the other ILCCO studies they were all categorised before collection. These were recate-
gorised to conform to the PLCO categories as follows;
PLCO Model Classification ILCCO Classification
White White/Caucasian
Black Black/African-American
Hispanic
Hispanic Black
Mexican
Other Latino
Asian Asian
American India or Alaskan Native Native American
Native Hawaiian or Pacific Islander Hawaiian
Table 12.3: Classifying Ethnicity for the ILCCO Prepared Datasets
All participants could be successfully reclassified. However there there were 46, 2, 28, and 253 partici-
pants from the UCLA, NY Wynder, New Zealand, and MSH-PMH studies respectively that had missing
information and were removed.
12.9.6 Body Mass Index
BMI is required by the PLCO Models. This may be provided in the study or can be calculated provided
information for height in metres (m) and weight in kilograms (kg) can be obtained. Then BMI is calculated
as follows;
BMI =
kg
m2
(12.1)
12.9.6.1 ReSoLuCENT
In the ReSoLuCENT dataset information for each participant’s weight (kg) and height (m) was provided.
There were 193 participants with missing information for weight and 188 participants for height. This
included 181 participants with missing information for both entries.
An assessment was made to assess if other information could be used to impute this information to
avoid removing the participants. However, there were no variables collected in the study, such as diet and
exercise; that may have been used to impute the missing information. As a result all participants with
missing information for either of the variables were removed from the study.
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Additionally there was 1 unreasonable measurement for weight (867.12kg) and 4 unexpected height
entries (4.32m, 0m, 0.84m, and 3.51m). The correct values could not be obtained so these participants
were also removed from the study.
12.9.6.2 NY Wynder Study
BMI was reported in the NY Wynder Study but there were 534 participants with missing information who
were removed. There were three unreasonable entries for BMI (92, 108, and 192) which were deemed too
high and so these participants were also removed from the study.
12.9.6.3 Remaining Studies
BMI was provided as a single measure rather than information for weight and height in the remaining
ILCCO studies when reported. In the UCLA, CARET, and Canadian Studies there were 4, 15, and 273
missing entries which were removed from the study. An analysis of the entries showed data ranging between
10.5–64 which are reasonable values so no further data modifications were required.
12.9.7 Education
Education is required for the PLCO models. Participants are asked their highest completed education level
based on six categories;
1. Less than high-school graduate (level 1)
2. High-school graduate (level 2)
3. Some training after high school (level 3)
4. Some college (level 4)
5. College graduate (level 5)
6. Postgraduate or professional degree (level 6).
The participants in the IPDs are required to be correctly classified into these categories as the information
was collected with the study objectives in mind rather than the PLCO models.
12.9.7.1 ReSoLuCENT Study
The ReSoLuCENT dataset allowed entrants to provide any information rather than selecting a predeter-
mined category. There were 382 different entries that had to be reclassified; the exhaustive list of the
reclassifying the entries is presented in Section ?? Table ??.
There were 188 participants with missing information and a further one participant who listed “No
information available”. These were removed from the study as this information could not be inferred from
the information for other variables.
12.9.7.2 Remaining Studies
Education was collected in the UCLA, CARET, NY Wynder, and MSH-PMH datasets. The entries for
the education in these datasets had been collected using the same categories. The participants required a
slight reclassification so the information was formatted into the PLCO categories as follows;
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PLCO Education Category Classified ILCCo Grade
Less than high-school graduate No education received
High-school graduate Basic/elementary
Some training after high school Apprentice/vocational
Some college Secondary schools ending by graduation/High school with degree
College graduate Post-secondary, but not university degree
Postgraduate or professional degree University and techn. univ. educ. by receiving title
Table 12.4: Reclassifying Education for the ILCCo Datasets
In the UCLA, CARET, NY Wynder, and MSH-PMH studies there were 1, 261, 14, and 168 missing
entries respectively. These were removed as the information could not be imputed.
12.9.8 Prior Malignant Tumour
A prior malignant tumour also defined as a “personal history of cancer” and was required as a dichotomous
response for the models.
12.9.8.1 ReSoLuCENT and MSH-PMH Study
Participants only provide information when a prior tumour was present in these datasets. Participants
were classified as “yes” when they reported a prior tumour and “no” for all blank entries. No participants
were removed.
12.9.8.2 UCLA, CARET, and NY Wynder Studies
The information was already formatted as a dichotomous response. There was 1 participant removed in
the CARET study with missing information but no further modifications were required.
12.9.9 Basic Smoking Information
Some form of basic smoking information (smoking status, start age, cessation age, duration, quit duration)
is required in every prediction model. It is important that the information is both complete and correct.
There were some concerns with the smoking start age as there are some very young entries. It was
determined any start ages below 6 were probably inaccurate but some participants may have began smoking
at a very young age younger than 10. The participants will be kept in the studies but the young values
will be highlighted.
12.9.9.1 ReSoLuCENT Study
There were 183 individuals who did not provide information for any of the basic smoking variables. These
could be never smokers who left the smoking section blank, however it would be careless to assume this
and assign all participants as never-smokers. Unfortunately the participants had to be removed from the
study as correct information could not be obtained.
Additionally there were 4 former smokers who had a missing start or cessation age and 6 current
smokers without a start age. This information could not be accurately determined and these participants
were also removed from the study.
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12.9.9.2 UCLA Study
In the UCLA study there were 23 ever-smokers with a missing start age who were removed. There were
no further concerns with the start age values. There were 12 former-smokers who did not list their quit
duration, although these were part of the 23 without a start age who had already been removed. The
23 participant with missing information were removed and no further modifications were required in the
UCLA study.
12.9.9.3 CARET Study
The heavy smoker CARET study had complete basic smoking information and the values provided were
reasonable so no preparation was required.
12.9.9.4 NY Wynder Study
Analysis in the NY Wynder study identified 1 participant who was classified as an ever smoker despite
quitting 27 years ago; this participant was reclassified as a former smoker.
There were 255 ever-smokers removed as they had not provided a start age. Further start age analysis
identified some entries between 8-10 years who remained in the study. There were no further concerns and
no additional formatting was conducted.
12.9.9.5 Singapore Study
In the Singapore dataset there was 1 participant removed as no smoking status was provided and another
participant removed who was missing information for all basic smoking variables.
There were another 6 ever-smokers removed as they did not provide information for start age or smoking
duration so neither variable could be inferred from complete information for the other variable and cessation
age. The remaining participants had complete information.
On assessment of the complete information in the dataset there are no errors and all the listed start ages
are reasonable (6-75) as is the cessation age (20-86). There is confidence that all the smoking information
is correct and no additional participants are removed from the study.
12.9.9.6 New Zealand Study
In the New Zealand dataset there were 7 ever-smokers without a start age who also did not provide their
duration or cessation age and were removed. The values reported for start age and cessation age are
reasonable and no cessation age is listed that is younger than their start age. No further modifications to
the dataset were required besides the removal of the 7 ever-smokers without information for start age.
12.9.9.7 CREST Study
The CREST dataset quit duration was not recorded however this can be calculated using the participant’s
age and cessation age provided this information is correct.
There were 2 participants classified only as ‘ever-smokers’ rather than former- or current-smokers.
Analysis of the other variables found they had missing information for all the variables so were removed
from the study. There were an additional 6 smokers with a missing start age who were removed. All former
smokers listed a reasonable cessation age and no start age was older than their cessation age. Analysing
the complete information, there are 3 start ages listed as ‘-9’ so these participants were removed. An
additional participant had a start age of 4 which was considered too young so they were removed. The
remaining start ages (6-60) and cessation ages (15-89) were all deemed reasonable.
In total 12 participants were removed from the study and the quit duration was calculated using
complete information for age and cessation age.
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12.9.9.8 Israel Study
In the Israel study there were 8 participants removed from the study due to no information for smoking
status. There was complete information and acceptable information for start ages (6-48) and cessation
ages, except for one former-smoker who listed a cessation age of “5” which was younger than their start
age. Correct information cannot be obtained so this individual was removed but there were no other
concerns. The remaining cessation ages (20-78) were reliable and required no further formatting.
There were a few small discrepancies in the duration recorded for ever-smokers, in this instance the
difference between the start and cessation ages were taken as this information was deemed reliable. There
were no concerns with the quit durations that are recorded. In total 9 participants were removed and
smoking duration was recalculated using the start and cessation age.
12.9.9.9 ESTHER Study
In the ESTHER study 6 participants had not listed a smoking status and a further 7 ever-smokers did
not provide a start age and were removed from the study. The complete start age information (9-40) are
acceptable values. There were no missing information for cessation ages and all ages listed were greater
than the start age. There were no discrepancies for the smoking duration.
In total 13 participants were removed but no additional formatting was required.
12.9.9.10 MSH-PMH Study
In the MSH-PMH Study 189 participants did not record their smoking status and were subsequently
removed. Another 56 participants listed their smoking status as “ever-smokers” which needed to be re-
classified as a current- or former-smoker. On analysis of the 56 participants; 54 were removed as they had
no other basic smoking information. The 2 other participants were reclassified as former smokers as the
remaining information indicates accordingly with a cessation age and quit duration provided. A further
130 ever-smokers in this large dataset were removed as they were also missing additional key smoking
information.
An ever-smoker listed an unreasonable start age of 1 but the remaining entries are reasonable (6-60)
as are the cessation ages (12-87). For the remaining participants there were no other discrepancies and
modifications required.
12.9.10 Cigarettes Per Day/Pack Years
Pack years and CPD were also required by the prediction. This information was reported in each study
but there were differences in reporting between studies. If information was only provided for one of these
variables then the other variable can be calculated as follows;
PackY ears =
CPD
20
× SmokeDuration (12.2)
There can be a range of values submitted for CPD but any value below 100 would be considered
reasonable.
12.9.10.1 ReSoLuCENT Study
The ReSoLuCENT data does not explicitly record the pack years or CPD quantities. Instead the study
reported the average CPD smoked at 20, 30, 40, 50, and last year; these were reported when applicable to
the participant. To calculate the pack year and CPD information the following assumptions are made;
1. The participants smoke at a constant rate from their start age until their first relevant entry.
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(a) Example: A participant who started smoking at 22 will only enter their first CPD at 30. From
22-30 they are considered to have smoked at the same consistency as at 30.
2. Between two consecutive gaps (20-30, 40-50, 30 - Last Year for a 38 year old) there is a yearly linear
increase or decrease between these values.
(a) Example: A participant who smoked 40 CPD at 30 and 20 CPD at 40: gives the following;
Age 30 31 32 33 34 35 36 37 38 39 40
CPD 40 38 36 34 32 30 28 26 24 22 20
Table 12.5: Example CPD based on information provided by the ReSoLuCENT data
For all never-smokers a true zero value could be entered. Across the ever-smokers there were 20 participants
who did not provide any smoking quantities and were removed. Next we evaluated the CPD values, here
there were 5 unreasonable entries over 100 CPD (1015, 140, 140, 9999, 810). These entries were reclassified
as omitted data at this stage.
The remaining ever-smokers either have complete information or semi-complete information across the
variables. This data may be successfully imputed as all participants now have some level of information
for these variables which may be used to infer the missing values rather than removing the participants.
Attempts were made to impute this missing information. If the values can be successfully imputed then
no further modifications are required in the dataset; otherwise these participants with partial missing
information will be removed.
12.9.10.2 UCLA Study
The UCLA dataset provided the pack years and CPD information; in all instances these two values were
consistent. 23 ever-smokers had missing information for both variables and were removed.
The complete CPD information was reasonable (0 - 80) which falls below the agreed 100 CPD ceiling
for a chain smoker.
12.9.10.3 CARET Study
The CARET provided pack year and CPD information which for every participant matched using Equation
12.9.10. The CPD ranged was from 1 to 80 and with no missing information no formatting was required
for the CARET dataset.
12.9.10.4 NY Wynder Study
Information for both CPD and pack years were provided in the NY Wynder study with no discrepancies
between these values. In 6 instances, pack years were not provided but can be calculated using the CPD
values and Equation 12.9.10. Analysing the CPD values all were below 100 CPD and with no missing
information there was no further formatting required.
12.9.10.5 Singapore Study
The CPD and pack years were provided in the Singapore study and 3 ever-smokers were removed due to
missing information for both variables. The remaining participants have complete information for pack
years and CPD with no discrepancies between the values. The completed CPD values ranged from 1 to 80
which were reasonable responses so no further removals were required.
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12.9.10.6 New Zealand Study
The New Zealand dataset records pack years and CPD although CPD was missing for several participants.
Despite this only 2 ever-smokers had to be removed missing information for both variables. An additional
19 ever-smokers report pack years as 0 therefore they cannot be classified as ever-smokers despite complete
information for start age and cessation age. As a result these were removed from the study. CPD was
calculated when missing using Equation 1.3.10 and an analysis of the complete CPD information was
conducted; the results were reasonable (1-75) so no participants were excluded. In total 21 ever-smokers
were removed.
12.9.10.7 CREST Study
The CREST dataset had complete CPD and pack years information. For 1 participants the CPD and
pack year results were ‘-9’ so they were removed from the study. A further 3 reported ‘-9’ for pack years
but these participants have correct CPD values reported so their pack year information can be correctly
calculated.
The CPD values ranged from 1-110 for ever-smokers; this included 1 participant who reported a CPD
exceeding 100 CPD. This participant was removed from the study as the value was deemed unrealistic. The
remaining results had no discrepancies between the pack years and the CPD values. In total 2 participants
were removed and 3 pack year results were recalculated but no further formatting was required.
12.9.10.8 Israel Study
In the Israel study there were some minor discrepancies between the CPD and pack years. In these cases
the pack years will be recalculated using the CPD values. 5 ever-smokers were removed because of missing
information for both variables but no additional modifications were required with the remaining CPD
values between 1− 100.
12.9.10.9 ESTHER Study
In the ESTHER study both CPD and pack years are reported with no discrepancies between the values.
There were 15 ever-smokers with missing CPD and pack years values or with reported values of 0 so were
excluded. The remaining CPD values (1-57) were reasonable.
12.9.10.10 MSH-PMH Trial
In the MSH-PMH study there are no discrepancies between the CPD and pack year values. 10 ever-smokers
were removed as they stated they smoked 0 CPD but the remaining entries (1 - 75) are reasonable so no
additional formatting is required.
12.9.11 Environmental Tobacco Smoke
Environmental tobacco smoke (ETS) is required as a dichotomous variable. The Spitz model article states
ETS as having been exposed to someone else’s cigarette smoke as home or at work on a regular basis
i.e. daily or weekly, as well as on years of exposure to ETS [75]. In the datasets, exposure durations and
intensity rates are not expected to be provided so the original values will be accepted.
12.9.11.1 CREST Study
ETS is reported in the CREST dataset as exposure at home or work. If a positive exposure is reported
for either location then this will be re-stated as a positive ETS exposure. There were 16 participants with
missing information for both variables that were removed from the study but the remaining participants
were successfully reclassified as having a positive or negative exposure.
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12.9.12 Family History of Cancer
When considering a family history of cancer in the LLP, Spitz, and PLCO models require a count of the
volume of cancers occurring in first degree relatives in specific subgroups of cancers. Information needs to
be reclassified into the following groups;
1. Any cancer
2. Any cancer except melanoma
3. Smoking related cancers
4. Lung cancer
All the groups are a nested subgroup of the groups above and the information will be obtained using the
Cancer Research UK website and their causes of each type of cancer [?]. Cancers were only defined as
melanomas if it is explicitly reported so skin cancer was not defined as a melanoma.
It is important the information is only reported for first degree relatives which are parents, siblings, and
children. Additionally, the age of onset is required; this is reported for each subgroup and for participants
with multiple family members with cancer in the same subgroup the youngest age of onset is reported.
12.9.12.1 ReSoLuCENT
In the ReSoLuCENT dataset all entries were first degree relatives to the participant. Cancers were reported
in the study as an open entry which required reformatting into the four categories. The comprehensive list
of results are listed in Section 12.11 in Table 12.7.
Analysing the age of onset 3 participants listed “999” who will be excluded. An additional 166 patients
listed “0” or left the entry blank which could not be resolved and they were also removed.
12.9.12.2 Remaining Studies
The UCLA, CARET, NY Wynder, New Zealand, CREST, and MSH-PMH Study all include a family
history of cancer. In all instances the cancer is only provided for first degree relatives. The type of cancer
is reported differently between studies from blank entries for the participant to report any value to a series
of ICD9 codes. The method of reclassifying the cancers is presented separately in the Appendix (Section
12.11) and the ICD9 codes were determined using an on-line database [122]. There were no concerns with
the age of onset of the cancer in any instance so the only formatting required was to reclassify the cancers.
12.9.13 Asbestos Exposure
Asbestos exposure is defined as a prolonged period of time working in a profession that has a high risk of
asbestos contact. In the studies the only information provided was a dichotomous response so these will
be accepted as the exact exposure duration or intensity cannot be determined.
12.9.13.1 ReSoLuCENT Study
There were 46 counts of missing information in the ReSoLuCENT data. These participants will not be
removed at this stage, as testing will be conducted to see if the missing information can be imputed. An
assessment will be made whether to impute this information in Chapter 4 Section 4.10. If the information
cannot be imputed then these participants with missing information will be removed.
12.9.13.2 CARET Study
Each participant of the CARET cohort is defined as either “Heavy smoker” or “Asbestos-exposed worker”.
There were no missing values in this information and a positive asbestos exposure was assigned to all
participants classified as “Asbestos-exposed worker”.
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12.9.13.3 NY Wynder Study
Asbestosis was only reported in the NY Wynder study when it is present in a participant. When this was
left blank they were confidently reclassified as not exposed. No participants were removed from the study.
12.9.13.4 New Zealand Study
In the New Zealand study asbestos exposure has complete information except for 2 participants who were
removed from the study.
12.9.13.5 CREST Study
In the CREST study asbestos exposure was reported for their present job and two most recent previous
jobs. If they were exposed in at least one of these job environments they were assigned a positive asbestos
exposure. No participants were removed from the study.
12.9.13.6 MSH-PMH Study
There were 380 participants with missing information for asbestos exposure. Before removing the partici-
pants with missing values, assessments were made to impute the values. This is reported in Chapter 4 and
if the missing values cannot be successfully imputed then the 380 participants will be removed from the
study.
12.9.14 Dust Exposure
Dust exposure is a dichotomous response for work exposures to dust.
12.9.14.1 ReSoLuCENT Study
Dust exposure was reported in the ReSoLuCENT. There were 240 participants with missing information
or stated as unknown in the dataset. This information will be evaluated to assess if it can be imputed.
This was presented in Section 4. If the information was not successfully imputed then these participants
were removed from the study
12.9.14.2 CREST Study
Dust exposure in the CREST dataset already has complete information so no formatting was required.
12.9.15 Hay Fever
Hay fever is required as a dichotomous response.
12.9.15.1 CREST Study
In the CREST dataset all previous lung diseases are reported in one entry using an ICD9 code. The ICD
code’s “477.0 - Allergic Rhinitis Due To Pollen” and “477.9 - Allergic Rhinitis Cause Unspecified” [122]
will be classified as hay fever. If this is not reported then it is assumed they do not have hay fever so no
participants were removed from the study.
12.9.16 Emphysema
Emphysema is required a dichotomous response.
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12.9.16.1 CREST Study
In the CREST dataset this is reported under previous lung conditions using ICD9 codes. The following
ICD9 codes’ “492.0 - Emphysematous Bleb” and “492.8 - Other Emphysema” will be classified as a positive
emphysema diagnosis. The remaining participants will be classified as a negative exposure.
12.9.16.2 MSH-PMH
There were 240 participants that had missing information for emphysema. Attempts will be made to
impute this information rather than remove participants at this stage. This is explored in Chapter 4.
12.9.17 Chronic Obstructive Pulmonary Disease
COPD is required a dichotomous response by the models.
12.9.17.1 ReSoLuCENT Study
In the ReSoLuCENT data COPD has 1 participant with missing information. Attempts are made to
impute the missing information rather than removing this participant which is reported in Chapter 4. If
this information cannot be successfully imputed then they will be removed from the study.
12.9.17.2 UCLA Study
COPD is fully reported in the UCLA dataset with no missing values so no alterations were made.
12.9.17.3 CARET
COPD is fully reported in the CARET dataset so no formatting was required.
12.9.17.4 NY Wynder Study
In the NY Wynder study COPD is reported when the condition was present. When this was not reported
the data was altered with confidence to not present.
12.9.17.5 CREST Study
COPD is reported in the CREST study as lung conditions using ICD9 codes. The following ICD9 codes
“491.20 - Obstructive Chronic Bronchitis Without Exacerbation”, “491.21 - Obstructive Chronic Bronchitis
With (Acute) Exacerbation” and “491.22 - Obstructive Chronic Bronchitis With Acute Bronchitis” are de
ned as a positive COPD diagnosis. If these ICD9 Codes were not reported then participants were defined
as no COPD.
12.9.17.6 MSH-PMH Study
There were 249 participants with missing information in the MSH-PMH study. Before removing the
participants with missing information, attempts will be made to impute this information. This will be
reported in Chapter 4 and if the information can be imputed no participants would be removed from the
study.
12.9.18 Pneumonia
Pneumonia is required as a dichotomous response and where possible missing information will be imputed.
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12.9.18.1 ReSoLuCENT Study
There were no concerns with Pneumonia in the ReSoLuCENT dataset.
12.9.18.2 CARET Study
Pneumonia is reported in the CARET study but 6 participants with missing information were removed.
12.9.18.3 CREST Study
Pneumonia is reported in the CREST study using ICD9 codes. Any ICD9 code between 480 - 486.9 [122]
will be reclassified as a positive pneumonia diagnosis.
12.9.18.4 MSH-PMH Study
In the MSH-PMH dataset there were 215 participants with missing information for this variable. This
information may be imputed using additional information. At this stage no participants were removed
from the study.
12.10 Categorising Education Levels and Types of Cancers
The datasets have now been prepared and the missing information will be imputed or removed. The table
for classifying the cancers are presented;
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12.10.1 ReSoLuCENT Education Levels
PLCO Education
Type
Classified Entries
Less than high-school
graduate
”CSE RSA 1 & 2 Word processing”, ”CSE State registered nurse”, CSS,
None, ”None School leaving certificate”, Health Care Certificate, H-G-V
Licence, P.S.V Licence., ”Level 1 Numeracy ITQ Level 2”, NDRM RHS ×
4 Certificate, NNEB class 1, Qualified HGV driver, Typing Certificate
High-school graduate CSE, ”CSE GCSE”, ”CSE GCSE G.C.E ’O’ level”, ”CSE GCSE NVQ 2”, ”CSE
GCSE NVQ 2 NVQ 3”, ”CSE GCSE NVQ 3”, ”CSE NVQ 1”, ”CSE NVQ 1 NVQ
2”, ”CSE NVQ 2”, ”CSE O level”, ”CSE O level BTEC Sports Management”,
”CSE O level GCSE”, ”CSE O level GCSE HND”, ”CSE O level GCSE NVQ 2
BTEC National Diploma”, ”CSE O level HND”, ”CSE O level NNEB”, ”CSE O
level NVQ 1 NVQ 2”, ”CSE O level NVQ 2”, ”CSE O level Registered Nurse”,
”CSE O level State Registered Nurse”, GCSE, ”GCSE Army Certificate of
Education”, ”GCSE City & Guilds NVQ 2”, ”GCSE HNC”, ”GCSE HND”,
”GCSE NVQ 1”, ”GCSE NVQ 1 NVQ 2”, ”GCSE NVQ 2”, ”GCSE Qualified
Nail Technician”, ”GCSE RGN”, ”GCSE SEN RGN”, NVQ 1, ”NVQ 1 Northern
counties english language/ History”, ”NVQ 1 NVQ 2”, ”NVQ 1 NVQ 2 School
leaving certificate CSE O level”, NVQ 2, ”NVQ 2 NVQ 3 GCSE”, O level, ”O
level BHSAI I”, ”O level City & Guilds”, ”O level City & Guilds ’Around drug
abuse’”, ”O level City & Guilds HND”, ”O level CSE”, ”O level CSE City &
Guilds NVQ 2”, ”O level GCSE”, ”O level HND”, ”O level MITD”, ”O level NVQ
2”, ”O level RGN”, ”O level RSA I,II and III typing RSA typing teacher”, ”O
level RSA School Cert Pitman shorthand RSA typing Book keeping”, ”O level
SRN”, ”O level Staff registered nurse”, School leaving certificate, ”School leaving
certificate City & Guilds”, RSA, ”School leaving certificate CSE”, ”School leaving
certificate CSE GCSE”, ”School leaving certificate CSE NVQ 3”, ”School leaving
certificate CSE O level NVQ 3”, ”School leaving certificate GCSE”, ”School
leaving certificate GCSE HND”, ”School leaving certificate GCSE NVQ 1 NVQ 2
NVQ 3”, ”School leaving certificate NVQ 1 NVQ 2”, ”School leaving certificate O
level”, ”Technical college exams CSE”, ”Technical college exams GCSE”,
”Technical college exams NVQ 1 NVQ 2”, South Africa std 8
Some training after
high school
A level or Highers ”A level or Highers GCSE” British Coal Deputy Course
Completed apprenticeship ”Completed apprenticeship Trade certificate”
”CSE A level or Highers” ”CSE Completed apprenticeship”
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Some training after
high school
”CSE Completed apprenticeship Trade certificate” ”CSE CPC Transport
management ADR hazardous goods handling” ”CSE NVQ 1 NVQ 2 NVQ
3” ”CSE NVQ 2 NVQ 3” ”CSE NVQ 2 NVQ 3 Trade certificate” ”CSE
NVQ 2 NVQ 3 Trade certificate BTEC” ”CSE O level A level or Highers”
”CSE O level A level or Highers HND” ”CSE O level A level or Highers
RGN” ”CSE O level A level or Highers Vocational Diploma” ”CSE O level
Completed apprenticeship” ”CSE O level GCSE A level or Highers” ”CSE
O level GCSE Technical college exams NVQ 2 NVQ 3” ”CSE O level NVQ
3” ”CSE O level NVQ 3 BTEC Level 2 Door Supervision” ”CSE O level
NVQ 3 ILM Diploma in Massage” ”CSE O level Technical college exams”
”CSE O level Technical college exams Completed apprenticeship” ”CSE O
level Technical college exams Pre-nursing Nursing” ”CSE Technical college
exams” ”CSE Technical college exams City & Guilds NVQ 3 Completed
apprenticeship Trade certificate” ”CSE Technical college exams Completed
apprenticeship Trade certificate” ”CSE Trade certificate” ”CSE Trade
certificate IOSH, RASWA Supervisor” ”GCSE A level or Highers” ”GCSE
A level or Highers HND” ”GCSE A level or Highers NVQ 1 NVQ 2”
”GCSE A level or Highers NVQ 2” ”GCSE A level or Highers NVQ 3”
”GCSE A level or Highers Trade certificate” ”GCSE City & Guilds NVQ 2
NVQ 3 Level 2 infection control Level 3 palliative care Level 2 health &
safety” ”GCSE City & Guilds NVQ 3 Completed apprenticeship Trade
certificate” ”GCSE NVQ 1 NVQ 2 NVQ 3” ”GCSE NVQ 1 NVQ 2 NVQ 3
NVQ 4” ”GCSE NVQ 3” ”GCSE NVQ 3 Completed apprenticeship”
”GCSE Completed apprenticeship” ”GCSE Technical college exams”
”GCSE Technical college exams City & Guilds Completed apprenticeship”
”GCSE Technical college exams City & Guilds Completed apprenticeship
Trade certificate” ”GCSE Technical college exams Completed
apprenticeship” ”GCSE Technical college exams Completed apprenticeship
Trade certificate” HND ”HND Completed apprenticeship” ”GCSE
University degree BTEC and GCE (A level equivalent)” ”GCSE City &
Guilds NVQ 1 NVQ 2 NVQ 3” Memeber of the Institute of Chirpodists
and Podiatrists ”NVQ 1 NVQ 2 Completed apprenticeship” ”NVQ 1 NVQ
2 NVQ 3” ”NVQ 1 NVQ 2 NVQ 3 Trade certificate Football coach First
aid, Health & Safety course Fire & Bomb awareness course” ”NVQ 2
Completed apprenticeship” ”NVQ 2 NVQ 3” NVQ 3 ”NVQ 3 City &
Guilds” NVQ 4 ”O level A level or Highers” ”O level A level or Highers
City & Guilds” ”O level A level or Highers City & Guilds HND Completed
apprenticeship” ”O level A level or Highers City & Guilds Trade
certificate” ”O level A level or Highers Civil Service Internal Qualifications”
”O level A level or Highers Fellow of Chartered Insurance Institute” ”O
level A level or Highers HND” ”O level A level or Highers HND HNC” ”O
level A level or Highers HND Qualified as a Chartered Accountant” ”O
level A level or Highers NIVEB (nursery nurse) RGN (nurse)”
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Some training after
high school
”O level A level or Highers NNEB Nursery Nurse RGN Nurse” ”O level A
level or Highers NVQ 4” ”O level A level or Highers RGN/RSCN” ”O level
City & Guilds Completed apprenticeship” ”O level City & Guilds
Completed apprenticeship Diploma in Financial Services” ”O level City &
Guilds NVQ 4” ”O level GCSE A level or Highers” ”O level GCSE A level
or Highers HND” ”O level GCSE A level or Highers NVQ 2 HNC” ”O level
GCSE Nurse Training” ”O level GCSE NVQ 2 NVQ 3 NVQ 4” ”O level
GCSE Technical college exams” ”O level NVQ 1 NVQ 2 NVQ 3” ”O level
NVQ 3” ”O level NVQ 4” ”O level Technical college exams City & Guilds
Completed apprenticeship Trade certificate” ”O level Technical college
exams City & Guilds NVQ 2 Managers Passport Managers Health and
Safety” ”O level Technical college exams City & Guilds NVQ 2 Trade
certificate” ”O level Technical college exams NVQ 1” OCN Horticultural
Course ”O level Technical college exams NVQ 3 Trade certificate NEBBS
Cert Various H&S Qualifications” ”O level Technical college exams Trade
certificate” ”School leaving certificate City & Guilds Completed
apprenticeship” ”School leaving certificate City & Guilds Completed
apprenticeship Trade certificate” ”School leaving certificate City & Guilds
NVQ 3” ”School leaving certificate City & Guilds Technical college exams”
”School leaving certificate Completed apprenticeship” ”School leaving
certificate Completed apprenticeship Trade certificate” ”School leaving
certificate Completed apprenticeship Trade certificate Painter and
decorating” ”School leaving certificate CSE A level or Highers City &
Guilds NVQ 1 Completed apprenticeship Trade certificate” ”School leaving
certificate CSE GCSE Technical college exams City & Guilds” ”School
leaving certificate CSE O level Technical college exams City & Guilds
Completed apprenticeship” ”School leaving certificate CSE Technical
college exams City & Guilds NVQ 1” ”School leaving certificate O level A
level or Highers” ”School leaving certificate O level Technical college exams
RSA Typing/Shorthand Book keeping” ”School leaving certificate
Technical college exams City & Guilds NVQ 1 Completed apprenticeship
Trade certificate Welder & Engineer” Technical college exams ”Technical
college exams City & Guilds” ”Technical college exams City & Guilds
Completed apprenticeship” ”Technical college exams City & Guilds
Completed apprenticeship Trade certificate” ”Technical college exams City
& Guilds HND” ”Technical college exams City & Guilds HND Mechanical
Engineering” ”Technical college exams City & Guilds NVQ 1 NVQ 2
Computer studies” ”Technical college exams City & Guilds ONC”
”Technical college exams City & Guilds Trade certificate Paramedic
(SYMAS)” ”Technical college exams Completed apprenticeship Trade
certificate” ”Technical college exams Completed apprenticeship Trade
certificate City & Guilds NVQ 2 NVQ 4”, Work Training / Computers /
SOS / Manager, ”Technical college exams RSA - WP Typing, Audio –
advanced Medical WP Doc Pres Mailmerge”, ”Technical college exams
Trade certificate”, TESOL (Teaching English), Trade certificate, ”Trade
certificate City & Guilds”, ”Trade certificate CSE O level”
xxx
Some college 3 Standard Grades, 1 HNC and various NCs ”CSE A level or Highers Technical
college exams” ”CSE City & Guilds Completed apprenticeship Technical college
exams” ”City & Guilds Technical college exams Completed apprenticeship” ”CSE
GCSE Secretarial college” ”CSE GCSE Technical college exams” ”CSE GCSE
Technical college exams NVQ 2” ”CSE NVQ 2 NVQ 3 NVQ 4 HND” ”CSE NVQ
3 NVQ 4” ”CSE O level A level or Highers Technical college exams HND” ”CSE
O level City & Guilds NVQ 2 NVQ 4 Management Qualifications” ”CSE O level
NVQ 1 NVQ 2 NVQ 3 NVQ 4 Trade certificate” ”CSE O level NVQ 3 Secretarial
college” ”CSE O level Secretarial college” ”CSE O level Secretarial college Royal
soc of arts” ”GCSE A level or Highers Diploma in Nursing” ”GCSE A level or
Highers NVQ 3 NVQ 4 Certificate in Social Science” ”GCSE A level or Highers
Teaching diploma Diploma in Special Education” ”GCSE A level or Highers
Technical college exams Teaching diploma” ”GCSE City & Guilds NVQ 3 Access
to Health & Nursing Studies” ”GCSE City & Guilds NVQ 3 HND Secretarial
college” ”GCSE City & Guilds NVQ 3 NVQ 4 Access into nursing” ”GCSE
Secretarial college” ”GCSE NVQ 2 NVQ 3 Advanced Diploma in Nursing Studies”
”GCSE NVQ 3Advanced Diploma in Nursing Studies” ”GCSE NVQ 4 Association
of Accounting Technicians” ”NVQ 3 Secretarial college” ”NVQ 4 Secretarial
college Diploma” ”O level A level or Highers HND Teaching diploma” ”O level A
level or Highers Secretarial college Teaching diploma” ”O level A level or Highers
Secretarial college University degree” ”O level A level or Highers Teaching
diploma” ”O level A level or Highers Teaching diploma University degree” ”O
level A level or Highers Technical college exams City & Guilds GCSE” ”O level A
level or Highers Technical college exams City & Guilds HND” ”O level A level or
Highers Technical college exams HND” ”O level Secretarial college” ”O level
Technical college exams” ”O level Technical college exams City & Guilds” ”O level
Technical college exams City & Guilds Trade certificate Teaching diploma” ”O
level Technical college exams Completed apprenticeship Secretarial college RSA”
”O level Technical college exams NVQ 3 Completed apprenticeship Secretarial
college” Secretarial college ”Secretarial college- RSA – Shorthand Typing –
English Secretarial college” ”Secretarial college O level” ”Secretarial college
School leaving certificate” ”Technical college exams City & Guilds Secretarial
college” ”Technical college exams Secretarial college” Advanced Diploma in
Nursing (Mental Health) City & Guilds ”City & Guilds BTEC’s” ”City & Guilds
Completed apprenticeship” ”City & Guilds Completed apprenticeship Teaching
diploma” ”City & Guilds Completed apprenticeship Trade certificate” ”City &
Guilds CSE” ”City & Guilds HND” ”City & Guilds NVQ 1 NVQ 2” ”City &
Guilds NVQ 1 NVQ 2 NVQ 3” ”City & Guilds NVQ 2” ”City & Guilds NVQ 2
Trade certificate” ”City & Guilds NVQ 3” ”City & Guilds O level CSE” ”City &
Guilds Secretarial college” ”City & Guilds Trade certificate” ”City & Guilds
Various Plant machinery / demolition” ”City & Guilds Youth Leaders Certificate”
”Completed apprenticeship Trade certificate City & Guilds” ”CSE A level or
Highers Nursing Diploma” ”CSE City & Guilds” ”CSE City & Guilds Completed
apprenticeship” ”CSE City & Guilds NVQ 1 NVQ 2” ”CSE City & Guilds NVQ 2
Completed apprenticeship Trade certificate” ”CSE City & Guilds NVQ 3 Teaching
diploma Nursing Othe Diplomas”
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Some College ”CSE City & Guilds Trade certificate” ”CSE GCSE NVQ 4 University Certificate”
”CSE GCSE O level Technical college exams City & Guilds Completed
apprenticeship Trade certificate” ”CSE O level A level or Highers Technical
college exams City & Guilds Completed apprenticeship Trade certificate” ”CSE O
level City & Guilds” ”CSE O level City & Guilds Completed apprenticeship”
”CSE O level City & Guilds NVQ 1 NVQ 2 NVQ 3 NVQ 4 Completed
apprenticeship Trade certificate” ”CSE O level GCSE A level or Highers Teaching
diploma” ”CSE O level GCSE Matriculation Technical college exams City &
Guilds HND Completed apprenticeship Trade certificate” ”CSE O level NVQ 4
Registered mental nurse” ”CSE O level Technical college exams City & Guilds”
”CSE O level Technical college exams City & Guilds NVQ 3 NVQ 4 Completed
apprenticeship” ”CSE O level Technical college exams NVQ 1 NVQ 2 NVQ 3
NVQ 4” ”CSE School leaving certificate City & Guilds NVQ 2 NVQ 3 NVQ 4
RMA IOSHH” ”CSE Teaching diploma” ”CSE Technical college exams City &
Guilds Completed apprenticeship” ”CSE Technical college exams City & Guilds
Completed apprenticeship Trade certificate” ”GCSE City & Guilds” ”GCSE City
& Guilds Completed apprenticeship Trade certificate” ”GCSE City & Guilds
National Certificate in Dental Nursing” ”GCSE City & Guilds NVQ 1” ”GCSE
City & Guilds NVQ 1 NVQ 2” ”GCSE City & Guilds NVQ 1 NVQ 2 Completed
apprenticeship” ”GCSE City & Guilds NVQ 1 NVQ 2 NVQ 3 NVQ 4” ”GCSE
City & Guilds NVQ 1 NVQ 2 NVQ 3 NVQ 4 Completed apprenticeship Trade
certificate” ”GCSE City & Guilds NVQ 2 NVQ 3 NVQ 4” ”O level A level or
Highers Diploma Interior Design Post grad diploma art therapy” ”O level A level
or Highers Teaching diploma Diploma in Educatiion” ”O level A level or Highers
Teaching diploma Post-graduate degree” ”O level GCSE Art College Diploma” ”O
level Teaching diploma” ”O level Teaching diploma SRN” RGN ”School leaving
certificate GCSE NVQ 2 Cache Diploma Child Care & Education” Teaching
diploma ”Teaching diploma Post-graduate degree A level or Highers CSE O level”
Postgraduate or
professional degree
”A level or Highers O level University degree Post-graduate degree” ”A level or
Highers GCSE Teaching diploma University degree Diploma in French, France”
”A level or Highers GCSE University degree” ”CSE O level A level or Highers
City & Guilds University degree Post-graduate degree” ”CSE O level A level or
Highers Nursing Diploma University degree” ”CSE O level GCSE A level or
Highers University degree Post-graduate degree” ”CSE O level GCSE Registered
Nurse RN Post Grad Diploma HE” ”CSE O level Teaching diploma University
degree Post-graduate degree” ”CSE O level Technical college exams City & Guilds
HND Completed apprenticeship Trade certificate Teaching diploma University
degree Post-graduate degree” ”CSE O level Technical college exams City & Guilds
Trade certificate University degree” ”CSE O level Technical college exams
Completed apprenticeship University degree HNC Mechanical Engineering” ”CSE
O level Technical college exams HND University degree Post-graduate degree”
”CSE O level University degree” ”GCSE A level or Highers City & Guilds NVQ 1
NVQ 2 HND Teaching diploma University degree” ”GCSE A level or Highers
HND University degree”
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Postgraduate or
professional degree
”GCSE A level or Highers University degree” ”GCSE A level or Highers
University degree HNC” ”GCSE A level or Highers University degree
Post-graduate degree” ”GCSE A level or Highers University degree Post-graduate
degree Chartered Public Finance Accountant (CPFA)” ”GCSE NVQ 3 Teaching
diploma University degree Nursing Diploma in Critical Care” ”GCSE Technical
college exams City & Guilds NVQ 1 NVQ 2 NVQ 3 University degree” ”GCSE
University Diploma” ”GCSE Technical college exams HND University degree” ”O
level A level or Highers City & Guilds HND University degree” ”O level A level or
Highers City & Guilds NVQ 3 University degree PGCE TDLB D32,33,34 Assessor
Awards” ”O level A level or Highers City & Guilds Teaching diploma University
degree” ”O level A level or Highers City & Guilds University degree” ”O level A
level or Highers NVQ 1 NVQ 2 NVQ 3 NVQ 4 HND University degree” ”O level
A level or Highers NVQ 4 University degree Post-graduate degree” ”O level A
level or Highers Post-graduate degree Fellowship of Royal College” ”O level A
level or Highers Post-graduate degree University degree” ”O level A level or
Highers Technical college exams HND Teaching diploma University degree
Post-graduate degree” ”O level A level or Highers Technical college exams NVQ 4
University degree ECDL” ”O level A level or Highers University degree” ”O level
A level or Highers University degree Certificate in Psychiatric Social Work” ”O
level A level or Highers University degree Diplomas (2) Radiography Registered
General Nurse Registered Health Visitor” ”O level A level or Highers University
degree Law Society, Solicitors Qualification” ”O level A level or Highers University
degree Post grad Diploma” ”O level A level or Highers University degree
Post-Grad diploma in town planning.” ”O level A level or Highers University
degree Post-graduate degree” ”O level A level or Highers University degree
Post-graduate degree PHD” ”O level A level or Highers University degree
Professional” ”O level GCSE A level or Highers University degree” ”O level GCSE
University degree” ”O level Post-graduate degree” ”O level University degree”
Post-graduate degree ”Post-graduate degree University degree A level or Highers
O level” ”School leaving certificate O level A level or Highers City & Guilds
Completed apprenticeship University degree BSc” University degree ”University
degree Post-graduate degree”
Table 12.6: Reclassifying the ReSoLuCENT Education Levels
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12.11 Classifying Cancers
12.11.1 ReSoLuCENT Data Cancer Types
Required Cancer
Type
Classified Entries
Melanoma Melanoma, ear (melanoma)
Any Type of Cancer Beast, Blood, Bone, Bone Marrow, Bones (possibly secondary), Bowel, Bowel
Cancer, Brain, Brain Tumor, Brain Tumor, Brain tumour, CLL, Caecum, Central
Nervous System, Colon, Duodenum, Eye, Intestines, Leg, Lymph, Lymphatic,
Lymphatic System, Lymphoma, Multiple, Multiple tumors., NHL, NK, Primary
unknown, diagnosed with multiple, Prostate, Prostate Cancer, Prostate cancer,
Prostrate, Right eye, Secondary bone cancer, Skin, Small Bowel, Spinal cord,
Testicle, Testicular, Tumours Left, UK, Uk, Unknown, Unknown primary, Uterus,
Womb, ampullary, blood, bone, bone marrow, bones, bowel, brain, colon, ear, ear
(NHL), leg, lymph, lymphoma, n/k, nk, not known, not stated, prostate, prostate,
bone, rectal, skin, skin (back), skin (face), skin on face, testicle, testicular,
thyroid, uk, unknown, uterus, vagina, womb, whole body!
Smoking Related Cancer ?gynae, Bladder, Bladder & Bowel, Bowel and Liver, Breast, Breast, Breast
cancer, Breast, Spine, Cancer of the breast, Cervical, Cervical Cancer, Cervix,
Cheek bone, Chin - BCC, Eyebrow and lips, Face, Gullet, Gum Head Groin
(Hodgkins), Hodgkins, Kidney, Kidneys, Larynx, Leukaemia, Liver, Liver ?
secondary to breast, Liver and Spleen, Liver/pancreas, Mouth, Naso/pharyngeal,
Nose, Nose/skin, Oesohagus, Oesophagus, Ovarian, Ovaries, Ovary, Ovary/Cervix,
Pancreas, Pancreatic, Renal, Stoma - Intestinech, Stomach, Stomach and bowel
cancer, Stomach, lymph glands, Throat, Throat and Bowel, Windpipe, bladder,
breast, breat, cervical, cervix, chin, face, forehead, head, kidney, kidney or liver,
kidney, liver & bowel, leukaemia, liver, liver & pancreas, mouth, mouth & throat,
neck, nose, oesophagus, oral, ovarian, ovaries, ovary, ovrian, pancreas, spleen,
stomach, throat
Lung Cancer Lung, ?Lung, Breast and Lung, Breast, Lung, Lung, Lung, Lung - Panoast, Lung
Cancer, Lung Cancer, Lung Caner, Lung and (Brain mets), Lung and Stomach,
Lung cancer, Lung, Brain, Lung, Liver, Lung, Spine, Lung, lymph, Lung/Brain,
Lung?, Lungs, Lungs, Lungs - Mesolithioma, Lungs and Brain, Lungs and Brian,
Testicle and Lung, Throat/Lung, brain, lung & adrenal, lung, lung, lung (mets
bones & liver), lungs, stomach/lung
Table 12.7: ReSoLuCENT: Classifying the Cancers
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12.11.2 UCLA Data Cancer Types
Required Cancer
Type
Classified Entries
Melanoma Basal skin melanoma, melanoma, melanoma/skin, multiple melanoma-skin, skin -
melanoma, skin : melanoma, skin melanoma, skin melanoma (nose), skin,
melanoma, skin-basal squamous and melanoma, skin-melanoma, skin–melanoma
Any Type of Cancer adreno carcenoma, Axillary Lymph Node, back, basal cell, basal cell carcinoma,
basal cell skin, basal skin cell, Blood, Blood (not leukemia), bone, bone cancer,
bowel/colon, brain, brain stem, brain tumor, brain/face, carcinoma, colon,
colorectal, Endometrial, Fibroid, fibromyalgia, intestinal, intestinal (upper),
lymph, lymph node, Lymph node, skin, lymphoma, lymphosarcoma, lympnoma on
sacrum, milofibrosis, multiple myeloma, multiple myloma, myloma, myloma
(bone), prostate, rectal, Recurring tumor on arm, renal. rhabdomyosarcoma, skin,
skin - basal cell, skin - benign, skin - not melanoma, skin (basal cell), skin
carcinoma, skin, basal, skin, carcinoma, skin, doesn’t know if melanoma, skin, non
melanoma, skin, non-melanoma, skin, not melanoma, skin, squamous cell, skin,
various, skin-basal, skin-carcinoma, skin–non-melanoma carcinoma, skin-nose
(minor), skin-squamous, skin–unknown if melanoma, spinal, spine, squamos cell
carcinoma, squamous cell, squamous cell carcinoma, testicular, thyroid, tumor
head/back region, unknown, uterus, uterus (doesn’t know type), vaginal
Smoking Related Cancer abdominal tumor, Acute leukemia, appendix and bowel, bilateral breast, bladder,
breast, breast, brain, cervical, esophagus, Facial Tumor, gynecological, Hodgkins
lymphoma, Hodgkins Nerve Disease, hysterectomy/cervix, jaw (oral), kidney,
larynx, leukemia, lip, lip/throat, liver, liver then to lung, mandible jaw,
Metastatic breast, neck, neck lymph nodes, nose, oral, ovarian, ovarian/ cervical,
pancreas, pancreas/liver, pharynx, salivary gland, some type of stomach or
abdominal, spleen, stomach, stomach OR colon, stomach–liver, throat, throat
(Laryngectomy), tongue, vocal cords
Lung Cancer breast, lungs, adrenal glands, kidney; Colorectal, lung; jaw and lung, lung, lung
(small cell), lung adenocarcinoma, lung cavity, lung or esophagus, lung,
adenocarcinoma, lung, small cell, lung/small cell, lymphoma/lung, misothelioma,
oat-cell carcinoma (lung), oral and lung, Sarcoidosis,
Table 12.8: UCLA: Classifying the Cancers
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12.11.3 CARET Data Cancer Types
Required
Cancer Type
Classified Entries
Melanoma 18 = Skin-Melanoma
Any Type of
Cancer
2 = Bone, 3 = Brain, 6 = Colon, 12 = Lymphoma, 16 = Prostate, 17 = Rectum, 19 =
Skin-Not melanoma, 20 = Skin-not specified, 22 = Thyroid, 23 = Uterus, 24 = Other or
unknown,
Smoking
Related
Cancer
1 = Bladder, 4 = Breast, 5 = Cervix, 7 = Oesophagus, 8 = Kidney, 9 = Liver, 10 =
Leukaemia, 13= Mouth ,oral; 14 = Ovary, 15 = Pancreas, 21 = Stomach
Lung Cancer 11 = Lung, bronchus
Table 12.9: CARET: Classifying the Cancers
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12.11.4 NY Wynder Data Cancer Types
Required Cancer Type Classified Entries
Melanoma 1720 - MALIGNANT MELANOMA OF SKIN OF LIP, 1723 - MALIGNANT
MELANOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE, 1725 -
MALIGNANT MELANOMA OF SKIN OF TRUNK EXCEPT SCROTUM, 1726 -
MALIGNANT MELANOMA OF SKIN OF UPPER LIMB INCLUDING SHOULDER,
1727 - MALIGNANT MELANOMA OF SKIN OF LOWER LIMB INCLUDING HIP,
1729 - MELANOMA OF SKIN SITE UNSPECIFIED
Any Type of Cancer V – Not recorded, 179 - MALIGNANT NEOPLASM OF UTERUS-PART UNS, 185 -
MALIGNANT NEOPLASM OF PROSTATE, 193 - MALIGNANT NEOPLASM OF
THYROID GLAND, 199 - DISSEMINATED MALIGNANT NEOPLASM, 1162 -
LOBOMYCOSIS, 1520 - MALIGNANT NEOPLASM OF DUODENUM, 1533 -
MALIGNANT NEOPLASM OF SIGMOID COLON, 1534 - MALIGNANT NEOPLASM
OF CECUM, 1539 - MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE,
1540 - MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION, 1541 -
MALIGNANT NEOPLASM OF RECTUM, 1561 - MALIGNANT NEOPLASM OF
EXTRAHEPATIC BILE DUCTS, 1590 - MALIGNANT NEOPLASM OF INTESTINAL
TRACT PART UNSPECIFIED, 1702 - MALIGNANT NEOPLASM OF VERTEBRAL
COLUMN EXCLUDING SACRUM AND COCCYX, 1706 - MALIGNANT NEOPLASM
OF PELVIC BONES SACRUM AND COCCYX, 1707 - MALIGNANT NEOPLASM OF
LONG BONES OF LOWER LIMB, 1709 - MALIGNANT NEOPLASM OF BONE
AND ARTICULAR CARTILAGE SITE UNSPECIFIED, 1712 - MALIGNANT
NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF UPPER LIMB
INCLUDING SHOULDER, 1713 - MALIGNANT NEOPLASM OF CONNECTIVE
AND OTHER SOFT TISSUE OF LOWER LIMB INCLUDING HIP, 1716 -
MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF
PELVIS, 1719 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT
TISSUE SITE UNSPECIFIED, 1733 - UNSPECIFIED MALIGNANT NEOPLASM OF
SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE, 1734 - UNSPECIFIED
MALIGNANT NEOPLASM OF SCALP AND SKIN OF NECK, 1735 - UNSPECIFIED
MALIGNANT NEOPLASM OF SKIN OF TRUNK, EXCEPT SCROTUM, 1736 -
UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF UPPER LIMB,
INCLUDING SHOULDER, 1737 - UNSPECIFIED MALIGNANT NEOPLASM OF
SKIN OF LOWER LIMB, INCLUDING HIP, 1739 - UNSPECIFIED MALIGNANT
NEOPLASM OF SKIN, SITE UNSPECIFIED, 1795 - MALIGNANT NEOPLASM OF
UTERUS-PART UNS, 1840 - MALIGNANT NEOPLASM OF VAGINA, 1849 -
MALIGNANT NEOPLASM OF FEMALE GENITAL ORGAN SITE UNSPECIFIED,
1855 - MALIGNANT NEOPLASM OF PROSTATE, 1857 - MALIGNANT NEOPLASM
OF PROSTATE, 1869 - MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED
TESTIS, 1909 - MALIGNANT NEOPLASM OF EYE PART UNSPECIFIED, 1919 -
MALIGNANT NEOPLASM OF BRAIN UNSPECIFIED SITE, 1936 - MALIGNANT
NEOPLASM OF THYROID GLAND, 1943 - MALIGNANT NEOPLASM OF
PITUITARY GLAND AND CRANIOPHARYNGEAL DUCT, 1953 - MALIGNANT
NEOPLASM OF PELVIS, 1955 - MALIGNANT NEOPLASM OF LOWER LIMB, 1958
- MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES, 1990 -
DISSEMINATED MALIGNANT NEOPLASM, 1991 - OTHER MALIGNANT
NEOPLASM OF UNSPECIFIED SITE, 2021 - MYCOSIS FUNGOIDES
UNSPECIFIED SITE, 2028 - OTHER MALIGNANT LYMPHOMAS UNSPECIFIED
SITE, 2029 - OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF
LYMPHOID AND HISTIOCYTIC TISSUE UNSPECIFIED SITE, 2030 - MULTIPLE
MYELOMA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION,
xxxvii
Required Cancer Type Classified Entries
Any Type of Cancer 2598 - OTHER SPECIFIED ENDOCRINE DISORDERS, 2899 - UNSPECIFIED
DISEASES OF BLOOD AND BLOOD-FORMING ORGANS
Smoking Related Cancer 171 - MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE
OF HEAD FACE AND NECK, 173 - UNSPECIFIED MALIGNANT NEOPLASM OF
SKIN OF LIP, 175 - MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF
MALE BREAST, 1409 - MALIGNANT NEOPLASM OF LIP UNSPECIFIED
VERMILION BORDER, 1419 - MALIGNANT NEOPLASM OF TONGUE
UNSPECIFIED, 1455 - MALIGNANT NEOPLASM OF PALATE UNSPECIFIED, 1459
- MALIGNANT NEOPLASM OF MOUTH UNSPECIFIED, 1460 - MALIGNANT
NEOPLASM OF TONSIL, 1490 - MALIGNANT NEOPLASM OF PHARYNX
UNSPECIFIED, 1509 - MALIGNANT NEOPLASM OF ESOPHAGUS UNSPECIFIED
SITE, 1519 - MALIGNANT NEOPLASM OF STOMACH UNSPECIFIED SITE, 1550 -
MALIGNANT NEOPLASM OF LIVER PRIMARY, 1552 - MALIGNANT NEOPLASM
OF LIVER NOT SPECIFIED AS PRIMARY OR SECONDARY, 1560 - MALIGNANT
NEOPLASM OF GALLBLADDER, 1579 - MALIGNANT NEOPLASM OF
PANCREAS PART UNSPECIFIED, 1600 - MALIGNANT NEOPLASM OF NASAL
CAVITIES, 1619 - MALIGNANT NEOPLASM OF LARYNX UNSPECIFIED, 1701 -
MALIGNANT NEOPLASM OF MANDIBLE, 1749 - MALIGNANT NEOPLASM OF
BREAST (FEMALE) UNSPECIFIED SITE, 1809 - MALIGNANT NEOPLASM OF
CERVIX UTERI UNSPECIFIED SITE, 1830 - MALIGNANT NEOPLASM OF
OVARY, 1889 - MALIGNANT NEOPLASM OF BLADDER PART UNSPECIFIED,
1890 - MALIGNANT NEOPLASM OF KIDNEY EXCEPT PELVIS, 1950 -
MALIGNANT NEOPLASM OF HEAD FACE AND NECK, 1951 - MALIGNANT
NEOPLASM OF THORAX, 1952 - MALIGNANT NEOPLASM OF ABDOMEN, 2001 -
LYMPHOSARCOMA UNSPECIFIED SITE, 2019 - HODGKIN’S DISEASE
UNSPECIFIED TYPE UNSPECIFIED SITE, 2089 - UNSPECIFIED LEUKEMIA,
WITHOUT MENTION OF HAVING ACHIEVED REMISSION, 5759 - UNSPECIFIED
DISORDER OF GALLBLADDER
Lung Cancer 1629 - MALIGNANT NEOPLASM OF BRONCHUS AND LUNG UNSPECIFIED 1639
- MALIGNANT NEOPLASM OF PLEURA UNSPECIFIED
Table 12.10: NY Wynder: Classifying the Cancers
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12.11.5 CREST Data Cancer Types
Required Cancer
Type
Classified Entries
Melanoma 172.9 - MELANOMA OF SKIN SITE UNSPECIFIED
Any Type of Cancer 153.9 - MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE
154.3 - MALIGNANT NEOPLASM OF ANUS UNSPECIFIED SITE
170.9 - MALIGNANT NEOPLASM OF BONE AND ARTICULAR
CARTILAGE SITE UNSPECIFIED 173.9 - UNSPECIFIED
MALIGNANT NEOPLASM OF SKIN, SITE UNSPECIFIED 184.9 -
MALIGNANT NEOPLASM OF FEMALE GENITAL ORGAN SITE
UNSPECIFIED 185.9 - MALIGNANT NEOPLASM OF PROSTATE
187.9 - MALIGNANT NEOPLASM OF MALE GENITAL ORGAN SITE
UNSPECIFIED 191 - MALIGNANT NEOPLASM OF CEREBRUM
EXCEPT LOBES AND VENTRICLES 194.9 - MALIGNANT
NEOPLASM OF ENDOCRINE GLAND SITE UNSPECIFIED 195.4 -
MALIGNANT NEOPLASM OF UPPER LIMB 199 - DISSEMINATED
MALIGNANT NEOPLASM 200 - RETICULOSARCOMA
UNSPECIFIED SITE
Smoking Related
Cancer
146.9 - MALIGNANT NEOPLASM OF OROPHARYNX UNSPECIFIED
SITE 149.9 - MALIGNANT NEOPLASM OF ILL-DEFINED SITES
WITHIN THE LIP AND ORAL CAVITY 150 - MALIGNANT
NEOPLASM OF CERVICAL ESOPHAGUS 151.9 - MALIGNANT
NEOPLASM OF STOMACH UNSPECIFIED SITE 155.9 - MALIGNANT
NEOPLASM OF LIVER PRIMARY 157.9 - MALIGNANT NEOPLASM
OF HEAD OF PANCREAS 159.9 - MALIGNANT NEOPLASM OF
ILL-DEFINED SITES WITHIN THE DIGESTIVE ORGANS AND
PERITONEUM 161.9 - MALIGNANT NEOPLASM OF LARYNX
UNSPECIFIED 174.9 - MALIGNANT NEOPLASM OF BREAST
(FEMALE) UNSPECIFIED SITE 182.9 - MALIGNANT NEOPLASM OF
CORPUS UTERI EXCEPT ISTHMUS 189 - MALIGNANT NEOPLASM
OF KIDNEY EXCEPT PELVIS 193 - MALIGNANT NEOPLASM OF
THYROID GLAND 195 - MALIGNANT NEOPLASM OF HEAD FACE
AND NECK 195.2 - MALIGNANT NEOPLASM OF ABDOMEN 196.9 -
SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF
LYMPH NODES SITE UNSPECIFIED
xxxix
Required Cancer
Type
Classified Entries
Lung Cancer 162.9 - MALIGNANT NEOPLASM OF BRONCHUS AND LUNG
UNSPECIFIED 163.9 - MALIGNANT NEOPLASM OF PLEURA
UNSPECIFIED
Table 12.11: CREST: Classifying the Cancers
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12.11.6 Canadian Study Data Cancer Types
Required Cancer
Type
Classified Entries
Melanoma Too many to list (NOT REQUIRED BY ANY MODEL)
Any Type of Cancer Too many to list (NOT REQUIRED BY ANY MODEL)
Smoking Related
Cancer
Too many to list (NOT REQUIRED BY ANY MODEL)
Lung Cancer bone, lung, stomach; Adenocarcinoma of lung; Left lung cancer; LUNG;
Lung (1st); lung (from asbestos); lung (non small cell); Lung (NSCLC);
LUNG (PARTIAL); lung + brain; Lung + Colon; LUNG + OTHER; Lung
and Bladder; LUNG AND BRAIN; Lung and Prostate; LUNG CANCER;
Lung Cancer, Brain Cancer; Lung(Small Cell); lung, bone; lung, brain;
lung, colon; lung, Hodgkin’s lymphoma; lung, liver, leukemia; lung,
possibly thymus; lung, prostate; lung, throat; lung.brain; lung/bone;
LUNG/BRAIN; LUNG/BREAST/BRAIN; lung/kidney; lung/prostate;
LUNG/SKIN; LUNG; ESOPHAGUS; Lung-spread to Bone; multiple
carcinoid tumours of lungs; non-small cell lung cancer; non-small-cell
carcinoma (lungs); pancreatic (spread to lungs or brain); Pancreatic/Lung;
SKIN, LUNG, THROAT; PROSTATE, BONE, LUNG; prostate/ lung;
PROSTATE/LUNG; prostate; spread to lungs & brain; RARE LUNG;
Small cell lung cancer; SMALL LUNG; SMALL-CELL LUNG; liver, lung;
Kidney,Lung,Bone; BOWEL LUNG; breast, bone, lung; BREAST/LUNG;
breast/ lung; colon, lung; colon-lung; Breast + Lung; PROSTATE AND
LUNG; stomach, lung; testicular, lung; stomach/lung/colon
Table 12.12: Canadian Study: Classifying the Cancers
12.12 Dataset Variable Codebook
Across the datasets and published Stata model codes the following variable codes were used;
xli
Variable Name Variable Code Variable Classification
Unique ID ID Unique ID
Case or Control Status CaseControl Case=”Case”, Control = “Control”
Age AgeRegistered Age nearest year
Gender Gender Male = 1, Female = 2
Ethnicity EthnicityScale
White = 1
Black = 2
Hispanic = 3
Asian = 4
American India or Alaskan Native = 5
Native Hawaiian or Pacific Islander = 6
BMI BMI American BMI calculation
Education PLCOEducationScale
Less than high-school graduate = 1
High-school graduate = 2
Some training after high school = 3
Some college = 4
College graduate = 5
Postgraduate or professional degree = 6
Prior Tumour PMT No = 0, Yes = 1
Smoking Status SmokingStatus
Never smoker = “No”
Former smoker = “Ex”
Current smoker = “Yes”
Start Age StartAge Age started smoking
Cessation Age CessationAge Age stopped smoking
Smoking Duration Duration Duration smoking
Cigarettes Per Day CPD Average CPD
Pack Years PackYears Total pack years
Quit Duration QuitDuration Duration since quitting
Environmental Smoke ETS No = 0, Yes = 1
Cases of Any Cancer ACFHC Family history of all cancers
Age of Onset for Any Cancer AoOACFHC Youngest recorded age of onset
Any Cancer w/o melanoma ACFHCeM All cancers except melanoma
Age of Onset for Any Cancer AoOAeMC Youngest recorded age of onset
Cases of Smoking Related Cancer SRCC Smoking related cancers
Age of Onset for Smoking Cancer AoOSRC Youngest recorded age of onset
Cases of Lung Cancer LCC Lung cancer
Age of Onset of Lung Cancer AoOLCC Youngest recorded age of onset
Asbestos Exposure Asbestos No = 0, Yes = 1
Dust Dust No = 0, Yes = 1
Hay fever Hayfever No = 0, Yes = 1
Asthma Asthma No = 0, Yes = 1
Emphysema Emphysema No = 0, Yes = 1
COPD COPD No = 0, Yes = 1
Pneumonia Pneumonia No = 0, Yes = 1
Table 12.13: Variable Code Book
12.13 Model Codes
xlii
PLCO(2012) Model Stata Code
E. Gray
2 Jun 2016
*PLCO 2012 Model Formula
*Import the Dataset
/DATASET IS IMPORTED HERE /
*Never Smokers Excluded
      .  drop if SmokingStatus == "No" 
      (972 observations deleted)
      
      
*Coefficient Preperation
*Ethnicity Coefficient - As categorised in the original article.
      .          foreach var of varlist ID {
      .         gen EthnicityCoefficient = 0 if EthnicityScale == 1
      .         replace EthnicityCoefficient = 0.3944778 if EthnicityScale == 2
      .         replace EthnicityCoefficient = -0.7434744 if EthnicityScale == 3
      .         replace EthnicityCoefficient = -0.466585 if EthnicityScale == 4
      .         replace EthnicityCoefficient = 1.027152 if EthnicityScale == 5
      .         replace EthnicityCoefficient = 0 if EthnicityScale == 6
      .         }
      (120 missing values generated)
      (19 real changes made)
      (8 real changes made)
      (86 real changes made)
      (7 real changes made)
      (0 real changes made)
      
      
*Age Coefficient
      .          foreach var of varlist ID {
      .         gen AgeCoefficient = (AgeRegistered - 62) * 0.0778868
      .         }
      
      
*Education Coefficient - As categorised in the original article
      .          foreach var of varlist ID {
      .         gen EducationCoefficient = -0.0812744 * (PLCOEducation - 4)
      .         }
      
      
*BMI Coefficient
      .          foreach var of varlist ID {
      .         gen BMICoefficient = -0.0274194 * (BMI - 27)
      .         }
      
      
*COPD Coefficient
      .          foreach var of varlist ID {
      .         gen COPDCoefficient = 0.3553063 * COPD 
      .         }
      
      
*Personal History of Cancer Coefficient
      .          foreach var of varlist ID {
      .         gen PHCCoefficient = 0.4589971 * PMT
      .         }
      
      
*Family Hisoty of Lung Cancer Coefficient
1
      .          foreach var of varlist ID {
      .         gen FHoLCCoefficient = 0
      .         replace FHoLCCoefficient = 0.587185 if LCC > 0
      .         }
      (216 real changes made)
      
      
*Smoking Status Coefficient
      .          foreach var of varlist ID {
      .         gen SSCoefficient = 0 if SmokingStatus == "Ex"
      .         replace SSCoefficient = 0.2597431 if SmokingStatus == "Yes"
      .         }
      (552 missing values generated)
      (552 real changes made)
      
      
*Smoking Intensity Coefficient
      .          foreach var of varlist ID {
      .         gen SICoefficient = -1.822606 * (((CPD/10)^-1)- 0.4021541613)
      .         }
      
      
*Smoking Duration
      .          foreach var of varlist ID {
      .         gen SDCoefficient = 0.0317321 * (Duration - 27) 
      .         }
      
      
*Quit Duration Coefficient
      .          foreach var of varlist ID {
      .         gen QuitCoefficient = 0 if SmokingStatus == "Yes"
      .         replace QuitCoefficient = -0.0308572 * (QuitDuration - 10) if SmokingStatus == "Ex"
      .         }
      (877 missing values generated)
      (877 real changes made)
      
      
*Sum of the predictors
      .                  foreach var of varlist ID {
      .                 gen Logit = -4.532506 + AgeCoefficient + EthnicityCoefficient + EducationCoefficient ///
                       + BMICoefficient + COPDCoefficient + PHCCoefficient + FHoLCCoefficient + SSCoefficient ///
                       + SICoefficient + SDCoefficient + QuitCoefficient
      
      .                 }
      
      
*Six Year Risk for PLCO_2012
      .  foreach var of varlist ID {
      . gen PLCO2012Risk = (exp(Logit)/(1+exp(Logit)))*100
      . }
      
      
*Clean the dataset
      .  drop (EthnicityCoefficient - Logit)
      
2
PLCO(2014) Model Stata Code
E. Gray
2 Jun 2016
*PLCO 2014 Model Formula
*Import the Dataset
/DATASET IS IMPORTED HERE /
*Variable Preperation
      .          keep ID AgeRegistered EthnicityScale PLCOEducation BMI SmokingStatus ///
               CessationAge Duration QuitDuration CPD LCC PMT COPD
      
      
      
*Coefficient Preperation
*Ethnicity Coefficient - As categorised in the original article.
      .                  foreach var of varlist ID {
      .                 gen EthnicityCoefficient = 0 if EthnicityScale == 1
      .                 replace EthnicityCoefficient = 0.3211605 if EthnicityScale == 2
      .                 replace EthnicityCoefficient = -0.8203332 if EthnicityScale == 3
      .                 replace EthnicityCoefficient = -0.5241286 if EthnicityScale == 4
      .                 replace EthnicityCoefficient = 0.952699 if EthnicityScale == 5
      .                 replace EthnicityCoefficient = -1.364379 if EthnicityScale == 6
      .                 }
      (328 missing values generated)
      (45 real changes made)
      (25 real changes made)
      (249 real changes made)
      (9 real changes made)
      (0 real changes made)
      
      
*Age Coefficient
      .                  foreach var of varlist ID {
      .                 gen AgeCoefficient = (AgeRegistered - 62) * 0.079597
      .                 }
      
      
*Education Coefficient - As categorised in the original article
      .                  foreach var of varlist ID {
      .                 gen EducationCoefficient = -0.0879289 * (PLCOEducation - 4)
      .                 }
      
      
*BMI Coefficient
      .                  foreach var of varlist ID {
      .                 gen BMICoefficient = -0.028948 * (BMI - 27)
      .                 }
      
      
*COPD Coefficient
      .                  foreach var of varlist ID {
      .                 gen COPDCoefficient = 0.3457265 * COPD
      .                 }
      
      
*Personal History of Cancer Coefficient
      .                  foreach var of varlist ID {
      .                 gen PHCCoefficient = 0.4845208 * PMT
      .                 }
      
      
*Family Hisoty of Lung Cancer Coefficient
      .                  foreach var of varlist ID {
      .                 gen FHoLCCoefficient = 0
      .                 replace FHoLCCoefficient = 0.5856777 if LCC > 0
      .                 }
      (318 real changes made)
      
1
      
*Smoking Status Coefficient
      .                  foreach var of varlist ID {
      .                 gen SSCoefficient = 0
      .                 replace SSCoefficient = 2.799727 if SmokingStatus == "Yes"
      .                 replace SSCoefficient = 2.542472 if SmokingStatus == "Ex"
      .                 }
      (552 real changes made)
      (877 real changes made)
      
      
*Smoking Intensity Coefficient
      .                  foreach var of varlist ID {
      .                 gen SICoefficient = 0
      .                 replace SICoefficient = -0.1815486 * (((CPD/100)^-1)- 4.021541613) ///
                       if SmokingStatus == "Yes" | SmokingStatus == "Ex"
      
      .                 }
      (1429 real changes made)
      
      
*Smoking Duration
      .                  foreach var of varlist ID {
      .                 gen SDCoefficient = 0
      .                 replace SDCoefficient = 0.0305566 * (Duration - 27) if SmokingStatus == "Yes" | ///
                       SmokingStatus == "Ex"
      
      .                 }
      (1400 real changes made)
      
      
*Quit Duration Coefficient
      .                  foreach var of varlist ID {
      .                 gen QuitCoefficient = 0
      .                 replace QuitCoefficient = -0.0321362 * (QuitDuration - 8.593417626) ///
                       if SmokingStatus == "Ex"
      
      .                 }
      (877 real changes made)
      
      
*Sum of the predictors
      .                          foreach var of varlist ID {
      .                         gen Logit = -7.02198 + AgeCoefficient + EthnicityCoefficient + EducationCoefficient ///
                                               + BMICoefficient + COPDCoefficient + PHCCoefficient + FHoLCCoefficient ///
                                               + SSCoefficient + SICoefficient + SDCoefficient + QuitCoefficient
      
      .                         }
      
      
*Six Year Risk for PLCO_2014
      .  foreach var of varlist ID {
      . gen PLCO2014Risk = (exp(Logit)/(1+exp(Logit)))*100
      . }
      
      
*Clean the dataset
      .  drop (EthnicityCoefficient - Logit)
      
2
African-American Model Stata Code
E. Gray
2 Jun 2016
*African American Five Year Risk
*Variable Preperation
      .  keep ID CaseControl AgeRegistered Gender SmokingStatus CessationAge QuitDuration PackYears Dust Asbestos HayFever COPD
      
      
*Removed if under 20
      .  drop if AgeRegistered < 20
      (1 observation deleted)
      
      
*Pack Years, Quit Duration and COPD Coefficient
      .          foreach var of varlist ID {
      .         gen SSCOPD = 1
      .         replace SSCOPD = 2.56 if PackYears >= 13.3 & PackYears < 26.4 & COPD == 0 
      .         replace SSCOPD = 2.69 if PackYears >= 26.4 & COPD == 0  & QuitDuration >= 3 & CessationAge < 56
      .         replace SSCOPD = 6.06 if PackYears >= 26.4 & COPD == 0  & QuitDuration < 3 & CessationAge < 56
      .         replace SSCOPD = 10.01 if PackYears >= 26.4 & COPD == 0  & CessationAge >= 56
      .         replace SSCOPD = 20 if PackYears < 26.4 & COPD == 1
      .         replace SSCOPD = 21.38 if PackYears >= 13.3 & PackYears < 26.4 & COPD == 0  & QuitDuration >= 23
      .         replace SSCOPD = 34.29 if PackYears >= 26.4 & COPD == 1  & SmokingStatus == "Yes"
      .         }
      (100 real changes made)
      (143 real changes made)
      (2 real changes made)
      (488 real changes made)
      (5 real changes made)
      (59 real changes made)
      (31 real changes made)
      
      
*Dust Exposure Coefficient
      .          foreach var of varlist ID {
      .         gen DustCoefficient = 1
      .         replace DustCoefficient = 1.46 if Dust == 1
      .         }
      (9 real changes made)
      
      
*Asbestos Exposure Coefficient
      .          foreach var of varlist ID {
      .         gen AsbestosCoefficient = 1.
      .         replace AsbestosCoefficient = 1.38 if Asbestos == 1
      .         }
      (9 real changes made)
      
      
*Hay Fever Coefficient
      .          foreach var of varlist ID { 
      .         gen HFCoefficient = 1
      .         replace HFCoefficient = 0.66 if HayFever == 1
      .         }
      (0 real changes made)
      
      
*Attrituable Risk by Gender Coefficient
*Male - 1, Female - 2
      .          foreach var of varlist ID {
      .         gen AttRisk = 0.79 if Gender == 1
      .         replace AttRisk = 0.59 if Gender == 2
      .         }
      (199 missing values generated)
      (199 real changes made)
      
      
*Age and Gender LC Incidence Rates
      .          foreach var of varlist ID {
      .         gen AGLCIRates = 0
      .         replace AGLCIRates = 0.2015/100000 if Gender == 1 & AgeRegistered >=20 & AgeRegistered <25
      .         replace AGLCIRates = 0.2/100000 if Gender == 2 & AgeRegistered >=20 & AgeRegistered <25
      .         replace AGLCIRates = 0.454/100000 if Gender == 1 & AgeRegistered >=25 & AgeRegistered <30
      .         replace AGLCIRates = 0.4212/100000 if Gender == 2 & AgeRegistered >=25 & AgeRegistered <30
1
      .         replace AGLCIRates = 1.1557/100000 if Gender == 1 & AgeRegistered >=30 & AgeRegistered <35
      .         replace AGLCIRates = 0.6739/100000 if Gender == 2 & AgeRegistered >=30 & AgeRegistered <35
      .         replace AGLCIRates = 3.988/100000 if Gender == 1 & AgeRegistered >=35 & AgeRegistered <40
      .         replace AGLCIRates = 4.9258/100000 if Gender == 2 & AgeRegistered >=35 & AgeRegistered <40
      .         replace AGLCIRates = 19.2688/100000 if Gender == 1 & AgeRegistered >=40 & AgeRegistered <45
      .         replace AGLCIRates = 15.5789/100000 if Gender == 2 & AgeRegistered >=40 & AgeRegistered <45
      .         replace AGLCIRates = 53.1998/100000 if Gender == 1 & AgeRegistered >=45 & AgeRegistered <50
      .         replace AGLCIRates = 33.6673/100000 if Gender == 2 & AgeRegistered >=45 & AgeRegistered <50
      .         replace AGLCIRates = 114.9708/100000 if Gender == 1 & AgeRegistered >=50 & AgeRegistered <55
      .         replace AGLCIRates = 64.067/100000 if Gender == 2 & AgeRegistered >=50 & AgeRegistered <55
      .         replace AGLCIRates = 230.228/100000 if Gender == 1 & AgeRegistered >=55 & AgeRegistered <60
      .         replace AGLCIRates = 108.8192/100000 if Gender == 2 & AgeRegistered >=55 & AgeRegistered <60
      .         replace AGLCIRates = 336.7714/100000 if Gender == 1 & AgeRegistered >=60 & AgeRegistered <65
      .         replace AGLCIRates = 160.2701/100000 if Gender == 2 & AgeRegistered >=60 & AgeRegistered <65
      .         replace AGLCIRates = 452.6758/100000 if Gender == 1 & AgeRegistered >=65 & AgeRegistered <70
      .         replace AGLCIRates = 236.0585/100000 if Gender == 2 & AgeRegistered >=65 & AgeRegistered <70
      .         replace AGLCIRates = 572.0534/100000 if Gender == 1 & AgeRegistered >=70 & AgeRegistered <75
      .         replace AGLCIRates = 272.7912/100000 if Gender == 2 & AgeRegistered >=70 & AgeRegistered <75
      .         replace AGLCIRates = 690.5254/100000 if Gender == 1 & AgeRegistered >=75 & AgeRegistered <80
      .         replace AGLCIRates = 302.721/100000 if Gender == 2 & AgeRegistered >=75 & AgeRegistered <80
      .         replace AGLCIRates = 647.7919/100000 if Gender == 1 & AgeRegistered >=80 & AgeRegistered <85
      .         replace AGLCIRates = 273.0735/100000 if Gender == 2 & AgeRegistered >=80 & AgeRegistered <85
      .         replace AGLCIRates = 650.5089/100000 if Gender == 1 & AgeRegistered >=85
      .         replace AGLCIRates = 229.61176/100000 if Gender == 2 & AgeRegistered >=85
      .         }
      (6 real changes made)
      (9 real changes made)
      (15 real changes made)
      (9 real changes made)
      (16 real changes made)
      (6 real changes made)
      (15 real changes made)
      (10 real changes made)
      (19 real changes made)
      (5 real changes made)
      (47 real changes made)
      (13 real changes made)
      (71 real changes made)
      (18 real changes made)
      (108 real changes made)
      (16 real changes made)
      (92 real changes made)
      (23 real changes made)
      (112 real changes made)
      (26 real changes made)
      (97 real changes made)
      (23 real changes made)
      (67 real changes made)
      (18 real changes made)
      (26 real changes made)
      (12 real changes made)
      (17 real changes made)
      (11 real changes made)
      
      
*Age and Gender Without LC Incidence Rates
      .          foreach var of varlist ID {
      .         gen AGWLCIRates = 0
      .         replace AGWLCIRates = 224.5/100000 if Gender == 1 & AgeRegistered >=20 & AgeRegistered <25
      .         replace AGWLCIRates = 70.6/100000 if Gender == 2 & AgeRegistered >=20 & AgeRegistered <25
      .         replace AGWLCIRates = 249.6/100000 if Gender == 1 & AgeRegistered >=25 & AgeRegistered <30
      .         replace AGWLCIRates = 93.6/100000 if Gender == 2 & AgeRegistered >=25 & AgeRegistered <30
      .         replace AGWLCIRates = 262.5/100000 if Gender == 1 & AgeRegistered >=30 & AgeRegistered <35
      .         replace AGWLCIRates = 132.5/100000 if Gender == 2 & AgeRegistered >=30 & AgeRegistered <35
      .         replace AGWLCIRates = 334.8/100000 if Gender == 1 & AgeRegistered >=35 & AgeRegistered <40
      .         replace AGWLCIRates = 213.1/100000 if Gender == 2 & AgeRegistered >=35 & AgeRegistered <40
      .         replace AGWLCIRates = 507.1/100000 if Gender == 1 & AgeRegistered >=40 & AgeRegistered <45
      .         replace AGWLCIRates = 325.1/100000 if Gender == 2 & AgeRegistered >=40 & AgeRegistered <45
      .         replace AGWLCIRates = 798.1/100000 if Gender == 1 & AgeRegistered >=45 & AgeRegistered <50
      .         replace AGWLCIRates = 486.7/100000 if Gender == 2 & AgeRegistered >=45 & AgeRegistered <50
      .         replace AGWLCIRates = 1220.7/100000 if Gender == 1 & AgeRegistered >=50 & AgeRegistered <55
      .         replace AGWLCIRates = 697.2/100000 if Gender == 2 & AgeRegistered >=50 & AgeRegistered <55
      .         replace AGWLCIRates = 1678/100000 if Gender == 1 & AgeRegistered >=55 & AgeRegistered <60
      .         replace AGWLCIRates = 671.3/100000 if Gender == 2 & AgeRegistered >=55 & AgeRegistered <60
      .         replace AGWLCIRates = 2437/100000 if Gender == 1 & AgeRegistered >=60 & AgeRegistered <65
      .         replace AGWLCIRates = 1445.8/100000 if Gender == 2 & AgeRegistered >=60 & AgeRegistered <65
      .         replace AGWLCIRates = 3312/100000 if Gender == 1 & AgeRegistered >=65 & AgeRegistered <70
      .         replace AGWLCIRates = 2047.3/100000 if Gender == 2 & AgeRegistered >=65 & AgeRegistered <70
      .         replace AGWLCIRates = 4818.6/100000 if Gender == 1 & AgeRegistered >=70 & AgeRegistered <75
      .         replace AGWLCIRates = 3020.5/100000 if Gender == 2 & AgeRegistered >=70 & AgeRegistered <75
      .         replace AGWLCIRates = 6952.6/100000 if Gender == 1 & AgeRegistered >=75 & AgeRegistered <80
      .         replace AGWLCIRates = 4495.8/100000 if Gender == 2 & AgeRegistered >=75 & AgeRegistered <80
      .         replace AGWLCIRates = 9796.1/100000 if Gender == 1 & AgeRegistered >=80 & AgeRegistered <85
      .         replace AGWLCIRates = 6654.1/100000 if Gender == 2 & AgeRegistered >=80 & AgeRegistered <85
      .         replace AGWLCIRates = 14876.3/100000 if Gender == 1 & AgeRegistered >=85
      .         replace AGWLCIRates = 13616.7/100000 if Gender == 2 & AgeRegistered >=85
      .         }
      (6 real changes made)
      (9 real changes made)
      (15 real changes made)
      (9 real changes made)
      (16 real changes made)
      (6 real changes made)
      (15 real changes made)
      (10 real changes made)
      (19 real changes made)
      (5 real changes made)
      (47 real changes made)
      (13 real changes made)
      (71 real changes made)
      (18 real changes made)
      (108 real changes made)
      (16 real changes made)
      (92 real changes made)
      (23 real changes made)
2
      (112 real changes made)
      (26 real changes made)
      (97 real changes made)
      (23 real changes made)
      (67 real changes made)
      (18 real changes made)
      (26 real changes made)
      (12 real changes made)
      (17 real changes made)
      (11 real changes made)
      
      
*Hazard Rate
      .                  foreach var of varlist ID {
      .                 gen HazardRate = AGLCIRates * (1 - AttRisk)
      .                 }
      
      
*Odds Rate
      .                  gen OddsRate = SSCOPD * DustCoefficient * AsbestosCoefficient * HFCoefficient
      
      
*African-American Model Five Year Risk
      .  gen AfricanAmericanRisk = ((HazardRate * OddsRate)/((HazardRate * OddsRate)+ AGWLCIRates))* ///
       (1 - exp((HazardRate * OddsRate* -5)-(5 * AGWLCIRates)))* 100 
      
      
      
*Clean the data
      .  drop (SSCOPD - OddsRate)
      
3
Bach Model Stata Code
*Bach Model Code
*Exclude ineligible participants
      .  keep ID CaseControl AgeRegistered Gender CPD SmokingStatus Duration QuitDuration PackYears Asbestos
      
      . keep if AgeRegistered >= 50 & AgeRegistered <= 75 & !(SmokingStatus == "No") & PackYears >= 30
      (231 observations deleted)
      
      
*Redefine Gender for the linear predictor - Male assigned 0, Female 1.
      .          foreach var of varlist ID {
      .         gen GenderScore = 0 if Gender == 1
      .         replace GenderScore = 1 if Gender == 2
      .         }
      (570 missing values generated)
      (570 real changes made)
      
      
*Calculate the One Year Risk of Incidence of Lung Cancer
*One Year Risk of Incidence Linear Predictor
      .                  foreach var of varlist ID {
      .                 gen Incidence_LP= -9.7960571 + (0.060818386 * CPD) - (0.00014652216 * max(CPD - 15,0)^3) ///
                       + (0.00018486938 * max(CPD - 20.185718, 0)^3) - (3.8347226e-005 * max(CPD - 40, 0)^3) +  ///
                       (0.11425297 *Duration) - (8.0091477e-005 * max(Duration - 27.6577, 0)^3) + ///
                       (0.00017069483 * max(Duration - 40, 0)^3) - (9.0603358e-005 * max(Duration - 50.910335, 0)^3) - ///
                       (0.085684793 * QuitDuration) + (0.0065499693 * max(QuitDuration, 0)^3) - ///
                       (0.0068305845 * max(QuitDuration - 0.50513347, 0)^3) + (0.00028061519 * max(QuitDuration - 12.295688, 0)^3) ///
                       + (0.070322812 * AgeRegistered - (9.382122e-005) * max(AgeRegistered - 53.459001, 0)^3) + (0.00018282661 * ///
                       max(AgeRegistered - 61.954825, 0)^3) - (8.9005389e-005 * max(AgeRegistered - 70.910335, 0)^3) ///
                       + (0.2153936*Asbestos) - (0.05827261*GenderScore)
      
      .                 }
      
      
*One Year Risk of Incidence Final Result
      .                  foreach var of varlist ID {
      .                 gen Bach_Incidence =(1- 0.99629^exp(Incidence_LP))
      .                 }
      
      
*Calculate One Year Risk of Death in the Absence of Lung Cancer
*Competing Risk of Death in the Absence of Lung Cancer Linear Predictor
      .                  foreach var of varlist ID {
      .                 gen Death_LP = -7.2036219 + (0.015490665 * CPD) - (0.00001737645 * max(CPD - 15,0)^3) + (0.000021924149 * ///
                       max(CPD - 20.185718, 0)^3) - (0.0000045476985 * max(CPD - 40, 0)^3) + (0.020041889 *Duration) + ///
                       (0.0000065443781 * max(Duration - 27.6577, 0)^3) - (0.000013947696 * max(Duration - 40, 0)^3) + ///
                       (0.0000074033175 * max(Duration - 50.910335, 0)^3) - (0.023358962 * QuitDuration) + (0.0019208669 * ///
                       max(QuitDuration, 0)^3) - (0.0020031611 * max(QuitDuration - 0.50513347, 0)^3) + (0.000082294194 * ///
                       max(QuitDuration - 12.295688, 0)^3) + (0.099168033 * AgeRegistered) + (0.0000062174577 * ///
                       max(AgeRegistered - 53.459001, 0)^3) - (0.000012115774 * max(AgeRegistered - 61.954825, 0)^3) + ///
                       (0.0000058983164 * max(AgeRegistered - 70.910335, 0)^3) + (0.06084611*Asbestos) - (0.49042298*GenderScore)
      
      .                 }
      
      
*One Year Risk of Death without Diagnosis Fina Result
      .                  gen Bach_No_Diagnosis =(1- 0.99629^exp(Death_LP))
      
      .                          foreach var of varlist ID {
      .                         gen Bach_Absolute_Risk = Bach_Incidence * (1 - Bach_No_Diagnosis)
      .                         }
      
      
*Final Percentages
      .  foreach var of varlist ID {
      . gen Bach_Incidence_Percentage = Bach_Incidence * 100
      . gen Bach_Absolute_Risk_Percentage = Bach_Absolute_Risk * 100
      . }
      
      
*Clean the dataset
      .  drop (GenderScore - Bach_Absolute_Risk)
      
      
*To run recursively update age, smoking duration, and quit duration dependant on the part icipant
*Example for 10 years
      .  forvalues i = 1/10 {
1
      . gen AgeRegistered_`i' = AgeRegistered + `i'
      . gen Duration`i' = Duration + `i' if SmokingStatus == "Yes" 
      . replace Duration`i' = Duration if SmokingStatus == "Ex"
      . gen QuitDuration`i' = QuitDuration + `i' if SmokingStatus == "Ex"
      . replace QuitDuration`i' = QuitDuration if SmokingStatus == "Yes"
      . }
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      (353 missing values generated)
      (353 real changes made)
      (1491 missing values generated)
      (1491 real changes made)
      
      
*Formula can be applied to calcualte risk and absolute risk in second year and so forth
*Then run recursively to calculate new risks
2
LLP Model Stata Code
*LLP Model Five Year Risk
*Pre-amble
      .  keep ID CaseControl AgeRegistered Gender Asbestos Pneumonia PMT Duration LCC AoOLCC
      
      
*Remove Participants who are ineligible for the model
      .  drop if AgeRegistered < 40 | AgeRegistered > 80
      (3 observations deleted)
      
      
*Where Age of Onset for Youngest Family Member with Lung Cancer assign 0
      .  foreach var of varlist ID {
      . replace AoOLCC = 0 if missing(AoOLCC)
      . }
      (21 real changes made)
      
      
*Assign participants an age of 'Their Age = 0.5' (Age Midpoint)
      .          foreach var of varlist ID {
      .         replace AgeRegistered = floor(AgeRegistered) + 0.5
      .         }       
      (28 real changes made)
      
      
*Determine with participant how long remaining in that age group and amount \
*of time for next 5 year in the next age group
      .          foreach var of varlist ID {
      .         gen LowerGroupTime = (floor(AgeRegistered/5)*5) + 5 - AgeRegistered
      .         gen UpperGroupTime = 5 - LowerGroupTime
      .         }
      
      
*Assign a category based on Gender and Age
      .                  forvalues i = 1/16 {
      .                 gen AgeGender_`i' = 0
      .                 }
      
      .                 foreach var of varlist ID {
      .                 replace AgeGender_1 = 1 if Gender == 1 & AgeRegistered > 40 & AgeRegistered < 45
      .                 replace AgeGender_2 = 1 if Gender == 1 & AgeRegistered > 45 & AgeRegistered < 50
      .                 replace AgeGender_3 = 1 if Gender == 1 & AgeRegistered > 50 & AgeRegistered < 55
      .                 replace AgeGender_4 = 1 if Gender == 1 & AgeRegistered > 55 & AgeRegistered < 60
      .                 replace AgeGender_5 = 1 if Gender == 1 & AgeRegistered > 60 & AgeRegistered < 65
      .                 replace AgeGender_6 = 1 if Gender == 1 & AgeRegistered > 65 & AgeRegistered < 70
      .                 replace AgeGender_7 = 1 if Gender == 1 & AgeRegistered > 70 & AgeRegistered < 75
      .                 replace AgeGender_8 = 1 if Gender == 1 & AgeRegistered > 75 & AgeRegistered < 80
      .                 replace AgeGender_9 = 1 if Gender == 2 & AgeRegistered > 40 & AgeRegistered < 45
      .                 replace AgeGender_10 = 1 if Gender == 2 & AgeRegistered > 45 & AgeRegistered < 50
      .                 replace AgeGender_11 = 1 if Gender == 2 & AgeRegistered > 50 & AgeRegistered < 55
      .                 replace AgeGender_12 = 1 if Gender == 2 & AgeRegistered > 55 & AgeRegistered < 60
      .                 replace AgeGender_13 = 1 if Gender == 2 & AgeRegistered > 60 & AgeRegistered < 65
      .                 replace AgeGender_14 = 1 if Gender == 2 & AgeRegistered > 65 & AgeRegistered < 70
      .                 replace AgeGender_15 = 1 if Gender == 2 & AgeRegistered > 70 & AgeRegistered < 75
      .                 replace AgeGender_16 = 1 if Gender == 2 & AgeRegistered > 75 & AgeRegistered < 80
      .                 }
      (1 real change made)
      (1 real change made)
      (4 real changes made)
      (5 real changes made)
      (2 real changes made)
      (0 real changes made)
      (1 real change made)
      (0 real changes made)
      (1 real change made)
      (5 real changes made)
      (4 real changes made)
      (3 real changes made)
      (0 real changes made)
      (0 real changes made)
      (1 real change made)
      (0 real changes made)
      
      .                 mkmat AgeGender_1 - AgeGender_16, matrix(Gender)
      
      
*Matrix of Incidence Coefficients
      .                  matrix IncidenceRate = (-9.06\-8.16\-7.31\-6.63\-5.97\-5.56\-5.31\-4.83\-9.9\-8.06\-7.46\-6.5\-6.22\-5.99\-5.49\-5.23)
      
      
*Matrix of Incidence Coefficients in Next Group
      .                  matrix NextIncidenceRate = (-8.16\-7.31\-6.63\-5.97\-5.56\-5.31\-4.83\-4.68\-8.06\-7.46\-6.5\-6.22\-5.99\-5.49\-5.23\-5.42)
      
      
*Coefficients
      .                  matrix A = Gender * IncidenceRate
      
      .                 matrix B = Gender * NextIncidenceRate
      
      .                 svmat double A, name(AgeIncidence)
1
      
      .                 svmat double B, name(NextAgeIncidence)
      
      
*Alpha Score based on incidences
      .                  foreach var of varlist ID {
      .                 gen Alpha = ((LowerGroupTime * AgeIncidence) + (UpperGroupTime * NextAgeIncidence))/5
      .                 }
      
      
*Model Coefficients
*Smoking Duration
      .          foreach var of varlist ID {
      .         gen SmokingDurationCoefficient = 0 if Duration == 0
      .         replace SmokingDurationCoefficient = 0.769 if Duration > 0 & Duration <= 20 
      .         replace SmokingDurationCoefficient = 1.452 if Duration > 20 & Duration <= 40
      .         replace SmokingDurationCoefficient = 2.507 if Duration > 40 & Duration <= 60
      .         replace SmokingDurationCoefficient = 2.724 if Duration > 60
      .         }
      (23 missing values generated)
      (2 real changes made)
      (14 real changes made)
      (7 real changes made)
      (0 real changes made)
      
      
*Pneumonia Coefficent - 1 if present, 0 otherwise
      .          foreach var of varlist ID {
      .         gen PneumoniaCoefficient = 0.602 * Pneumonia
      .         }
      
      
*Asbestos Coefficent - 1 if present, 0 otherwise
      .          foreach var of varlist ID {
      .         gen AsbestosCoefficient = 0.634 * Asbestos
      .         }
      
      
*Prior Malignant Tumour Coefficent - 1 if present, 0 otherwise
      .          foreach var of varlist ID {
      .         gen PMTCoefficient = 0.675 * PMT
      .         }
      
      
*Family History of Lung Cancer with Early or Late Onset
      .          foreach var of varlist ID {
      .         gen FHCoefficient = 0
      .         replace FHCoefficient = 0.703 if LCC > 0 & AoOLCC < 60 
      .         replace FHCoefficient = 0.168 if LCC > 0 & AoOLCC >= 60
      .         }
      (7 real changes made)
      (0 real changes made)
      
      
*LLP Model Linear Predictor
      .  foreach var of varlist ID {
      . gen LLPPredictor = Alpha + SmokingDurationCoefficient + ///
       PneumoniaCoefficient + AsbestosCoefficient + PMTCoefficient + FHCoefficient
      
      . }
      
      
*Final LLP 5 Year Risk
      .  foreach var of varlist ID {
      . gen LLP5YearRisk = (1/(1 + exp(LLPPredictor * - 1))) * 100
      . }
      
      
*Clean the data
      .  drop LowerGroupTime - LLPPredictor
      
2
Spitz Model Stata Code
*Spitz Model One Year Risk
*Pre-amble
*ETS = Environmental Tobacco Smoke, SRCC = Count of Relatives with Smoking Related Cancer , LCC = Count of Relatives with Lung Cancer
      .  keep ID CaseControl AgeRegistered Gender SmokingStatus CessationAge PackYears ETS SRCC LCC HayFever Emphysema Dust Asbestos 
      
      
*Drop ineligible participants
      .  foreach var of varlist ID {
      . drop if AgeRegistered < 40
      . }
      (8 observations deleted)
      
      
*Model Coefficients
*Former Smoker Coefficient
      .          foreach var of varlist ID {
      .         gen CessationCoefficient = 1 if !(SmokingStatus == "Ex") | (SmokingStatus == "Ex" & Cessation < 42)
      .         replace CessationCoefficient = 1.24 if SmokingStatus == "Ex" & CessationAge >= 42 & CessationAge <= 53 
      .         replace CessationCoefficient = 1.50 if SmokingStatus == "Ex" & CessationAge > 53
      .         }
      (79 missing values generated)
      (23 real changes made)
      (56 real changes made)
      
      
*Current Smokers Pack Years Coefficient
      .          foreach var of varlist ID {
      .         gen PYCoefficient = 1 if !(SmokingStatus == "Yes") | (SmokingStatus == "Yes" & PackYears < 28)
      .         replace PYCoefficient = 1.25 if SmokingStatus == "Yes" & PackYears >= 28 & PackYears < 42
      .         replace PYCoefficient = 1.45 if SmokingStatus == "Yes" & PackYears >= 42 & PackYears < 57.5
      .         replace PYCoefficient = 1.85 if SmokingStatus == "Yes" & PackYears >= 57.5
      .         }
      (66 missing values generated)
      (6 real changes made)
      (26 real changes made)
      (34 real changes made)
      
      
*Emphysema Coefficient for Former and Current Smokers
      .          foreach var of varlist ID {
      .         gen EmphysemaCoefficient = 1 if SmokingStatus == "No" | Emphysema == 0
      .         replace EmphysemaCoefficient = 2.65 if SmokingStatus == "Ex" & Emphysema == 1
      .         replace EmphysemaCoefficient = 2.13 if SmokingStatus == "Yes" & Emphysema == 1
      .         }
      (3 missing values generated)
      (2 real changes made)
      (1 real change made)
      
      
*ETS in never-smokers
      .          foreach var of varlist ID {
      .         gen ETSCoefficient = 1 if !(SmokingStatus == "No") | ETS == 0
      .         replace ETSCoefficient = 1.8 if SmokingStatus == "No" & ETS == 1
      .         }
      (26 missing values generated)
      (26 real changes made)
      
      
*Dust Coefficient in Former and Current Smokers
      .          foreach var of varlist ID {
      .         gen DustCoefficient = 1 if SmokingStatus == "No" | Dust == 0
      .         replace DustCoefficient = 1.59 if SmokingStatus == "Ex" & Dust == 1
      .         replace DustCoefficient = 1.36 if SmokingStatus == "Yes" & Dust == 1
      .         }
      (3 missing values generated)
      (2 real changes made)
      (1 real change made)
      
      
*Asbestos Exposure in Current Smokers
      .          foreach var of varlist ID {
      .         gen AsbestosCoefficient = 1 if !(SmokingStatus == "Yes") | Asbestos == 0
      .         replace AsbestosCoefficient = 1.51 if SmokingStatus == "Yes" & Asbestos == 1
      .         }
      (1 missing value generated)
      (1 real change made)
      
      
*Family History of Cancers (Different based on smoking status)
      .          foreach var of varlist ID {
      .         gen FHCoefficient = 1
      .         replace FHCoefficient = 2 if SmokingStatus == "No" & SRCC >= 2
      .         replace FHCoefficient = 1.59 if SmokingStatus == "Ex" & SRCC >= 2
      .         replace FHCoefficient = 1.47 if SmokingStatus == "Yes" & LCC >= 1
      .         }
      (3 real changes made)
1
      (3 real changes made)
      (9 real changes made)
      
      
*Hay Fever Coefficient in ever-smokers - as no exposure
      .          foreach var of varlist ID {
      .         gen HFCoefficient = 1 if SmokingStatus == "No" | HayFever == 1
      .         replace HFCoefficient = 1.45 if SmokingStatus == "Ex" & HayFever == 0
      .         replace HFCoefficient = 1.49 if SmokingStatus == "Yes" & HayFever == 0
      .         }
      (163 missing values generated)
      (91 real changes made)
      (72 real changes made)
      
      
*Linear Predictor of Coefficients
      .          foreach var of varlist ID {
      .         gen OddsRatio = CessationCoefficient * PYCoefficient * EmphysemaCoefficient * ETSCoefficient * ///
               DustCoefficient * AsbestosCoefficient * FHCoefficient * HFCoefficient
      
      .         }
      
      
*Clean the dataset
      .          drop (CessationCoefficient - HFCoefficient)
      
      
*Incidence Scaling Factors
*Attrituable Risk by Smoking Status
      .                  foreach var of varlist ID {
      .                 gen AttRisk = 0.4751 if SmokingStatus == "No"
      .                 replace AttRisk = 0.45352 if SmokingStatus == "Ex"
      .                 replace AttRisk = 0.51404 if SmokingStatus == "Yes"
      .                 }
      (163 missing values generated)
      (91 real changes made)
      (72 real changes made)
      
      
*Gender and Smoking Status Risk Factor - Male = 1, Female = 2
      .                  foreach var of varlist ID {
      .                 gen GSSRisk = 0.21 if SmokingStatus == "No" & Gender == 1
      .                 replace GSSRisk = 3.17 if SmokingStatus == "Ex" & Gender == 1
      .                 replace GSSRisk = 3.88 if SmokingStatus == "Yes" & Gender == 1
      .                 replace GSSRisk = 0.34 if SmokingStatus == "No" & Gender == 2
      .                 replace GSSRisk = 3.76 if SmokingStatus == "Ex" & Gender == 2
      .                 replace GSSRisk = 4.17 if SmokingStatus == "Yes" & Gender == 2
      .                 }
      (191 missing values generated)
      (85 real changes made)
      (60 real changes made)
      (28 real changes made)
      (6 real changes made)
      (12 real changes made)
      
      
*Categorise by Age and Gender for lung cancer incidence and death SEER rates
*Year for SEER reference in the article
      .                  forvalues i = 1/20 {
      .                 gen AgeGender_`i' = 0
      .                 }
      
      .                 foreach var of varlist ID {
      .                 replace AgeGender_1 = 1 if Gender == 1 & AgeRegistered >= 40 & AgeRegistered < 45
      .                 replace AgeGender_2 = 1 if Gender == 1 & AgeRegistered >= 45 & AgeRegistered < 50
      .                 replace AgeGender_3 = 1 if Gender == 1 & AgeRegistered >= 50 & AgeRegistered < 55
      .                 replace AgeGender_4 = 1 if Gender == 1 & AgeRegistered >= 55 & AgeRegistered < 60
      .                 replace AgeGender_5 = 1 if Gender == 1 & AgeRegistered >= 60 & AgeRegistered < 65
      .                 replace AgeGender_6 = 1 if Gender == 1 & AgeRegistered >= 65 & AgeRegistered < 70
      .                 replace AgeGender_7 = 1 if Gender == 1 & AgeRegistered >= 70 & AgeRegistered < 75
      .                 replace AgeGender_8 = 1 if Gender == 1 & AgeRegistered >= 75 & AgeRegistered < 80
      .                 replace AgeGender_9 = 1 if Gender == 1 & AgeRegistered >= 80 & AgeRegistered < 85
      .                 replace AgeGender_10 = 1 if Gender == 1 & AgeRegistered >= 85
      .                 replace AgeGender_11 = 1 if Gender == 2 & AgeRegistered >= 40 & AgeRegistered < 45
      .                 replace AgeGender_12 = 1 if Gender == 2 & AgeRegistered >= 45 & AgeRegistered < 50
      .                 replace AgeGender_13 = 1 if Gender == 2 & AgeRegistered >= 50 & AgeRegistered < 55
      .                 replace AgeGender_14 = 1 if Gender == 2 & AgeRegistered >= 55 & AgeRegistered < 60
      .                 replace AgeGender_15 = 1 if Gender == 2 & AgeRegistered >= 60 & AgeRegistered < 65
      .                 replace AgeGender_16 = 1 if Gender == 2 & AgeRegistered >= 65 & AgeRegistered < 70
      .                 replace AgeGender_17 = 1 if Gender == 2 & AgeRegistered >= 70 & AgeRegistered < 75
      .                 replace AgeGender_18 = 1 if Gender == 2 & AgeRegistered >= 75 & AgeRegistered < 80
      .                 replace AgeGender_19 = 1 if Gender == 2 & AgeRegistered >= 80 & AgeRegistered < 85
      .                 replace AgeGender_20 = 1 if Gender == 2 & AgeRegistered >= 85
      .                 }
      (2 real changes made)
      (6 real changes made)
      (16 real changes made)
      (15 real changes made)
      (21 real changes made)
      (35 real changes made)
      (27 real changes made)
      (20 real changes made)
      (7 real changes made)
      (3 real changes made)
      (3 real changes made)
      (2 real changes made)
      (4 real changes made)
      (4 real changes made)
      (6 real changes made)
      (11 real changes made)
      (5 real changes made)
      (7 real changes made)
      (1 real change made)
      (3 real changes made)
      
2
      .                 mkmat AgeGender_1 - AgeGender_20, matrix(AgeGender)
      
      
*Matrix of Incidence Coefficients
      .                  matrix SEERLCRate = (10.78/100000\25.49/100000\50.6/100000\116.58/100000\221.18/100000\346.77/100000\ ///
                       478.1/100000\564.36/100000\532.36/100000\498.44/100000\11.03/100000\23.19/100000\45.51/100000\93.93/100000\ ///
                       164.9/100000\246.85/100000\318.69/100000\344.67/100000\308.28/100000\266.72/100000)
      
      
      
*Matrix of Incidence Coefficients in Next Group
      .                  matrix SEERDeathRate = (275.1/100000\400.7/100000\560/100000\786.9/100000\1210.2/100000\1855.1/100000\ ///
                       2947.4/100000\4836.4/100000\7980.7/100000\15559.4/100000\153.2/100000\218.8/100000\313.4/100000\479.1/100000\ ///
                       762.9/100000\1197/100000\1968.3/100000\3306.1/100000\5761.2/100000\14016.2/100000)
      
      
      
*Coefficients
      .                  matrix A = AgeGender * SEERLCRate
      
      .                 matrix B = AgeGender * SEERDeathRate
      
      .                 svmat double A, name(SEERLCRate)
      
      .                 svmat double B, name(SEERDeathRate)
      
      
*Clean the dataset drop (AgeGender_1 - AgeGender_20)
*Baseline Risk
      .          foreach var of varlist ID {
      .         gen BaseRisk = SEERLCRate * GSSRisk * (1-AttRisk)
      .         }
      
      
*Spitz Model One Year Risk - percentage
      .  foreach var of varlist ID {
      . gen SpitzRisk = ((OddsRatio * BaseRisk) / ((OddsRatio *BaseRisk)+ SEERDeathRate))*(1 - exp(-((OddsRatio *BaseRisk)+ SEERDeathRate)))*100
      . }
      
      
*Clean the dataset
      .  drop (OddsRatio - BaseRisk)
      
3
Pittsburgh Model Stata Code
*Pittsburgh Predictor for 6 Year Risk
*Pre-Amble
      .  keep ID CaseControl AgeRegistered SmokingStatus CPD Duration
      
      
*Drop ineligible participants
      .  foreach var of varlist ID {
      . drop if SmokingStatus == "No" | AgeRegistered < 35
      . }
      (251 observations deleted)
      
      
*Model Coefficients
*Smoke Duration Coefficient
      .          foreach var of varlist ID {
      .         gen DurationCoefficient = -10 if Duration < 30
      .         replace DurationCoefficient = 0 if Duration >= 30 & Duration < 40
      .         replace DurationCoefficient = 8 if Duration >= 40 & Duration < 50
      .         replace DurationCoefficient = 14 if Duration >= 50
      .         }
      (600 missing values generated)
      (324 real changes made)
      (261 real changes made)
      (15 real changes made)
      
      
*Age Coefficient
      .          foreach var of varlist ID {
      .         gen AgeCoefficient = 0
      .         replace AgeCoefficient = 4 if (AgeRegistered >= 57 & Duration < 30) | ///
               (AgeRegistered >= 59 & Duration >= 30 & Duration < 40) | ///
               (AgeRegistered >= 61 & Duration >= 40 & Duration < 50) | (AgeRegistered >= 68 & Duration >= 50) 
      
      .         }
      (167 real changes made)
      
      
*Smoking Status Coefficient
      .          foreach var of varlist ID {
      .         gen SSCoefficient = 0 if SmokingStatus == "Yes"
      .         replace SSCoefficient = -3 if SmokingStatus == "Ex"
      .         }
      (501 missing values generated)
      (501 real changes made)
      
      
*Smoking Intensity Coefficient
      .          foreach var of varlist ID {
      .         gen SICoefficient = -4 if CPD < 20
      .         replace SICoefficient = 0 if CPD >= 20 & CPD < 30
      .         replace SICoefficient = 2 if CPD >= 30 & CPD < 40
      .         replace SICoefficient = 5 if CPD >= 40
      .         }
      (365 missing values generated)
      (283 real changes made)
      (61 real changes made)
      (21 real changes made)
      
      
*Final Pittsburgh Six Year Risk as percentage
      .  foreach var of varlist ID {
      . gen PittsburghRisk = 1/(1+(exp(4.2195 - 0.10*(DurationCoefficient + ///
       AgeCoefficient + SSCoefficient + SICoefficient))))*100
      
1
      . }
      
      
*Clean the Dataset
      .  drop (DurationCoefficient - SICoefficient)
      
2
